



United States
Environmental Protection Agency

EPA Document# EPA-740-R-25-061


December 2025

Office of Chemical Safety and
Pollution Prevention

Human Health Hazard Assessment for 1,3-Butadiene

Technical Support Document for the Risk Evaluation

CASRN 106-99-0



December 2025

SUMMARY	8
1 INTRODUCTION	10
1.1 Risk Evaluation Scope.....	10
2 APPROACH AND METHODOLOGY	12
2.1 Systematic Review.....	12
2.2 Problem Formulation and Focus of Analysis.....	13
2.3 Updates Following Peer Review	14
3 TOXICOKINETICS.....	15
3.1 Absorption	15
3.2 Distribution.....	15
3.3 Metabolism (Including Species Differences)	16
3.4 Elimination	20
3.5 PBPK Modeling Approach	20
4 NON-CANCER HAZARD ASSESSMENT	22
4.1 Hazard Identification	22
4.1.1 Ovarian Atrophy and Associated Female Reproductive System Toxicity	22
4.1.1.1 Human Evidence.....	23
4.1.1.2 Laboratory Animal Evidence.....	23
4.1.1.3 Mechanistic Evidence and Mode of Action Analysis	23
4.1.1.3.1 Key Event 1: Bioactivation of 1,3-Butadiene to DEB and Other Epoxide Metabolites	25
4.1.1.3.2 Key Event 2: Distribution of Metabolites into Ovarian Tissue	25
4.1.1.3.3 Key Event 3: Destruction of Ovarian Follicles via Apoptosis	25
4.1.1.3.4 Key Event 4: Premature Ovarian Failure and Atrophy	26
4.1.1.3.5 Uncertainties.....	26
4.1.1.3.6 Conclusions for Proposed MOA	26
4.1.1.3.7 Applicability of Ovarian Atrophy to Human Health Risk Assessment	27
4.1.2 Critical Non-Cancer Hazard Outcomes	28
4.1.2.1 Exposure During Gestation: Developmental and Maternal Toxicity.....	29
4.1.2.1.1 Human Evidence	29
4.1.2.1.2 Laboratory Animal Evidence.....	29
4.1.2.1.3 Mechanistic and Supporting Evidence	30
4.1.2.1.4 Summary and Conclusions	30
4.1.2.2 Male Reproductive System and Resulting Developmental Toxicity	31
4.1.2.2.1 Human Evidence	31
4.1.2.2.2 Laboratory Animal Evidence.....	31
4.1.2.2.3 Mechanistic and Supporting Evidence	31
4.1.2.2.4 Summary and Conclusions	32
4.1.2.3 Hematological and Immune Effects	32
4.1.2.3.1 Human Evidence	32
4.1.2.3.2 Laboratory Animal Evidence.....	32
4.1.2.3.3 Mechanistic and Supporting Evidence	33
4.1.2.3.4 Evidence Integration Summary and Conclusions.....	33
4.2 Non-Cancer Dose-Response Assessment	34

4.2.1	Selection of Studies and Endpoints for Non-Cancer Toxicity Dose-Response Analysis	34
4.2.1.1	Non-Cancer Endpoints for Acute Exposures	34
4.2.1.2	Non-Cancer Endpoints for Intermediate and Chronic Exposures	36
4.2.2	Dose-Response Derivation for Non-Cancer Hazard Values	37
4.2.2.1	Duration, Dosimetric, and Unit Adjustments for Inhalation Hazard Values	37
4.2.2.2	Benchmark Concentration Analysis	38
4.2.2.2.1	Exposure During Gestation: Maternal and Developmental Effects	39
4.2.2.2.2	Dominant Lethality	40
4.2.2.2.3	Anemia	40
4.2.2.3	POD Selection for Risk Estimation	41
4.2.2.3.1	Sensitivity Analysis for Potential Acute PODs	41
4.2.2.3.2	Endpoints for Intermediate and Chronic Exposures	43
4.2.2.4	Uncertainty Factors Used for Non-Cancer Endpoints	45
4.2.2.5	Non-Cancer Hazard Values Selected for Use in Risk Estimation	45
5	CANCER HAZARD ASSESSMENT.....	46
5.1	Cancer Hazard Identification	46
5.1.1	Epidemiology Studies	46
5.1.1.1	Lymphohematopoietic cancers	46
5.1.1.2	Bladder Cancer	47
5.1.1.3	Central Nervous System Cancers	47
5.1.1.4	Breast Cancer	48
5.1.1.5	Other Cancer Types	48
5.1.2	Laboratory Animal Studies	49
5.1.3	Mechanistic and Supporting Evidence	53
5.1.4	Cancer Classification and Evidence Integration Conclusions	53
5.2	Genotoxicity and Mutagenicity	54
5.3	Mutagenic Mode of Action Analysis	58
5.3.1	Key Event 1: Bioactivation of 1,3-Butadiene to DNA-Reactive Metabolites	59
5.3.2	Key Event 2: Formation of DNA Adducts and DNA Damage by 1,3-Butadiene Metabolites in Target Cells	59
5.3.3	Key Event 3: Chromosomal Damage and/or Mutations Arising from 1,3-Butadiene- Induced DNA Damage	60
5.3.4	Key Event 4: Development of Cancer from 1,3-Butadiene-Induced Mutations	62
5.3.5	Mutagenic MOA: Weight of Evidence Analysis	62
5.3.6	Summary and Conclusions	65
5.4	Cancer Dose-Response Assessment	65
5.4.1	Selection of Studies and Endpoint Derivation for Carcinogenic Dose-Response Assessment	65
5.4.1.1	Analysis of Leukemia and Bladder Cancer Epidemiological Studies from the SBR Cohort	69
5.4.1.1.1	Study Population	69
5.4.1.1.2	Exposure Assessment and Concentration	70
5.4.1.1.3	Statistical Analysis and Confounding Adjustment	72
5.4.1.2	Analysis of One Ecological and Two Case-Control Studies	74
5.4.1.3	Comparison of SBR Cohort Studies and Other Ecological and Case-Control Studies ...	75
5.4.1.4	Study Selection for Leukemia and Bladder Cancer IUR Derivation	76
5.4.2	Duration, Dosimetric and Unit Adjustments	77
5.4.3	Cancer IUR and UR for Leukemia and Bladder Cancer from Lifetime Exposures	78

5.4.3.1	Selection of Study, Statistical Model, and Data for Leukemia IUR Derivation.....	78
5.4.3.2	Leukemia Lifetable Analysis	80
5.4.3.3	Leukemia IUR and UR Calculation.....	82
5.4.3.4	Leukemia IUR and UR Results	83
5.4.3.5	Selection for Study, Statistical Model, and Data for Bladder Cancer	84
5.4.3.6	Bladder Cancer Lifetable Analysis	85
5.4.3.7	Bladder Cancer IUR and UR Calculation.....	86
5.4.3.8	Bladder Cancer IUR and UR Results	86
5.4.4	Combined IUR Derivation.....	88
5.4.5	Derivation for Combined Unit Risk for Workers	89
5.4.6	Results for Combined IUR and UR for Workers	91
6	WEIGHT OF SCIENTIFIC EVIDENCE CONCLUSIONS FOR HUMAN HEALTH HAZARD	92
6.1	Strengths, Limitations, Assumptions, and Key Sources of Uncertainty for the Hazard Identification and Selection of PODs for Human Health Hazard Assessment	92
6.1.1	Acute Non-Cancer	92
6.1.2	Intermediate/Chronic Non-Cancer.....	92
6.1.3	Cancer: Leukemia and Bladder Cancer	94
7	CONSIDERATION OF PESS AND AGGREGATE EXPOSURE.....	96
7.1	Hazard Considerations for Aggregate Exposure.....	96
7.2	PESS Based on Greater Susceptibility	96
8	HUMAN HEALTH HAZARD ASSESSMENT CONCLUSIONS	101
	REFERENCES.....	104
	APPENDICES	124
	Appendix A EVIDENCE INTEGRATION TABLES	124
	Appendix B BENCHMARK DOSE MODELING RESULTS FOR CRITICAL ENDPOINTS.	160
	Appendix C OTHER HAZARD OUTCOMES	170
C.1	Neurotoxicity, Sensory Effects, and Non-Cancer Mortality.....	170
C.2	Respiratory Toxicity	171
C.3	Liver Toxicity	172
C.4	Kidney Toxicity	172
	Appendix D HUMAN HEALTH HAZARD CONFIDENCE SUMMARY.....	174
D.1	Human Health Hazard Confidence Summary	174
D.2	Other Uncertainty Factors Not Applied in this Assessment	174

LIST OF TABLES

Table 4-1.	Potential Acute PODs Compared to the Intermediate POD.....	42
Table 4-2.	Dose-Response Analysis of Selected Studies and Endpoints Considered for Deriving Intermediate and Chronic PODs	44
Table 4-3.	Non-Cancer Points of Departure and Critical Endpoints Used for Risk Estimates of Each Exposure Scenario	45
Table 5-1.	Evidence Integration Judgments for Each Cancer Type	54
Table 5-2.	Summary of Mutagenicity and Chromosome Damage Studies From KE3	55

Table 5-3. Summary of 21 Leukemia Epidemiological Studies Providing Dose-Response Association Based on at Least 2 Exposure Levels (+ a Reference Level) or Continuous Exposure Levels	67
Table 5-4. Summary of Bladder Cancer Epidemiological Studies that Provided at Least Two Exposure Levels (+ a Reference Level) or Continuous Exposure Levels	69
Table 5-5. Updates and Description of Recruitment, Follow-Up, and Expansion of the SBR Cohort Study	70
Table 5-6. Comparison of Estimated Slope Coefficients and Relative Risks (RRs) for Leukemia from Comparable Log-Linear Relative Risk Models in Analyses of the U.S.–Canada SBR Cohort, 0-Year Lag	72
Table 5-7. Characteristics of the SBR Cohort (Sathiakumar et al., 2021b).....	78
Table 5-8. Summary of Crucial Cox Regression Models to Analyze Exposure-Response Relations for Leukemia in (Sathiakumar et al., 2021b).....	79
Table 5-9. Calculation of Cancer Unit Risk Estimate for Leukemia.....	83
Table 5-10. Cancer Hazard Values for Occupational Cancer Risk Estimation for Leukemia	84
Table 5-11. Incorporation of Age-Dependent Adjustment Factors for General Population Leukemia Risk Estimation	84
Table 5-12. Summary of Crucial Cox Regression Models to Analyze Exposure-Response Relations for Bladder Cancer in Sathiakumar et al. (2021a)	85
Table 5-13. Calculation of Bladder Cancer Unit Risk Estimate	87
Table 5-14. Cancer Hazard Values for Occupational Cancer Risk Estimation for Bladder Cancer	87
Table 5-15. Incorporation of Age-Dependent Adjustment Factors for General Population Risk Estimation for Bladder Cancer.....	87
Table 5-16. Upper and Central Estimates of Adult-Based Unit Risk of Leukemia and Bladder Cancer. 88	
Table 5-17. Incorporation of ADAF to Obtain the Combined IUR of Leukemia and Bladder Cancer....	89
Table 5-18. Upper-Bound and Central Estimates of Adult-Exposure-Only Unit Risks of Leukemia and Bladder Cancer.....	90
Table 5-19. Combined IUR and Combined Unit Risk for Workers of Leukemia and Bladder Cancer ...	91
Table 5-20. Potential Effects of Certain Characteristics on the Estimated IURs Between EPA ORD (2002) and OPPT (2025).....	91
Table 7-1. PESS Evidence Crosswalk for Biological Susceptibility Considerations	97
Table 8-1. Non-Cancer Points of Departure and Critical Endpoints Used for Risk Estimates of Each 1,3-Butadiene Exposure Scenario	102
Table 8-2. Cancer Hazard Values for Occupational Cancer Risk Estimation for 1,3-Butadiene	102
Table 8-3. Incorporation of Age-Dependent Adjustment Factors (ADAFs) for General Population Risk Estimation for 1,3-Butadiene	103

LIST OF FIGURES

Figure 1-1. Risk Assessment Document Map Summary	10
Figure 2-1. EPA Approach to Hazard Identification, Evidence Integration, and Dose-Response Analysis for 1,3-Butadiene	12
Figure 3-1. Schematic of 1,3-Butadiene Metabolism	17
Figure 4-1. Proposed MOA for Ovarian Toxicity and Associated Mechanisms	24

LIST OF APPENDIX TABLES

Table_Apx A-1. Evidence Integration for Ovarian Atrophy and Associated Female Reproductive System Toxicity	124
Table_Apx A-2. Evidence Integration for Maternal and Related Developmental Toxicity	127

Table_Apx A-3. Evidence Integration for Male Reproductive System and Resulting Developmental Toxicity	130
Table_Apx A-4. Evidence Integration for Hematological and Immune Effects	134
Table_Apx A-5. Evidence Integration for Carcinogenicity	138
Table_Apx B-1. BMD Modeling Results for Maternal and Related Developmental Toxicity Endpoints	161
Table_Apx B-2. BMD Modeling Results for Male Reproductive System and Resulting Developmental Toxicity Endpoints	167
Table_Apx B-3. BMD Modeling Results for Hematological Endpoints	168
Table_Apx D-1. Confidence Summary for Human Health Hazard Assessment	174

KEY ABBREVIATIONS AND ACRONYMS

ADAF	Age-dependent adjustment factor
ADME	Absorption, distribution, metabolism, and elimination
AEGL	Acute Exposure Guideline Levels (EPA)
ALL	Acute lymphoblastic leukemia
ALM	Acute myelogenous or monocytic leukemia
AML	Acute myeloid leukemia
AOP	Adverse Outcome Pathways
ATSDR	Agency for Toxic Substances and Disease Registry
BMD(L)	Benchmark dose (lower 95 percentile)
BMR	Benchmark response
CASRN	Chemical Abstracts Service Registry Number
CML	Chronic myeloid leukemia
CYP	Cytochrome P450
DDEF	Data-derived extrapolation factor
EB	3,4-Epoxy-1-butene (epoxybutane)
EBD	3,4-Epoxybutane-1,2-diol
EC ₀₁	Maximum likelihood estimate of the exposure concentration associated with a 1 percent increased risk
EPA	Environmental Protection Agency
ER	Extra risk
DDEF	Data-derived extrapolation factor
DEB	1,2;3,4-Diepoxybutane
GD	Gestational day
Hb	Hemoglobin
HEC	Human equivalent concentration
IARC	International Agency for Research of Cancer
IRIS	Integrated Risk Information System (EPA)
i.p.	Intraperitoneal
IUR	Inhalation unit risk
LB	Lower-bound estimate
LEC ₀₁	The 5 percent lower confidence limit of the exposure concentration associated with a 1 percent increased risk
LO(A)EL	Lowest-observed-(adverse)-effect level
MLE	Maximum Likelihood Estimate
MOA	Mode of action
MOE	Margin of exposure

MRL	Minimum risk level
NHL	Non-Hodgkin lymphoma
NIOSH	National Institute for Occupational Safety and Health
NO(A)EL	No-observed-(adverse)-effect level
OCSPP	Office of Chemical Safety and Pollution Prevention (EPA)
OEHHA	Office of Environmental Health Assessment (California)
OPPT	Office of Pollution Prevention and Toxics (EPA)
ORD	Office of Research and Development (EPA)
OQD	Overall Quality Determination
OSHA	Occupational Safety and Health Administration (U.S.)
PBPK	Physiologically based pharmacokinetic
PEL	Permissible exposure limit
PESS	Potentially exposed and susceptible subpopulations
POD	Point of departure
RD	Relative deviation
RfC	Reference concentration
SBR	Styrene-butadiene rubber
SCE	Sister chromatid exchanges
SD	Standard deviation
SMR	Standardized mortality ratio
STEL	Short-term exposure limit
SMR	Standardized mortality ratio
TCEQ	Texas Commission on Environmental Quality
TSCA	Toxic Substances Control Act
TSD	Technical support document
TWA	Time-weighted average
UB	Upper-bound estimate
UF	Uncertainty factor
U.S.	United States
VCH	4-Vinylcyclohexene
VCD	4-Vinylcyclohexene dioxide

SUMMARY

1,3-butadiene is a colorless, volatile gas at room temperature. Based on physical and chemical properties and expected exposure scenarios, EPA (or the Agency) quantitatively evaluated hazards via the inhalation route. Oral and dermal exposure is not expected. Inhalation hazards were assessed through systematic review of reasonably available evidence, which includes human epidemiology, animal toxicology, and mechanistic data (including *in vitro* studies). The Agency refined the systematic review approach for 1,3-butadiene by including previous authoritative reviews by federal agencies to better target the assessment. To this end, EPA's Integrated Risk Information System (IRIS) Health Assessment of 1,3-Butadiene ([2002a](#)) and the Agency for Toxic Substances and Disease Registry's (ATSDR), *Toxicological Profile for 1,3-Butadiene* ([2012](#)) were used to identify the primary hazards and key studies. Key studies from these assessments were supplemented with other literature that was "filtered" based on whether it was informative for dose-response analysis; however, all reasonably available information was considered for evaluating the weight of scientific evidence.

1,3-Butadiene is readily absorbed through the lungs and distributed throughout the body with higher partitioning to adipose tissue. The primary metabolites are reactive mono- or di-epoxides, which can interact with biomolecules and induce toxicity. Qualitatively, metabolic pathways are identical between mice, rats, and humans. However, they are quantitatively different, with mice producing much greater levels of metabolites—especially di-epoxides. 1,3-Butadiene is primarily eliminated through exhalation, with additional excretion via urination, and individual urinary metabolites corresponding to specific epoxy metabolites and/or pathways. Because these metabolites are considered to be the source of toxicity, species-specific toxicokinetic differences can influence relative species sensitivity.

EPA began the assessment by focusing on the endpoints and studies considered for deriving hazard values in ([U.S. EPA, 2002a](#)) and ([ATSDR, 2012](#)). Ovarian atrophy was the basis of the chronic reference concentration (RfC) in ([U.S. EPA, 2002a](#)) while ([ATSDR, 2012](#)) elected not to derive an inhalation minimum risk level (MRL) due to uncertainty in how to accurately extrapolate the mouse data to humans. Following a mode of action analysis, EPA concluded that ovarian atrophy observed in mice is not appropriate for quantitative use in human health risk assessment due to evidence suggesting greatly increased susceptibility in mice and difficulty in confidently quantifying cross-species differences. Instead, the Agency determined that the following three other critical, non-cancer hazard outcomes were appropriate for dose-response analysis: (1) maternal and related developmental toxicity, (2) male reproductive system and resulting developmental toxicity, and (3) hematological and immune effects.

1,3-Butadiene is a potent multi-organ carcinogen in laboratory animals, notably inducing lymphomas in mice and exhibiting greater carcinogenic potential in mice than rats. Epidemiological evidence consistently links occupational 1,3-butadiene exposure to increased mortality from lymphatic and hematopoietic cancers. EPA determined that 1,3-butadiene "is carcinogenic to humans," based primarily on robust human, animal, and mechanistic evidence for lymphohematopoietic and bladder cancers—though varying evidence for other cancer types was also identified, such as bladder cancer. Furthermore, the weight of scientific evidence supports a mutagenic mode of action (MOA) for carcinogenicity.

Candidate endpoints for an acute point of departure (POD) from repeat-dose studies were considered but have substantial uncertainties as to whether they are relevant to acute exposures. They were also found to be less protective than the intermediate/chronic POD. Therefore, a hazard value was *not* derived for risk estimation of acute exposures because it is unlikely any adverse effects will result following a single exposure at concentrations relevant to human exposures. Additionally, the POD for repeated exposures is expected to be protective of any potential acute hazard. EPA performed dose-response analysis for

multiple repeated-dose non-cancer endpoints under each hazard domain. Decreased fetal body weight associated with other developmental toxicity outcomes was selected as the most sensitive and robust human-relevant endpoint for use in risk characterization of intermediate and chronic exposures. A human equivalent concentration (HEC) of 2.5 ppm (5.5 mg/m³) with a total uncertainty factor (UF) of 30 was derived from benchmark dose modeling with a benchmark response of either 5 or 10 percent extra risk (ER) following dichotomization of male mouse fetal body weight data. All other candidate PODs were higher but within 2- to 4-fold of this value.

EPA used an occupational epidemiological cohort with more than 50 years of follow-up and subsequent exposure estimate updates to derive inhalation hazard values for leukemia and bladder cancer that are applicable to general population and occupational exposures. Due to an identified mutagenic mode of action for cancer, the Agency applied an age-dependent adjustment factor (ADAF) to the inhalation unit risk (IUR) for leukemia and bladder cancer for the general population; that is, risk scenarios where children or adolescents aged less than 16 years may be exposed. The IUR for general population risk estimation incorporating the ADAF is 0.00129 per ppm (5.83×10⁻⁶ per µg/m³) and the chronic unit risk (UR) for occupational scenarios applied to adolescent and adult workers (16+ years) is 0.00644 per ppm (2.91×10⁻⁶ per µg/m³).

EPA has robust overall confidence in the assessments and associated hazard values for maternal/developmental toxicity and leukemia and bladder cancer, which will be used for risk estimation. These confidence ratings were based on the weight of scientific evidence considering evidence integration, selection of the critical endpoint and study, relevance to exposure scenarios, dose-response considerations, and incorporation of potentially exposed and susceptible subpopulations (PESS).

This human health hazard assessment for 1,3-butadiene was released for public comment and was externally peer-reviewed by the Science Advisory Committee on Chemicals ([SACC](#); accessed November 19, 2025) during the April 1 to 4, 2025, SACC Meeting (<https://www.regulations.gov/document/EPA-HQ-OPPT-2024-0425-0123>). Following SACC peer review and public comment, this technical support document (TSD) was revised to incorporate recommendations from the SACC and the public.

1 INTRODUCTION

This TSD presents the human health hazard assessment in support of the TSCA *Risk Evaluation for 1,3-Butadiene* ([U.S. EPA, 2025h](#)), also referred to as the “risk evaluation,” conducted under the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which amended TSCA on June 22, 2016. The law includes statutory requirements and deadlines for actions related to conducting risk evaluations of existing chemicals.

Under TSCA section 6(b), EPA must designate chemical substances as high-priority substances for risk evaluation or low-priority substances for which risk evaluations are not warranted at the time. Upon designating a chemical substance as a high-priority substance, the Agency must initiate a risk evaluation. TSCA section 6(b)(4) directs EPA to conduct risk evaluations for existing chemicals to “determine whether a chemical substance presents an unreasonable risk of injury to health or the environment, without consideration of costs or other nonrisk factors, including an unreasonable risk to a potentially exposed or susceptible subpopulation [PESS] identified as relevant to the risk evaluation by the Administrator under the conditions of use [COUs].”

TSCA section 6(b)(4)(D) and implementing regulations require that EPA publish the scope of the risk evaluation to be conducted, including the hazards, exposures, COUs, and PESS that the Administrator expects to consider, within 6 months after the initiation of a risk evaluation. In addition, a scope is to be published pursuant to 40 CFR 702.41. In December 2019, EPA published a list of 20 chemical substances that had been designated high priority substances for risk evaluations (Docket ID: [EPA-HQ-OPPT-2019-0131](#)) (84 FR 71924, December 30, 2019) as required by TSCA section 6(b)(2)(B), which initiated the risk evaluation process for those chemical substances. 1,3-Butadiene is one of the chemicals designated as a high priority substance for risk evaluation.

1.1 Risk Evaluation Scope

The TSCA risk evaluation of 1,3-butadiene includes human health, environmental, fate, and exposure assessment modules, and a risk evaluation document. A diagram showing the relationships between assessments is provided in Figure 1-1. This human health hazard assessment (highlighted in blue) is one of the five TSD that are outlined in green.




Figure 1-1. Risk Assessment Document Map Summary

Considering the physical and chemical properties, along with anticipated exposure scenarios, EPA only evaluated hazards via inhalation route. This assessment includes EPA's assessment for both non-cancer (Section 4) and cancer (Section 5) outcomes. Section 2 presents EPA's approach and methodology for the human health hazard assessment, including refinement of systematic review processes. The toxicokinetics of 1,3-butadiene are discussed in Section 3. The hazard identification and evidence integration for each organ system are presented in Section 4.1 for non-cancer and Section 5.1 for cancer (with genotoxicity/mutagenicity and MOA analysis presented in Sections 5.2 and 5.3). The dose-response analysis is provided in Sections 4.2.2 and 5.4 for non-cancer and cancer, respectively. The weight of scientific evidence conclusions are discussed in Section 6, and a detailed analysis of PESS along with considerations for aggregate exposure are described in Section 7. Finally, the hazard values to be used for risk estimates are presented in Section 8.

This TSD includes four appendices, including the evidence integration tables presented in Appendix A.

2 APPROACH AND METHODOLOGY

EPA's Office of Pollution Prevention and Toxics (OPPT) utilized systematic review processes to search, screen, evaluate, extract, and integrate reasonably available information to make conclusions about relevant adverse health effects from 1,3-butadiene exposure. Following evidence integration, the Agency performed dose-response analysis to derive hazard values for use in risk characterization. These values are binned into one of the following four duration categories, to match the corresponding human exposure scenarios for risk estimation:

- Acute (single dose or exposure to an air concentration for no more than 24 consecutive hours);
- Intermediate (a repeated dosing ranging from a few days to <10% of lifetime, typically from short-term or subchronic studies);
- Chronic non-cancer (repeated dosing covering >10% of lifetime); and
- Chronic/lifetime cancer (repeated dosing averaged over the relevant chronic period up to a full lifetime).

The Agency then evaluated the weight of scientific evidence for each aspect of the assessment and determined overall confidence ratings for each critical hazard outcome. The generalized process for conducting human health assessment under TSCA as applied to 1,3-butadiene is presented in Figure 2-1.




Figure 2-1. EPA Approach to Hazard Identification, Evidence Integration, and Dose-Response Analysis for 1,3-Butadiene

2.1 Systematic Review

The searching and screening steps of the systematic review process for 1,3-butadiene generally followed the *Draft Systematic Review Protocol Supporting TSCA Risk Evaluations for Chemical Substances, Version 1.0: A Generic TSCA Systematic Review Protocol with Chemical-Specific Methodologies* (also called the “Draft Systematic Review Protocol”) ([U.S. EPA, 2021](#)) covering all reasonably available literature published through September 2019. Full details and screening results for all the identified studies are described in the *Systematic Review Protocol for 1,3-Butadiene* ([U.S. EPA, 2025i](#)).

EPA used a refined approach to evaluate human health hazard information relevant to deriving hazard values through a filtering process to target data evaluation/extraction on key studies that may inform dose-response. Results of the filtering process can be found in *Further Filtering Results for Human*

Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene ([U.S. EPA, 2025d](#)). For all other Population Exposure Comparator and Outcome (PECO)-included studies that did not pass the filtering step, basic study-level information was extracted during the filtering process and used to support evidence integration and weight of evidence analysis. The following steps were taken to filter for laboratory animal studies and epidemiological studies:

- Studies were included if they were considered and/or referenced for hazard value derivation in ([U.S. EPA, 2002a](#)) or ([ATSDR, 2012](#)); and
- Additional open literature studies and studies submitted to EPA not previously identified by EPA IRIS or ATSDR were also included if they contained at least two exposure groups plus a control.

For studies that went through data evaluation and extraction, formal extraction results can be found in *Data Extraction Information for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene* ([U.S. EPA, 2025b](#)).

The Agency performed an initial investigation of the hazard identification, critical endpoints, and key scientific issues associated with 1,3-butadiene by reviewing previous assessments. The EPA IRIS Health Assessment of 1,3-Butadiene ([2002a](#)) and ATSDR *Toxicological Profile for 1,3-Butadiene* ([2012](#)) were the key federal government sources for this review. EPA also consulted U.S. state assessments—namely by the Texas Commission on Environmental Quality (TCEQ) ([Grant et al., 2010](#)) and California Office of Environmental Health Assessment ([OEHHA, 2013](#)).

In 2024, prior to completion of the draft assessment, EPA selectively updated the literature pool with studies published after the September 2019 literature cutoff date through manual PubMed keyword searching, reviewing key studies and dose-response analyses provided by stakeholders, and backwards searching of references cited in those stakeholder comments. More specifically, the Agency searched for recent information on 1,3-butadiene hemoglobin adducts and metabolites to inform the modes of action for each health outcome; EPA also incorporated all updates to the original occupational cancer cohort ([Delzell et al., 1996](#)) to support an updated cancer hazard value. Among the studies identified were two updates to the cancer cohort that were used for the cancer dose-response analysis (see Section 5.4.1). There were no animal toxicology studies with apical or other adverse outcome data identified post-2019, and all key studies that informed the weight of evidence were captured within the ([U.S. EPA, 2002a](#)) and/or ([ATSDR, 2012](#)) assessments. Following peer review of the draft risk evaluation in April 2025, EPA reviewed all studies referenced in SACC or public comments to identify any studies that may have been missed. Following this review, three additional epidemiology/mechanistic studies recommended by the SACC panel were screened for PECO relevance and added to the literature pool ([U.S. EPA, 2025i](#)).

As part of this human health risk assessment, EPA incorporated all reasonably available information into the hazard identification, hazard characterization, evidence integration, and weight of evidence analyses.

2.2 Problem Formulation and Focus of Analysis

As mentioned in Section 2.1 above, the Agency used the EPA IRIS Health Assessment of 1,3-Butadiene ([2002a](#)) and ATSDR *Toxicological Profile for 1,3-Butadiene* ([2012](#)) as starting points to inform this human health hazard assessment. Through the systematic review process, EPA did not identify any additional laboratory animal studies examining non-cancer health effects published since the ATSDR assessment ([2012](#)) that would be considered for dose-response analysis. However, EPA did identify new 1,3-butadiene studies relevant for evaluation of MOA toxicokinetic differences across species. Recent non-cancer epidemiological studies were incorporated into the evidence integration for their respective

hazard domains. The Agency began the assessment by focusing on the endpoints and studies considered for deriving hazard values in those assessments.

Ovarian atrophy was the basis of the chronic RfC in the 2002 EPA IRIS Assessment ([U.S. EPA, 2002a](#)). Ovarian atrophy was also cited as the critical chronic endpoint in assessments by TCEQ ([Grant et al., 2010](#)) and California's OEHHA ([OEHHA, 2013](#)). In contrast, ATSDR in 2012 ([ATSDR, 2012](#)) did not derive a chronic-duration inhalation minimal risk level (MRL). Fetal body weight was cited as the primary or co-critical acute endpoint by IRIS, TCEQ, and OEHHA. ATSDR also did not derive an acute MRL.

Each of these four existing assessments acknowledge uncertainty in species extrapolation. For example, ATSDR cited "large species differences in the metabolism of 1,3-butadiene and the lack of chemical-specific data to adjust for these differences" in the decision to not derive any quantitative summary values for the assessment. Therefore, EPA performed a detailed examination of 1,3-butadiene toxicokinetics, mechanisms/MOAs, and quantitative consideration of species differences. The Agency also updated PODs and UFs in accordance with OPPT procedures and EPA guidance (*e.g.*, benchmark dose [BMD] modeling guidance ([U.S. EPA, 2012b](#))) published since the original assessments.

With respect to cancer assessment, a combined IUR for leukemia and bladder cancer was derived in ([U.S. EPA, 2002a](#)) based on an occupational cohort of male workers. Multiple updates to this epidemiological cohort have been published since 2002 that added additional follow-up years, female workers, and refined exposure analyses to the dataset. EPA therefore focused the updated cancer assessment on the evaluation, evidence integration, and weight of scientific evidence of these newer studies. Based on this updated information, the Agency updated IURs for leukemia and bladder cancer relevant to general population and occupational exposures. EPA also developed a mutagenic mode of action analysis for 1,3-butadiene. As for non-cancer PODs, the Agency also considered updates to EPA guidance (*e.g.*, *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)) and *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#))) for quantitative analysis.

Based on the physical and chemical properties of 1,3-butadiene (see *Physical Chemistry and Fate Assessment for 1,3-Butadiene* ([U.S. EPA, 2025g](#))) as well as expected exposure scenarios (see *Occupational Exposure Assessment for 1,3-Butadiene* ([U.S. EPA, 2025c](#)) and *General Population Exposure Assessment for 1,3-Butadiene* ([U.S. EPA, 2025e](#))), EPA only evaluated hazards via the inhalation route. The most appropriate studies and specific endpoints for hazard value derivation relevant to intermediate, chronic, and/or lifetime exposure durations were then selected and points of departure (PODs)/inhalation unit risks (IURs) were derived (cancer values were specific either to the general population or workers).

2.3 Updates Following Peer Review

The *Draft Human Health Hazard Assessment for 1,3-Butadiene* ([U.S. EPA, 2024a](#)) was published in November 2024 and subject to expert peer review by the SACC. This document reflects considerations and updates based on SACC feedback and public comments. Generally, the SACC supported EPA's approach and conclusions; however, some updates were made to align with recommendations. These included combining bladder and leukemia cancer risk, expanding the consideration of acute hazards, and a broader discussion of species metabolic differences and how they may affect the human dose-response for various endpoints. EPA additionally added several clarifications, improved justifications for Agency conclusions, and included discussion of more recent studies recommended by SACC regarding breast cancer.

3 TOXICOKINETICS

This section describes the absorption, distribution, metabolism, and elimination (ADME) data available for 1,3-butadiene. Because the primary route of exposure to 1,3-butadiene is via inhalation, and there are no data on ADME via oral and dermal routes, this section focuses on factors affecting its ADME through inhalation.

3.1 Absorption

As a highly volatile gas at room temperature, 1,3-butadiene is primarily absorbed through inhalation, where it readily diffuses from the lungs into the bloodstream. In both humans and animals, inhalation is recognized as the predominant exposure route ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). The blood:air partition coefficient, which measures the propensity of a chemical to partition into blood from the lungs, provides insight into absorption efficiency. In rodents, the blood:air partition coefficient was determined to be 1.95 ([Kohn and Melnick, 2001](#)). The coefficient in humans has been measured as 1.22 (± 0.30) ([Brochot et al., 2007](#)). Inhalation of 2 ppm 1,3-butadiene for 20 minutes resulted in an absorbed fraction ranging from 18 to 74 percent, with variations observed among demographic populations and potentially influenced by blood triglycerides levels ([Lin et al., 2002](#); [Lin et al., 2001](#)). In *Macaca fascicularis* (monkeys), uptake was calculated as 16.40 $\mu\text{mol}/\text{hour}/10$ ppm of inhaled and 3.20 $\mu\text{mol}/\text{hour}/10$ ppm of retained 1,3-butadiene ([Dahl et al., 1990](#)). Rodent studies have also demonstrated that absorption rates vary depending on the exposure level. In one study, rats and mice exposed to 20 ppm ^{14}C -1,3-butadiene for 6 hours showed relatively low absorption, with only 2.2 and 1.6 percent of the total radioactivity absorbed, respectively ([Swain et al., 2003](#)). In addition, uptake in mice was linear up to 2,000 ppm, and in rats up to 1,000 ppm, indicating that metabolic saturation occurs at higher concentrations ([Kohn and Melnick, 2001](#)). Beyond rodents, studies in rabbits revealed rapid pulmonary absorption, with distribution coefficients between blood and air of 0.603 *in vitro* and 0.654 *in vivo* ([Carpenter et al., 1944](#)).

Absorption has also been confirmed by studies measuring various 1,3-butadiene metabolites. For example, 3,4-epoxy-1-butene or epoxybutane (EB), was detected in exhaled air and blood after exposure to 1 to 10,000 ppm in rats and 1 to 6,000 ppm in mice ([Filser et al., 2007](#)). In rats, EB levels in the test chamber plateaued at all exposure concentrations, while in mice, EB levels plateaued only up to 1,000 ppm, indicating potential species differences in metabolism (see Section 3.3). Additional studies detected metabolites in the blood and tissues of rats and mice exposed to 62.5 ppm of 1,3-butadiene, further confirming absorption ([Thornton-Manning et al., 1995](#)). Furthermore, variations in study protocols and limited data across exposure levels create some uncertainty in directly comparing absorption rates across species. Based on the limited available information quantifying absorption across varying exposure levels and longer durations, EPA assumes 100 percent absorption through the lungs in this risk evaluation.

3.2 Distribution

The distribution of 1,3-butadiene following inhalation exposure has been studied in various species. Due to its lipophilic nature, 1,3-butadiene is absorbed through the lungs into the bloodstream and rapidly distributed throughout the body, with notable accumulation in adipose tissue ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Consistent with this, physiologically based pharmacokinetic (PBPK) studies show that adipose tissue exhibits the highest partition coefficient in humans, whereas well- and poorly-perfused tissues show similar coefficients (0.69 and 0.72, respectively) ([Brochot et al., 2007](#)). Similarly, PBPK studies in rats demonstrate the highest partition coefficient from blood in adipose (21.9) followed by a decreasing trend in liver, kidney, muscle, and spleen (0.87–0.94 and the lowest in the brain (0.43) ([Johanson and Filser, 1993](#)). *In vivo* studies confirm these observations. Specifically, mice and rats exposed to up to

625 ppm of 1,3-butadiene attained equilibrium within 2 hours, with mice showing three- to four-fold increased blood concentrations of 1,3-butadiene compared to rats at all times—potentially due to interspecies differences in metabolism rates and respiratory physiology ([Himmelstein et al., 1994](#)). Additionally, species-specific differences in the distribution of inhaled 1,3-butadiene were also observed. Studies comparing Sprague-Dawley rats and B6C3F1 mice found significantly higher molar tissue concentrations of ^{14}C -1,3-butadiene in mice, with up to 80-fold higher levels in the lung and 17-fold higher levels in the thyroid. Blood concentrations were also considerably higher in mice (57-fold) compared to rats, and intestinal radioactivity was 110- to 120-fold higher in mice ([Bond et al., 1987](#); [Bond et al., 1986](#)). In human volunteers exposed to low levels (2 ppm) of 1,3-butadiene through inhalation, blood concentrations reached equilibrium within 5 minutes, demonstrating rapid absorption and distribution in humans ([Smith et al., 2001](#)).

3.3 Metabolism (Including Species Differences)

1,3-Butadiene undergoes a complex metabolic process involving oxidation, hydrolysis, and conjugation reactions—ultimately generating reactive epoxides with varying toxicological effects ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Initially, 1,3-butadiene is oxidized to 3,4-epoxy-1-butene (EB), primarily mediated by the cytochrome P450 (CYP) isozyme CYP2E1 (see Figure 3-1 below). EB undergoes further oxidation to produce 1,2,3,4-diepoxybutane (DEB). Concurrently, 1,3-butadiene is detoxified through conjugation with glutathione, facilitated by glutathione S-transferase (GST), and hydrolysis mediated by epoxide hydrolase (EH), resulting in 1,2-dihydroxy-3-butene (B-diol). These metabolites undergo further transformations. Specifically, DEB is hydrolyzed by epoxide hydrolase (EH) to 1,2-dihydroxy-3,4-epoxybutane (EBD), while B-diol is metabolized by alcohol dehydrogenase (ADH) and CYP2E1 to form hydroxymethylvinylketone (HMVK) ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Although the metabolic pathways of 1,3-butadiene are similar across species, including in humans, significant quantitative differences exist in how these metabolites are formed and detoxified ([Kirman et al., 2010b](#)). Quantitative species difference in 1,3-butadiene metabolism are substantial, driven by higher P450-mediated bioactivation in mice vs. rats and humans. *In vitro* intrinsic clearance (V_{max}/km) for the cytochrome-mediated oxidation of EB to DEB is 15, 11, and $8\ \mu\text{L}\ \text{mg}^{-1}\ \text{min}^{-1}$ in mouse, rat and human liver microsomes, respectively, whereas detoxification via epoxide hydrolase mediated hydrolysis of EB to butanediol is 5, 3, and $16\ \mu\text{L}\ \text{mg}^{-1}\ \text{min}^{-1}$, respectively ([Kreuzer et al., 1991](#); [Csanady et al., 1992](#)). These kinetic differences underlie the greater than 100-fold higher DEB derived hemoglobin adducts observed in mice compared to humans at equivalent exposures ([Swenberg et al., 2007](#)).




Figure 3-1. Schematic of 1,3-Butadiene Metabolism

ADH = alcohol dehydrogenase; B-diol = butenediol; bis BDMA = bis-butanediol-mercapturic acid; DEB = diepoxybutane; EB = epoxybutane; EBD = epoxybutane diol; EH = epoxide hydrolase; GSH = glutathione; GST = glutathione-S transferase; HBVal = N-(2-hydroxy-3-butenyl)valine; HMVK = hydroxymethylvinyl ketone; DHBMA = 1,2-dihydroxy-4-(N-acetylcysteinyl)-butane; MHBMA = 1-(N-acetylcysteinyl)-2-hydroxy-3-butene; P450 = cytochrome P450; pyrVal = N,N-(2,3-dihydroxy-1,4-butadiyl)-valine; THBMA = 1,2,3-trihydroxy-4-(N-acetylcysteinyl)-butane; THBVal = N (2,3,4 trihydroxybutyl)-valine.

Source: Kirman et al (2022), obtained under a Creative Commons license.

In vitro studies demonstrate the significance of these quantitative differences, revealing variations in metabolic rates across species (ATSDR, 2012; U.S. EPA, 2002a). Studies using microsomal and cytosolic preparations from the livers of mice, rats, and humans indicated that mice exhibit the highest rate of 1,3-butadiene oxidation to EB, with a Vmax of 2.6 nmol/mg protein/minute, compared to 1.2 in humans and 0.6 in rats (Csanady et al., 1992). Notably, only mouse liver microsomes demonstrated a quantifiable rate of EB metabolism to DEB. In contrast, human liver microsomes showed the highest rate of EB hydrolysis to B-diol via epoxide hydrolase, with Vmax values at least twice those measured for rats and mice (Csanady et al., 1992). Additionally, the rate of EB glutathione conjugation was found to be highest in mouse cytosol. The overall activation/ detoxification ratios determined from these experiments were significantly higher in mice (72) compared to rats (5.8) and humans (5.9), underscoring the interspecies differences in 1,3-butadiene oxidation to DEB (Csanady et al., 1992). Further studies using liver homogenates from various species revealed that mice formed the most EB from 1,3-butadiene compared to rats, humans, and rhesus monkeys (Schmidt and Loeser, 1986). Additionally, epoxide hydrolase activity was higher in humans and monkeys compared to both rodent species (Schmidt and Loeser, 1986). Human cytochrome P450 (CYP) 2E1, expressed from complementary DNA, was efficient in metabolizing EB to DEB (Krause et al., 1997), though with considerable variability (approximately 60-fold) across human samples. In studies using rodent

microsomes and c-DNA CYP isozymes, the enzyme efficiency (defined as V_{max}/K_m) for metabolism of EB to DEB was 15 in mice, 11 in rats, and 8 in humans ([Kreuzer et al., 1991](#)). Motwani et al. (2014) also observed higher enzymatic efficiency *in vitro* for the oxidative steps of EB to DEB and B-diol to EBD in mice compared to rats or humans. Furthermore, they noted that the hydrolysis of DEB to EBD was substantially faster than the oxidation of B-diol for all species, being 2.5-, 11-, and 25-fold faster than formation of EBD from B-diol in mice, rats, and humans, respectively. More recently, *in vitro* studies have identified additional bifunctional metabolites of 1,3-butadiene. These include a chlorinated metabolite formed via myeloperoxidase and hypochlorous acid as well as ketone/aldehyde metabolites of EBD formed via alcohol dehydrogenase ([Nakamura et al., 2021](#); [Wu et al., 2019](#); [Wang et al., 2018](#); [Elfarrar and Zhang, 2012](#)). Importantly, a recent study ([Nakamura et al., 2021](#)) demonstrated that EBD damages DNA and exhibits toxicity to cells lacking Fanconi anemia (FANC) genes. This latter cytotoxic effect, similar to the more potent DEB, suggests that EBD likely forms bifunctional DNA interstrand cross-links upon metabolic activation by ADH, thus contributing to its potential role in leukemia and lymphoma development. Collectively, *in vitro* studies reveal that mice exhibit greater metabolic efficiency in oxidizing 1,3-butadiene to EB and from EB to DEB, compared to both rats and humans.

These *in vitro* findings further support observations in *ex vivo* and *in vivo* studies in mice and rats that consistently demonstrate greater metabolic efficiency in mice than in rats. For instance, isolated perfused liver studies showed that following 1,3-butadiene exposure, mouse livers produced EB, DEB, EBD, and B-diol, while rat livers primarily produced EB and B-diol ([Filser et al., 2010](#); [Filser et al., 2001](#)). The lower levels of DEB in rats compared to mice suggest species-specific differences in the formation of DEB. Several animal studies have confirmed this trend, with DEB detected in the blood of exposed mice but not rats ([Filser et al., 2007](#); [Himmelstein et al., 1994](#)). Similarly, hemoglobin adducts related to DEB exposure (pyr-Val) were substantially higher in mice than rats at equivalent 1,3-butadiene exposure concentration ([Svenberg et al., 2011](#); [Georgieva et al., 2010](#)). In contrast, primates appear to metabolize 1,3-butadiene more similarly to rats than mice ([Henderson et al., 2001](#); [Henderson et al., 1996](#); [Dahl et al., 1991](#)). Dal et al ([Dahl et al., 1991](#)) demonstrated that total 1,3-butadiene metabolites in the blood of monkeys were 5 to 50 times lower than in mice and 4 to 14 times lower compared to rats. Furthermore, primates demonstrate significantly higher epoxide hydrolase activity compared to rodents. This increased enzyme activity results in the rapid conversion of EB to B-diol. This point is evident from the higher levels of the B-diol-derived metabolite M-I in primate urine ([Sabourin et al., 1992](#)).

Findings from animal models, supported by studies of hemoglobin (Hb) adducts in workers exposed to 1,3-butadiene, provide valuable evidence for human 1,3-butadiene metabolism. Hb adducts were identified in workers occupationally exposed to 1,3-butadiene at monomer production and polymerization facilities in the Czech Republic using liquid chromatography-mass spectrometry (LC-MS) ([Boysen et al., 2022](#); [Boysen et al., 2012](#); [Vacek et al., 2010](#); [Albertini et al., 2007](#); [Albertini et al., 2003](#)). Exposure concentrations were measured on 10 occasions over a 2- to 4-month period using personal monitoring devices worn for an 8-hour work shift. Boysen et al. (2012) specifically measured the concentrations of certain Hb adducts (HB-Val, pyr-Val, and THB-Val) in male workers, including administrative controls, monomer workers, and polymerization workers. Interestingly, Hb adducts were also detected in control workers, likely due to background exposure to acrolein from cigarette smoke or vehicle exhaust ([ATSDR, 2012](#); [Albertini et al., 2003](#)). The amount of the DEB adducts (pyr-Val) increased with higher 1,3-butadiene exposure levels in polymerization workers compared to controls and monomer workers. Also, pyr-Val adduct levels exhibited high variability in male workers, and no clear exposure-response relationship was observed ([Boysen et al., 2012](#)). Notably, THB-Val, linked to EBD exposure, was the dominant adduct in all worker groups (>99%), highlighting EBD as a primary 1,3-butadiene metabolite in humans. While THB-Val may also form as a direct adduct of DEB, metabolism

data suggest that DEB hydrolysis to yield EBD occurs rapidly in humans via epoxide hydrolase ([Motwani and Törnqvist, 2014](#)). This extensive EB hydrolysis is further supported by the finding that in humans, greater than 97 percent of urinary mercapturic acid formed after 1,3-butadiene inhalation is DHBMA, indicating that most EB is hydrolyzed via EH rather than forming the diepoxide ([Henderson et al., 1996](#)). The low levels of DEB-specific hemoglobin adduct observed in exposed workers and the significantly higher levels of EBD-specific hemoglobin adducts, suggest high epoxide hydrolase activity in humans. Biomarker studies further demonstrate substantial inter-individual differences in 1,3-butadiene metabolism. Female workers exhibit 3 to 5 times lower DEB derived hemoglobin adducts per ppm 1,3-butadiene than males ([Boysen et al., 2012](#); [Vacek et al., 2010](#)).

Variability among subpopulations are also evident in urinary mercapturic acid metabolites of 1,3-butadiene; however, these differences are decreased substantially in individuals who possess a null variant of glutathione S-transferase theta 1 (GSTT1) gene, indicating that GSTT1 polymorphism significantly influences 1,3-butadiene metabolism ([Park et al., 2014](#)). Active smokers excrete approximately 8-fold higher levels of MHBMA than non-smokers (31.5 vs. 41.1 µg/g creatinine) ([Nieto et al., 2021](#)). Furthermore, carriers of specific P450 2E1 or epoxide hydrolase 1 polymorphism display Hb adduct concentrations approximately 2-fold higher than individuals with reference genotype, indicating a substantial genetic modulation of adduct formation. When considered in conjunction with GSTT1 genotype, these polymorphisms account for the majority of remaining variability in 1,3-butadiene metabolism ([Motwani and Törnqvist, 2014](#)). Additionally, the variability in Hb adduct data among humans and how to interpret the measurements makes it difficult to use adduct results for directly quantifying exposure and metabolism differences between humans and other species.

Although Hb adduct data confirm metabolic activation of 1,3-butadiene in humans, several limitations restrict their use in quantitative risk assessment. These include the high variability and weak correlation with exposure observed for Pyr-Val adduct levels ([Boysen et al., 2022](#); [Boysen et al., 2012](#)), limiting their utility for dose-response analysis. Furthermore, background adducts are consistently detected in unexposed individuals, mainly from sources like cigarette smoke and vehicle exhaust, though no general background level has been established ([Albertini et al., 2003](#)). Additionally, the available human data on hemoglobin adducts were derived from a narrow cohort of Czech workers, limiting generalizability. Sex-based differences were also evident; for example, female workers had THB-Val adducts levels similar to those in controls, even when occupationally exposed ([Vacek et al., 2010](#)). These factors collectively limit the confidence in using human Hb adducts to inform interspecies extrapolation or in quantitative risk assessment.

In addition to Hb adducts, DNA adducts resulting from 1,3-butadiene metabolism have been identified in both animal models and occupationally exposed humans. Various types of DNA adduct have been identified including monoadducts and DNA-DNA cross-links formed by epoxide metabolites, with mice generally forming higher levels of these adducts than rats or humans at similar exposure concentrations. In humans, the N-1-(2,3,4-trihydroxybutyl)adenine (N-1-THB-Ade) adduct has been reported at higher levels in the lymphocytes of exposed workers compared to controls ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). However, the use of DNA adducts as quantitative biomarkers for animal-to-human extrapolation is significantly limited due to high inter-individual metabolic variability, limited human data, and uncertainties in directly linking DNA adduct burden to internal dose or health outcomes. A recent study by Erber et al. ([2021](#)) further demonstrated this variability by reporting that urinary DNA adducts vary by less than x in mice but more than 10x in humans.

Overall, studies across various models, including *in vitro*, *ex vivo*, animal and human demonstrate significant interspecies differences in 1,3-butadiene metabolism. Although the metabolic pathways of

1,3-butadiene are similar across species, there are significant quantitative differences in the formation and detoxification of these metabolites. Mice exhibit a greater capacity for oxidizing 1,3-butadiene to its more reactive epoxide forms, EB and DEB, compared to rats and humans. DEB has been identified as the primary metabolite in mice, whereas EBD is the predominant metabolite observed in humans. Rats, by contrast, metabolize 1,3-butadiene at lower overall levels. Furthermore, recent studies have identified novel 1,3-butadiene metabolites, such as chlorinated and ketone/aldehyde bifunctional metabolites, but whose role in species-specific differences and potential health effects remains to be evaluated. Despite the unique effect of DEB on ovarian atrophy in mice, there is currently insufficient evidence to attribute specific health outcomes directly to any individual 1,3-butadiene metabolites.

3.4 Elimination

The main route of elimination of 1,3-butadiene and its metabolites in rodents and primates is through exhalation and urinary excretion, with minor biliary excretion also observed ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Studies in rats, mice, and monkeys have quantified the routes and amounts of excretion following inhalation. In rodents, exhalation and urinary excretion are the primary routes of elimination, with similar elimination patterns observed across different exposure concentrations and species ([Bond et al., 1986](#)). Rapid elimination of radioactivity was observed in mice and rats following exposure to ^{14}C -1,3-butadiene, with 77 to 99 percent of the initial tissue amount cleared within 2 to 10 hours ([Bond et al., 1987](#)). Elimination kinetics in both blood and tissues were biphasic, exhibiting rapid initial clearance followed by a slower elimination phase ([Bond et al., 1986](#)). In addition, exhalation of radiolabeled carbon was a major pathway for the elimination of ^{14}C -1,3-butadiene in mice and rats, particularly at higher concentrations ([Bond et al., 1986](#)). This result was further corroborated by a substantial decrease in blood 1,3-butadiene concentration within minutes after a 6-hour inhalation exposure, although the rate of decline was slower in rats compared to mice ([Himmelstein et al., 1996](#)). Similar to rodents, nonhuman primates also exhibit efficient elimination of 1,3-butadiene. Studies in *Cynomolgus* monkeys showed that approximately 2 percent of inhaled 1,3-butadiene was excreted as metabolites, regardless of exposure concentration. The composition of these metabolites exhibited dose-dependent variation, with carbon dioxide being predominantly exhaled at lower concentration and epoxy metabolites become more prominent at higher exposure levels ([Sun et al., 1989](#)). In a separate study with *Macaca fascicularis* monkeys exposed to low concentration (10 ppm) of 1,3-butadiene, 39 percent of the total metabolite radioactivity was eliminated in urine, 0.8 percent in feces, and 56 percent as exhaled carbon dioxide within 70 hours post-exposure ([Dahl et al., 1990](#)). In humans, the primary urinary metabolite of 1,3-butadiene is dihydroxybutenylmercapturic acid (DHBMA), accounting for over 97 percent of the excreted mercapturic acids ([ATSDR, 2012](#); [Henderson et al., 1996](#)). A minor pathway involving glutathione-S-transferase (GST) conjugation also contributes to the formation of MHBMA.

The relative abundance of MHBMA and DHBMA in urine has been established as a biomarker of exposure in both environmental and occupational monitoring of 1,3-butadiene ([ATSDR, 2012](#)). Studies have revealed sex-based differences in 1,3-butadiene metabolism, with women excreting lower levels of both DHBMA and MHBMA compared to men following 1,3-butadiene exposure ([Albertini et al., 2007](#)). However, the ratio of DHBMA to MHBMA remains consistent between the sexes, suggesting a difference in metabolic activity rather than a shift in the metabolic pathway.

3.5 PBPK Modeling Approach

Although several PBPK models have been developed to simulate the 1,3-butadiene kinetics in mice, rats, and humans, current models remain limited in reliably predicting internal doses of all the key metabolites for quantitative risk assessment across species ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). A useful model must be able to accurately estimate and extrapolate equivalent internal doses across routes and species at greater confidence than existing approaches in accordance with Agency guidance to be

considered for use in risk assessment. For example, the hazard assessment by ([OEHHA, 2013](#)) reviewed existing PBPK models, but most only contained rodent parameters, and the only dosimetric adjustment used was based on relative blood:air coefficient, which is addressed by existing EPA approaches aligned with guidance (Section 4.2.2.1). As discussed in Section 3.3, major uncertainties persist in the quantitative understanding of metabolism across species, including the incomplete understating of alternative oxidation and detoxification pathways, limited validation of *in vitro*-to-*in vivo* metabolic extrapolations, insufficient treatment of intrahepatic first-pass and regional lung metabolism, and uncertainty in the kinetics of newly identified metabolites such as chlorinated and ketone/aldehyde bifunctional metabolites ([Nakamura et al., 2021](#); [Wu et al., 2019](#); [Wang et al., 2018](#); [Elfarra and Zhang, 2012](#)). These uncertainties would also impact confidence in selection of the appropriate dose metric for a given target organ/endpoint and exposure scenario.

These significant and unresolved uncertainties render existing PBPK models unsuitable for quantitative human health risk assessment of 1,3-butadiene.

4 NON-CANCER HAZARD ASSESSMENT

4.1 Hazard Identification

The sections below describe adverse outcome and mechanistic data available, evidence integration, and weight of scientific evidence conclusions for relevant human health hazard outcomes for 1,3-butadiene. Full details on all evaluated health outcomes from all key studies are in *Data Extraction Information for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene* ([U.S. EPA, 2025b](#)). Additional hazard information supporting evidence integration is presented in *Further Filtering Results for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene* ([U.S. EPA, 2025d](#)).

For complete details on evidence integration judgments within and across evidence streams, see the evidence profile tables for data-rich organ systems in Appendix A. Evidence integration judgments were determined based on considerations described in Chapter 7 of the *Draft Systematic Review Protocol Supporting TSCA Risk Evaluations for Chemical Substances* ([U.S. EPA, 2021](#)). In short, strength of the evidence judgments (robust, moderate, slight, indeterminate, or compelling evidence of no effect) for individual evidence streams (*i.e.*, human, animal, mechanistic) were determined by expert judgment based on quality of the database, consistency, magnitude and precision, dose-response, and biological significance. These were then integrated into an overall summary classification (see Appendix A for overall judgment classifications).

As described in Section 2, EPA used previous governmental assessments as the starting point for focusing hazard identification efforts. EPA used results from systematic review, existing analyses, and additional metabolite/analog studies to independently evaluate the weight of scientific evidence for each hazard outcome. Hazard outcomes with sufficient confidence and quantitative study data then underwent dose-response analysis (Section 4.2).

This section begins with an evaluation of ovarian atrophy in Section 4.1.1 as this was the critical chronic endpoint in the prior assessments by EPA IRIS ([2002a](#)) TCEQ ([Grant et al., 2010](#)) and California OEHHA ([OEHHA, 2013](#)). EPA has proposed a mode of action for ovarian atrophy in accordance with the IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans ([Boobis et al., 2008](#)). The Agency then performed evidence integration and considers the weight of scientific evidence based on human, animal, and mechanistic data for other critical hazard outcomes described in Section 4.1.2. These critical hazard outcomes are the following: developmental and maternal and toxicity from exposure during gestation, male reproductive system and resulting developmental toxicity, and hematological and immune effects. Other hazard outcomes with more limited evidence are in Appendix C. As discussed in Section 2.2, toxicokinetic species differences—especially relative rates of metabolism and the significance of individual metabolites—were an important consideration in the evaluation of all hazard outcomes.

4.1.1 Ovarian Atrophy and Associated Female Reproductive System Toxicity

As mentioned in Section 2.2, ovarian atrophy based on observations in mice was the basis of the chronic RfC and the most sensitive endpoint in the 2002 EPA IRIS Assessment ([U.S. EPA, 2002a](#)). It was also cited as the critical chronic endpoint in assessments by TCEQ ([2010](#)) and California OEHHA ([2013](#)). There has been extensive scientific discussion concerning the relevance of mouse data for this endpoint to humans in both these assessments and other publications. The sections below outline the reasonably available evidence, proposed MOA, and overall conclusions for the endpoint.

4.1.1.1 Human Evidence

EPA did not identify any human studies that examined the female reproductive system or any measurements related to ovarian atrophy.

4.1.1.2 Laboratory Animal Evidence

Toxicity of 1,3-butadiene to female reproductive organs, especially the ovaries, has been examined in multiple studies covering a wide range of durations and doses. No histopathological changes were observed in a 5-day study where mice were exposed to 1,3-butadiene at 0, 625, 1,250, 2,500, 5,000 or 8,000 ppm ([NTP, 1984](#)). However, this examination was rated as uninformative due to reliability questions about the associated contract laboratory and the result is not given any consideration in the weight of scientific evidence. Ovarian atrophy was observed in mice following 13 weeks of exposure to 1,3-butadiene at 980 ppm (no other doses tested) for 5 hours/day, 5 days/week ([Bevan et al., 1996](#)), and in multiple studies following 40 weeks to 2 years of exposure ([NTP, 1993, 1984](#); [Battelle PNL, 1982](#)). Ovarian atrophy was observed at all doses in a 2-year mouse study performed in accordance with Good Laboratory Practice (GLP) with concentrations of 6.21, 19.8, 61.4, 199, and 619 ppm ([NTP, 1993](#)). Thirty-nine percent of mice demonstrated atrophy at the lowest concentration following 2 years of exposure, while statistically significant increases to 90 percent of mice were observed at 62.5 ppm for 15 months and 200 ppm for 9 months of exposure, respectively. Ovarian toxicity was accompanied in these studies by an absence of oocytes, follicles, and corpora lutea, along with angiectasis and uterine involution.

In contrast to mice, no signs of ovarian atrophy or other toxicity to female reproductive organs were observed in a chronic rat study following up to 2 years of 1,000 or 8,000 ppm exposure ([Hazleton Labs, 1981b](#)).

4.1.1.3 Mechanistic Evidence and Mode of Action Analysis

Given the extensive discussion about the human relevance in previous authoritative assessments, EPA evaluated the MOA for ovarian toxicity and how it may inform the human relevance of the mouse-specific observations. Kirman et al ([2012](#)) suggested an MOA for ovarian toxicity to support a proposed data-derived UF for extrapolation of the mouse data to humans. EPA below proposes a modified MOA from that of Kirman et al. based on consideration of all reasonably available mechanistic and toxicokinetic evidence.

The proposed key events are

- KE1: Bioactivation of 1,3-butadiene to DEB and other epoxide metabolites.
- KE2: Distribution of metabolites into ovarian tissue.
- KE3: Destruction of ovarian follicles via apoptosis.
- KE4: Premature ovarian failure and atrophy.

Figure 4-1 presents the proposed MOA for ovarian toxicity, including a summary of available evidence for each step and underlying mechanisms.




Figure 4-1. Proposed MOA for Ovarian Toxicity and Associated Mechanisms

Red boxes represent potential mechanisms for metabolite-induced destruction of ovarian follicles.

4.1.1.3.1 Key Event 1: Bioactivation of 1,3-Butadiene to DEB and Other Epoxide Metabolites

The metabolism of 1,3-butadiene is described in detail in Section 3.3. In short, 1,3-butadiene is oxidized to the mono-epoxide EB which is then either detoxified into the alcohol B-diol or further oxidized to the di-epoxide DEB. B-diol can then be subsequently oxidized to EBD. Oxidative metabolism is much more active in mice compared to rats or humans ([Motwani and Törnqvist, 2014](#)) and mice appear to have greater metabolic efficiency overall as perfused mouse livers produce all the aforementioned metabolites while rats primarily produce only EB and B-diol ([Filser et al., 2010](#); [Filser et al., 2001](#)). Consistent with these data, blood DEB levels are estimated to be 40 to 100 times higher in mice compared to rats and 100 to 300 times or more higher in mice compared to humans ([Motwani and Törnqvist, 2014](#); [ATSDR, 2012](#); [Csanády et al., 2011](#); [Swenberg et al., 2011](#); [Georgieva et al., 2010](#)) for the same administered dose of 1,3-butadiene.

A key study for understanding the impact of different metabolites and species sensitivity is Doerr et al., (1996), which exposed mice and rats intraperitoneally for 30 days to either the mono-epoxide EB or di-epoxide DEB. While the EB induced ovotoxicity in mice (but not rats), the DEB caused effects in both (in contrast to parental 1,3-butadiene), with a much stronger effect in mice. A similar response is seen with the 1,3-butadiene analog 4-vinylcyclohexene (VCH). Similar to 1,3-butadiene, vinylcyclohexene can be metabolized into either a mono- or di-epoxide form. As with 1,3-butadiene, VCH induces ovarian atrophy only in mice but not rats. In a study mirroring the design of Doerr and colleagues, the di-epoxide form (4-vinylcyclohexene dioxide [VCD]) was 2 to 3 times more potent at inducing follicle loss than the mono-epoxide form, and both epoxides were 2 to 3 times more active in mice compared to rats when directly administered ([Hoyer and Sipes, 2007](#)). The results from these two studies demonstrate that mice are not only toxicokinetically more sensitive from producing more epoxide metabolites, they are also more toxicodynamically sensitive than rats to the same metabolite exposure.

4.1.1.3.2 Key Event 2: Distribution of Metabolites into Ovarian Tissue

Distribution of the toxic metabolites to the ovary is assumed based on the observed ovarian toxicity. DEB has been measured in the ovary of both mice and rats, with over an order of magnitude higher concentration observed in mice ([Thornton-Manning et al., 1997](#)). Both EB and DEB have been detected in the ovary of rats, though DEB concentrations range from 200 to 400 times more than EB ([Thornton-Manning et al., 1998](#)).

4.1.1.3.3 Key Event 3: Destruction of Ovarian Follicles via Apoptosis

Follicle depletion appears to be a key event in ovarian atrophy resulting from exposure to the 1,3-butadiene analog VCH and DEB analog VCD, which destroys primary and primordial follicles ([Hoyer and Sipes, 2007](#)). However, the mechanism for how 1,3-butadiene metabolites lead to follicle depletion is unclear. Mechanistic evidence suggests that the di-epoxide form VCD inhibits the c-kit signaling pro-survival pathway in oocytes ([Kappeler and Hoyer, 2012](#)), leading to induction of apoptosis in follicles ([Hu et al., 2001](#)).

The vinylcyclohexene mechanism of c-kit-mediated induction of apoptosis plausibly applies to DEB-induced ovotoxicity; DEB induces apoptosis in lymphocytes ([Yadavilli and Muganda, 2004](#)). However, the available mechanistic evidence is all indirect and there is no direct, quantifiable data demonstrating DEB-induced apoptosis in primordial ovarian follicles. In a potential alternative mechanism, DEB has been shown to induce chromosome aberrations in oocytes ([Tiveron et al., 1997](#)).

4.1.1.3.4 Key Event 4: Premature Ovarian Failure and Atrophy

Multiple mechanisms may contribute to the progression of follicle destruction to premature ovarian failure. As the ovary loses follicles, its ability to produce essential hormone, like estrogen, is compromised, ultimately leading to ovarian dysfunction ([Torrealday et al., 2017](#)). Data on VCH demonstrates that destruction of small ovarian follicles leads to subsequent increase in serum follicle stimulating hormone and loss of estrous cycling ([Hoyer and Sipes, 2007](#)), suggesting the connection between follicle loss, hormonal imbalance, and ovarian failure. The observed ovarian damage may in fact be caused by a combination of DNA damage, oxidative stress, and inflammation ([Liu et al., 2015](#); [Hoyer and Sipes, 2007](#)), ultimately leading to atrophy.

While ovarian atrophy is the apical endpoint and the final key event in the mode of action, it may not represent an actual adverse outcome. The downstream outcome of ovarian atrophy is premature menopause due to follicle loss, with uncertain effects on fertility. Although ovarian atrophy was observed with histological examination, there is no evidence of reduced fertility from 1,3-butadiene exposure in humans or laboratory animals (see 4.1.2.1). As suggested by the VCH data, follicular damage may also lead to hormonal imbalance that would have additional detrimental health effects, however the actual impact is uncertain.

4.1.1.3.5 Uncertainties

Bioactivation of 1,3-butadiene to epoxide metabolites is a critical component in the proposed MOA based on the large differences in metabolism across species, although the quantification of individual metabolites is indirect and variable. Although multiple lines of evidence indicate lower levels of epoxide metabolites in rats and humans compared to mice (*e.g.*, relative rates of activating oxidation vs detoxification, see Section 3.3), the absolute measurements of metabolites are indirect based on Hb adducts and the human data demonstrate high variability across sexes, exposure levels, and studies ([Boysen et al., 2022](#); [Boysen et al., 2012](#); [Vacek et al., 2010](#); [Albertini et al., 2007](#); [Albertini et al., 2003](#)).

Mice appear to be both toxicokinetically and more toxicodynamically sensitive to ovotoxicity (see evidence for Key event 1 above in Section 4.1.1.3.1). The Kirman et al. ([2012](#)) MOA proposes that only DEB is responsible for ovarian toxicity. While mechanistic studies on 1,3-butadiene metabolites and the VCH analog clearly demonstrate that DEB is more potent than EB, they do not indicate that DEB alone is ovotoxic. The presence of both metabolites in rat ovaries and evidence of some toxicity from mono-epoxides suggests that the induction of ovotoxicity may be based on relative epoxide dose delivered to the ovary (of which mice would have more of across all metabolites) rather than a specific metabolite, while later key events may contribute to the increased toxicodynamic sensitivity.

The underlying mechanisms for the destruction of ovarian follicles via apoptosis (Key event 3) are also uncertain. EPA has identified plausible mechanisms for this key event based on the molecular interactions of DEB; however, this evidence is only indirect. Additionally, it is unclear if follicular apoptosis (Key event 3) is a required event upstream of ovarian failure (Key event 4), though they are both likely connected to hormonal dysregulation. Overall, this complexity makes it harder to pinpoint a single, precise mechanism or define a specific order of required key events.

4.1.1.3.6 Conclusions for Proposed MOA

EPA has preliminarily concluded that the evidence is sufficient to conclude that the proposed MOA is operational in rodents and that mice are particularly sensitive.

- Exposure to 1,3-butadiene results in ovarian atrophy and other associated reproductive toxicity in mice (Section 4.1.1.2).

- 1,3-Butadiene is oxidized into bioactive epoxide metabolites—especially DEB—that appear to be responsible for the ovarian toxicity (Sections 4.1.1.3.1 and 4.1.1.3.3).
- Mice appear to be uniquely sensitive to 1,3-butadiene-induced ovarian toxicity, both due to increased oxidative metabolism resulting in much greater DEB levels as well as increased toxicodynamic sensitivity (Section 4.1.1.3.1).
- Inhibition of the c-kit pro survival signaling pathway and/or cytogenetic damage represent potential mechanisms leading to ovarian follicle destruction (Section 4.1.1.3.3).

4.1.1.3.7 Applicability of Ovarian Atrophy to Human Health Risk Assessment

EPA applied the IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans ([Boobis et al., 2008](#)) in considering how to interpret the human relevance of ovarian toxicity. In building off a set of papers establishing the MOA framework and how it can inform human relevance ([Seed et al., 2005](#); [Meek et al., 2003](#); [Sonich-Mullin et al., 2001](#); [U.S. EPA, 1999](#)), the framework poses a series of questions to help organize decision-making into a step-wise process “to determine whether to apply the default assumption that all effects seen in animals are relevant to humans.”

1. Is the weight of scientific evidence sufficient to establish an MOA in animals?

Yes. Although there are several uncertainties as to the specific mechanisms, including whether DEB alone or epoxides generally are required, and whether ovarian atrophy represents or leads to an adverse reproductive outcome, the general steps and key events as described above are supported. The proposed key events are sufficiently supported by the evidence to support an MOA for ovarian toxicity in mice.

2. Can human relevance of the MOA be reasonably excluded on the basis of fundamental, qualitative differences in key events between experimental animals and humans?

No. Metabolism pathways are qualitatively the same across species and DEB does form in humans (Section 3.3). Further, mono-epoxides can induce ovarian atrophy ([Hoyer and Sipes, 2007](#); [Doerr et al., 1996](#)) and humans produce substantial amounts of the mono-epoxide EBD, though there are no studies examining EBD in relation to ovarian toxicity. Additionally, the c-kit receptor and kit ligand have been detected in human ovaries ([Tuck et al., 2015](#)), indicating that this potential mechanism supporting Key event 3 may function similarly in humans.

3. Can human relevance of the MOA be reasonably excluded on the basis of quantitative differences in key events between experimental animals and humans?

No. Ovarian atrophy is observed in mice in a dose- and duration-responsive manner in multiple studies, including all medium- and high-quality studies. As discussed above, strong evidence indicates that mice are both toxicokinetically and toxicodynamically more sensitive than rats, and that humans may be even less toxicokinetically sensitive than rats based on estimates of relative DEB levels. DEB rapidly hydrolyzes to yield EBD occurs rapidly in humans via epoxidase hydrolase ([Motwani and Törnqvist, 2014](#)). Therefore, any DEB-mediated mode of action for ovarian atrophy in humans would likely require orders of magnitude higher exposure to 1,3-butadiene to produce a comparable level of ovotoxicity, albeit the relative quantification of metabolites involves several uncertainties. While the evidence indicates that mice are likely more sensitive to ovarian toxicity both kinetically and dynamically, much of this evidence is based on an analog that overall has uncertain toxicological similarity to 1,3-butadiene and it is difficult to precisely quantify metabolite levels in humans (Section 3.3). Because ovarian atrophy is the final key event and not necessarily an adverse outcome itself, the impact of any downstream reproductive effects on humans is unclear. Moreover, potentially increased oxidative metabolism in certain subpopulations may lead to greater production of bioactive metabolites, suggesting for potential for increased susceptibility (Table 7-1). Additionally, the MOA framework states that “since quantitative exposure assessment is part of the subsequent risk characterization...the

difference would have to be of such a magnitude that human exposure could not possibly be envisaged to reach such levels.” Ovarian toxicity cannot be explicitly ruled out for humans. However, the framework does recommend bringing forward any quantitative differences into the dose-response analysis, and EPA concludes that there is very low confidence in the direct applicability of the hazard values from mice studies to human exposures. The Agency considered whether these issues could be accounted for as part of the dose-response analysis, which leads to the fourth question of the framework.

4. Are there any quantitative differences in the key events such that default values for uncertainty factors for species or individual differences could be modified?

Yes, but the appropriate adjustment cannot be determined. As stated above, though the metabolic pathways for 1,3-butadiene conversion are qualitatively similar across species, significant differences exist in the amounts of reactive metabolites formed and tissue sensitivity (*e.g.*, mice form orders of magnitude more DEB than humans) and thus must be explicitly acknowledged as source of uncertainty in extrapolating between species. TCEQ applied a reduced uncertainty factor for interspecies extrapolation of ovarian toxicity, and some recent analyses have attempted to quantitatively address these species differences by calculating a data-derived extrapolation factor based on relative hemoglobin adduct levels ([Kirman et al., 2022](#); [Kirman and Grant, 2012](#)) that results in an adjusted reference concentration many orders of magnitude higher than earlier assessments. Although EPA considered deriving a data-derived extrapolation factor ([U.S. EPA, 2014](#)) to dosimetrically adjust the mouse results based on human metabolism, there is substantial uncertainty in quantifying an appropriate human equivalent concentration for the endpoint. DEB levels are estimated to be at least 100 times lower and possibly 300 times or more lower in humans compared to mice; however, they may have more similar levels of EBD ([Swenberg et al., 2011](#)) and Section 3.3); urinary DNA adduct biomarkers of butadiene exposure have also been shown to vary by more than 10-fold in humans ([Erber et al., 2021](#)).

Additionally, recent studies have identified bifunctional metabolites in humans that have unknown relevance for ovarian toxicity, while EBD (the primary metabolite in humans) can cause genetic and cellular toxicity ([Nakamura et al., 2021](#); [Wu et al., 2019](#); [Wang et al., 2018](#); [Elfarrar and Zhang, 2012](#)). Therefore, human sensitivity may be greater than implied purely based off relative DEB levels, while any toxicodynamic differences between humans and mice are unknown. Determining an appropriate quantitative adjustment with any confidence is therefore not reasonable. Regardless of the most appropriate adjustment, it is evident that any potential data-derived extrapolation factor (DDEF) ([U.S. EPA, 2014](#)) would result in a hazard value likely orders of magnitude higher than the animal POD and would probably be less protective and with much greater uncertainty than any POD derived from the other critical hazard outcomes (see subsequent sections). Therefore, EPA did not utilize the ovarian atrophy endpoint for dose-response analysis.

There is (1) indeterminate human evidence for ovarian toxicity due to an absence of relevant studies; (2) moderate animal evidence due to consistent results of a strong effect observed in only mice; and (3) indeterminate mechanistic evidence, including an MOA analysis suggesting there may be greatly reduced sensitivity in humans. See Table_Apx A-1 for the evidence integration table for this outcome. Based on the weight of scientific evidence, while the possibility of 1,3-butadiene-induced ovarian atrophy in humans cannot be ruled out, EPA has concluded that ovarian atrophy observed in mice is not appropriate for quantitative use in human health risk assessment.

4.1.2 Critical Non-Cancer Hazard Outcomes

The sections below summarize the hazard identification and evidence integration of maternal and related developmental toxicity (*e.g.*, fetal body weight), male reproductive system and resulting developmental toxicity (*e.g.*, dominant lethality), and hematological and immune effects (*e.g.*, anemia), which are the

most relevant human health hazard outcomes associated with exposure to 1,3-butadiene. Details on the evidence database and evidence integration judgments are presented in Appendix A. See full data extraction information for all relevant studies in the *Data Extraction Information for Human Health Hazard Animal Toxicology and Epidemiology* ([U.S. EPA, 2025b](#)) and *Further Filtering Results for Human Health Hazard Animal Toxicology and Epidemiology* ([U.S. EPA, 2025d](#)).

4.1.2.1 Exposure During Gestation: Developmental and Maternal Toxicity

4.1.2.1.1 Human Evidence

An epidemiological study examined the risks for autism in children associated with a location relative to an air monitor measuring ambient 1,3-butadiene concentrations ([von Ehrenstein et al., 2014](#)). That study found that *in utero* exposure to 1,3-butadiene was positively associated with autism, with higher risk observed at closer distance to the air monitor. However, exposure levels were not directly quantified in the study. Furthermore, EPA did not identify any other studies assessing the effects of 1,3-butadiene exposure on maternal and related developmental toxicity in humans.

4.1.2.1.2 Laboratory Animal Evidence

Several studies have investigated the effects of 1,3-butadiene exposure on maternal and developmental toxicity in laboratory animals. One study investigated the effects of 1,3-butadiene exposure in pregnant mice, exposing them to concentrations of 0, 40, 200, or 1,000 ppm for 6 hours per day from GD (gestational day) 6 through 15 ([Battelle PNL, 1987b](#)). The measured mean (\pm standard deviation [SD]) concentrations were 39.9 (\pm 0.06), 199.8 (\pm 3.0), and 1,000 (\pm 13.1 ppm). Significant maternal toxicity was observed at 1,000 ppm—including three mortalities, two due to dehydration, and early parturition in the third. Additional signs of maternal included decreased maternal weight gain at greater or equal to 199.8 ppm. Body weight gain between GD 11 and 16, as well as gravid uterine weight and extra gestational weight gain, were significantly reduced at 1,000 ppm. Weight gain reductions were also observed at 199.8 ppm, while no significant maternal toxicity was observed at 39.9 ppm.

In contrast, fetal body weight reductions were observed at lower concentrations than those that caused maternal toxicity. Overall fetal body weights (males and females combined) were reduced by 4.5 percent at 39.9 ppm, 15.7 percent at 199.8 ppm, and 22.4 percent at 1,000 ppm. A significant dose-response relationship was identified, with reductions in fetal body weights being significant for males at all exposure levels (39.9, 199.8, and 1,000 ppm) and for females at 199.8 and 1,000 ppm. In addition to fetal effects, placental weights were reduced across exposed groups compared to controls. Although sporadic malformations occurred infrequently across all exposure groups, significant increases in skeletal variations, such as supernumerary ribs and reduced ossification of the sternebrae, were observed at 199.8 and 1,000 ppm. Certain skeletal malformations/variations such as fused sternebrae were observed only at 1,000 ppm, while “abnormal sternebrae”—including misaligned, scrambled, or cleft sternebrae—demonstrated a statistically significant linear dose-response with a statistically elevated incidence at the highest dose.

Similar findings of maternal and developmental toxicity were observed in rats but at higher concentrations. Female rats exposed for 10 days (GD 6–15) to less than or equal to 7,647 ppm for 6 hours/day ([Hazleton Labs, 1981a](#)) and less than or equal to 1,005 ppm for 6 hours/day ([Battelle PNL, 1987a](#)) showed decreased maternal body weight gain during exposure at greater than or equal to 200 ppm and 1,005 ppm, respectively. Fetuses showed significant 6.1 percent decreases in body weight and crown-rump length at 7,647 ppm, with dose responsive skeletal defects at greater or equal to 990 ppm. These skeletal defects included wavy ribs, increasing in a dose-dependent manner, ranging from minor

at lower doses to more pronounced at higher concentrations. At 7,647 ppm, major fetal abnormalities were noted, including severe skeletal malformation such as fused ribs and angiectasis.

In a separate reproductive toxicity screening study conducted according to OECD 421 guideline in rats, males were exposed for 83 to 84 days, and females for 60 to 70 days, with one group of F1 pups sacrificed at weaning and others exposed for 7 days post-weaning ([WIL Research, 2003](#)). In that study, female rats exposed before and during mating and throughout gestation and lactation showed clinical signs of toxicity (chromodacryorrhea, chromorhinorrhea, and increased salivation) in the 1 hour following exposure at greater than or equal to 1,507 ppm. In addition, body weight was statistically significantly reduced in female F1 pups (males had a biologically but not statistically significant reduction) exposed for 7 days to greater than or equal to 1,507 ppm either with or without previous gestational/lactational exposure ([WIL Research, 2003](#)).

Inconsistent results were observed across rat studies using the same strain. In one study, no decrease in maternal body weight was noted following a total exposure period of 60 to 70 days to concentrations up to 6,006 ppm ([WIL Research, 2003](#)). However, other studies reported maternal body weight reduction at 7,647 and 1,005 ppm during shorter exposure periods ([Battelle PNL, 1987a](#); [Hazleton Labs, 1981a](#)).

4.1.2.1.3 Mechanistic and Supporting Evidence

As described in Section 3.3, multiple studies have demonstrated species-specific differences in 1,3-butadiene metabolism, which may vary based on factors such as sex, dose, duration, and other variables. Nevertheless, the specific role of 1,3-butadiene metabolites in during gestation and early post-natal periods remains unclear. It is a reasonable hypothesis that 1,3-butadiene epoxide metabolites likely contribute to the observed maternal and developmental toxicity. However, there are key gaps in knowledge with respect to the available pharmacokinetic data in pregnant animals, fetuses, and early post-natal laboratory animals. Evidence does not support a role for any particular metabolite over another. Two studies in both mice and rats demonstrated that DEB is toxic to developing fetuses and embryos ([Chi et al., 2002](#); [Clerici et al., 1995](#)). A proposed mechanism involves decreased progesterone and inhibition of placental pituitary adenylate cyclase-activating polypeptide expression and matrix metalloproteinase activity in rats ([Chi et al., 2002](#)). Mechanistic studies on parental 1,3-butadiene or other metabolites are not available. Therefore, there are not sufficient data available for EPA to make a determination as to species sensitivity as was performed for ovarian atrophy.

4.1.2.1.4 Summary and Conclusions

There is slight human evidence from a single study that identified an association between 1,3-butadiene exposure and autism risks. Robust animal evidence is based on studies that show and concordant and dose-responsive effects in mice that are relevant for human health risk assessment. The robustness of the animal evidence is supported by qualitatively similar findings in rats at higher doses. Mechanistic evidence is slight based on two studies demonstrating fetal and embryonic toxicity of DEB. See Table_Apx A-2 for the evidence integration table for this outcome.

Based on the weight of scientific evidence, evidence integration judgments, and available dose-response data for maternal and developmental toxicity, dose-response analysis is considered appropriate for assessing maternal and developmental toxicity following gestational exposures.

4.1.2.2 Male Reproductive System and Resulting Developmental Toxicity

4.1.2.2.1 Human Evidence

EPA did not identify any reasonably available information assessing effects of 1,3-butadiene exposure on the male reproductive system or associated developmental toxicity in humans.

4.1.2.2.2 Laboratory Animal Evidence

Male reproductive toxicity has been examined in several rodent studies across short-term, subchronic, and chronic exposures, including dominant lethal assays and other reproductive toxicity assessments, revealing a range of adverse effects on sperm and testicular function. Exposure for 5 days to concentrations up to 1,300 ppm for 6 hours/day led to reductions in testis weight ([Xiao and Tate, 1995](#)), with similar findings of reduced testis weight and immature spermatoid counts at 130 ppm ([Pacchierotti et al., 1998](#)). Subchronic exposure of mice to 980 ppm for 13 weeks resulted in pronounced reproductive effects, including testicular atrophy and reduced testis weight, with histopathological evaluations showing decreased cellularity of the seminiferous tubules ([Bevan et al., 1996](#)). Long-term studies further demonstrated the dose-dependent, reproductive effects of 1,3-butadiene. Mice exposed for 60 weeks to concentrations up to 1,236 ppm for 6 hours/week showed histopathological changes in male reproductive organs ([NTP, 1984](#)). In a 2-year study, exposure to concentrations 619 ppm for 6 hours/day, 5 days/week resulted in testicular atrophy, which became most pronounced after 2 years ([NTP, 1993](#)).

Dominant lethality, a marker of reproductive toxicity, was observed in several mouse studies in a dose- and duration-responsive manner. In dominant lethality studies, males were exposed to the 1,3-butadiene and then mated with unexposed females to assess and reproductive/developmental outcomes. Increased fetal deaths were observed at greater or equal to 65 ppm following 4 weeks of exposure (0, 12.5, 65, or 130 ppm for 6 hours/day, 5 days/week) ([Anderson et al., 1998](#); [BIBRA, 1996b](#)) and at greater or equal to 12.5 ppm following 10 weeks of exposure (0, 12.5, or 125 ppm for 6 hours/day, 5 days/week) ([Brinkworth et al., 1998](#); [Anderson et al., 1996](#)). External and skeletal abnormalities were also observed in these studies included exencephaly, hydrocephaly, and runt formations—with skeletal defects particularly affecting the skull, vertebra, ribs, and limbs. Ten weeks of exposure also resulted in decreased implantation ([Anderson et al., 1996](#)) and delayed time-to-coition ([Brinkworth et al., 1998](#)). Additionally, early fetal deaths were observed following only 5 days of exposure to 500 ppm ([Adler et al., 1998](#)) and 1,300 ppm ([Adler et al., 1994](#)). Interestingly, one study reported clear effects seen at 5 days of exposure to less than or equal to 1,000 ppm but weaker results at 5,000 ppm ([Hackett et al., 1988b](#)). The only acute study did not report any dominant lethality at 1,250 or 6,250 ppm, and reduced implantations were seen only at 1,250 ppm ([Anderson et al., 1993](#)), summarized in ([Anderson et al., 1996](#)).

In contrast to the findings in mice, studies in rats did not demonstrate significant male reproductive toxicity. A subchronic study conducted according to the OECD 421 guideline in rats, with exposure to concentrations up to 6,006 for 12 weeks, found no adverse effects on fertility, sperm parameters, or testicular histopathology ([WIL Research, 2003](#)). Additionally, no reproductive effects were observed in rats exposed to as high as 1,250 ppm for 4 weeks ([Anderson et al., 1998](#)) or 10 weeks ([BIBRA, 1996a](#)).

4.1.2.2.3 Mechanistic and Supporting Evidence

Various indications of genotoxicity have been observed in developing sperm and testicular cells from both 1,3-butadiene and metabolites, which provide mechanistic insight into the dominant lethal effects observed in several reproductive studies. Data from animal studies show that 1,3-butadiene causes micronuclei, chromosome aberrations, and DNA damage in sperm, testicular cells, and embryos from

mice. The three common metabolites EB, DEB, and EBD all induce chromosomal damage in both mouse ([U.S. EPA, 2002b](#); [Xiao and Tate, 1995](#)) and rat ([U.S. EPA, 2002b](#); [Lahdetie et al., 1997](#)) spermatids. However, only DEB (but not EBD) induces genotoxicity in rat seminiferous tubule sections ([U.S. EPA, 2002b](#); [Sjoblom and Lahdetie, 1996](#)), and mixed dominant lethality results in mice from exposure to DEB or EB suggest that developing sperm have stage-specific sensitivity ([U.S. EPA, 2002b](#)). The mechanistic evidence suggests a genotoxic MOA, potentially mediated through 1,3-butadiene metabolites; however, definitive data linking a specific metabolite to the observed reproductive toxicity and dominant lethality remains inconclusive. Overall, there are not sufficient data available for EPA to make a determination as to species sensitivity as was performed for ovarian atrophy.

4.1.2.2.4 Summary and Conclusions

There is an absence of any relevant human data, moderate animal evidence showing both dominant lethality and associated male reproductive system toxicity (but only in mice), and moderate mechanistic evidence indicating genotoxic effects of parental 1,3-butadiene in mice and genotoxicity of metabolites in both mice and rats. See Table_Apx A-3 for the evidence integration table for this outcome.

Based on the weight of scientific evidence, evidence integration judgments, and available dose-response data for dominant lethality, dose-response analysis is considered appropriate for male reproductive system and resulting developmental toxicity.

4.1.2.3 Hematological and Immune Effects

4.1.2.3.1 Human Evidence

Epidemiology data on hematological effects of 1,3-butadiene are limited by small population sizes and evaluation of few hematological parameters. Two studies suggested associations between 1,3-butadiene and hemoglobin levels. None of the studies reported exposure-related alterations in erythrocyte counts. A slight but statistically significant decrease in hemoglobin concentration was observed among petrochemical workers exposed to 1,3-butadiene, compared to an unexposed internal referent group ([Tsai et al., 2005](#)). After adjusting for confounders, a significant association was observed between 1,3-butadiene exposure level and increased mean corpuscular hemoglobin concentration in a health survey of styrene-butadiene workers ([Checkoway and Williams, 1982](#)). However, a low-quality cohort study with small numbers of participants found no association between erythrocyte count and 1,3-butadiene exposure ([Hayes et al., 2000](#)). In other human studies, no association between erythrocyte count and 1,3-butadiene exposure was observed in petrochemical workers ([Tsai et al., 2005](#); [Cowles et al., 1994](#)) or styrene-butadiene workers ([Checkoway and Williams, 1982](#)). In another study, ([Tsai et al., 2001](#)), no association was identified for any hematological measure.

4.1.2.3.2 Laboratory Animal Evidence

The hematotoxicity of 1,3-butadiene has been extensively studied in animal models—particularly in mice—with multiple studies demonstrating its role in inducing anemia and associated hematological changes. One study investigated the myelotoxic effects of 1,3-butadiene exposing mice to 1,250 ppm for 6 hours/day, 5 days/week, over 6 weeks. Significant decreases in red blood cell counts, hemoglobin concentrations, and hematocrit, along with increases in mean cell volume (MCV) and circulating micronuclei were observed ([Irons et al., 1986a, b](#)). Another study evaluated mice exposed to 1,250 ppm for either 6 or 12 weeks and found no persistent effects on humoral or cell-mediated immunity. However, exposed mice exhibited a 20 percent reduction in relative spleen weight and a 29 percent decrease in spleen cellularity ([Thurmond et al., 1986](#)).

Long-term studies further demonstrated the dose-dependent hematological effects of 1,3-butadiene. In a 13-week subchronic study, exposure to 980 ppm led to hematological changes indicative of anemia—including decreases in erythrocyte counts, hemoglobin concentrations, and mean erythrocyte volume—along with an increase in Howell-Jolly bodies and MCV ([Bevan et al., 1996](#)). A 9-month GLP study found that male mice exposed to 62.5 ppm and female mice exposed to 200 ppm had significant reductions in erythrocyte counts, hemoglobin concentrations, and packed cell volume, while MCV was elevated in male mice exposed to 625 ppm and female mice exposed to 200 ppm ([NTP, 1993](#)). These hematological changes persisted only at 625 ppm after 15 months of exposure, with increases in the percentage of erythrocytes with Howell-Jolly body inclusions and elevated mean cell hemoglobin (MCH) were observed at both 9 and 15 months.

In contrast, studies in rats did not demonstrate treatment related hematological changes. In a 13-week exposure to 980 ppm, no alterations in hematology or histopathology of the spleen and bone marrow were observed ([Bevan et al., 1996](#)). Similarly, even at concentrations as high as 8,000 ppm over a 2-year period, rats showed no significant hematological effects ([Hazleton Labs, 1981b](#)).

4.1.2.3.3 Mechanistic and Supporting Evidence

Inhalation exposure to 1,3-butadiene in mice resulted in significant alterations in key cytotoxicity and genotoxic parameters, including sister chromatid exchanges, chromosomal aberrations, micronuclei formation—all of which suggest potential damage to hematopoietic cells. ([ATSDR, 2012](#); [U.S. EPA, 2002b](#)). The observed genotoxicity, particularly in bone marrow, may impair the production and function of red blood cells aligning with the development of anemia. Multiple studies have demonstrated genotoxic effects in the bone marrow and spleen of mice following exposure to 1,3-butadiene and its metabolites. However, studies in rats exposed to 1,3-butadiene by inhalation showed no increases in micronuclei or sister chromatid exchanges (SCEs) in bone marrow, suggesting species-specific difference in susceptibility ([ATSDR, 2012](#); [U.S. EPA, 2002b](#)). Furthermore, an alternative mechanism involving the inhibition of stem cell differentiation has also been proposed, which could contribute to the bone marrow dysfunction and subsequent anemia observed in mice ([Leiderman et al., 1986](#)). This observed bone marrow dysfunction may also be linked to 1,3-butadiene-induced lymphohematopoietic cancers in both mice and humans, further highlighting the role of bone marrow toxicity in the broader hematological effects, including anemia ([ATSDR, 2012](#); [U.S. EPA, 2002b](#); [Leiderman et al., 1986](#)). Overall, there are not sufficient data available for EPA to make a determination as to species sensitivity as was performed for ovarian atrophy.

4.1.2.3.4 Evidence Integration Summary and Conclusions

There is indeterminant evidence from human data, which provides conflicting data concerning hematological effects. However, moderate evidence from animal studies—particularly in mice—indicates that 1,3-butadine exposure leads to dose and duration responsive changes in hematology parameters, which are consistent with red blood cell anemia. Limited data also suggests potential effects on white blood cell count at high exposure concentration. Slight mechanistic evidence suggests that genotoxicity in bone marrow cells might contribute to the hematological effects observed in mice, but the presence of blood cancer in humans (Section 5.1.1.1) and alternative MOAs support relevance to humans. See Table_Apx A-4 for the evidence integration table for this outcome.

Based on the weight of scientific evidence, evidence integration judgments, and available dose-response data for hematological parameters, dose-response analysis is considered appropriate for hematological effects, with insufficient support for immunotoxicity.

4.2 Non-Cancer Dose-Response Assessment

4.2.1 Selection of Studies and Endpoints for Non-Cancer Toxicity Dose-Response Analysis

EPA considered studies and endpoints from the suite of epidemiological and animal toxicology studies for which the weight of scientific evidence supported adverse health outcomes following 1,3-butadiene exposure, as described in Section 4.1.2. These were the critical hazard domains of (1) developmental and maternal toxicity from exposure during gestation, (2) male reproductive system and resulting developmental toxicity, and (3) hematological and immune effects. When considering non-cancer PODs for estimating risks for acute, intermediate, and chronic exposure scenarios, EPA reviewed the available evidence and studies within these hazard domains.

The Agency selected specific studies and targeted endpoints within each hazard domain for dose-response analysis based on the following considerations:

- overall quality determinations;
- exposure duration;
- dose range;
- relevance (*e.g.*, what species was the effect in, was the study directly assessing the effect, is the endpoint the best marker for the tox outcome?);
- uncertainties not captured by overall quality determination;
- endpoint sensitivity;
- total UF; and
- uncertainty and sensitivity of benchmark response (BMR) selection from BMD modeling.

4.2.1.1 Non-Cancer Endpoints for Acute Exposures

The preponderance of evidence supports no adverse effect from acute 1,3-butadiene exposure in humans under relevant exposure circumstances. Other health effects following single exposures in humans or animals were only observed at air concentrations in the thousands of ppm (Appendix C.1). However, EPA considered all potential endpoints relevant to acute exposure as discussed below. As stated in Section 2, EPA considers acute exposure to refer to either a single dose or a single dose or exposure to an air concentration for no more than 24 hours consecutive hours.

Fetal Body Weight

Fetal body weight was the basis of the acute reference concentration (RfC) in the EPA IRIS Assessment ([U.S. EPA, 2002a](#)). At this time, the Agency finds that a biologically relevant decrease in fetal body weight or maternal weight gain is unlikely to result from a single exposure to 1,3-butadiene. Fetal body weight in mice was decreased by less than 5 percent at the lowest concentration (40 ppm) during a repeat-dose study in which no teratogenic or other effects were observed at comparable doses ([Battelle PNL, 1987b](#)). This suggests a progressive, repeated-dose effect related to decreased maternal body weight gain (<5%) that is unlikely to present at a similar dose following a single exposure. Although there are several instances of EPA assessments in pesticides and other programs citing fetal body weight as an adverse effect associated with an acute POD, the effect is associated with severe effects such as mortality (*e.g.*, resorptions, pup death) or teratogenicity (*i.e.*, malformations). Reduced fetal body weight has resulted from a single maternal exposure to certain pain management pharmaceuticals ([Thaete et al., 2013](#)); however, these results cannot be reliably used for conclusions. Only one of these chemicals was administered externally (isoflurane), at a very high concentration of 3 percent (30,000 ppm), and bone growth (for the humerus, specifically) was more consistently impacted than fetal body weight. In the case of 1,3-butadiene, reduced fertility or offspring mortality were not observed in any study while

potential defects were only seen at much higher doses (discussed below). Therefore, the fetal body weight changes seen at the lowest dose tested in the absence of other fetal effects cannot be reasonably assumed to result from a single dose—especially at any quantitatively similar level. Other options for acute endpoints are discussed below.

Teratogenic Effects

In contrast with continuous measures such as body weight, teratogenic effects are usually dichotomous and can be impacted by a single exposure. Various skeletal observations were reported in both mice and rats, including supernumerary ribs at similar concentrations as body weight changes as well as malformations, such as abnormal sternbrae and fused ribs, at higher concentrations (Section 4.1.2.1.2). It is unclear whether supernumerary ribs can develop following acute exposures because they are associated with reduced fetal body weight, and there is uncertainty as to their overall adversity ([Desesso and Scialli, 2018](#)). Additionally, supernumerary ribs may be linked to maternal stress and weight loss ([Beyer and Chernoff, 1986](#)), which would not be a significant effect following a single dose. Therefore, supernumerary ribs are not considered applicable to acute exposures. The other skeletal malformations (e.g., abnormal sternbrae including misaligned, scrambled, cleft, or fused sternbrae) have similar uncertainty as to their adversity in humans, as some observations may be considered more of a variation than a malformation ([Desesso and Scialli, 2018](#)). However, they could be considered relevant adverse effects that may arise from a single exposure albeit at higher concentrations than the more sensitive repeated-dose effects.

Acute Eye Irritation

The Acute Exposure Guideline Level ([AEGL](#); accessed November 19, 2025) AEGL-1 value (for non-disabling discomfort) for [1,3-butadiene](#) (accessed November 19, 2025) is extrapolated from human data in ([Carpenter et al., 1944](#)), which reported mild eye irritation at 2,000 ppm. The AEGL-2 (irreversible disabling effects) is based on the absence of any observed effects defined by AEGL-2 at 8,000 ppm (the highest dose exposed) in humans (([Carpenter et al., 1944](#)). The AEGL-3 (life-threatening) is based on the rat mortality data from ([Shugaev, 1969](#)). With uncertainty factors to account for human variability, the most sensitive acute exposure level (AEGL-1) is 670 ppm at all durations for difficulty to focus ([NAC/AEGL, 2009](#)). AEGL-2 is 2,700 ppm at 8 hours and AEGL-3 is 6,800 ppm at 8 hours. There is uncertainty in use of the AEGL-1 as an acute POD because it was based on only two volunteers and no subjective complaints were reported at higher concentrations.

Dominant Lethality

Observed damage to developing sperm and dominant lethality are likely downstream of germ cell genotoxicity (Section 4.1.2.2.3 and Table_Apx A-3), which can potentially result from single exposures. The data for male reproductive/developmental toxicity suggests that apical outcomes likely require multiple days of exposure. While effects on spermatogenesis and sperm quality were observed in mice following as little as 5 days of exposure, these effects were either at 1,000 ppm or higher ([Hackett et al., 1988a](#)) or from a low-quality study ([Pacchierotti et al., 1998](#)). More importantly, dominant lethality studies demonstrated a clear relationship between dose sensitivity and exposure duration/frequency. Lethality was observed following 10 weeks of exposure to as low as 12.5 ppm and following 4 weeks of exposure to as low as 65 ppm, while a few studies observed lethality at 500 ppm or above following 5 days of exposure ([Adler et al., 1998](#); [Adler et al., 1994](#); [Hackett et al., 1988b](#))—dependent on the timing of mating relative to specific stages of spermatogenesis. A single acute study ([Anderson et al., 1993](#)), summarized in ([Anderson et al., 1996](#)) did not observe any dominant lethality following 1 day of exposure to 1,250 or 6,250 ppm. Although the study did observe reduced implantations, this was only seen at the lower dose and is not corroborated by other developmental toxicity studies. Overall, the evidence suggests that functional male reproductive and downstream developmental effects in 1,3-

butadiene require more than a single day of exposure. Any potential impact on fertility would not be considered adverse as it would be for a very narrow window relative to mating and not at relevant exposure concentrations.

As discussed above, there is significant uncertainty in the relevance of any potential acute endpoints to human health risk assessment. Nonetheless, effects and hazard values that could plausibly result from a single exposure will be considered for POD derivation.

4.2.1.2 Non-Cancer Endpoints for Intermediate and Chronic Exposures

EPA determined that the weight of scientific evidence supports dose-response analysis for the three critical hazard domains from Section 4.1.2. As a first step, EPA identified the most appropriate studies and set of endpoints to undergo BMD modeling for comparison. All considered studies received either a medium or high overall quality determination (OQD) across relevant endpoints.

For developmental and maternal toxicity from gestational exposure, one mouse study ([Battelle PNL, 1987b](#)) and three rat studies ([WIL Research, 2003](#); [Battelle PNL, 1987a](#); [Hazleton Labs, 1981a](#)) were considered. Both mouse and rat data were considered relevant to humans due to the lack of any mechanistic data supporting any species-specific relevance (Section 4.1.2.1.4). Three were 10-day developmental toxicity studies ([Battelle PNL, 1987a, b](#); [Hazleton Labs, 1981a](#)). The WIL Research study ([2003](#)), a reproductive screening study conducted according to the OECD 421 guideline in rats, contained several different exposure groups covering 60 to 70 days of exposures through pre-mating, gestation, and lactation, for one group through weaning, and for another group only during weaning. EPA performed dose-response analysis for decreased maternal weight gain, decreased fetal body weight, and increased incidence of supernumerary ribs from the mouse study, ([Battelle PNL, 1987b](#)). Reduced fetal body weight and skeletal variations/malformations were inconsistently observed across the rat studies, so these results were not modeled. A dose-responsive decrease in maternal body weight gain was observed in ([Hazleton Labs, 1981a](#)) so this data set was also considered for dose-response assessment. These endpoints are relevant to both intermediate and chronic exposure because they were observed in a 10-day developmental toxicity study that exposed animals specifically during gestation.

For male reproductive system and resulting developmental toxicity, EPA determined that dominant lethality was the endpoint appropriate for dose-response modeling. Dominant lethality was observed in mice in a dose- and duration-responsive manner spanning orders of magnitude of exposure levels for a range of 5 days to 10 weeks. The two medium-quality, 10-week studies by Brinkworth et al. ([1998](#)) and Anderson et al. ([1996](#)) were considered equally relevant and used the same lowest dose. Therefore, using an approach consistent with EPA's Office of Research and Development (ORD) IRIS assessment ([U.S. EPA, 2002a](#)), the datasets from these studies were combined to increase statistical power and the total number of dose groups examined. Dominant lethality is also relevant to both intermediate and chronic exposure because it results from exposure of male mice to 1,3-butadiene during a critical window of spermatogenesis followed by mating shortly thereafter.

Hematological effects were only consistently observed in mice. The 1993 National Toxicology Program study ([NTP, 1993](#)) is the most appropriate study for dose-response analysis of hematological effects. An earlier NTP study ([1984](#)) used higher dose levels and other mouse studies only used single doses ([Bevan et al., 1996](#); [Thurmond et al., 1986](#)). Therefore, results from ([NTP, 1993](#)) were used for dose-response modeling because it contained multiple dose groups less than 1,000 ppm. EPA performed dose-response analysis on three hematological parameters from ([NTP, 1993](#)) indicative of anemia: decreased erythrocytes, decreased hemoglobin, and decreased packed red blood cell volume (hematocrit). In that

study, hematological outcomes were measured following 9 and 15 months of exposure and therefore are only considered applicable to chronic exposures.

4.2.2 Dose-Response Derivation for Non-Cancer Hazard Values

As described in Section 4.2, EPA considered studies for 1,3-butadiene for quantitative dose-response analysis. The sections below describe the steps used to derive the hazard values used to calculate risks for 1,3-butadiene. Exposure via dermal or oral pathways are not expected for 1,3-butadiene (see *Occupational Exposure Assessment for 1,3-Butadiene* ([U.S. EPA, 2025c](#)) and *General Population Exposure Assessment for 1,3-Butadiene* ([U.S. EPA, 2025e](#))). Therefore, only inhalation hazard values were derived.

4.2.2.1 Duration, Dosimetric, and Unit Adjustments for Inhalation Hazard Values

Dosimetric Adjustments

EPA considers 1,3-butadiene to be a category 3 gas for dosimetry of all systemic endpoints, in accordance with EPA's RfC guidance ([U.S. EPA, 1994](#)). Therefore, the relative blood:air partition coefficient between the test organism and humans is considered the driving factor underlying relative dosimetry. The estimated coefficient is greater for rodents than humans (Section 3.1), so in accordance with guidance ([U.S. EPA, 2012a, 1994](#)), the Agency defaults to a relative ratio of 1. Therefore, the internal dose is considered equivalent for rodents and humans. Although limited evidence suggests that 1,3-butadiene may be mildly irritating to the respiratory system (Appendix C.2), this does not impact dosimetry for systemic effects.

EPA did not apply a DDEF for any of the critical hazard outcomes. EPA guidance ([U.S. EPA, 2014](#)) on the use of DDEFs requires a strong understanding of the MOA for the endpoint of interest, supported by relevant quantitative data that inform specific key events and characterize the associated toxicokinetic exposure response relationship. Supporting data must be specific to the affected tissue and identification of the most appropriate dose metric. In the case of fetal body weight reduction, which is identified as the most sensitive and reliable endpoint, substantial uncertainties remain regarding its mode of action. It is unknown if any particular metabolite is responsible for the observed developmental toxicity, and emerging research has identified additional bifunctional metabolites across species (Section 3.3). While Kirman et al. ([2022](#)) proposed a DDEF based on a cytotoxicity or general toxicity MOA, these hypotheses lack experimental validation of key events directly linking 1,3-butadiene exposure to fetal body weight reduction. Critical data gaps include limited characterization of 1,3-butadiene metabolism during pregnancy and within fetal tissues, as well as uncertainty regarding the primary metabolites responsible for the reduced fetal body weight. Furthermore, the mechanistic data underlying the Kirman et al. DDEF was derived from *in vitro* cytotoxicity assays conducted across diverse cell lines (*e.g.*, human bone marrow, TK6 cells, rodent fibroblasts, chicken lymphoid cells) display considerable variability and have not been demonstrated to directly predict fetal body weight outcomes *in vivo*. EPA guidance explicitly states that MOAs from one tissue or outcome cannot be extrapolated to support DDEF for another ([U.S. EPA, 2014](#)). The MOA for ovarian toxicity in mice cannot be extrapolated to other endpoints. Consequently, due to the poorly defined and inadequately supported MOA in Kirman et al, 2022 ([2022](#)) and the identified uncertainties, applying a DDEF for 1,3-butadiene induced fetal body weight reduction is deemed inappropriate, in accordance with EPA guidance ([U.S. EPA, 2014](#)).

For other critical hazard outcomes, mechanistic data similarly remain insufficient to support specific MOAs for maternal and developmental toxicity following gestational exposure. Also, the relative contribution of individual metabolites remains unclear, and biomarkers of exposure suggest that there is large intra-species variability in humans ([Boysen et al., 2022](#); [Boysen et al., 2012](#), ([Erber et al., 2021](#))). Although some evidence suggests potential genotoxic mechanisms for male reproductive and

hematological effects, these findings are inconclusive, and the precise role of DEB, EB, and EBD are not well characterized. Therefore, EPA relied on default dosimetric adjustments and did not establish a DDEF to derive HECs for these endpoints in accordance with Agency guidance ([U.S. EPA, 2014](#)).

Duration Adjustments

The studies selected for dose-response assessment utilized differing exposure durations and frequencies. In order to better compare results across studies and exposure scenarios, administered doses/concentrations were linearly adjusted to continuous exposure (24 hours/day, 7 days/week) prior to POD derivation based on Haber's Law ([Haber, 1924](#)) using the following equation:

Equation 4-1. Adjusting Average Exposure Concentration or Inhalation POD for Differences in Days and Hours of Exposure Across Scenarios

$$Concentration_{continuous} = Concentration_{study} \times \left(\frac{D_s}{7}\right) \times \left(\frac{H_s}{24}\right)$$

Where:

$Concentration_{continuous}$	=	Adjusted air concentration/inhalation POD
$Concentration_{study}$	=	Air concentration/inhalation POD from study dataset
D_s	=	Days per week/year exposure in study dataset
H_s	=	Hours per day exposure in study dataset

HECs were derived incorporating both dosimetric and duration adjustments, resulting in a lower value than the original study POD.

Unit Conversion

It is often necessary to convert between ppm and mg/m³ due to variation in concentration reporting in studies and the default units for different OPPT models. Therefore, EPA presents all inhalation hazard values in Section 4.2.2.5 and Section 8 in both units. The following equation presents the conversion of the HEC from mg/m³ to ppm.

Equation 4-2. Converting ppm to mg/m³

$$\begin{aligned} \text{HEC (mg/m}^3\text{)} &= \text{HEC (ppm)} \times (\text{molecular weight} \div 24.45^1) \\ \text{HEC (mg/m}^3\text{)} &= \text{HEC (ppm)} \times (54.0916 \div 24.45^1) \end{aligned}$$

4.2.2.2 Benchmark Concentration Analysis

EPA conducted BMD modeling in accordance with Agency guidance ([U.S. EPA, 2012b](#)) to refine PODs for the endpoints and studies described in Section 4.2.1. EPA decisions on modeling of specific datasets and results are described below. See Table 4-2 for PODs for each hazard outcome and Appendix B for a summary of all BMD modeling results, including model selection, selection of relative deviation (RD) and extra risk (ER), and alternative endpoint options. See *Benchmark Dose Modeling Results for 1,3-Butadiene* ([U.S. EPA, 2025a](#)) for full modeling details, including statistical tests, results from all models, and any associated graphs.

¹ The Ideal Gas Law can be used to convert between ppm and mg/m³. At standard temperature and pressure (STP; 25 °C and 760 mm Hg), 1 mole of gas occupies 24.45 L. However, when conditions differ from STP, a different gas conversion factor can be calculated using the reported experimental temperature or pressure.

4.2.2.2.1 Exposure During Gestation: Maternal and Developmental Effects

Reduced Fetal Body Weight

For reduced fetal body weight from ([Battelle PNL, 1987b](#)), male data was selected as males demonstrated a clearer dose-response and relative body weight change compared to females. The lowest dose tested of 40 ppm was identified as a statistically significant lowest-observed-adverse-effect level (LOAEL); however, the fetal body weight was reduced only a minor amount at this dose and a subsequent re-analysis determined that the result may not in fact be statistically significant ([Green, 2003](#)). EPA therefore BMD-modeled the endpoint in order to refine the POD as mean fetal body weight in male fetuses/litter.

Although litter is the relevant unit of measurement for developmental outcomes, mean fetal body weight for males and for all fetuses combined were also BMD-modeled for comparison purposes; BMD modeling failed for these datasets. BMD modeling for mean fetal body weight per litter as a continuous variable failed without dropping the top dose group. A BMD model with a reasonable fit was obtained when the dataset was constrained to remove the highest dose, which significantly contributed to poor model fit (Table_Apx B-1). However, due to the uncertainty in utilizing a result from BMD modeling requiring removal of the top dose group, EPA additionally applied a different method for dose-response modeling. The Agency utilized one of the approaches from ([U.S. EPA, 2002a](#)); specifically, a hybrid approach was used based on first applying defined cut-offs for variation from the control response and then applying a dichotomous model. This approach is detailed in EPA's *BMD Modeling Guidance* ([U.S. EPA, 2012b](#)). A benefit of this approach is that it allows the use of nested BMD modeling (a continuous nested model does not exist in the BMDS software), which accounts for both inter- and intra-litter covariates. EPA evaluated multiple parameters for BMD modeling, specifically considering (1) the percentile cutoff of the probability distribution at 5 or 10 percent, and (2) a BMR of 5 or 10 percent that would correspond to calculating a BMDL₅ or BMDL₁₀.

For this approach, EPA first dichotomized the individual male fetal body weight data in treatment groups based on whether it was below the 5th or 10th percentile of the probability distribution for the control group, essentially defining whether a weight measurement was statistically different from controls. As discussed above, the Agency focused the BMD modeling on male data. The resulting dichotomized data were then nested (individual fetal data associated with the corresponding litter) and BMD modeled.

Each nested dataset (using 5th or 10th percentile cutoffs) was then BMD modeled using both 5 percent and 10 percent extra risk BMRs. The dichotomized BMD modeling was successful with inclusion of all dose groups. EPA determined that use of a 5th percent cutoff for dichotomizing the dataset was most appropriate because a 5th percentile significance threshold matches the typical 5 percent α value (and associated 95 percent confidence interval) typically used for statistical significance. For dichotomous modeling, a 5 percent BMR is recommended by BMD modeling guidance for nested developmental datasets ([U.S. EPA, 2012b](#)) and has been consistently used for modeling of developmental outcomes in previous risk evaluations including 1-bromopropane, hexabromocyclododecane, N-methyl-2-pyrrolidone, and others. The BMDL₅ result from the 5th percentile cutoff was selected as the most appropriate modeling option. In fact, the resulting BMDL from the nested logistic model (lsc-ilc+) based on overall mean was the same for the 5 percent BMR from the 5th percentile cutoff (hereafter referred to as simply the BMDL₅) and the 10 percent BMR from the 10th percentile cutoff (BMDL₁₀). The resulting BMDL of 2.5 ppm is therefore well-supported regardless of modeling option.

Although there is some uncertainty because the associated BMDs for the BMDL₅ and BMDL₁₀ (5.5 ppm and 6.1 ppm, respectively, see Table_Apx B-1) are below the lowest dose tested, they are less than 2-

fold below the lowest concentration (10 ppm when adjusted to HEC), which was also determined to be a LOAEL in the study. The BMDS Model (software) does not recommend using a result when the BMD or BMDL value is more than 10-fold below the lowest dose (<https://bmdsonline.epa.gov/>; accessed November 19, 2025), which does not apply to this result. Additionally, with application of a LOAEL to no-observed-adverse-effect level (NOAEL) uncertainty factor the risk threshold would be either similar or lower than the BMDL₅. Therefore, the BMDL value of 2.5 ppm was chosen as most appropriate POD for reduced fetal body weight, based either on BMDL₅ or BMDL₁₀ (hereafter referred to as BMDL_{5or10}).

Reduced Maternal Body Weight Gain

EPA also performed BMD analysis on ([Battelle PNL, 1987b](#)) both absolute body weight gain from GD 11 to 16 and extra-gestational weight gain from GD 0 to 18. In accordance with BMD modeling guidance ([U.S. EPA, 2012b](#)) EPA used a default BMR of 1 standard deviation (SD) and both measurements were successfully modeled. The more sensitive BMDL_{1SD} using the recommended exponential 5 model (constant variance) was 10.4 ppm, for GD 11 to 16 maternal absolute body weight gain. There is over a 5.5-fold range between the BMD (58.2 ppm) and BMDL (suggested range is under 3-fold), so this POD has some increased uncertainty.

The parallel rat datasets were also modeled for comparison from ([Hazleton Labs, 1981a](#)): absolute body weight gain from GD 6 to 15, extragestational weight at GD 20, and extragestational weight gain from GD 0 to 20. Absolute body weight gain was successfully modeled as the most sensitive rat POD with a BMDL_{1SD} of 48.9 from the Hill model (constant variance), less than five times higher than the mouse POD. The corresponding BMD was 101.3 ppm—less than 2 times higher than the mouse BMD and with smaller modeling uncertainty. See Table_Apx B-1 for more modeling details.

Supernumerary Ribs

EPA also modeled the number of litters and fetuses with supernumerary ribs as well as the mean percentage of supernumerary ribs per litter. The data was also nested to account for inter- and intra-litter variation. The nested data was successfully modeled, with both 5 and 10 percent extra risk (ER) considered for BMR due to the questionable adversity/severity of the endpoint ([Desesso and Scialli, 2018](#)). The BMDL₁₀ was 6.1 ppm and the BMDL₅ was 2.9 ppm using the nested logistic (lsc-isc+) model based on overall mean. The BMD for both PODs was only about 2 times higher, indicating low modeling uncertainty, and the BMD₁₀ is above the lowest HEC tested (Table_Apx B-1).

4.2.2.2.2 Dominant Lethality

As mentioned in Section 4.2.1.2, dominant lethality was the endpoint selected for dose-response assessment of male reproductive system and resulting developmental toxicity. The combined dataset from Brinkworth et al. (1998) and Anderson et al. (1996) was used for BMD modeling. The total incidence of all fetal deaths was modeled, and the associated litter for each fetus was not tracked due to paternal-specific exposure. Previous modeling in ([U.S. EPA, 2002a](#)) separated early and late deaths, but this distinction was not considered relevant/important. A 5 percent ER was selected as BMR due to the severe developmental effect (the large number of fetuses may have supported as low as a 1 percent ER), with BMDL₅ from the log-probit model equal to 4.8 ppm. The BMD is above the lowest HEC tested and 2.7 times greater than the BMDL (Table_Apx B-2).

4.2.2.2.3 Anemia

All three hematological parameters indicative of anemia were BMD modeled as continuous parameters, and all three failed BMD modeling without dropping at least one dose. Reduced erythrocyte counts were successfully modeled with the highest concentration dropped, hemoglobin concentration required the dropping of two doses, and packed red cell volume required dropping of the highest dose. The default

BMR of 1 SD was applied to all three datasets, with resulting BMDL_{1SD} of 8.07, 7.95, and 3.91 ppm, using the Exponential 5, Power, and Hill models, respectively (all constant variance). The BMD for all three values was 10.8 (± 0.1), within the range of the tested concentrations but suggesting that modeling uncertainty explains much of the variation across the endpoints (Table_Apx B-3).

4.2.2.3 POD Selection for Risk Estimation

4.2.2.3.1 Sensitivity Analysis for Potential Acute PODs

Table 4-1 presents potential options for acute hazard values based on endpoints that could plausibly result from a single exposure. These were not BMD modeled due to the uncertainty in the relevance of these endpoints. The potential risk thresholds based on the nominal acute POD/UF value were compared to that of the selected intermediate/chronic POD (see Section 4.2.2.3.2).

Table 4-1. Potential Acute PODs Compared to the Intermediate POD

Endpoint	Study POD (ppm)	HEC (ppm) ^a	POD/UF [UF]	Comments	Confidence	Source
Potential acute PODs						
Difficulty to focus / eye irritation in humans	LOAEC = 2,000	2,000	220 ppm [UF=3×3]	AEGL-1 value; considered a very mild effect closer to NOAEL, this analysis conservatively adds UF _L =3.	Moderate	(NAC/AEGL, 2009)
Abnormal sternebrae in mice	NOAEC = 200	50	1.7 ppm [UF=30]	Uncertain if these effects are adverse or would result from a single exposure and may be secondary to reduced maternal/fetal body weight.	Slight	(Battelle PNL, 1987b)
Dominant lethality / reduced male fertility	NOAEC = 130	32.5	1.1 ppm [UF=30]	Candidate POD based on 5 days of exposure; no effects seen at 6,250 from a single dose (Anderson et al., 1996).	Slight	(Adler et al., 1998)
Intermediate/chronic POD used for risk estimation						
Reduced fetal body weight	LOAEC = 40 ppm	2.5 ppm [UF=30]	0.08 ppm	See Section 4.2.2.3.2 for derivation; Unlikely to apply to single exposure.	See Section 4.2.2.3.2	(Battelle PNL, 1987b)
OSHA regulatory limits						
OSHA STEL	5 ppm	N/A	N/A	STEL = 5 × PEL; OSHA PEL = 1 ppm based on cancer.	N/A	FR 61: 56746–56856
HEC = human equivalent concentration; LOAEC = lowest-observed-adverse-effect concentration; NOAEC = no-observed-adverse-effect concentration; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; POD = point of departure; STEL = short-term exposure limit; UF = uncertainty factor						
^a HECs are derived based on adjusting for continuous exposure and default dosimetry approaches (see Section 4.2.2.1).						

All the acute PODs and risk thresholds derived in Table 4-1 are at least one order of magnitude greater than the POD for repeated exposure (reduced fetal body weight). Even when considering higher exposures for acute scenarios, acute risks based on any of these options would never approach that of intermediate risks from reduced fetal body weight. The only potential POD that likely applies to acute exposure is eye irritation in humans which has a theoretical POD/UF of 220 ppm when applying an additional $3 \times \text{UF}_L$ to the AEGL-1. The Occupational Safety and Health Administration (OSHA) enforces a 15-minute short-term exposure limit (STEL) of only 5 ppm, which is several orders of magnitude below the lowest concentration at which even these mild acute symptoms have been observed. This STEL is not based on any acute hazard but was set at five times the permissible exposure limit (PEL), which is based on cancer (FR 61:56746-56856, <https://www.osha.gov/laws-regs/federalregister/1996-11-04>; accessed November 20, 2025). Although the STEL does not provide any indication of acute hazard, it suggests that any risk threshold higher than 5 ppm is not necessary as it would not provide additional protection beyond existing regulatory limits.

In considering all reasonably available information, EPA has determined that it is unlikely any adverse effects will result following a single exposure at concentrations relevant to human exposures (*e.g.*, below the OSHA STEL). Therefore, the Agency has decided not to propose an acute non-cancer hazard value for risk estimation because any options would have low confidence and are less protective than the intermediate POD or existing regulatory limits.

4.2.2.3.2 Endpoints for Intermediate and Chronic Exposures

All the modeled intermediate endpoints are related to developmental toxicity and only differ by a few-fold across all endpoints and BMD results. Although all critical hazard outcomes categories were considered appropriate for dose-response analysis, maternal and developmental toxicity from gestational exposure are considered the most reliable for application to human risk characterization. These effects were observed to some extent in both rats and mice, underlying the “robust” judgment for the animal data that is being used for POD derivation. In contrast, dominant lethality was only observed in mice, resulting in a “moderate” judgment for animal evidence. Additionally, mechanistic evidence suggests some potential differential species sensitivity through genotoxicity of metabolites. Appendix A presents details on these weight of scientific evidence judgments.

Among the maternal and related developmental effects, fetal body weight reduction is usually associated with both reduced maternal weight (gain) and skeletal malformations ([Desesso and Scialli, 2018](#)). Reduced fetal body weight represents the least ambiguously adverse endpoint and presents the most sensitive POD among the hazard outcome via the nested dichotomous BMD modeling approach. EPA has high confidence in the resulting POD of 2.5 ppm because the result was identical within two significant figures from two combinations of percentile thresholds and BMRs (see details described in 4.2.2.2.1 and Table_Apx B-1). The POD for reduced fetal body weight is also protective of the POD for dominant lethality ($\text{BMDL}_5 = 4.83 \text{ ppm}$). This POD for fetal body weight therefore covers all developmental toxicity endpoints and will thus be used for risk estimation of intermediate exposures. The selection of fetal body weight as the basis of the intermediate POD is in agreement with EPA IRIS ([2002a](#)), who used fetal body weight for their subchronic (and acute) POD.

Similar to dominant lethality, chronic hematological effects were only observed in mice. Although there is evidence of a genotoxic contributing mechanism, genotoxicity in white blood cells and bone marrow have been observed in humans (Sections 4.1.2.3.3 and 5.2), suggesting that these effects are unlikely to be specific to mice only (Section 4.1.2.3.4). Nonetheless, the animal data was assigned a judgment of moderate (compared to robust for maternal developmental toxicity) and there is lower confidence in the POD estimates for anemia endpoints due to the failed BMD modeling with all doses. Additionally, the

BMDL_{5or10} for fetal body weight (2.5 ppm) that was selected for risk estimates of intermediate exposure is protective of the most sensitive POD for anemia (BMDL₅ = 3.91 ppm), which can be considered co-critical. Therefore, the POD for fetal body weight was also selected for risk estimation of chronic exposures. The selected POD and associated dataset are **bolded** in Table 4-2, which also presents the other PODs that EPA considered across the critical hazard domains.

Table 4-2. Dose-Response Analysis of Selected Studies and Endpoints Considered for Deriving Intermediate and Chronic PODs

Reference and Study Details (mg/kg-day)	Study POD/Type (ppm)	Effect/Dataset	HEC (ppm)	UFs
Battelle PNL (1987b) Pregnant CD-1 mice; inhalation; 0, 40, 200, 1,000 ppm; 6 h/day; GD 6-15 Toxicity following gestational exposure	LOAEL = 40 (NOAEL based on statistical reanalysis) (HEC = 10)	Male fetal body weight, continuously modeled	BMDL ₅ = 10.7 (Highest concentration dropped)	UF _A = 3 UF _H = 10 Total UF = 30
		Nested model, male data dichotomized based on 5th percentile of the control distribution	BMDL _{5or10} = 2.5 ^a	
	NOAEL = 40 (HEC = 10)	Absolute maternal body weight gain, GD 11–16	BMDL _{1SD} = 10.4	
	NOAEL = 40 (HEC = 10)	Incidence of supernumerary ribs, nested model	BMDL ₅ = 2.9 BMDL ₁₀ = 6.1	
Hazleton Labs (1981a) Pregnant SD rats; inhalation; 0, 200, 1,000, 8,000 ppm; 6 h/day; GD 6-15 Toxicity following gestational exposure	NOAEL = 200 (HEC = 50)	Absolute body weight gain (GD 6–15)	BMDL _{1SD} = 48.9	UF _A = 3 UF _H = 10 Total UF = 30
Brinkworth et al. (1998) ; Anderson et al. (1996) (combined) Male CD-1 mice; inhalation; 0, 12.5, 125 ppm, 1,250 ppm; 6 h/day; 5 days/week; 10 weeks Dominant lethality	NOAEL = 12.5 (LOAEL for Anderson et al., 1996) dataset (HEC = 2.14)	Combined incidence of deaths across two datasets	BMDL ₅ = 4.83	UF _A = 3 UF _H = 10 Total UF = 30
NTP (1993) Male B6C3F1 mice; inhalation; 0, 6.21, 19.8, 61.4, 199, or 619 ppm; 6 h/day; 5 days/week; 40 weeks Anemia	NOAEL = 19.8 (HEC = 3.54)	Absolute erythrocyte counts (10 ⁶ /μl) in males following 9 months of exposure	BMDL _{1SD} = 8.07 (Highest concentration dropped)	UF _A = 3 UF _H = 10 Total UF = 30
		↓ Hemoglobin concentration in males following 9 months of exposure	BMDL _{1SD} = 7.95 (Two highest concentrations dropped)	
		↓ Packed red cell volume (hematocrit) in males following 9 months of exposure	BMDL _{1SD} = 3.91 (Highest concentration dropped)	
*The BMDL ₅ based on the 5th percentile of the control distribution and the BMDL ₁₀ based on the 10th percentile of the control distribution are the same value of 2.5 ppm.				

4.2.2.4 Uncertainty Factors Used for Non-Cancer Endpoints

As shown in Table 4-2, EPA used a total UF of 30 for the benchmark MOEs for intermediate and chronic exposure durations based on BMDLs or NOAELs. Details on each UF are provided below. EPA guidance from ([U.S. EPA, 1994](#)), ([2002c](#)), and ([2012a](#)) further discuss considerations for application of UFs in human health hazard dose-response assessment. Other potential uncertainty factors not relevant to this assessment that EPA may consider are described in Appendix D.2.

1. Interspecies Uncertainty Factor (UF_A) of 3

EPA used data from inhalation toxicity studies in animals to derive relevant HECs. As described in Section 4.2.2.1, interspecies toxicokinetic dosimetry for systemic endpoints utilized relative blood:air coefficient across species, which defaults to 1. This consideration is expected to account for interspecies toxicokinetic differences for the selected endpoints. Therefore, only toxicodynamic differences across species are not accounted for in the HEC derivation, and the standard 10× UF_A is reduced to 3.

2. Intraspecies Uncertainty Factor (UF_H) of 10

EPA used a default UF_H of 10 to account for variation in sensitivity within human populations due to limited information regarding the degree to which human toxicokinetic and toxicodynamic variability may impact the disposition of or response to 1,3-butadiene.

4.2.2.5 Non-Cancer Hazard Values Selected for Use in Risk Estimation

The POD for reduced fetal body weight from ([Battelle PNL, 1987b](#)) is being proposed for risk estimation of intermediate and chronic exposures. Table 4-3 presents this POD along with the UFs and basic study information for the endpoint.

Table 4-3. Non-Cancer Points of Departure and Critical Endpoints Used for Risk Estimates of Each Exposure Scenario

Target Organ System	Species	Duration	Study POD/ Type	Effect	HEC (ppm) [mg/m ³]	Uncertainty Factors (UFs)	Reference	Overall Quality Determin.
Intermediate/chronic exposure scenarios								
Maternal/ Developmental	Mouse (Male)	10 days throughout gestation (GD 5–16)	LOAEL = 40 ppm	Reduced fetal body weight and other indications of	BMDL _{50r10} = 2.5 ppm (5.5 mg/m ³)	UF _A = 3; UF _H = 10; Total UF = 30	(Battelle PNL, 1987b)	Medium

5 CANCER HAZARD ASSESSMENT

The sections below outline human (Section 5.1), animal (Section 5.1.2), and mechanistic (Section 5.1.3) evidence for carcinogenicity. The cancer classification and summary of evidence integration conclusions is in Section 5.1.4. For complete details on the evidence for cancer, see the evidence profile tables organized by cancer type in Table_Apx A-5. Full details on all evaluated health outcomes from all key studies are in *Data Extraction Information for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene* ([U.S. EPA, 2025b](#)). Additional hazard information supporting evidence integration is presented in *Further Filtering Results for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene* ([U.S. EPA, 2025d](#)).

5.1 Cancer Hazard Identification

5.1.1 Epidemiology Studies

Following the TSCA systematic review process ([U.S. EPA, 2025i](#)), EPA identified 72 epidemiological publications. Of those, the Agency identified 35 publications that conducted dose-response association based on at least 2 exposure levels (plus a reference level) of continuous exposure data. Of these 35 epidemiological publications with dose-response analyses and cumulative exposure, 21 investigated leukemia and 7 investigated bladder cancer.

5.1.1.1 Lymphohematopoietic cancers

Numerous retrospective occupational cohort publications of SBR workers, involving more than 22,000 men and women, have studied the health effects of 1,3-butadiene ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021b](#); [Sathiakumar et al., 2019](#); [Sathiakumar et al., 2015](#); [Sielken and Valdez-Flores, 2013, 2011](#); [Graff et al., 2009](#); [Sathiakumar and Delzell, 2009](#); [Sielken, 2007](#); [Delzell et al., 2006](#); [Graff et al., 2005](#); [Sathiakumar et al., 2005](#); [Delzell et al., 2001](#); [Sielken and Valdez-Flores, 2001](#); [IISRP, 1999](#); [Delzell et al., 1996](#); [UAB, 1995a](#); [IISRP, 1986](#)). Similarly, another retrospective occupational cohort study that used data from a part of the same cohort study focused specifically on 2,800 butadiene monomer workers (n = 2,800 men) ([Divine and Hartman, 2001](#)). Most of these occupational cohort studies or publications found a positive association between 1,3-butadiene exposure and leukemia.

Beyond occupational studies, several case-control studies have investigated the association between 1,3-butadiene exposure and childhood leukemia. A study investigated maternal exposure to 1,3-butadiene exposure during pregnancy and the risk of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in children aged under 6 years, using air monitoring data from the nearest station to the maternal address ([Heck et al., 2014](#)). Another study focused ALL in children aged less than 5 years, utilizing modeled air concentrations at the maternal address at birth ([Symanski et al., 2016](#)). An ecological study investigated leukemia, Hodgkin's disease, and non-Hodgkin lymphoma (NHL) in individuals under 20 years old based on modeled air concentrations at the residence at diagnosis ([Whitworth et al., 2008](#)).

Governmental reviews of older epidemiology data concluded that occupational exposure to 1,3-butadiene was associated with increased mortality from leukemia and NHL ([ATSDR, 2012](#)). One semiquantitative study assessed relative levels of male hematopoietic cancer near hydrocarbon processing centers in Canada ([Simpson et al., 2013](#)). In a large cohort of styrene-butadiene rubber (SBR) workers, exposure to 1,3-butadiene was associated with an increased risk of mortality from leukemia in men and women. The risk increased with the magnitude and duration of exposure and remained elevated after control for covariates including styrene exposure, consideration of alternative exposure

assessments, and longer follow-up times ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021b](#); [Sathiakumar et al., 2019](#); [Sathiakumar et al., 2015](#); [Sielken and Valdez-Flores, 2013, 2011](#); [Graff et al., 2009](#); [Cheng et al., 2007](#); [Graff et al., 2005](#); [Sathiakumar et al., 2005](#); [Delzell et al., 2001](#); [Sielken and Valdez-Flores, 2001](#); [IISRP, 1999](#); [Delzell et al., 1996](#); [UAB, 1995a](#); [IISRP, 1986](#)). The most recent analyses with the longest follow-up of this cohort reported an exposure-response trend for lymphoid leukemia but not myeloid leukemia, and trends for B-cell malignancies in some, but not all, analyses ([Sathiakumar et al., 2021b](#)). Consistent with the occupational cohort, in butadiene monomer workers, exposure to 1,3-butadiene was associated with increased mortality from lymphohematopoietic cancer ([Divine and Hartman, 2001](#)). Furthermore, in case-control studies of non-occupational populations, higher measured or modeled air concentration of 1,3-butadiene was associated with increased odds of leukemia, ALL, and/or AML ([Symanski et al., 2016](#); [Heck et al., 2014](#); [Whitworth et al., 2008](#)). Male hematopoietic cancers were elevated (no statistics provided) near a hydrocarbon processing center with high 1,3-butadiene levels, but the causal association between these cancers and 1,3-butadiene exposure cannot be confirmed due to the study design ([Simpson et al., 2013](#)). In butadiene monomer workers, the relative risk of leukemia death was not correlated with increasing 1,3-butadiene exposure ([Divine and Hartman, 2001](#)). The classification of lymphohematopoietic cancers is complex and has changed over time. Overall, extensive analyses of a large cohort of SBR workers reveal a clear association between occupational 1,3-butadiene exposure and elevated mortality from leukemia. Based on the human evidence, the overall judgment for the association between 1,3-butadiene exposure and leukemia and other lymphohematopoietic cancers is robust.

5.1.1.2 Bladder Cancer

Bladder cancer mortality has been linked to exposure to 1,3-butadiene in SBR workers. The most recent analysis with the most extended follow-up has demonstrated an increased risk of mortality from bladder cancer associated with 1,3-butadiene exposure, exhibiting a clear exposure-response trend ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021a](#); [Sathiakumar et al., 2019](#)). This association may be confounded by smoking, as smoking data were unavailable for the cohort ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021a](#); [Sathiakumar et al., 2019](#)). However, the use of Cox Proportional Hazard controls with similar smoking histories can resolve this issue. In contrast, no association between 1,3-butadiene exposure and bladder cancer was observed in a smaller cohort of butadiene monomer workers ([Divine and Hartman, 2001](#)). Overall, an association between 1,3-butadiene exposure and exposure-related increase in bladder cancer mortality was observed in SBR workers, the absence of smoking data does not necessarily limit the interpretation of these findings.

5.1.1.3 Central Nervous System Cancers

Central nervous system cancer has been studied in relation to 1,3-butadiene exposure, with varied results. An increased incidence rate ratio for astrocytomas other than juvenile pilocytic astrocytoma (JPA) were associated with modeled 1,3-butadiene concentrations in quartile 2 (Q2) and Q3, but not in Q4 ([Danysh et al., 2015](#)). Additionally, increased odds of primitive neuroectodermal tumors were associated with 1,3-butadiene in ambient air during pregnancy and first year of life ([Von Ehrenstein et al., 2016](#)). In the study conducted by Danysh, ([2015](#)), there may have been misclassification of exposure due to the use of census tract-level estimates to represent individual exposure. In addition, exposure estimates were assigned based on address at time of diagnosis. Furthermore, confounding factors are possible because exposure estimates were higher near major metropolitan areas, though urban/rural status was not evaluated as a potential confounder. Also, the modeled 1,3-butadiene concentration was highly correlated with modeled concentrations of other chemicals but confounding by co-exposures was not evaluated ([Danysh et al., 2015](#)). No association was observed between 1,3-butadiene exposure and astrocytomas in the study by ([Von Ehrenstein et al., 2016](#)), nor with central nervous system cancer and/or central nervous system cancer mortality in various occupational cohort publications ([Sathiakumar](#)

[et al., 2019](#); [Sathiakumar and Delzell, 2009](#); [Sathiakumar et al., 2005](#); [Divine and Hartman, 2001](#); [IISRP, 1986](#)). Overall, an association between modeled 1,3-butadiene concentration and non-JPA astrocytomas in children was reported in an ecological study but not in the highest quartile of exposure. The study was limited by its design as well as lack of adjustment for important confounders and co-exposures.

5.1.1.4 Breast Cancer

Two cohort and one nested case-control of a population-based cohort epidemiological studies investigated the association between 1,3-butadiene exposure and breast cancer. In the SBR cohort, two publications ([Sathiakumar et al., 2019](#); [Sathiakumar and Delzell, 2007](#)) investigated the standardized mortality ratio (SMR) of breast cancer but did not find significantly higher breast mortality. One cohort ([Heck et al., 2024](#)) and one nested case-control study of a cohort study ([Ellis et al., 2025](#)) investigated the 1,3-butadiene exposure and breast cancer. Both studies investigated female breast cancer risk and 1,3-butadiene exposure in ambient air from the National Air Toxics Assessment (NATA) for the general public, but their study results are not consistent. Heck et al. ([2024](#)) studied 48,665 California women and found a statistically significant adjusted Hazard Ratio (HR) for breast cancer risk of 1.18 (95% CI = 1.13–1.23). When stratified by breast cancer subtypes, the HR for hormone receptor-positive (HR+) female breast cancers (positive for estrogen receptors or progesterone receptors [ER+ or PR+]) was 1.24 (95% CI = 1.14–1.35) and the HR for hormone receptor-negative (HR–) female breast cancers (negative for estrogen and progesterone receptors [ER– and PR–]) was 1.17 (95% CI = 1.11–1.23). On the other hand, a nested case-control study ([Ellis et al., 2025](#)) found no statistically significant odds ratio (OR) of overall breast cancer risk for Arkansas women. First-degree family history is an important risk factor for breast cancer development. The authors separated the study participants by first-degree family history and found that, for women without first-degree family history, there is no statistically significant OR for the association between 1,3-butadiene and breast cancer. In conclusion, based on the results of these epidemiological studies, the association between 1,3-butadiene and breast cancer is slight due to the lack of coherence.

5.1.1.5 Other Cancer Types

Exposure to 1,3-butadiene has been investigated for its potential link to germ cell tumors. Increased odds of all germ cell tumors and yolk sac tumors associated with 1,3-butadiene concentration in ambient air during the second trimester ([Hall et al., 2019](#)). However, no associations were identified for germ cell tumors or yolk sac tumors with 1,3-butadiene concentration in ambient air during the first or third trimester ([Hall et al., 2019](#)). One known risk factor for germ cell tumors, cryptorchidism, was not accounted for in the study because data were not available for the study population. Overall, in a single study, an association was observed between 1,3-butadiene concentration in ambient air during pregnancy and all germ cell tumors and yolk sac tumors in children. No other studies of this endpoint were located.

Exposure to 1,3-butadiene has been studied in relation to lung cancer—particularly in occupational settings. In a large cohort of SBR workers, exposure to 1,3-butadiene was associated with increased mortality (standardized mortality ratio) from lung cancer among female workers ([Sathiakumar et al., 2019](#); [Sathiakumar et al., 2009](#); [Sathiakumar and Delzell, 2009](#); [Sathiakumar et al., 2005](#); [UAB, 1995a](#); [IISRP, 1986](#)). However, there was no exposure response trend observed, and the analysis was adjusted for smoking. The publication authors indicated that indirect adjustment for smoking partially explained the increase in mortality among female workers ([Sathiakumar et al., 2019](#)). In contrast, no association between 1,3-butadiene exposure and lung cancer was observed in male SBR workers ([Sathiakumar et al., 2019](#); [Sathiakumar et al., 2009](#); [Sathiakumar et al., 2005](#); [Divine and Hartman, 2001](#); [UAB, 1995a](#); [IISRP, 1986](#)). General population studies provided limited information on lung cancer due to ecological

study design ([Luo et al., 2011](#)) or analysis limited to male smokers ([Yuan et al., 2012](#)). Overall, an association between 1,3-butadiene exposure and lung cancer mortality was observed in female SBR workers, but this association was not seen in male workers. The lack of a dose-response relationship and potential confounding by smoking complicate the interpretation of these findings.

Increased odds of retinoblastoma were associated with 1,3-butadiene concentration in ambient air during pregnancy ([Heck et al., 2015](#)). However, no association was observed between 1,3-butadiene exposure and mortality from ocular tumors in a large cohort of male SBR workers, tumors affecting vision are still adverse even if not fatal ([IISRP, 1986](#)). Overall, an association between 1,3-butadiene concentration in ambient air during pregnancy and retinoblastoma in children was observed in a single study.

Regarding other cancers, in a retrospective cohort study of a small group of butadiene monomer workers, employment in the rubber reserve unit for at least 2 years was associated with increased mortality from stomach cancer, although exposure levels were not quantified ([Ward et al., 1996a](#); [Ward et al., 1995](#)). In contrast, larger retrospective cohort publications of SBR workers ([Sathiakumar et al., 2019](#); [Sathiakumar and Delzell, 2009](#); [Sathiakumar et al., 2005](#); [UAB, 1995a](#); [IISRP, 1986](#)) and butadiene monomer workers ([Divine and Hartman, 2001](#)), found no association between 1,3-butadiene exposure and mortality from cancers of the gastrointestinal tract. Overall, available studies have also identified no association between 1,3-butadiene exposure and cancers of the breast, liver, ovaries, pancreas, skin, thyroid, or uterus. The weight of evidence from available studies also does not support an association with stomach cancer.

5.1.2 Laboratory Animal Studies

In laboratory animals, 1,3-butadiene consistently induced tumors at multiple sites in both mice and rats. A total of four studies were conducted, with four in mice and one rats. These studies assessed various tumor types, including lung, liver, mammary gland, as well as testicular tumors, across different exposure durations and concentrations. The majority of these studies, such as those conducted by NTP ([NTP, 1993](#)) and Hazleton labs ([Hazleton Labs, 1981b](#)) were guideline-like studies (*i.e.*, did not formally follow a guideline but the methods and level of detail presented are highly similar to current OECD guideline requirements).

Regarding lymphohematopoietic system cancers, one study exposed mice to concentrations up to 1,250 ppm for 60 to 61 weeks ([NTP, 1984](#)), while another study exposed mice up to 619 ppm for 103 weeks ([NTP, 1993](#)). Additional studies included stop exposure experiments focusing on males ([NTP, 1993](#)) and a separate study where mice were exposed to up to 10,000 ppm for a single 2-hour exposure followed by a 2-year observation period ([Bucher et al., 1993](#)). The NTP 1993 study demonstrated significant dose related trends and pairwise comparison with concurrent controls for histiocytic sarcoma in both male and female mice, with significant increases persisting after survival adjustment ([NTP, 1993](#)). In male mice, all stop-exposure groups exhibited significantly elevated tumor incidence, including those exposed for shorter durations at higher concentrations, such as 625 ppm for 13 weeks. Furthermore, significant dose related trends were observed for malignant lymphoma/lymphatic lymphoma in both male and female mice across the studies in all groups of the stop-exposure experiment ([NTP, 1993](#)).

In the 103-week study, these increases remained significant even after survival adjustment. Malignant lymphomas, appearing as early as weeks 20 to 23, were identified as the primary cause of early deaths in exposed mice ([NTP, 1993](#)). Importantly, no increase in hematopoietic system tumors were observed in rats, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)). Overall, exposure to 1,3-butadiene induced dose-related increased incidences of hematopoietic system cancers in male and female mice, which were the primary cause of early deaths in these studies.

Regarding heart hemangiosarcomas, two studies demonstrated significant dose-related increases in both male and female mice exposed to 1,3-butadiene. These increases remained significant even after adjusting for survival and were observed in all stop-exposure groups of male mice ([NTP, 1993](#)). Importantly, heart angiosarcomas are rare in B6C3F1 mice and were not observed in historical control ([NTP, 1993](#)). In the 103-week study, heart hemangiosarcomas were the second-most common cause of early death ([NTP, 1993](#)). In contrast, there was no increase in heart tumor incidence in rats, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)). Overall, exposure to 1,3-butadiene induced dose-related increases in the incidences of heart hemangiosarcomas in male and female mice, and these cancers were the second-most common cause of early deaths in exposed mice in both studies. No increase in heart tumor incidence was observed in exposed rats.

Regarding gastrointestinal tumors, significant dose-related trends and/or pairwise comparisons with concurrent controls were observed for forestomach papilloma or carcinoma incidences in male and female mice in two studies ([NTP, 1993, 1984](#)). In the 103-week study, significant increases remained after adjustment for survival. Significantly increased incidences of forestomach papilloma or carcinoma were also seen in male mice in stop-exposure studies ([NTP, 1993](#)). Exposure to 1,3-butadiene induced increased incidences of forestomach papilloma or carcinoma in male and female mice, but no such increase was observed in exposed rats. Rats are obligate nasal breathers while mice can also breathe through their mouth, suggesting there could be oral swallowing of the 1,3-dichloropropene in mice and dual route exposures.

Regarding Harderian gland tumors, mouse studies showed significant dose-related trends and pairwise comparisons with concurrent controls for Harderian gland adenoma or carcinoma in male mice, with exposure up to 619 ppm for 103 weeks ([NTP, 1993](#)). These significant increases remained after adjustment for survival and were noted in all stop-exposure groups, males only ([NTP, 1993](#)). Additionally, survival-adjusted incidences of Harderian gland adenoma or carcinoma were significantly increased (pairwise relative to concurrent control) in female mice ([NTP, 1993](#)). In contrast, rat studies involved exposure to up to 8,000 ppm for 105 to 111 weeks but showed no increase in Harderian gland tumor incidence, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)). The concurrent female mouse control incidence exceeded the upper limit of historical control incidence ([NTP, 1993](#)). Overall, exposure to 1,3-butadiene induced increased incidences of Harderian gland adenoma or carcinoma in male and female mice. However, no increase in Harderian gland tumor incidence was observed in exposed rats.

Significant dose-related trends and pairwise comparisons with concurrent controls were observed for hepatocellular adenoma and/or carcinoma in female mice in two studies ([NTP, 1993, 1984](#)). Survival-adjusted incidences were significantly increased in both male and female mice in the 103-week study ([NTP, 1993](#)). However, no increase in liver tumor incidence was observed in rats, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)).

Significant dose-related trends and pairwise comparisons with concurrent controls were observed for alveolar/bronchiolar adenoma, adenocarcinoma, and/or carcinoma in male and female mice in two studies ([NTP, 1993, 1984](#)). In the 103-week study, while incidences exceeded the upper limit for historical control ranges, the most significant findings were observed in comparison to concurrent controls, with increases persisting even after adjustment of survival. Significantly increased incidences were also seen in male mice in all stop-exposure groups ([NTP, 1993](#)). In the 103-week study, the incidence of alveolar/bronchiolar adenoma, adenocarcinoma, or carcinoma in concurrent control males exceeded the upper limit for historical controls ([NTP, 1993](#)). However, no increase in lung tumor

incidence in rats, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)). Exposure to 1,3-butadiene induced increased incidences of lung tumors in male and female mice. No increase in lung tumor incidence was observed in exposed rats.

Significant dose-related trends and pairwise comparisons with concurrent control were observed for mammary gland acinar cell carcinoma in female mice ([NTP, 1984](#)) and for mammary gland adenocarcinoma, carcinoma, or malignant mixed tumor in female mice ([NTP, 1993](#)). In the 103-week study, significant increases in adenocarcinoma or carcinoma incidence remained after adjustment for survival. Furthermore, significant dose-related trends and pairwise comparisons with concurrent controls showed increased incidences of benign and total (benign + malignant) mammary gland tumors in female rats ([Hazleton Labs, 1981b](#)). However, historical control incidences were not reported for mice or rats. Overall, exposure to 1,3-butadiene induced increased incidences of mammary gland tumors in female mice and female rats.

A significant dose-related trend for the increased incidence of brain glial cell tumors was observed in male rats ([Hazleton Labs, 1981b](#)). Similarly, in a 60-week study, brain gliomas were identified in two male mice at 619 ppm and one male mouse at 1,260 ppm, while an ependymoma of the brain was observed in one male mouse at 619 ppm ([NTP, 1984](#)). Furthermore, in the 103-week study, a malignant glioma was observed in one male mouse at 199 ppm ([NTP, 1993](#)). In the stop-exposure studies at 619 ppm, malignant gliomas were found in two male mice after 13 weeks of exposure and in one male mouse after 26 weeks. Additionally, malignant neuroblastomas were identified in two male mice after 13 weeks ([NTP, 1993](#)). Gliomas and neuroblastomas are rare in B6C3F1 mice and were not seen in historical controls according to ([NTP, 1993](#)). There were no statistically significant pairwise comparisons with concurrent control group for male rats. No historical control data were reported ([Hazleton Labs, 1981b](#)). No statistically significant pairwise comparisons with the concurrent control group for male rats and no historical control data were reported ([Hazleton Labs, 1981b](#)). No brain glial cell tumors were observed in female rats ([Hazleton Labs, 1981b](#)). Similarly, no gliomas, ependymomas, or neuroblastomas were observed in female mice ([NTP, 1993](#)), indicating a lack of consistency across sexes. Overall, brain glial cell tumors were observed in exposed male rats with dose-related trends and low incidences of gliomas, neuroblastomas, and ependymoma in exposed male B6C3F1 mice. These tumors are rare in B6C3F1 mice.

Ovarian atrophy was observed in female mice exposed to 1,3-butadiene (Section 4.1.1). Significant dose-related trends and pairwise comparisons with concurrent control were observed for ovarian granulosa cell tumors in female mice in two studies ([NTP, 1993, 1984](#)). In the 103-week study, significant increases remained after adjustment for survival, and survival-adjusted rates exhibited monotonicity with exposure ([NTP, 1993](#)). Conversely, no increase in ovarian tumor incidence was observed in female rats, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)). Overall, exposure to 1,3-butadiene induced increased incidences of ovarian granulosa cell tumors in mice. No increase in ovarian tumor incidence was observed in exposed rats.

Pancreatic tumors showed a significant dose-related trend and pairwise comparison with concurrent control for the increased incidence of pancreatic exocrine adenomas in male rats ([Hazleton Labs, 1981b](#)). However, no increase in pancreatic tumor incidence was observed in mice ([NTP, 1993, 1984](#)), indicating a lack of consistency across species. Similarly, no increase in pancreatic tumor incidence was observed in female rats, suggesting a lack of consistency across sexes of rat ([Hazleton Labs, 1981b](#)). Historical control incidences were not reported ([Hazleton Labs, 1981b](#)). Overall, exposure to 1,3-butadiene induced increased incidences of pancreatic exocrine adenomas in male rats; no increase in pancreatic tumor incidence was observed in exposed female rats or in exposed male or female mice.

Significant pairwise comparisons with concurrent controls were observed for preputial gland adenoma or carcinoma in mice in the stop-exposure experiments with highest cumulative exposures ([NTP, 1993](#)). In the 103-week experiment, the survival-adjusted incidence for preputial gland carcinoma was significantly increased compared to concurrent controls. Importantly, preputial gland carcinomas are rare in B6C3F1 mice and were not observed in historical controls according to ([NTP, 1993](#)). Overall, increased incidences of preputial gland adenomas and/or carcinomas were observed in mice exposed to higher cumulative levels of 1,3-butadiene in a single study ([NTP, 1993](#)), with no corresponding data available for rats.

Subcutaneous skin tumors exhibited significant dose-related trends and pairwise comparisons with concurrent control for increased incidences of subcutaneous skin hemangiosarcoma and neurofibrosarcoma or sarcoma in female mice. Significantly, incidences in several groups exceeded the upper limits of the respective historical control ranges ([NTP, 1993](#)). In contrast, no increase in subcutaneous skin tumor incidence was observed in male mice across two studies ([NTP, 1993, 1984](#)), and similarly, no increase was found in rats, indicating a lack of consistency across species ([Hazleton Labs, 1981b](#)). Overall, exposure to 1,3-butadiene resulted in increased incidences of subcutaneous skin tumors in female mice. However, no such increase was observed in exposed male mice or male or female rats.

Testicular tumors exhibited significant dose-related trends and pairwise comparisons with concurrent controls, indicating an increased incidence of testicular Leydig cell tumors in male rats ([Hazleton Labs, 1981b](#)). However, no increase in testicular tumor incidence was observed in male mice across two studies ([NTP, 1993, 1984](#)), indicating a lack of consistency across species. Overall, increased incidences of testicular Leydig cell tumors were observed in rats. In contrast, no similar increase in testicular tumor incidence was observed in male mice.

Studies showed significant dose-related trends and pairwise comparisons with concurrent control for increased incidence of thyroid follicular cell adenomas in female rats ([Hazleton Labs, 1981b](#)). However, no increase in thyroid tumor incidence was observed in male rats ([Hazleton Labs, 1981b](#)), indicating a lack of consistency across sexes. In addition, no increase in thyroid tumors was observed in mice ([NTP, 1993, 1984](#)), indicating a lack of consistency across species. Overall, Increased incidences of thyroid tumors were observed in female rats. No increase in thyroid tumor incidence was observed in exposed male rats or mice of either sex.

Significant dose-related trend for increased incidence of Zymbal gland carcinomas was observed in female rats ([Hazleton Labs, 1981b](#)). In contrast, low incidences of Zymbal gland adenomas and carcinomas were observed in male and/or female mice in all mouse studies including stop-exposure studies ([NTP, 1993, 1984](#)). Importantly, Zymbal gland tumors are rare in B6C3F1 mice and were not seen in historical controls according to ([NTP, 1993](#)). No significant pairwise comparisons for Zymbal gland carcinomas were found in female rats. No increase in tumor incidence in male rats. Historical control incidences were not reported ([Hazleton Labs, 1981b](#)). In addition, tumor incidences in mice were not significantly increased over concurrent controls at any exposure level, and there were no significant dose-related trends ([NTP, 1993, 1984](#)). Overall, Zymbal gland tumors were observed in female rats with dose-related trend and at low incidences in male and female B6C3F1 mice, where these tumors are rare.

Uterine tumors exhibited a significant dose-related trend for increased incidence of uterine sarcomas in female rats ([Hazleton Labs, 1981b](#)). However, no significant pairwise comparisons with concurrent control for uterine sarcomas were found in female rats and no historical control data were reported for

uterine tumors in female rats ([Hazleton Labs, 1981b](#)). Additionally, there was no increase in uterine tumor incidence in female mice across two studies ([NTP, 1993, 1984](#)). This indicates a lack of consistency across species. Overall, although a dose-related trend for increased uterine tumors was observed in rats, the absence of significant pairwise comparison weakens the strength of these findings.

Across multiple studies, dose related increases in tumors were consistently observed in mice, particularly affecting lymphohematopoietic system, heart, gastrointestinal tract, lungs. These findings persisted even after survival adjustments and were noted in stop-exposure studies, confirming the carcinogenic potential of 1,3-butadiene. However, rats did not exhibit similar tumor profiles. For example, while malignant lymphomas were prevalent in mice, rats exposed to 1,3-butadiene did not show a corresponding increase in hematopoietic system cancers. Similarly, heart hemangiosarcomas and gastrointestinal tumors were seen in mice, but not in rats, suggesting a species-specific response. Moreover, tumors observed at the lowest dose of 6.25 ppm in mice, particularly alveolar bronchiolar adenoma or carcinoma in females, whereas in rats, significant tumor development was only seen at doses of 1,000 ppm and higher.

5.1.3 Mechanistic and Supporting Evidence

Mechanistic studies have provided substantial evidence regarding the mutagenic and carcinogenic properties of 1,3-butadiene. As outlined in Section 3.3, the bioactivation of 1,3-butadiene into DNA reactive metabolite is a critical step in its carcinogenic MOA, leading to DNA adduct formation, DNA damage, and mutations, as extensively discussed in Section 5.3. These effects have been observed in both human and rodent cells. The evidence shows that 1,3-butadiene exposure causes genotoxicity through DNA adduct formation and mutations in cancer-related genes, correlating with species difference in metabolism.

5.1.4 Cancer Classification and Evidence Integration Conclusions

Under the *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)), 1,3-butadiene is considered “Carcinogenic to Humans” based on the adequate evidence demonstrating 1,3-butadiene’s carcinogenic potential in both humans and animals across multiple tumor types.

Table 5-1 summarizes the evidence integration judgments for each evidence stream across all cancer types. Evidence for lymphohematopoietic cancer was robust across all three evidence streams. Bladder cancer had moderate human evidence, and all other cancers had indeterminate human evidence. See Appendix A for the full evidence integration table for 1,3-butadiene, organized by cancer type. For complete details on evidence integration judgments within and across evidence streams, see the evidence profile tables for data-rich organ systems in Appendix A. Evidence integration judgments were determined based on considerations described in Chapter 7 of the Draft Systematic Review Protocol ([U.S. EPA, 2021](#)). In short, strength of the evidence judgments (robust, moderate, slight, indeterminate, or compelling evidence of no effect) for individual evidence streams (*i.e.*, human, animal, mechanistic) were determined by expert judgment based on quality of the database, consistency, magnitude and precision, dose-response, and biological significance. For cancer, the overall cancer classification incorporates considerations across evidence streams for all cancers, consistent with ([U.S. EPA, 2005a](#)).

Table 5-1. Evidence Integration Judgments for Each Cancer Type

Cancer Type	Human	Animal	Mechanistic
Lymphohematopoietic	Robust	Robust	Robust
Bladder	Moderate	Indeterminate	Slight
Brain	Indeterminate	Slight	Slight
GI	Indeterminate	Moderate	Slight
Harderian	N/A	Moderate	Slight
Heart	Indeterminate	Robust	Slight
Liver	Indeterminate	Moderate	Slight
Lung	Indeterminate	Moderate	Slight
Mammary/Breast	Indeterminate	Moderate	Slight
Ovary	Indeterminate	Slight	Slight
Pancreas	Indeterminate	Slight	Slight
Preputial	Indeterminate	Slight	Slight
Skin	Indeterminate	Slight	Slight
Testes	Indeterminate	Slight	Slight
Thyroid	Indeterminate	Slight	Slight
Zymbal	N/A	Slight	Slight
CNS	Indeterminate	Indeterminate	Slight
Germ cell	Indeterminate	Indeterminate	Slight
Ocular	Indeterminate	Indeterminate	Slight
Uterus	Indeterminate	Indeterminate	Slight

5.2 Genotoxicity and Mutagenicity

Extensive evidence has demonstrated the genotoxic potential of 1,3-butadiene across various biological systems. In brief, 1,3-butadiene has been found to induce genotoxic effects in a wide range of *in vitro* and *in vivo* test systems. 1,3-Butadiene genotoxicity is attributed to its metabolic activation into DNA-reactive epoxide intermediates, primarily the epoxide metabolites EB, DEB, and EBD ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)).

Studies have shown that these epoxide metabolites cause various types of genetic damage, including SCEs, micronuclei, and DNA adducts ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Moreover, this genotoxic effect has been consistently observed in various experimental models, including bacterial mutagenicity assays, mammalian cell cultures, and *in vivo* studies ([Albertini et al., 2010](#)). Studies on the genotoxicity of 1,3-butadiene in bacteria show variable results, with positive findings consistently observed only in the presence of liver S9 metabolic activation system ([ATSDR, 2012](#); [IARC, 2008b](#); [U.S. EPA, 2002a](#)). Numerous inhalation studies have consistently demonstrated the genotoxic effects of 1,3-butadiene in rodents, including the increased formation of micronuclei in erythrocytes, spermatocytes, and bone marrow cells, as well as increased sister chromatid exchanges in mice ([ATSDR, 2012](#); [IARC, 2008b](#); [U.S. EPA, 2002a](#)). In both mice and rats, an increased phosphoribosyltransferase HPRT locus (*HPRT* gene) mutation was observed in splenic T cells ([ATSDR, 2012](#)).

Limited studies in rats suggest that exposure to 1,3-butadiene at tested doses does not increase micronuclei or SCEs in bone marrow ([Autio et al., 1994](#); [Cunningham et al., 1986](#)). The decreased

genotoxicity observed in rats, potentially linked to the reduced formation DNA reactive metabolites compared to mice, may also play a role in the lower incidence of 1,3-butadiene induced cancers in rats.

In rodent models, DEB is recognized as the most genotoxic metabolite due to its ability to form DNA interstrand cross-links and is considered the primary carcinogenic metabolite ([Swenberg et al., 2011](#); [Cochrane and Skopek, 1994](#)). Furthermore, quantitative genotoxicity studies in mice have revealed that DEB is 40-fold more genotoxic than EB and 100-fold genotoxic than EBD ([Cochrane and Skopek, 1994](#)). In contrast, humans predominantly metabolize 1,3-butadiene into EBD, as evidenced by higher levels of EBD-derived hemoglobin adducts compared to other metabolites ([Boysen et al., 2012](#); [Albertini et al., 2003](#)). A recent study has revealed that EBD and analogs have the potential to induce DNA damage at a similar rate to DEB in cells deficient in Fanconi anemia genes (FANC) ([Nakamura et al., 2021](#)). This is significant due to the high bioavailability of EBD in humans, with bone marrow being the primary target of 1,3-butadiene toxicity ([Tice et al., 1987](#)). However, the precise contribution of these metabolites to 1,3-butadiene-induced carcinogenicity in humans remains to be fully elucidated.

Several occupational exposure cohorts have investigated 1,3-butadiene's genotoxicity with variable results. Some studies, particularly in Texas, have reported *HPRT* gene mutations significantly elevated in BD-exposed workers while studies in China and the Czech Republic did not find such elevations, possibly due to differences in exposure levels and methodologies ([ATSDR, 2012](#)). However, several studies using micronucleus assay on exposed humans have consistently shown that occupational 1,3-butadiene exposure induces chromosome damage ([Federico et al., 2019](#); [Xiang et al., 2015](#); [Cheng et al., 2013](#); [Xiang et al., 2012](#); [Wang et al., 2010](#)). Despite some variability in human studies, the overall weight of scientific evidence strongly suggests that 1,3-butadiene poses a significant genotoxic and mutagenic risk.

Results from mutagenicity or chromosome/cytogenetic damage assays are summarized together in Table 5-2. This table includes all data summarized in EPA IRIS ([2002a](#)), ATSDR ([2012](#)), and IARC ([2008b](#)). Positive studies are bolded. A formal evaluation of mutagenicity as the primary MOA for carcinogenicity follows in Section 5.3.

Table 5-2. Summary of Mutagenicity and Chromosome Damage Studies From KE3

Assay Type	Test System (Species/ Strain/ Sex)	Metabolic Activation	Results	Reference
Gene mutations – <i>in vitro</i>				
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA100	With S9 fraction activation	Positive	Araki et al. (1994)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA1535	With S9 fraction activation	Positive	De Meester et al. (1980)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA1535	With S9 fraction activation	Positive	Arce et al. (1990)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA1535	With S9 fraction activation	Positive	Araki et al. (1994)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA1535	With S9 fraction activation	Positive	Madhusree et al. (2002)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA1537	With and without activation	Negative	Araki et al. (1994)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA98	With and without activation	Negative	Arce et al. (1990)

Assay Type	Test System (Species/ Strain/ Sex)	Metabolic Activation	Results	Reference
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA98	With and without activation	Negative	Araki et al. (1994)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA97	With and without activation	Negative	Arce et al. (1990)
Bacterial reverse mutation assay	<i>E. coli</i> WP2 <i>uvrA</i>	With and without activation	Negative	Araki et al. (1994)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA100	With and without activation	Negative	Victorin and Ståhlberg (1988)
Bacterial reverse mutation assay	<i>S. typhimurium</i> TA100	With and without activation	Negative	Arce et al. (1990)
Gene mutations – rodents <i>in vivo</i>				
Mice data				
<i>hprt</i> locus in T lymphocytes	CD1 mice	Not applicable	Negative	Tates et al. (1998)
<i>hprt</i> locus in T lymphocytes	B6C3F1 mice	Not applicable	Positive	Tates et al. (1994)
<i>hprt</i> locus in T lymphocytes	(102 × C3H)F1 mice	Not applicable	Positive	Tates et al. (1998)
<i>hprt</i> locus in T lymphocytes	B6C3F1 mice	Not applicable	Positive	Meng et al. (1999); Meng et al. (1998)
<i>hprt</i> locus in T lymphocytes (high dose)	B6C3F1 mice	Not applicable	Positive	Meng et al. (1998)
<i>hprt</i> locus in T lymphocytes (low dose)	B6C3F1 mice	Not applicable	Positive	Meng et al. (1999)
<i>hprt</i> loci mutations in splenic T lymphocytes	B6C3F1 mice	Not applicable	Positive	Cochrane and Skopek (1994)
Spot test	T-stock female mice	Not applicable	Positive	Adler et al. (1994)
<i>lacI</i> locus in bone marrow (i.e., Big Blue)	B6C3F1 mice	Not applicable	Positive	Recio et al. (1996); Sisk et al. (1994)
<i>lacI</i> locus in spleen (i.e., Big Blue)	B6C3F1 mice	Not applicable	Positive	Recio et al. (1998)
<i>lacZ</i> mutant frequency in lung	B6C3F1 mice	Not applicable	Positive	Recio et al. (1992)
<i>lacZ</i> -mutant frequency in liver and bone marrow	B6C3F1 mice	Not applicable	Negative	Recio et al. (1992)
Rat data				
<i>hprt</i> locus in T lymphocytes (high dose)	F344 rats	Not applicable	Positive	Meng et al. (1998)
<i>hprt</i> locus in T lymphocytes (lower dose)	F344 rats	Not applicable	Positive	Meng et al. (1999)
Gene mutations – humans				
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Negative	Hayes et al. (2001); Hayes et al. (2000); Hayes et al. (1996)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Negative	Tates et al. (1996)

Assay Type	Test System (Species/ Strain/ Sex)	Metabolic Activation	Results	Reference
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Negative	Albertini et al. (2007) ; Albertini et al. (2001)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Negative	Liu et al. (2008)
Hprt exon deletion	Humans	Not applicable	Positive	Liu et al. (2008)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Positive	Ward et al. (1994)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Positive	Abdel-Rahman et al. (2005) ; Abdel-Rahman et al., 2003 ; Abdel-Rahman et al. (2001) ; Ammenheuser et al. (2001)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Positive	Ma et al. (2000)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Positive	Ward et al. (2001) ; Ward et al. (1996b)
Hprt loci in peripheral lymphocytes	Humans	Not applicable	Positive	Wickliffe et al. (2009)
Somatic cytogenetic effects				
Rodent studies				
Micronuclei and sister chromatid exchange	B6C3F1 mice	Not applicable	Positive	Cunningham et al. (1986)
Micronuclei in bone marrow and peripheral blood	(102 × C3H)F1 mice	Not applicable	Positive	Adler et al. (1994)
Micronuclei in spleen and peripheral blood	(102 × C3H)F1 mice	Not applicable	Positive	Stephanou et al. (1998)
Chromosomal aberration, sister chromatid exchange, Average generation time, mitotic index	B6C3F1 mice	Not applicable	Positive	Tice et al. (1987)
Micronuclei	B6C3F1 mice	Not applicable	Positive	Autio et al. (1994)
Micronuclei	Swiss mice	Not applicable	Positive	Irons et al. (1987)
Micronuclei	B6C3F1 mice	Not applicable	Positive	Jauhar et al. (1988)
Micronuclei	NMRI mice	Not applicable	Positive	Vodicka et al. (2006)
Micronuclei, Chromosomal aberration, sister chromatid exchange	B6C3F1 mice	Not applicable	Positive	Tice (1988)
Chromosomal aberration, sister chromatid exchange	C57B1/6 mice	Not applicable	Positive	Sharief et al. (1986)

Assay Type	Test System (Species/ Strain/ Sex)	Metabolic Activation	Results	Reference
Micronuclei	Wistar rats	Not applicable	Negative	Autio et al. (1994)
Micronuclei and sister chromatid exchange	SD rats	Not applicable	Negative	Cunningham et al. (1986)
Human studies				
Chromosome aberrations in peripheral blood	Humans	Not applicable	Negative	Au et al. (1995)
Chromosomal aberration, Sister chromatid exchange	Humans	Not applicable	Negative	Lovreglio et al. (2006)
Chromosomal aberration, Sister chromatid exchange	Humans	Not applicable	Positive	Šrám et al. (1998)
Micronuclei	Humans	Not applicable	Positive	Wang et al. (2010)
Micronuclei	Humans	Not applicable	Positive	Xiang et al. (2012)
Micronuclei	Humans	Not applicable	Positive	Cheng et al. (2013)
Micronuclei	Humans	Not applicable	Positive	Xiang et al. (2015)
Micronuclei	Humans	Not applicable	Positive	Federico et al. (2019)
Positive results are bolded .				

5.3 Mutagenic Mode of Action Analysis

1,3-butadiene is a potent multi-organ carcinogen in laboratory animals, notably inducing lymphomas in mice and exhibiting greater carcinogenic potential in mice than rats ([NTP, 1993](#); [Hazleton Labs, 1981b](#)). Epidemiological evidence consistently links occupational 1,3-butadiene exposure to increased mortality from lymphatic and hematopoietic cancers ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). As an alkylating agent, 1,3-butadiene induces genotoxic effects across various biological systems ([Albertini et al., 2010](#)). 1,3-Butadiene is an indirect carcinogen, requiring biotransformation into electrophilic metabolites to exert mutagenicity and carcinogenicity ([Kirman et al., 2010a](#)). The MOA underlying the development of cancer in humans and tumors in rodents is hypothesized to be associated with the mutagenic potential of one or more of 1,3-butadiene metabolites. Although 1,3-butadiene's genotoxic and carcinogenic potential is clearly linked to its DNA-reactive metabolites, the specific metabolites responsible for its multi-organ carcinogenicity remain to be fully elucidated. EPA evaluated the potential for 1,3-butadiene to exhibit a mutagenic MOA ([Albertini et al., 2010](#); [Kirman et al., 2010a](#); [Preston, 2007](#)) and the mutagenic analysis previously presented by EPA ([U.S. EPA, 1985](#)). Evidence for each key event (KE) through which a mutagenic MOA might be instrumental in 1,3-butadiene-induced hematopoietic cancers is presented in the subsequent section. This analysis was performed in accordance with EPA *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)) and the framework for determining a mutagenic mode of action for carcinogenicity ([U.S. EPA, 2007](#)). The key events described below are consistent with well-characterized Adverse Outcome Pathways (AOP) for genotoxic carcinogens, particularly those involving DNA reactive metabolites. This analysis incorporates OECD AOP principles while maintaining a chemical-specific focus on the mode of action of 1,3-butadiene.

The mutagenic MOA involves the following sequence of key events (KEs):

- KE1: Bioactivation of 1,3-butadiene to DNA-reactive metabolites.
- KE2: Formation of DNA adducts and DNA damage by 1,3-butadiene metabolites in target cells (AOP-Wiki Event ID 97).

- KE3: Chromosomal aberrations and/or mutations arising from 1,3-butadiene-induced DNA damage (AOP-Wiki Event ID 1636).
- KE4: Development of cancer from 1,3-butadiene-induced mutations (AOP-Wiki Event ID 885).

KE 1 lacks a standalone AOP Event ID in the AOP-Wiki. KE2 aligns with Event ID 97. KE3 aligns with Event ID 1636. The final adverse outcome, cancer development, is listed under Event ID 885.

5.3.1 Key Event 1: Bioactivation of 1,3-Butadiene to DNA-Reactive Metabolites

Metabolism plays a crucial role in determining 1,3-butadiene's carcinogenicity. Specifically, as detailed in Section 3.3, 1,3-butadiene undergoes metabolic activation primarily in the liver by cytochrome P450 enzymes. This process converts 1,3-butadiene into electrophilic intermediates, including EB, EBD, and DEB. In brief, cytochrome P450 initially transforms 1,3-butadiene into EB, which can then be further metabolized into DEB or B-Diol through epoxide hydrolase. Subsequently, B-Diol can be converted into EBD, which can undergo further bioactivation to form a bifunctional epoxy aldehyde. Additionally, DEB can also be converted into EBD via epoxide hydrolase. These three epoxides—EB, DEB, and EBD—are highly reactive with nucleophilic sites in DNA, forming adducts that are genotoxic and mutagenic ([Albertini et al., 2010](#)).

The substantial interspecies variation in cancer susceptibility to 1,3-butadiene, with mice exhibiting markedly higher sensitivity than rats, is consistent with documented differences in 1,3-butadiene metabolism and resulting genotoxicity ([Albertini et al., 2010](#); [Kirman et al., 2010a](#); [Himmelstein et al., 1997](#)). Specifically, mice exhibit faster rates of metabolism to DNA reactive metabolites and slower rates of hydrolysis compared to other species, resulting in higher DEB blood levels ([Kirman et al., 2010b](#)). Importantly, both species, as well as humans, metabolize 1,3-butadiene into reactive intermediates capable of DNA interaction, thereby presenting a potential carcinogenic hazard. Human enzyme kinetics result in greater EBD compared to rats and mice. This point is evident from the higher levels of EBD-derived hemoglobin adducts detected in humans compared to other metabolites ([Boysen et al., 2012](#); [Albertini et al., 2003](#)). In addition to these well-characterized 1,3-butadiene metabolites, recent studies have identified alternative pathways leading to the formation of additional bifunctional metabolites. These include chlorinated metabolites formed via myeloperoxidase and hypochlorous acid ([Wu et al., 2019](#); [Wang et al., 2018](#); [Elfarrar and Zhang, 2012](#)) as well as ketone/aldehyde metabolites of EBD formed via alcohol dehydrogenase ([Nakamura et al., 2021](#)). These bifunctional metabolites are particularly significant because of their unique ability to induce complex DNA damage, such as DNA-protein cross-links or DNA interstrand cross-links. These complex lesions are more difficult for DNA repair mechanisms to resolve, thereby increasing the risk of mutations and contributing to cellular toxicity. Although the potential contribution of these additional bifunctional metabolites to 1,3-butadiene induced mutagenicity and carcinogenicity remains to be fully elucidated, they may play a critical role in human carcinogenicity. Given the high bioavailability of EBD in humans and the presence of myeloperoxidase in neutrophils and monocytes, these alternative pathways may exist in the bone marrow and blood, potentially leading to the production of leukemia, with bone marrow being a primary target of 1,3-butadiene ([Tice et al., 1987](#)). See Section 3.3 for more details.

5.3.2 Key Event 2: Formation of DNA Adducts and DNA Damage by 1,3-Butadiene Metabolites in Target Cells

The formation of DNA adducts by 1,3-butadiene is a crucial step in initiating its carcinogenic process. These adducts arise from the covalent binding of 1,3-butadiene metabolites to DNA, leading to mutations that ultimately contribute to cancer development. 1,3-Butadiene's electrophilic metabolites—specifically EB, DEB, and EBD—are highly reactive with nucleophilic sites in DNA, forming a variety of adducts and playing a central role in mediating the genotoxic and mutagenic effects ([ATSDR, 2012](#);

[U.S. EPA, 2002a](#)). These adducts have been detected *in vitro* and *in vivo*, as well as in occupationally exposed workers ([ATSDR, 2012](#)). *In vitro* studies across bacterial, mammalian, and human cell lines demonstrate the DNA damaging potential of 1,3-butadiene metabolites ([IARC, 2008b](#)). These electrophilic metabolites have been shown to form DNA adducts, induce DNA strand breaks, stimulate unscheduled and DNA excision repair ([Albertini et al., 2010](#)). In addition to being observed in *in vitro*, DNA adducts are detected *in vivo* across multiple tissues in 1,3-butadiene exposed mice, including within tissues identified as targets of carcinogenesis ([ATSDR, 2012](#)). The specific types of adducts identified in mice include N7-(2-hydroxy-3-butenyl)guanine and N6-(2-hydroxy-3-buten-1-yl)-2-deoxyadenosine, which are primarily derived from the 1,3-butadiene metabolite DEB ([Goggin et al., 2009](#)). 1,3-Butadiene exposure has been linked to increased formation of N-7-(2,3,4 trihydroxybutyl) guanine adducts in liver DNA across various mouse strains ([Koturbash et al., 2011b](#); [Koturbash et al., 2011a](#)). N7-(2,3,4-trihydroxybutyl)guanine adducts, formed from B-diol, were also found in the liver DNA of the animals ([Walker and Meng, 2000](#)).

Evidence from human studies supports the link between 1,3-butadiene exposure and DNA damage. The diepoxide, DEB, which is detected in human blood at significantly lower amounts compared to rodents ([ATSDR, 2012](#); [Swenberg et al., 2011](#)), is considered the most potent genotoxic moiety among 1,3-butadiene metabolites (see Section 5.2 and ([ATSDR, 2012](#); [U.S. EPA, 2002a](#))). However, it has also been hypothesized that EBD, rather than DEB, is the primary metabolite responsible for human DNA adducts and resulting carcinogenicity ([Nakamura et al., 2021](#); [Boogaard et al., 2001](#)). In a DNA repair assay on repair-deficient chicken DT40 B lymphocyte and human TK6 lymphoblastoid cells, EBD and analogs were similarly genotoxic to DEB, and authors propose that EBD may bioactivate into a bifunctional moiety through alcohol dehydrogenase ([Nakamura et al., 2021](#)). Several studies have also shown a positive correlation between occupational exposure to 1,3-butadiene and levels of DNA adducts in peripheral blood lymphocytes ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). One study found that workers exposed to 1,3-butadiene had significantly higher levels of DNA adducts than control groups ([Zhao et al., 2000](#)). Another study found that the level of DNA adducts, specifically N-1-(2,3,4-trihydroxybutyl) adenine (N-1-THB-Ade) formed from EBD, increased with increasing levels of exposure to 1,3-butadiene ([Zhao et al., 2001](#)). Furthermore, 1,3-butadiene exposure might hinder DNA repair mechanisms due to the potential formation of cross-links between DNA and proteins by its bifunctional metabolites ([Albertini et al., 2010](#)). Ultimately, these DNA adducts can induce mispairing during DNA replication, leading to point mutations, deletions, chromosome damage and other forms of genetic damage that contribute to tumor initiation and progression ([Goggin et al., 2011](#); [Albertini et al., 2010](#); [Kirman et al., 2010a](#)).

5.3.3 Key Event 3: Chromosomal Damage and/or Mutations Arising from 1,3-Butadiene-Induced DNA Damage

A critical mechanism underlying 1,3-butadiene induced carcinogenicity is its ability to induce chromosomal aberrations and mutations across various biological systems, from prokaryotes to humans. The mutagenic potential of 1,3-butadiene is well supported by extensive evidence, including numerous positive results from both *in vivo* and *in vitro* mutation assays conducted on human and rodent cells ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Studies have shown that 1,3-butadiene's mutagenic activity primarily arises from its metabolites—particularly the epoxides DEB, EB, and EBD—as well as potentially novel bifunctional metabolites such as chlorinated and ketone/aldehyde derivatives. Studies have demonstrated the mutagenic activity of 1,3-butadiene in bacterial systems, specifically inducing gene mutations in *Salmonella typhimurium* strains TA100 and TA1535 with metabolic activation using an S9 fraction ([Madhusree et al., 2002](#); [Araki et al., 1994](#); [Arce et al., 1990](#); [De Meester et al., 1980](#)).

In animals, even brief (10-day) exposures can significantly increase the frequency of SCEs and chromosomal aberrations in blood cells, even at the lowest concentration tested in mice ([Tice et al., 1987](#); [Cunningham et al., 1986](#)). Moreover, exposure to inhaled 1,3-butadiene has been shown to elevate micronucleus induction in erythrocytes, spermatocytes, and bone marrow cells in mice ([Vodicka et al., 2006](#); [Tommasi et al., 1998](#); [Xiao and Tate, 1995](#); [Autio et al., 1994](#); [Jauhar et al., 1988](#); [Irons et al., 1987](#); [Tice et al., 1987](#)). However, results from a limited number of rat studies indicate that exposure to 1,3-butadiene does not result in increased induction of micronuclei ([Autio et al., 1994](#)) or SCEs ([Cunningham et al., 1986](#)) in the bone marrow at the doses tested. This interspecies difference in response may contribute to the lower incidence of 1,3-butadiene induced cancer in rats, which is potentially attributable to reduced genotoxic metabolite formation and more efficient detoxification via epoxide hydrolase. Increased mutations in cancer-related oncogenes (*e.g.*, *K-ras*) and tumor suppressor genes (*e.g.*, TP53), as well as those in the Wnt signaling pathway, have been observed in butadiene-induced tumors ([ATSDR, 2012](#); [U.S. EPA, 2002a](#)). Specifically, A:T to T:A transversions at codon 61 of *K-ras* and G:C to T:A transversions at codon 273 of TP53 have been documented in forestomach tumors of chronically exposed B6C3F1 ([Sills et al., 2001](#)). Although these tumors may be less relevant to humans, evidence of mutagenicity would apply to all cancer types. This combination of oncogene activation and tumor suppressor inactivation creates the cellular environment necessary for malignant transformation through compromised cell-cycle checkpoints and apoptotic responses.

In vivo studies have also examined gene mutations at reporter genes (*lacI* and *lacZ*) in the tissues of transgenic mice. Specifically, transgenic B6C3F1 mice exposed to 1,3-butadiene exhibited an elevated *lacZ*-mutant frequency in lung tissue ([Recio et al., 1992](#)). Similarly, inhalation exposure to 1,3-butadiene significantly increased the mutant frequency of *lacI* transgene (*i.e.*, Big Blue assay) in bone marrow of B6C3F1 transgenic mice, with a predominance of point mutations occurring at A base pairs ([Sisk et al., 1994](#)). This increase in mutation frequency was consistent across both short-term (5 days) and extended (4-week) exposures, indicating relatively short inhalation exposure of 1,3-butadiene can induce significant mutagenic effect in mouse bone marrow ([Recio et al., 1996](#)) and spleen ([Recio et al., 1998](#)). Furthermore, increased incidence of *H-ras* and *K-ras* proto-oncogene mutations were observed in forestomach neoplasms of mice following chronic inhalation exposure to 1,3-butadiene ([Sills et al., 2001](#)). Similarly, mice and rats exhibited increased HPRT locus mutations in splenic T cells ([Meng et al., 2007](#); [Meng et al., 2004](#); [Meng et al., 2000](#); [Meng et al., 1999](#); [Cochrane and Skopek, 1994](#)). Studies on exposed male mice ([Adler et al., 1998](#); [Anderson et al., 1998](#); [Brinkworth et al., 1998](#); [Anderson et al., 1996](#); [BIBRA, 1996b](#); [Adler et al., 1995](#); [Xiao and Tate, 1995](#)) but not rats ([Anderson et al., 1998](#); [BIBRA, 1996a](#)) have also consistently observed germ cell-specific cytogenetic damage and resulting dominant lethality following mating with unexposed females.

In contrast, epidemiological studies have produced mixed but still mostly positive (6 of 10 studies) findings regarding the association between 1,3-butadiene exposure and genetic damage in workers using HPRT and SCE assays ([ATSDR, 2012](#)). Some studies involving Texas workers found a potential association between elevated 1,3-butadiene exposure and increased frequencies of HPRT variants in lymphocytes ([Wickliffe et al., 2009](#); [Abdel-Rahman et al., 2005](#); [Abdel-Rahman et al., 2003](#); [Abdel-Rahman et al., 2001](#); [Ammenheuser et al., 2001](#); [Ward et al., 2001](#); [Ma et al., 2000](#); [Ward et al., 1996b](#)). However, other studies found no significant increase in chromosome aberrations or HPRT mutations among workers exposed to 1,3-butadiene, such as those in the Czech Republic and China ([Albertini et al., 2007](#); [Albertini et al., 2001](#); [Hayes et al., 2001](#); [Hayes et al., 2000](#); [Hayes et al., 1996](#); [Tate et al., 1996](#)). Despite these mixed results, more recent studies using micronucleus assay have consistently demonstrated that occupational exposure to 1,3-butadiene causes chromosomal damage in humans.

One study on highly exposed Chinese workers reported a positive association between 1,3-butadiene exposure and micronuclei induction in peripheral blood lymphocytes ([Wang et al., 2010](#)). Similarly, workers exposed to high levels of 1,3-butadiene in a poly-butadiene latex plant exhibited significantly higher micronucleus frequencies ([Xiang et al., 2012](#)). A follow-up study in a rubber factory confirmed this trend, demonstrating elevated micronucleus frequencies even at lower 1,3-butadiene exposure, though no significant changes in sister chromatid exchange were observed ([Cheng et al., 2013](#)). These studies also highlighted the influence of genetic polymorphisms on micronucleus frequency. In another study, the workers at a petrochemical factory exposed to high levels of 1,3-butadiene exhibited elevated micronucleus and nucleoplasmic bridge frequencies, with gene polymorphisms influencing these outcomes ([Xiang et al., 2015](#)).

An Italian study also observed increased micronuclei frequency in petroleum refinery workers and nearby residents, although 1,3-butadiene concentrations were not measured ([Federico et al., 2019](#)). While earlier studies using HPRT and SCE assay showed mixed results due to variations in exposure assessments (active vs. passive sampling) and mutation analysis methodologies (autoradiography vs. cloning HPRT assays), recent studies employing the micronucleus assay consistently demonstrate that occupational 1,3-butadiene exposure induces chromosome damage. Furthermore, chronic myeloid leukemia (CML) has been reported with increased incidence among worker populations exposed to 1,3-butadiene ([Delzell et al., 2006](#)), and CML requires a specific t(9:22) translocation that can only arise via mutagenicity. A relatively recent study found that DEB does *not* induce t(9:22) translocations in a cultured leukemia cell line ([Walker et al., 2019](#)), supporting evidence from ([Nakamura et al., 2021](#)) and ([Boogaard et al., 2001](#)) suggesting that metabolites other than DEB may lead to lymphohematopoietic carcinogenesis, especially in humans. Additionally, EBD is positive for HPRT mutations or micronuclei formation in four of five studies summarized by ([U.S. EPA, 2002a](#)), including human cells *in vitro*, with the only negative study from rats. For comparison, DEB is consistently positive for cytogenetic damage in all studies and species but mixed for gene mutations in mice and rats while EB is mostly positive for cytogenetic damage but mixed for mutations ([U.S. EPA, 2002a](#)). Table 5-2 summarizes results from mutagenicity and chromosome/cytogenetic damage assays relevant to this key event.

5.3.4 Key Event 4: Development of Cancer from 1,3-Butadiene-Induced Mutations

Following the induction of mutations as described previously, uncontrolled cell proliferation emerges as the final key event in 1,3-butadiene induced carcinogenesis. This arises from the cumulative effect of genetic damage, including mutations and chromosome aberrations. In rodent studies, chronic exposure to 1,3-butadiene leads to the development of tumors in various organs, including the hematopoietic system ([NTP, 1993](#); [Hazleton Labs, 1981b](#)). Supporting these findings, numerous epidemiological studies have established a strong correlation between occupational exposure to 1,3-butadiene and increased mortality due to hematological malignancies in humans ([Sathiakumar et al., 2021b](#); [Delzell et al., 2006](#); [Delzell et al., 1996](#)).

5.3.5 Mutagenic MOA: Weight of Evidence Analysis

In accordance with the EPA's 2005 *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)), this analysis of a mutagenic MOA follows the Bradford Hill criteria (or considerations) developed for evaluating epidemiological studies ([Hill, 1965](#)). Hill considerations are indicated in *italics* in the following discussion.

Strength and Consistency

The association between 1,3-butadiene exposure and the mutagenic outcomes is well established. As described above, numerous studies have demonstrated the formation of reactive metabolites along with statistically significant increases in DNA adducts, gene mutations, chromosome aberrations, and

micronucleus formation following exposure to 1,3-butadiene ([ATSDR, 2012](#)). Although the bifunctional epoxide metabolite DEB (considered the most genotoxic moiety) is formed at low levels in humans (Section 3), evidence from Hb adducts indicates that EBD levels are the same or higher in humans compared to mice and significantly higher compared to rats ([Boysen et al., 2012](#); [Swenberg et al., 2011](#)).

A recent study suggests that EBD may be as genotoxic as DEB through a novel bioactivation mechanism ([Nakamura et al., 2021](#)). Moreover, this association is relatively consistent across epidemiological and animal studies, which have consistently reported genetic damage and associated mutations due to 1,3-butadiene exposure with few exceptions; the only two studies in rats did not demonstrate genotoxicity in bone marrow at the dose tested. There is also some variability in results on peripheral lymphocytes across human occupational studies, but this may be explained by differences in polymorphism rates across populations (Section 7.2) or study methodologies. Additionally, the presence of chromosomal damage (which is difficult to repair and is associated with increased risk of cancer) is observed consistently across exposed occupational cohorts. Overall, the weight of scientific evidence, including the consistent demonstration of DNA damage and resulting mutations across species and assay types, strongly supports the association between 1,3-butadiene exposure and mutagenic outcomes.

Specificity

Specificity is not required or even necessarily expected for a multisite mutagen and carcinogen such as 1,3-butadiene ([U.S. EPA, 2005a](#)). Nonetheless, mutations have been commonly observed in immune cells (including from transgenic mice assays)([ATSDR, 2012](#)), corresponding to the blood cancers observed in both mice and humans as well as spleen and bone marrow ([ATSDR, 2012](#)). Among leukemia cases identified in the Alabama cohort, the strongest association in one study ([Delzell et al., 2006](#)) was identified for CML, cancer that requires a specific activating t(9:22) genomic translocation. Increased incidence of a cancer for which a mutation is both necessary and sufficient strongly supports the mutagenic MOA human evidence of carcinogenicity in humans.

Temporality

A clear temporal relationship is evident, with genetic damage ([Jauhar et al., 1988](#); [Tice et al., 1987](#)) and transgene mutations ([Recio et al., 1996](#)) observed shortly (*e.g.*, within days) after the exposure in various acute and subchronic studies. Lymphocytic lymphoma also developed very quickly in mice, appearing as early as 23 weeks into exposure ([NTP, 1993](#)), indicative of mutagen-induced carcinogenesis. While some epidemiological studies have reported leukemia cases with latency period of 10 years or longer ([Sathiakumar et al., 2021b](#)), a 0-year lag time was utilized for the lifetable analysis discussed in Section 5.4.3. This decision was based on testing multiple lag periods (0, 5, 10, 15, 20 years), which demonstrated no significant alteration in the coefficient or risk estimates. This approach is consistent with observations that the average latency period for many chemical- and radiation-induced leukemias can be less than 10 years

Dose-Response

Animal studies demonstrate a clear dose-response relationship between 1,3-butadiene exposure and genetic damage. Higher exposure levels consistently correlate with increased frequencies of DNA adducts, gene mutations, chromosome aberrations, and micronuclei formation ([ATSDR, 2012](#)). Some studies have observed genetic damage to peripheral blood in mice ([Tice et al., 1987](#)) (in the absence of cytotoxicity) at the same dose, resulting in blood cancer development ([NTP, 1993](#)) (lowest dose tested). This suggests that even relatively low exposure levels can induce genetic alterations sufficient for tumorigenesis. Furthermore, a parallel increase in both the types and magnitude of tumors and mutations are observed at increasing dose, including in bone marrow from transgenic mice *in vivo* ([ATSDR, 2012](#)).

Biological Plausibility

The biological plausibility of 1,3-butadiene's carcinogenicity is strongly supported by its ability to form mutagenic metabolites that directly interact with DNA and cause mutations both in mice and humans. DNA damage and mutations, which are known to cause cancer, are observed in bone marrow and blood cells, the primary targets of leukemia. CML is associated with 1,3-butadiene exposure in humans ([Delzell et al., 2006](#)) and requires a specific activating genomic translocation [(t9;22)].

Coherence

Experimental evidence from animal studies aligns with epidemiological data, demonstrating tumor formation in various tissues following chronic exposure. Genotoxicity and mutagenicity data on parental 1,3-butadiene also agrees with data on metabolites, with primarily positive results from *in vivo* mammalian/human studies and metabolic activation required for prokaryotes. Observed non-cancer blood effects such as anemia (Section 4.1.2.3) may be related to bone marrow dysfunction either upstream or downstream of carcinogenesis. Evidence of dominant lethality due to genotoxicity of male germ cells (Section 4.1.2.2.3) further supports mutagenicity as an important mode of action for 1,3-butadiene toxicity. The carcinogenic potential of 1,3-butadiene is further corroborated by evidence that its bifunctional metabolite, DEB, induces nasal and respiratory tumors in rats and mice following short-term inhalation exposures ([Henderson et al., 1999](#)). Moreover, structurally related olefins (isoprene, chloroprene) and other epoxide forming chemical (ethylene oxide, vinyl chloride) are similarly bioactivated to reactive epoxides that bind DNA, cause mutations, and are classified as reasonably anticipated human carcinogens via a mutagenic mode of action ([IARC, 2024](#)). These parallels strongly reinforce a mutagenic MOA for 1,3-butadiene.

Uncertainties and Alternative Modes of Action

Although the weight of evidence sufficiently supports a mutagenic MOA for the carcinogenicity of 1,3-butadiene, the possibility of alternative or additional MOAs cannot be excluded. Alternative modes of action have not been definitively identified or supported by the existing data. One study observed delayed differentiation and reduced maturation of bone marrow stem cells in mice following 6 weeks of exposure to 1,250 ppm 1,3-butadiene ([Leiderman et al., 1986](#)). However, EPA did not identify any subsequent supporting evidence for this mechanism. Additionally, this study applied an elevated dose well above that which causes blood cancer in mice, and genotoxicity cannot be ruled out as the initial key event for any impacts on stem cell differentiation.

Is the Hypothesized MOA Sufficiently Supported in Test Animals?

As detailed above, the weight of evidence strongly supports a mutagenic MOA for 1,3-butadiene in laboratory animals.

Is the Hypothesized MOA Relevant to Humans?

The evidence discussed above demonstrates that 1,3-butadiene is a mutagen in test animals as well as in humans. There is compelling evidence that 1,3-butadiene induces lymphohematopoietic cancer in humans and mice, which correlates with the observed genotoxicity and mutation data from blood and bone marrow. Additionally, no information has been identified to suggest that the interactions between 1,3-butadiene reactive metabolites and DNA are unique to any particular species. Therefore, the proposed mutagenic MOA is relevant to humans.

Which Populations or Life Stages Can Be Particularly Susceptible to the Hypothesized MOA?

1,3-Butadiene exhibits a mutagenic MOA, which is generally considered to pose a risk across all life stages and populations. According to the *EPA's Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)), there may be increased susceptibility to

early-life exposures to carcinogens with a mutagenic MOA. Therefore, given that the weight of evidence supports a mutagenic mode of action for 1,3-butadiene's carcinogenicity and no chemical-specific data on susceptibility differences, increased early-life susceptibility should be assumed. If early-life exposure occurs, age-dependent adjustment factors should be applied in accordance with the aforementioned guidance ([U.S. EPA, 2005b](#)). In conclusion, the weight of evidence supports a mutagenic MOA for 1,3-butadiene lymphohematopoietic carcinogenicity and the application of age-dependent adjustment factors (ADAFs) to address assumed early-life susceptibility.

5.3.6 Summary and Conclusions

The weight of scientific evidence strongly supports a mutagenic MOA for 1,3-butadiene in the development of lymphohematopoietic malignancies in both rodents and humans, in agreement with previous analyses ([Kirman et al., 2010a](#); [Preston, 2007](#); [U.S. EPA, 1985](#)). Other authoritative assessments reached the same conclusion ([NTP, 2021a](#); [IARC, 2008a](#)), stating that 1,3-butadiene is carcinogenic through metabolism into direct-acting mutagens, likely resulting in modified function of oncogenes or tumor suppressors. Although there is more limited evidence for mutagenicity in other cell types, there is no basis to assume that mutagenicity would not similarly apply to all tissues. Therefore, a mutagenic MOA is applied to all tumor types.

The primary driver of 1,3-butadiene's mutagenic MOA is the formation of electrophilic metabolites (KE1), which readily react with DNA, causing adduct formation and other types of DNA damage (KE2). If not repaired, this persistent damage can lead to mutations, particularly in oncogenes and tumor suppressor genes, driving the process of carcinogenesis. Ultimately, the accumulation of mutations in critical genes results in uncontrolled cell proliferation and cancer development (KE3). The variability in 1,3-butadiene's mutagenic and carcinogenic potential across species and cancer types may be attributed to differences in its metabolism, resulting in varying levels and types of DNA damaging electrophilic metabolites. The extent and nature of this DNA damage ultimately determines the carcinogenic outcome in different biological contexts.

Given that a mutagenic MOA for 1,3-butadiene is sufficiently supported based on evidence from both laboratory animals and humans, a linear cancer assessment approach with the incorporation of ADAFs is used to calculate an inhalation unit risk (IUR) for lymphohematopoietic cancer and bladder cancer in accordance with considerations of the 2005 *Guidelines for Carcinogen Risk Assessment* ([U.S. EPA, 2005a](#)) and *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* ([U.S. EPA, 2005b](#)).

5.4 Cancer Dose-Response Assessment

5.4.1 Selection of Studies and Endpoint Derivation for Carcinogenic Dose-Response Assessment

The selection of representative cancer studies and locations of tumors/tumor types for dose-response analysis is described below based on the following considerations:

- Overall Quality Determinations (OQD);
- Dose range and sufficiency of dose-response information;
- Strength of the evidence supporting the associated tumor type;
- MOA conclusions;
- Relevance (*e.g.*, what species was the effect in, was the study directly assessing the effect, is the endpoint the best marker for the tox outcome?);
- Uncertainties not captured by overall quality determinations;

- Endpoint sensitivity; and
- Uncertainty and sensitivity of BMR selection from BMD modeling.

According to the TSCA systematic review process ([U.S. EPA, 2025i](#)), the EPA systematic review process identified 82 epidemiological publications. Of the 82 epidemiological publications, EPA identified 35 that conducted dose-response association based on at least 2 exposure levels (plus a reference level) or continuous exposure data. Of these 35 epidemiological publications with dose-response analyses and cumulative exposure, 21 investigated leukemia and 7 investigated bladder cancer. Based on the evidence from Section 5.1.1, EPA concluded that the human evidence for increased risks of leukemia and other lymphohematopoietic cancers was robust and that of bladder cancer was moderate (summarized in Table 5-1) but strong enough to support the derivation of unit risk estimates. Due to the availability of substantial epidemiological dose-response information and uncertainties surrounding the most relevant rodent species for human cancer risk, animal data was not considered for cancer dose-response analysis. Human cancer risk evidence is summarized below.

Leukemia

The most recent hazard assessment by the International Agency for Research on Cancer (IARC) recognized sufficient evidence of carcinogenicity only for cancers of the hematolymphatic system ([IARC, 2012](#)). Similarly, the earlier listing of butadiene as a known human carcinogen in the National Toxicology Program (NTP's) *Report of Carcinogens, Fifteenth Edition* cites only evidence of an increased risk of leukemia ([NTP, 2021b](#)). Additionally, the evidence integration judgment for lymphohematopoietic cancer was robust for human, animal, and mechanistic evidence (Table_Apx A-5). Therefore, leukemia is considered as the most critical cancer outcome caused by the 1,3-butadiene exposure and was the focus of EPA's dose-response analysis.

Of the 21 leukemia epidemiological publications providing dose-response results, 18 used data from the U.S.-Canadian SBR worker cohort study, 2 used data from the Texas Cancer Registry, and 1 used data from California Cancer Registry (Table 5-3). The exposure pathway of all 21 leukemia publications is inhalation.

Bladder Cancer

Eighty-two epidemiologic publications were identified in the TSCA Systematic Review process ([U.S. EPA, 2025i](#)). Of those 82 publications, 7 investigated bladder cancer and included exposure-response analyses and /or cumulative exposure information. All seven publications used data from the original U.S.-Canadian SBR worker cohort study ([Delzell et al., 1996](#)). Details of this SRB cohort study in terms of study population, exposure assessment and concentrations, and statistical analyses are described in in Section 5.4.1.1.

Table 5-3. Summary of 21 Leukemia Epidemiological Studies Providing Dose-Response Association Based on at Least 2 Exposure Levels (+ a Reference Level) or Continuous Exposure Levels

Data Source	Reference	Study Period or Follow-up	Exposure Range in the Dose-Response Model	Health Outcomes	Statistically Significant Result?	Systematic Review Score
SBR Cohort	UAB (1995a)	1950–1992	0 to >200 ppm-years	Leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute myelogenous or monocytic leukemia mortality	Significant positive associations	Medium
SBR Cohort	Delzell et al. (1996)	1943–1992	0 to 200+ ppm-years	Leukemia mortality	Significant positive associations	Medium
SBR Cohort	IISRP (1999)	1944–1991	0 to >635.9 ppm-years	Leukemia, CLL, CML, AML or monocytic leukemia mortality	Significant positive associations	Medium
SBR Cohort	Delzell et al. (2001)	1944–1991	0 to >362.2 ppm-years	Leukemia mortality	Significant positive associations	Medium
SBR Cohort	Sielken and Valdez-Flores (2001)	1943–1992	0–1,776 ppm-years	Leukemia mortality	Not reported, no confidence interval	Low
SBR Cohort	Graff et al. (2005)	1943–1998	0 to >124.7 ppm-years	Leukemia mortality	Significant positive associations	Medium
SBR Cohort	Sathiakumar et al. (2005)	1944–1998	No quantitative data reported	Leukemia (Hodgkin's disease, multiple myeloma, all leukemia, non-Hodgkin's lymphoma) mortality	No significant associations	Medium
SBR Cohort	Cheng et al. (2007)	1944–1998	Average BD intensity ppm: mean (SD) leukemia cases = 35.5 (71.4), non-cases = 24.0 (54.8)	Leukemia mortality	Significant positive associations	Medium
SBR Cohort	UAB (2007)	1943–2003	0 to >56.3 ppm-years	Leukemia mortality	No significant associations	Medium
SBR Cohort	Sielken (2007)	1943–1998	No quantitative data reported	Leukemia mortality, CML mortality, CLL mortality, acute myelogenous or monocytic leukemia (ALM) mortality, all lymphoid neoplasms mortality, and all myeloid neoplasms mortality	Significant positive associations	Low
SBR Cohort	Sathiakumar and Delzell (2009)	1943–2003	No quantitative data reported	Leukemia mortality, non-Hodgkin's lymphoma mortality	No significant associations	Medium
SBR Cohort	Graff et al. (2009)	1943–1998	0 to >425.0 ppm-years	Leukemia mortality	Significant positive associations	Medium

Data Source	Reference	Study Period or Follow-up	Exposure Range in the Dose-Response Model	Health Outcomes	Statistically Significant Result?	Systematic Review Score
SBR Cohort	Sielken and Valdez-Flores (2011)	1943–1998	0–1,338 ppm-years	Leukemia mortality, CML mortality, CLL mortality, ALM mortality, all lymphoid neoplasms mortality, and all myeloid neoplasms mortality	Significant positive associations	Medium
SBR Cohort	Sielken and Valdez-Flores (2013)	1943–1998	0–1,338 ppm-years	Leukemia mortality, CML mortality, CLL mortality, ALM mortality, all lymphoid neoplasms mortality, and all myeloid neoplasms mortality	Significant positive associations	Low
SBR Cohort	Sathiakumar et al. (2015)	1943–2009	0 to >908.35 ppm-years	Leukemia mortality	Significant positive associations	Medium
SBR Cohort	Sathiakumar et al. (2019)	1943–2009	No quantitative data reported	Leukemia mortality	Significant positive associations	Medium
SBR Cohort	Sathiakumar et al. (2021b)	1943–2009	0–7,741 ppm-years	Leukemia mortality, lymphoid leukemia mortality	Significant positive associations	Medium
SBR Cohort	Valdez-Flores et al. (2022)	1943–2009	0 to 7,743 ppm-years	Leukemia, lymphoid leukemia, myeloid leukemia, multiple myeloma, or non-Hodgkins' lymphoma mortality	Significant positive associations	Low
Texas Cancer Registry	Whitworth et al. (2008)	1995–2004	No quantitative data reported	Leukemia, ALL	Significant positive associations	Medium
Texas Cancer Registry	Symanski et al. (2016)	1995–2011	No quantitative data reported	ALL	Significant positive associations	Medium
California Cancer Registry (Air Pollution and Childhood Cancer Studies)	Heck et al. (2014)	1990–2007	No quantitative data reported	ALL, AML	Significant positive associations	Medium
ALL = acute lymphoblastic leukemia; ALM = acute myelogenous or monocytic leukemia; AML = acute myeloid leukemia; CML = chronic myelogenous leukemia; SBR = styrene-butadiene rubber						

Table 5-4. Summary of Bladder Cancer Epidemiological Studies that Provided at Least Two Exposure Levels (+ a Reference Level) or Continuous Exposure Levels

Data Source	Reference	Study Period or Follow-up	Exposure Range in the Dose-Response Model	Health Outcomes	Statistically Significant Result?	Systematic Review Score
SBR Cohort	Delzell et al. (1996)	1943–1992	0 to 200+ ppm-years	Bladder cancer mortality	No significant associations.	Medium
SBR Cohort	Sathiakumar et al. (2005)	1944–1998	No quantitative data reported	Bladder cancer mortality	No significant associations.	Medium
SBR Cohort	UAB (2007)	1943–2003	0 to >56.3 ppm-years	Bladder cancer mortality	No significant associations.	Medium
SBR Cohort	Sathiakumar and Delzell (2009)	1943–2003	No quantitative data reported	Bladder cancer mortality	Significant SMR for residual operation and no significant SMR for SBR workers	Medium
SBR Cohort	Sathiakumar et al. (2019)	1943–2009	No quantitative data reported	Bladder cancer mortality	Significant SMR	Medium
SBR Cohort	Sathiakumar et al. (2021a)	1943–2009	0 to >328.79 ppm-years	Bladder cancer mortality	Significant positive associations	Medium
SBR Cohort	Valdez-Flores et al. (2022)	1943–2009	0 to 7,900 ppm-years	Bladder cancer mortality	Significant positive associations	Low
SBR = styrene-butadiene rubber; SMR = standardized mortality ratio						

5.4.1.1 Analysis of Leukemia and Bladder Cancer Epidemiological Studies from the SBR Cohort

Eighteen leukemia and 7 bladder cancer research publications used data from the original U.S.-Canadian SBR worker cohort study ([Delzell et al., 1996](#)). This occupational cohort study was conducted in eight plants and their employees were followed from 1943 to 2009 by a research group at the University of Alabama (UAB) ([Delzell et al., 1996](#)). The SBR cohort is a 66-year cohort study. All study participants were male and female adults. The cohort started recruiting male workers in 1943, originally followed up until 1991, then extended to 1998. It was expanded further to recruit female workers until 2002, and lastly, the follow-up was extended through 2009 (Table 5-5). As summarized in Table 5-5, (1) the SBR cohort recruited the large male and female study populations (16,579 men and 4,508 women); (2) had 20 years of follow-up period; and (3) collected long-term 1,3-butadiene exposure data. The 18 leukemia and 7 bladder cancer publications on the SBR cohort listed in Table 5-3 and Table 5-4 were evaluated using several criteria, including study populations, exposure assessment, associated exposure concentrations, statistical analysis, confounder adjustments, and estimates of population risk as follows.

5.4.1.1.1 Study Population

Leukemia

Of the 18 SBR cohort publications for leukemia, 14 publications showed a statistically significant relationship between 1,3-butadiene exposure and leukemia (Table 5-3). These 14 publications include either male-only or both male and female participants. Among the 18 publications, one ([Sathiakumar et al., 2005](#)) that investigated the male population showed no significant association. Two publications ([Sathiakumar and Delzell, 2009](#); [UAB, 2007](#)) that investigated only female-only populations did not show a statistically significant relationship between 1,3-butadiene exposure and leukemia. These results show gender differences in the positive association.

Bladder Cancer

Table 5-4 summarizes the study populations, exposure levels, and results of seven SBR bladder cancer epidemiological publications. All study participants were adults and all SMR and dose-response associations were either statistically significant or not. Three ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021a](#); [Sathiakumar et al., 2019](#)) publications found a statistically significant association between 1,3-butadiene and bladder cancer and SMRs higher than 100. In contrast, three publications ([UAB, 2007](#); [Sathiakumar et al., 2005](#); [Delzell et al., 1996](#)) showed no associations. The remaining study, [Sathiakumar and Delzell \(2009\)](#), reported both significant SMRs for workers in residual operation and non-significant SMRs for SBR workers. Overall, male-only populations did not show a statistically significant association between 1,3-butadiene exposure and bladder cancer, but combined male and female populations had a statistically significant association.

Table 5-5. Updates and Description of Recruitment, Follow-Up, and Expansion of the SBR Cohort Study

Historical Changes in the SBR Cohort	Period of Recruitment and Follow-Up	Gender of Participant Recruitment	Number of Workers	Number of Deaths
Original study plan	1943–1991	Male	17,964	4,665
Extended follow-up for male workers	1943–1998	Male	17,924	6,237
Expanded recruitment for female workers	1943–2002	Female	4,861	1,198
Extended follow-up for male and female workers	1943–2009	Male and Female	21,087 (16,579 men and 4,508 women)	9,665 (8,214 men and 1,451 women)
SBR = styrene-butadiene rubber				

5.4.1.1.2 Exposure Assessment and Concentration

During the follow-up period of the SBR cohort, Macaluso et al. ([2004](#)) revised the exposure estimates for 1,3-butadiene that incorporated additional information, including historical industrial hygiene surveys by the National Institute for Occupational Safety and Health (NIOSH). The revised exposure assessment ([Macaluso et al., 2004](#)) identified tasks and jobs involving exposure, identified factors influencing historical changes, and utilized mathematical models to compute job- and time-period-specific exposure. [Macaluso et al., 2004](#) reports higher exposure estimates than the original exposure assessment described in ([Delzell et al., 1996](#)) due to several refinements: (1) the exposure scenarios were more specific than the previously grouped tasks; (2) the verification for the parameters' values in the exposure models through published materials; (3) plant personnel provided feedback on the exposure scenarios, which validated the assumptions for computing estimates; (4) the measured air velocities at selected locations replaced arbitrary assumptions in the original estimates with empirical data; (4) providing uncertainty ranges for the exposure parameters improved estimates and sensitivity analyses; and (5) peak exposure was further characterized.

The authors concluded that their original estimates ([Macaluso et al., 1996](#)) were low and noted that the revised estimates for 1,3-butadiene exposure were up to an order of magnitude higher—particularly for the period of the 1940s to 1960s. However, the estimated number of 1,3-butadiene peaks declined following the revision ([Macaluso et al., 2004](#)). Overall, the pattern of the updated 1,3-butadiene exposure is high exposure prevalence and intensity during the 1940s to 1960s, with time-weighted averages (TWAs) around 10 ppm during those decades, sharply decreased in the 1970s and a lesser reduction in the 1980s. Median cumulative butadiene exposure was 71 ppm-years for all employees and 209 ppm-years for leukemia decedents. To compare the slope coefficients and rate ratios estimated from

the revised exposure data in Cheng et al., Sathiakumar et al., and Valdez-Flores et al. publications ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021b](#); [Cheng et al., 2007](#)), the slope coefficients and rate ratios are lower by about an order of magnitude.

Most publications in Table 5-3 and Table 5-4 used the cumulative 1,3-butadiene (ppm-years) exposure to estimate the dose-response association in statistical models. Table 5-3 and Table 5-4 show that the cumulative exposures ranged widely, from 0 to 7,743 ppm-years.

In addition to the improvements in exposure assessment, comparisons between Macaluso et al. ([2004](#)) and other exposure assessment publications below support that ([Macaluso et al., 2004](#)) is the most appropriate source of occupational exposure values for IUR derivation. There are several exposure assessment publications ([Sathiakumar and Delzell, 2009](#); [Sathiakumar et al., 2007](#); [Macaluso et al., 2004](#); [Macaluso et al., 1996](#); [UAB, 1995b](#); [Fajen et al., 1990](#)) during the SBR cohort study. The following bullets summarize the appropriateness of these studies' exposure assessments for use in the 1,3-Butadiene IUR derivation:

- Fajen et al. ([1990](#)) is the single NIOSH survey conducted from 1984 to 1987. There are no available monitoring data from the NIOSH survey prior to 1984. The monitored data from the NIOSH survey represent only 3 years, which is not representative of the SBR cohort exposure from 1944 to 1999. Additionally, no dose-response association was solely dependent on the NIOSH monitored data in previous studies.
- Delzell et al. ([1995b](#)) and Macaluso et al. ([1996](#)) conducted the original exposure assessment, and Health Canada and EPA assessments used them to derive an IUR in 2002. The SBR cohort dates back to 1943. In the late 1970s, all participating rubber manufacturing plants in the SBR cohort started industrial hygiene monitoring programs. ([UAB, 1995b](#)). In the mid-1980s, NIOSH conducted an industry-wide survey of synthetic rubber manufacturing that included five plants ([Fajen et al., 1990](#)). The EPA IRIS ([2002a](#)) utilized a modeled exposure assessment based on the aforementioned industrial monitoring data, NIOSH monitoring data, and a statistical model developed by Delzell et al. ([1995b](#)). However, the SBR cohort had collected exposure data after Macaluso et al. ([1996](#)), so these two studies ([Macaluso et al., 1996](#); [UAB, 1995b](#)) did not include the exposure data after 1996.
- Sathiakumar et al. ([2007](#)) assessed the validity of estimates of 1,3-butadiene exposure developed for the validation study plant that had both typical SBR operations and extensive other operations that were not typical SBR production. The exposure estimates in this validation study were developed without using historical measurement data and have not been previously validated. Therefore, the main objective of this study was to measure differences and correlations between calendar year- and job-specific estimates and measurements of 1,3-butadiene concentrations. Exposure estimates were about 10 percent lower than measurements on average, but several reasons show that the data from this validation study are not appropriate for developing a dose-response relationship: (1) The monitoring data of this validation study plant were limited to the period of 1977 to 1991; however, the time period covered by the SBR cohort study began in 1943; (2) 1,3-butadiene measurements of this validation study plant were available only for 11 percent of the job/year combinations in subjects' work histories during 1977 to 1991; (3) this validation study plant is the only study plant that had major other operations, which the other five study plants did not have. Data on determining exposure were plant-specific. Since this validation study plant had major other operations that the other five study plants did not have, data from this validation study plant cannot represent the exposure of the other five study plants.

- Sathiakumar et al. (2009) investigated the association between 1,3-butadiene exposure and mortality from several diseases among women in the synthetic rubber industry, which was never assessed in previous epidemiological studies. The procedure to estimate women's 1,3-butadiene exposure in this publication is identical to that for men's exposure, and these estimation procedures are described in Macaluso et al. (1996; 2004). That indicates Sathiakumar et al. (2009) results are built upon the exposure assessments of Macaluso et al. (1996; 2004).
- Macaluso et al. (Macaluso et al., 2004) updated exposure assessment, and it was used in the dose-response analyses from Sathiakumar et al., (Sathiakumar et al., 2021b; Sathiakumar et al., 2021a). The updated exposure assessment from Macaluso (Macaluso et al., 2004) utilized the aforementioned industrial monitoring and NIOSH monitoring data, along with an updated model that refined job groups and other inputs, as described in the first paragraph of Section 5.4.1.1.2. Two scientific advantages are recognized by using the updated exposure assessment from Macaluso (Macaluso et al., 2004):
 - OPPT's 1,3-butadiene IUR derivation aims to update the EPA IRIS 1,3-butadiene IUR. The updated modeling process for exposure estimates (Macaluso et al., 2004) represents the best available science.
 - IUR derivation requires an existing published dose-response analysis. It would not be appropriate to perform a novel dose-response analysis by mixing and matching cancer outcome data with exposure estimates in the different periods of time. Since Macaluso et al. (Macaluso et al., 2004) include exposure data from monitoring and modeling processes throughout the entire SBR cohort period, there were no concerns about mixing and matching.

5.4.1.1.3 Statistical Analysis and Confounding Adjustment

Leukemia

Table 5-6 compares estimates of slope parameters and rate ratios for the association of leukemia mortality with cumulative butadiene exposure from log-linear relative risk models with quantitative exposure variables in successive analyses by the UAB researchers, Environment Canada (2000), and Valdez-Flores et al. (2022). Although analyses of various other cancer outcomes, exposure metrics, and model forms have been reported, only the relationship shown in the table has been reported consistently across studies.

Table 5-6. Comparison of Estimated Slope Coefficients and Relative Risks (RRs) for Leukemia from Comparable Log-Linear Relative Risk Models in Analyses of the U.S.–Canada SBR Cohort, 0-Year Lag

Reference	Cohort ^a	Coefficient (SE)	RR per 100 ppm-years (95% CI)	Model	Adjustments
Delzell et al. (1996)	1991; men original exposure	0.0041 (0.0019)	1.507 (1.038–2.187)	Grouped Poisson	Age, period, time since hire, race, STY
EC (2000)	1991; men original exposure	0.0029 (0.0014)	1.336 (1.016–1.758)	Grouped Poisson	Age, period, time since hire, race, STY
Cheng et al. (2007)	1991; men, revised exposure	0.0003 (0.0001)	1.029 (1.009–1.050)	Proportional hazards	Age, birth year, time since hire, race, plant, DMDTC

Reference	Cohort ^a	Coefficient (SE)	RR per 100 ppm-years (95% CI)	Model	Adjustments
Sathiakumar et al. (2021b)	2009; men and women; revised exposure	0.00026 (0.0001)	1.026 (1.006–1.047)	Proportional hazards	Age, age at hire, year of hire, sex, race, plant, hourly status
Valdez-Flores et al. (2022)	2009; men and women; revised exposure	0.00028 (0.0001)	1.028 (1.009–1.049)	Proportional hazards	Age
Valdez-Flores et al. (2022)	2009; men and women; revised exposure	0.00013 (0.0001)	1.013 (0.997–1.029)	Proportional hazards	Age, peak exposure
STY = styrene; DMDTC = dimethyldithiocarbamate; peak exposure = cumulative number of tasks with estimated butadiene concentration ≥ 100 ppm					
^a Last year of follow-up, inclusion, original or revised exposure estimates					

The most notable difference among the estimates shown in Table 5-6 is a 10-fold reduction in slope estimates that occurs with the 2007 publication of Cheng et al. (2007). That paper was based on the same cohort as earlier analyses but incorporated new exposure estimates that were revised upward by as much as an order of magnitude (Macaluso et al., 2004). Cheng et al. (2007) also used proportional hazards regression, rather than the grouped Poisson regression models used previously. However, while decisions in grouping and assigning exposure scores in grouped Poisson regression can induce bias in exposure-response estimates, as discussed above, the bias is unlikely to be as large as the order-of-magnitude difference between the results of Cheng et al. (2007) and Environment Canada (2000).

Valdez-Flores et al. (2022) used the data from the Styrene-Butadiene Rubber (SBR) worker cohort and the Cox proportional hazards statistical model to address the exposure-response association between 1,3-butadiene and leukemia. In this Cox model, cumulative exposure to 1,3-butadiene (ppm-years) was used as the dose metric, and the number of leukemia decedents was used as the response in exposure-response modeling. To improve the likelihood of this Cox model, Valdez-Flores and colleagues tested various covariates and selected the covariate effects (*i.e.*, cumulative number of 1,3-butadiene high-intensity tasks) that significantly improved the likelihood of the Cox model. A covariate is a variable that can influence the outcome but is not the main variable being investigated or controlled; for example, age would be a covariate when investigating the relationship between physical activity and blood pressure. Age is not the variable of interest but impacts physical activity. Likelihood describes how well a statistical model explains the observed data. Afterward, as is standard practice, select covariates were added to the Cox model in a process called the “adjustment for the covariates in the model.” However, EPA epidemiologists do not agree with the covariate selected in Valdez-Flores et al. (2022). The flaw of Valdez-Flores et al. (2022) proposed IUR is the inclusion of 1,3-butadiene high-intensity tasks (*i.e.*, tasks with exposure ≥ 100 ppm 1,3-butadiene) as a covariate, called “peak exposure,” to adjust for the relationship between cumulative 1,3-butadiene exposure and leukemia mortality.

Macaluso et al. (2004) reported that peak exposure accounted for a large portion of cumulative 1,3-butadiene exposure in the SBR worker cohort. Exposure, peak or otherwise, is the main variable in the exposure-response relationship for 1,3-butadiene and leukemia mortality. By adjusting for peak exposure as a covariate, the effect of exposure to 1,3-butadiene on leukemia mortality is reduced. Valdez-Flores et al. (2022) showed that an adjustment for peak 1,3-butadiene exposure in their Cox model reduced the coefficient of cumulative 1,3-butadiene exposure from 0.0002808 (no adjustment for peak exposure) to 0.0001316, a notable change in the slope parameter. This results in a 53 percent reduction in the slope of the line that describes the relationship between cumulative 1,3-butadiene

exposure and leukemia mortality, representing less cancer potency. EPA believes that peak exposure is an inappropriate adjustment for the statistical model describing the impact of cumulative 1,3-butadiene exposure on leukemia mortality.

Other differences in input data and analytical methods are unlikely to have had major effects on the findings. The addition of women to the cohort and extension of follow-up in a subsequent analysis by Sathiakumar et al. (2021b) did not result in a notable change in the slope parameter. Adjustments for multiple occupational and demographic covariates does not appear to have had notable effects on the estimated slope parameter, either. Cheng et al. (Cheng et al., 2007) reported that results were similar with adjustment for age alone and for the full suite of covariates; Sathiakumar et al. (2021b) also reported similar results for full models with all covariates and reduced models. Valdez-Flores et al. (2022) obtained similar results to those of Sathiakumar et al. (2021b) from models adjusted only for age, but not for butadiene peaks.

It therefore appears that when comparable exposure-response models are used, differences in key parameter estimates are due primarily to changes in exposure estimates for the SBR cohort and, to a lesser extent, to adjustment for peak exposures in the analysis by Valdez-Flores et al. (2022). Although exposure-response models of similar forms with comparable adjustments for covariates provide parameter estimates that vary by about a factor of 10, as shown above, the risk estimates of EPA (U.S. EPA, 2002a) and Valdez-Flores (Valdez-Flores et al., 2022) are based on models of different forms. Health Canada's analysis using four model forms, including the linear model ultimately used by the Agency (U.S. EPA, 2002a) and the log-linear model used by Valdez-Flores et al. (2022) illustrates the effect of model form on the estimated relative risk.

Bladder Cancer

Table 5-4 summarizes the study populations, exposure levels, and results of seven bladder cancer epidemiological publications. Among the seven publications, only two publications (Valdez-Flores et al., 2022; Sathiakumar et al., 2021a) report statistically significant associations between 1,3-butadiene exposure and bladder cancer in statistical models. Sathiakumar et al. (2021a) used the same statistical model for bladder cancer (proportional hazard and confounders (age, age at hire, year of hire, sex, race, plant, hourly status) as Sathiakumar et al. (2021b) did for leukemia. The statistical analysis and confounder adjustments are listed in Table 5-6.

5.4.1.2 Analysis of One Ecological and Two Case-Control Studies

Three studies (Symanski et al., 2016; Heck et al., 2014; Whitworth et al., 2008) did not use SBR cohort data to estimate dose-response associations between 1,3-butadiene exposure and leukemia and showed a statistically positive association. Whitworth et al. (2008) used data from the Texas Cancer Registry to conduct an ecological study. Symanski et al. (2016) and Heck et al. (2014) use data from the Texas Cancer Registry and California Cancer Registry to conduct case-control studies, respectively.

An ecological study (Whitworth et al., 2008) assessed hazardous air pollutant (HAP) levels in Texas against lymphohematopoietic cancer incidence in children per census tract (953 cases). The Whitworth et al. (2008) assessment is considered a quality study, aside from a limitation in exposure assessment: the study correlates cancer incidence with only 1 year of HAP data that is during the period of diagnoses (1999 vs. 1994–2004) and may not have been etiologically relevant exposure for some if not all, cancer incidences. Additionally, the study was limited by the modeled exposure and the fact that 1,3-butadiene and benzene exposures were closely correlated and could not be assessed individually. Even though the study observed significantly increased rates of all leukemia in tracts with the highest levels of 1,3-

butadiene (RR = 1.40), this study result is not appropriate to be considered as a dose-response relationship.

Symanski et al. (2016) conducted a case-control study (1,248 cases; 12,172 controls) analyzing the relationship between estimated ambient outdoor exposure to 1,3-butadiene and acute lymphocytic leukemia (ALL) diagnosed in children aged younger than 5 years old. Cases in the Texas Cancer Registry diagnosed in 1995 to 2011 were matched to controls identified from Texas birth certificates by birth year and month. Children included were born between 1991 and 2011. Exposure during pregnancy was estimated based on maternal address at delivery and census tract EPA National-Scale Air Toxics Assessment (NATA) estimates available for 1996, 1999, 2002, and 2005. Estimates available for 1,3-butadiene were available for very few years, and misclassification of personal exposure is a potentially important concern. In adjusted single pollutant models, the authors reported an odds ratio of 1.28 (95% CI 1.08–1.52) for the association between the highest vs. lowest quartile of 1,3-butadiene and childhood ALL. Exposure model validity for 1,3-butadiene was not discussed. Sources of error include using spatial variation (*e.g.*, use of census tract level modeling as an estimate of personal exposure) as well as temporal variation (data were available for limited years, and seasonal variation was not discussed). In co-pollutant models, after adjusting for benzene, although not after adjusting for polycyclic organic matter (POM), associations with 1,3-butadiene remained significant. Data analysis used exposure variables defined using quartiles for each year of NATA data; there were substantial changes in levels of exposure over time. Another potential concern is that quantitative differences in levels of exposure within these quartiles were not taken into account: effect estimates appear to pool associations with exposure ranked as low, medium, medium-high, and high, regardless of temporal shifts. Even though no evidence of bias would differentially misclassify exposure, the mentioned concerns in exposure assessment and misclassification may cause uncertainties in the effect estimate.

The Air Pollution and Childhood Cancer Study (APCC) (Heck et al., 2014) is a case-control study that used the California Cancer Registry to examine the association between 1,3-butadiene levels in ambient air and two forms of leukemia among children under the age of 6 in California. The 1,3-butadiene exposure during the 3rd trimester and across the entire pregnancy was associated with increased odds of acute lymphoblastic leukemia (3rd trimester OR [95% CI]: 1.54 [1.19, 1.99], entire pregnancy OR [95% CI]: 1.76 [1.09, 2.86]). 1,3-Butadiene exposure during the child's first year of life was associated with increased odds of acute myeloid leukemia (OR [95% CI]: 2.35 [1.02, 5.39]). Concerns include the potential for exposure misclassification due to exposure assignment based on birth address, which only estimated exposure throughout pregnancy and into infancy, and limited information on some aspects of the analysis (*e.g.*, missing data) and study aspects related to sensitivity (*e.g.*, no information provided on the exposure distribution in this subset of the overall study population).

5.4.1.3 Comparison of SBR Cohort Studies and Other Ecological and Case-Control Studies

EPA compares the SBR cohort, ecological, and case-control studies based on the study design, statistical power, and beta value, regression coefficient, as described below.

Study Design

The ecological study design cannot investigate the causal relationship between 1,3-butadiene exposure and leukemia. Thus, Whitworth et al., (2008) study results are not appropriate for IUR derivation. Between cohort and case-control studies, both the case-control and cohort designs have unique strengths and limitations. Some of the major advantages of cohort studies over case-control studies are (1) the ability to study multiple outcomes that can be associated with a single exposure or multiple exposures in a single study; (2) well suited for assessing the effects of rare exposures, especially those in occupational

settings; and (3) the proportions of exposed persons among a group of individuals with the disease would be far too small to permit meaningful comparisons of risk. The SBR cohort had 65 years of health outcome and long-term exposure data, a long follow-up period (20 years), and very large male and female study participants (16,579 men and 4,508 women); therefore, SBR cohort studies are more suitable than the case-control studies for deriving leukemia IUR.

Regression Coefficient

These two case-control studies did not provide beta values from regression models, so their study results cannot be used for IUR. On the other hand, the dose-response analyses by Sathiakumar et al. and Valdez-Flores et al. ([Valdez-Flores et al., 2022](#); [Sathiakumar et al., 2021b](#)) include beta values from regression models, which are essential to derive an IUR.

Statistical Power

Compared to Symanski et al. and Heck et al. studies ([2016](#); [2014](#)), the SBR cohort has very large male and female study participants (16,579 men and 4,508 women) and long-term exposure data. The 18 studies that used SBR cohort data have higher statistical power than the other three studies.

Based on these advantages of cohort study design, regression coefficients, and study power in the dose-response models from SBR cohort publications, and a thorough systematic review of the scientific literature in the TSCA systematic review process, EPA concluded that epidemiology publications using SBR cohort data would be appropriate to derive 1,3-butadiene IUR and evaluate human cancer risk.

5.4.1.4 Study Selection for Leukemia and Bladder Cancer IUR Derivation

To ensure the best available science, EPA selected studies for dose-response analysis based on the following criteria: (1) studies that used the full cohort data through 2009 and as well as quantitative exposure data; (2) studies that includes all male and female study participants (cohort size is 21,087 workers); (3) studies that used the updated exposure assessment from Macaluso (2004); and (4) the quality of the publication is rated High or Medium in the TSCA systematic review process ([U.S. EPA, 2025i](#)). The follow-up period of the SBR cohort ended in 2009 (Table 5-3 and Table 5-4). Thus, only publications from 2009 onwards, which include all male and female participants, were considered for the next step of IUR derivation as they have the most complete data on leukemia, bladder cancer, and exposure, as well as the longest follow-up period. After considering all these factors, only the dose-response relationship in two publications ([Sathiakumar et al., 2021b](#); [Sathiakumar et al., 2019](#)) were considered in the study selection for IUR derivation for leukemia. For bladder cancer, only one publication ([Sathiakumar et al., 2021a](#)) met the criteria.

Leukemia

EPA's standard approach for deriving an IUR estimate using results from epidemiology studies involves using a regression coefficient that describes the relationship between increases in cancer risk and increases in cumulative exposure and estimates an upper-bound lifetime extra risk-per-unit exposure concentration through a lifetable analysis. The results of the statistical models of Sathiakumar et al. publication ([Sathiakumar et al., 2021b](#)) supported the classification of butadiene as a human carcinogen, confirmed a positive exposure-response relationship between butadiene and all leukemia, provided the regression coefficients, β , that described the relationship between increases in cancer risk and increases in cumulative exposure, which can be used for the lifetable analysis. As a result, the Sathiakumar et al. ([2021b](#)) publication was selected to derive leukemia IUR, which is described in Section 5.4.3.

Bladder Cancer

According to the evidence integration in Section 5.1.1.2 and Table 5-4, the evidence integration judgment for human evidence of bladder cancer from 1,3-butadiene exposure is moderate. After excluding publications with low or uninformative data quality scores, two of seven publications showed positive dose-response relationships. However, in these publications with positive dose-response relationships, two concerns were raised: (1) bladder cancer case numbers were small, and (2) smoking was not adjusted for the dose-response association in statistical models. However, EPA notes that (1) the use of Cox Proportional Hazard Models for analysis limits potential confounding by smoking through the use of internal controls with similar smoking histories; and (2) a study by the National Cancer Institute showed that, across many occupational cohorts, the impact of smoking on lung cancer results was relatively small ([Blair et al., 2007](#)). Based on the judgment of evidence integration, EPA has determined that evidence to support the causation between 1,3-butadiene exposure and bladder cancer risk is moderate. The IUR derivation process and results of 1,3-butadiene dose-response analysis for bladder cancer are described in Section 5.4.3.7.

5.4.2 Duration, Dosimetric and Unit Adjustments

Dosimetric Adjustments

As described in Section 5.4.1.4, dose-response data in Sathiakumar et al. studies were selected to derive IUR for leukemia ([Sathiakumar et al., 2021b](#)) and bladder cancer ([Sathiakumar et al., 2021a](#)), respectively. Because both studies are occupational epidemiology studies, the occupational exposure was converted to continuous exposures in the lifetable analysis and adjusting for the total amount of 1,3-butadiene in air inhaled per day (20/10 m³). Based on the EPA methods for the derivation of inhalation reference concentrations and application of inhalation dosimetry ([U.S. EPA, 1994](#)) 10 m³ is the default occupational ventilation volume for an 8-hour work shift, and 20 m³ is the default 24-hour ambient ventilation volume.

Duration Adjustments

The studies selected for dose-response assessment utilized differing exposure durations and frequencies. To better compare results across studies and exposure scenarios, administered doses/concentrations were linearly adjusted to continuous exposure (24 hours/day, 7 days/week) prior to POD derivation based on Haber's Law ([Haber, 1924](#)) using the following equation:

Equation 5-1. Adjusting Average Exposure Concentration or Inhalation POD for Differences in Days and Hours of Exposure Across Scenarios

$$Concentration_{continuous} = Concentration_{study} \times \left(\frac{D_s}{7}\right) \times \left(\frac{H_s}{24}\right)$$

Where:

$Concentration_{continuous}$	=	Adjusted air concentration/inhalation POD
$Concentration_{study}$	=	Air concentration/inhalation POD from study dataset
D_s	=	Days per week/year exposure in study dataset
H_s	=	Hours per day exposure in study dataset

IURs were derived incorporating both dosimetric and duration adjustments, resulting in a lower value than the original study POD.

Unit Conversions

It is often necessary to convert between ppm and mg/m³ due to variation in concentration reporting in studies and the default units for different OPPT models. Therefore, EPA presents all inhalation hazard

values in Section 8 in both units. The following equation presents the conversion of the HEC from mg/m^3 to ppm.

Equation 5-2. Converting Risk per ppm to Risk per mg/m^3

$$\begin{aligned}\text{IUR (per mg/m}^3\text{)} &= \text{IUR (ppm)} \times (24.45 \div \text{molecular weight}) \text{ (see footnote 1)} \\ \text{IUR (per mg/m}^3\text{)} &= \text{IUR (ppm)} \div (24.45 \div 54.0916)\end{aligned}$$

5.4.3 Cancer IUR and UR for Leukemia and Bladder Cancer from Lifetime Exposures

5.4.3.1 Selection of Study, Statistical Model, and Data for Leukemia IUR Derivation

Based on the dose-response analysis in Section 5.4.1, the Sathiakumar et al. (2021b) publications were ultimately chosen as the best available science to derive unit risks for three reasons. First, the relationship between 1,3-butadiene and leukemia in this publication is consistent with those reported earlier by other researchers in supporting a positive association in the synthetic rubber polymer industry. Second, it includes male and female workers, the revised exposure assessment from Macaluso and colleagues (Macaluso et al., 2004) that is described in above paragraph, long follow-up period until 2009 (additional 20 years of follow-up), updated analytical framework using proportional hazards models, and reasonable confounder adjustment. Thirdly, adding women to the cohort provides essential data for population risk assessment, and the additional 20 years of follow-up that added 418,546 person-years of observation and 5,000 deaths, enhance statistical power to assess the association between 1,3-butadiene exposure and leukemia. The vital features of this SBR worker cohort study are summarized in Table 5-7.

Table 5-7. Characteristics of the SBR Cohort (Sathiakumar et al., 2021b)

Descriptor	Overview of the Study and Cohort Data
Cohort period (years)	1943–2009
Health outcomes	Hematopoietic cancers, including Leukemia, in all published studies using data from the SBR worker cohort study; bladder cancer in few published studies.
Number of all workers in the cohort	21,087 workers (16,579 men; 4,508 women)
Number of workers exposed to butadiene	14,004
Number of male workers exposed to butadiene	12814 (77% of butadiene-exposed workers)
Number of female workers exposed to butadiene	1190 (26% of butadiene-exposed workers)
Number of all leukemia decedents	132
Number of all leukemia decedents exposed to butadiene	103

Sathiakumar et al. (2021b) showed that their analyses of exposure-response relations in the SBR cohort by UAB researchers improved and extended their previous analyses, including those that informed the IRIS assessment. The cohort had been expanded and updated over 66 years. The analytical framework provided in Sathiakumar and colleagues was also updated by replacing classical grouped Poisson regression models with proportional hazards models, which can allow analysts to avoid bias from grouping and assigning exposure values.

Table 5-8. Summary of Crucial Cox Regression Models to Analyze Exposure-Response Relations for Leukemia in ([Sathiakumar et al., 2021b](#))

Statistical Model	Lag Time (years)	β (Beta Coefficient)	Upper 95% Confidence Bound on β	Trend P Value
1. All person-time (untrimmed, including unexposed)	0	2.55E-04	4.57E-04	0.014
2. All person-time (untrimmed, including unexposed)	10	2.58E-04	4.78E-04	0.022
3. All person-time (untrimmed, including unexposed)	20	2.63E-04	5.31E-04	0.055
4. Exposed person-time (exclude unexposed)	0	2.50 E-04	4.73E-04	0.028
5. Exposure person time \leq 95th percentile: Restricted cubic spline (RCS) Cox regression model (trim to restrict data)	0	9.94E-04	18E-04	0.016

Table 5-8 shows that Sathiakumar et al. ([2021b](#)) used various models to estimate the association between butadiene exposure and leukemia. The first three models in Table 5-8 include the unexposed and exposed populations. Because the purpose of 1,3-butadiene IUR derivation is for butadiene exposure and leukemia, the first three models that include the unexposed population are not under Agency consideration. More than 90 percent of the leukemia cases died 20 years or more after hire. Given that beta-coefficients in the first three models with lag times of 0, 10, and 20 years are very close, lagging exposure had little effect on results for leukemia. As exposure diminished over calendar time, lagging exposure was not a concern when updating the IUR process. In addition, the CDC ([2015](#)) concluded that the minimum latency of leukemia is 0.4 years. Since β values in the first three models are not significantly different for lag time of 0, 10, and 20 years, and the minimum latency of leukemia is 0.4 years, 0 years is chosen as the lag time in the lifetable analysis to update the IUR.

Between the fourth and fifth models, the beta-coefficients of the fifth model are selected to conduct the lifetable analysis because of (1) previous study results before Sathiakumar et al. ([2021b](#)); and (2) better model fitting of Sathiakumar et al. ([2021b](#)), which are described below.

A. Evidence from Previous Study Results Before the Sathiakumar et al. Study

[Sathiakumar et al. \(2021b\)](#) cited several previous study results to describe statistical analysis and provided the rationale to determine the exposure data input for the fifth model (Cox regression \leq 95th percentile), “Cohort studies in other industry settings have reported that exposure-response curves tend to diminish at higher exposure levels. Two of our earlier studies of male synthetic rubber polymer workers found stronger exposure-response trends for butadiene and leukemia in analyses that excluded exposures above the 95th percentile or categorized butadiene into deciles. Both of the latter procedures can reduce the impact of exposure outliers. In addition, an investigation at the largest study plant to validate our butadiene exposure estimates found greater misclassification for jobs entailing higher exposures than for jobs with lower exposures.” These previous study results support the use of exposure person time less than or equal to 95 percent in three aspects below:

1. *At high exposure levels:* (i) excluding greater than 95 percent exposure person time can reduce the impact of exposure outliers ([Sathiakumar et al., 2015](#); [Cheng et al., 2007](#)), and (ii) greater misclassification for jobs entailing higher exposures than for jobs with lower exposures according to the validation investigation at the largest study plant ([Sathiakumar et al., 2007](#)).

2. *At low exposure levels:* Exposure-response curves tend to diminish at higher exposure levels. IUR represents a lower exposure range ([Stayner et al., 2003](#)) so the concern about high-exposure workers is not as relevant to IUR derivation.
3. *Model fitting performance:* Cheng et al. ([Cheng et al., 2007](#)) showed stronger exposure-response trends for butadiene and leukemia in analyses while excluding exposures above the 95th percentile.

B. Model Fitting of Sathiakumar et al. Study

[Sathiakumar et al. \(2021b\)](#) showed more robust model fitting than other models and stated, “Trimming to restrict data to ppm-years greater than 0 and less than or equal to the 95th percentile (1,144 ppm-years) of all leukemia decedents yielded a somewhat stronger exposure-response trend for butadiene ($\beta=9.94 \times 10^{-4}$, (95% CI 1.88 to 18.00) $\times 10^{-4}$, trend $p=0.016$).”

In summary, according to the described study results above, the fifth model results are acceptable for conducting lifetable analysis.

5.4.3.2 Leukemia Lifetable Analysis

To be consistent with EPA IRIS method, the Agency adopted the same method of lifetable analysis to derive the 1,3-butadiene IUR ([U.S. EPA, 2002a](#)). This mathematical methodology was established by the BEIR (Biological Effect of Ionizing Radiation) Committee ([BEIR, 1988](#)), and EPA IRIS started implementing it in the 2002 assessment ([U.S. EPA, 2002a](#)). Lifetables are an actuarial procedure to account for the dose-response effects of exposure over the lifetimes of a population in the presence of competing causes of death and account for the apportionment, an ever-smaller number of people in each increasing age category accordingly. It is used to transform occupational effect estimates to estimates suitable for general lifetable unit risks. The steps to conduct lifetable analysis are as follows.

A. Data Input

Three kinds of inputs are essential to be used in the lifetable analysis:

1. Population statistics including U.S. age-specific all-cause mortality and cause-specific incidence/mortality. U.S. age-specific all-cause mortality rates for deaths in 2019 among all race and gender groups combined were retrieved from the Multiple Cause of Death (final) database of the Wide-ranging ONline Data for Epidemiologic Research (WONDER) from the Centers for Disease Control and Prevention (CDC) ([CDC, 2024](#)). For 1,3-butadiene lifetable analysis, the leukemia-specific incidence was obtained from the Surveillance, Epidemiology, and End Results (SEER) 22 from the National Cancer Institute (NCI), National Institutes of Health ([NIH, 2024](#)). Both U.S. all-cause mortality and leukemia incidence are age-specific, and rates are available up to 84.99 years. The lifetable represents the U.S. population using 84.99 years as the top age for the lifetable analysis.
2. Epidemiological studies with cumulative exposure: In epidemiological studies that provide exposure-response analyses, β -and upper 95 percent confidence bound (CB) on β -were incorporated into the lifetable analysis ([U.S. EPA, 2005a](#)). Beta is the estimate of the increase in the outcome (*e.g.*, leukemia) that results from an increase of one unit of exposure to 1,3-butadiene. Depending on cancer outcomes, if the dose-response had an exposure lag (*e.g.*, 0 or 10 years), that should also be included in the lifetable analysis. Table 5-8 shows that varying lag time for leukemia has no significant impact on β .
3. Selection of Benchmark Response (BMR): BMR is usually 1 percent for cancer data ([U.S. EPA, 2012b](#)), but other BMR values are possible for rare outcomes (*e.g.*, 0.1%). Because the selected health outcome is leukemia, EPA used 1 percent for BMR.

B. Data Output

The lifetable analysis aims to find the 95 percent lower confidence limit of the exposure concentration (LEC_{BMR}) that results in leukemia's extra risk (ER) after exposure to 1,3-butadiene. ER is a calculation of the risk of adverse effects that adjusts for background incidence rates of the same effect by estimating risk at dose only among the fraction of the population not expected to respond to the background causes ([U.S. EPA, 2024b](#)). The target extra risk in this lifetable analysis is set as 0.01. LEC_{BMR} is the cumulative lifetime exposure levels that yield extra risk as 0.01 by interpolating the exposure level corresponding to the 95 percent upper bound on β . Through an iterative process that evaluates the risk levels resulting from selected exposure levels, the exposure expected to result in a specified level of excess risk (e.g., 1%) can be determined.

C. Assumptions of Lifetable Analysis

The definition of the IUR refers to exposure over a lifetime. Lifetable analysis and IUR derivation have two assumptions: (1) no child exposure from the occupational setting, and (2) the initiation of occupational exposure is at age 16 years for people working in the occupational setting. These two assumptions lead to two settings in the lifetable as follows:

1. Set zero for exposure duration for ages 0 to 15 years in column I in the lifetable;
2. For exposure duration for ages 16 to 85 years in column I, Exposure Duration (years), in the lifetable ([U.S. EPA, 2025f](#)), the exposure duration starts at age 16 and the exposure duration for age 16 is set to be 0.495 years. Accordingly, the exposure duration for age 17 is 1.495 years and for age 18, it is 2.495 years (etc).

Due to the assumption of no child exposure before age 16, “adult-exposure-only” unit risk is computed from the 95 percent lower confidence limit of the exposure concentration that results in cancer's extra risk in the lifetable analysis. The “adult-exposure-only” unit risk (UR) is used as the workers' IUR. Afterwards, “adult-exposure-only” unit risk is rescaled to yield “adult-based” unit risk based on 78 years of U.S. average life expectancy ([U.S. EPA, 2011](#)) and 62 years of adult work-years. The “adult-based” unit risk is incorporated with ADAF to derive IUR for the general population. The detailed process to derive the updated unit risks and IUR is described in Section 5.4.3.3.

D. Parameter Values in the Lifetable Calculations

- Occupational exposure duration: lifetables include exposures from age 16 to 85 years. Even though a reasonable upper bound on occupational exposure is 40 years beginning at age 16 years, the adjustment for 40 years of exposure is made in the risk calculations, not in the unit risk computation, because the IUR represents the risk of cancer per unit of daily exposure over lifetime exposure.
- Occupational exposure days: EPA's IRIS program established the lifetable procedure for estimating IUR values and assumes that workers are exposed for 240 days (48 work weeks) per year. This assumption has also been applied by OPPT previously for the *Risk Evaluation for Asbestos, Part I* ([U.S. EPA, 2020](#)). To be consistent, EPA also used 240 days per year as the occupational exposure days per year for IUR derivation.
- Ventilation rate adjustment: the dose-response function (the slope) from the occupational cohort is based on workers. EPA assumes that workers breathe at a faster rate than the general population and adjusted the IUR in accordance with EPA guidance to derive an IUR for the general population ([U.S. EPA, 1994](#)). For this adjustment, the Agency assumed that workers breathe 10 m^3 per 8-hour day ([U.S. EPA, 2011, 1991](#)) while the resting rate for the general population was set at 20 m^3 per 24-hour day based on EPA guidance from the time when the

cohort was exposed ([U.S. EPA, 1994](#)). This daily rate is equivalent to 7,300 m³ per year. Age range of data in the lifetable analysis: The purpose of the lifetable analysis is to derive the unit risk of cancer after exposure to 1,3-butadiene. EPA used the best available age-specific mortality and morbidity data to compute “adult-exposure-only” unit risk, and these age-specific data go up to 84.99 years old. While age-specific data is up to 84.99 years old is included in the lifetable analysis, EPA did not assume every occupational worker lives to 84.99 years old and this value was not used in any equations. In contrast, the expected lifetime of 78 years from the *Exposure Factors Handbook* was used for calculating the adult-based unit risk value ([U.S. EPA, 2011](#)).

Exposure parameters specific to occupational exposure for the purposes of risk characterization were adjusted in the exposure estimates as part of risk calculations. These include increased worker breathing rate, and typical working hours/days/years compared to continuous exposure at a resting breathing rate. See Section 5.3.1.3 in the *Risk Evaluation for 1,3-Butadiene* ([U.S. EPA, 2025h](#)) for more details.

5.4.3.3 Leukemia IUR and UR Calculation

IRIS defines Inhalation Unit Risk as “The upper-bound excess lifetime cancer risk estimated to result from continuous exposure to an agent at a concentration of 1 µg/m³ in air.” ([U.S. EPA, 2024c](#)). For 1,3-butadiene IUR, excess lifetime cancer risk means the additional or extra risk of developing cancer due to exposure to a 1,3-butadiene over the lifetime of an individual ([U.S. EPA, 2024b](#)). LEC_{BMR}, the 95 percent lower confidence limit of the exposure concentration associated with a 1 percent increased risk, is used to calculate the unit risk (UR) at 95 percent upper-bound estimate using the equation below:

Equation 5-3. UR at 95% upper-bound estimate = BMR/LEC_{BMR} per unit of exposure

BMR is the benchmark response of an adverse effect and is used to define a benchmark dose. The change in response rate over the background of the BMR is usually in the range of 5 to 10 percent, which is the limit of responses typically observed in well-conducted animal experiments. EPA used epidemiologic data in the 1,3-butadiene IUR derivation because of the rich and good-quality data collected from a 66-year SBR worker cohort study. As the EPA *Benchmark Dose Technical Guidance* indicated, based on biological and statistical considerations, BMR is set as 1 percent for most cancers, except for rare cancers ([U.S. EPA, 2012b](#)). Therefore, the 1 percent value is referred to as an extra risk for the BMR for leukemia and bladder cancer, respectively. As a result, the equation can be expressed as follows:

$$\text{UR at 95\% upper-bound estimate} = \text{BMR}_{01} / \text{LEC}_{01} = 0.01 / \text{LEC}_{01}.$$

$$\text{Similarly, UR at the maximum likelihood estimate} = \text{BMR}_{01} / \text{EC}_{01} = 0.01 / \text{EC}_{01}.$$

The “adult-exposure-only” unit risk at 95 percent upper-bound estimate (UB) is to divide the benchmark response of 1 percent by LEC₀₁, and the LEC₀₁ is computed in the lifetable using 95 percent UB of β. The “adult-exposure-only” unit risk at the maximum likelihood estimate (MLE) is to divide the benchmark response of 1 percent by EC₀₁, and the EC₀₁ is computed in the lifetable using MLE of β.

The average lifespan for calculating unit risk is determined to be 78 years according to the CDC’s U.S. life expectancy of both sexes, 78.4 years (<https://www.cdc.gov/nchs/fastats/life-expectancy.htm>; accessed November 17, 2025), consistent with EPA’s *Exposure Factors Handbook* ([U.S. EPA, 2011](#)). Since one of the assumptions of the lifetable analysis is that the initiation of occupational exposure starts at 16 years old, the “adult-exposure-only” unit risk estimates were multiplied by 78 ÷ 62 to rescale the 62-year adult period to 78 years and to yield the “adult-based” lifetime unit risk.

The last step is to apply the ADAF to the “adult-based” unit risk at 95 percent UB to obtain the lifetime IUR (Table 5-11). EPA has determined that 1,3-butadiene is “Carcinogenic to Humans” and exhibits a mutagenic MOA as described in Section 5.3. In accordance with the *Supplemental Guidance for Assessing Susceptibility from Early-life Exposure to Carcinogens*, the following ADAFs were applied to the adult unit risk: 10 for children ages less than 2 years; 3 for children aged 2 to 15 years; and 1 for persons aged 16 to 78 years ([Barton et al., 2005](#)). The weighted sum of these three partial unit risks is the ADAF-adjusted lifetime IUR ([Barton et al., 2005](#)). This lifetime IUR is used for estimating the general population risk for leukemia based on lifetime exposure (0–78 years). The “adult-exposure-only” UR at 95 percent upper-bound is used for the occupational risk estimate and defined as the chronic occupational UR.

5.4.3.4 Leukemia IUR and UR Results

Based on the above computation, the LEC_{01} calculated by lifetable analysis is 2.046 ppm, and the adult-exposure-only UR at 95 percent upper-bound based on ages from less than 1 to 84.9 years old is 0.0049 per ppm (2.2×10^{-6} per $\mu\text{g}/\text{m}^3$). The chronic occupational UR is 0.0049 per ppm (2.2×10^{-6} per $\mu\text{g}/\text{m}^3$) (Table 5-10). Due to the carcinogenic mode of action of 1,3-butadiene, the age-dependent adjustment factor (ADAF) is applied to the adult-based UR at 95 percent upper-bound to yield the IUR. After applying the ADAF to the adult-based UR at 95 percent upper-bound, the IUR is computed to be 0.0098 per ppm (4.4×10^{-6} per $\mu\text{g}/\text{m}^3$) (Table 5-11). The interpretation of the IUR (4.4×10^{-6} per $\mu\text{g}/\text{m}^3$) is that 4.4 excess leukemia cases (as the upper-bound estimate) are expected to develop per 1,000,000 people if exposed daily for a lifetime to 1 μg of 1,3-butadiene per m^3 of air.

Table 5-9. Calculation of Cancer Unit Risk Estimate for Leukemia

Model of the Beta-Coefficient (β), Reference	β		Exposure Concentration Associated with BMR (1% Extra Risk) Starting Exposure at Age 16 Year		Adult-Exposure-Only Unit Risk (62 year) ^d		Adult-Based Unit Risk (78 year) ^e	
	MLE ^a	95% UB ^b	EC ₀₁ (16+) MLE	LEC ₀₁ (16+) 5% LB ^c	MLE	95% UB ^b	MLE	95% UB ^b
Cox regression model Sathiakumar et al. (2021b)	0.00094	0.0018	3.69 ppm	2.046 ppm	0.0027 per ppm	0.0049 per ppm	0.0034 per ppm	0.0062 per ppm

^a MLE = maximum likelihood estimate, a statistical method for estimating a population parameter most likely to have produced the sample observations. This will be used for potential benefits analysis.

^b UB = the upper-bound estimate. This is the inhalation unit risk (IUR) to be used for risk estimation.

^c LB = the lower-bound estimate.

^d Adult-exposure-only unit risk (62 year) means the unit risks for the 62-year period between age 16 and 78 years (OPPT assumption of a lifetime).

^e Adult-based unit risk (78 year) means to rescale the “adult-exposure-only” unit risk from 62-year adult period to 78-years by multiplying $78 \div 62$.

Table 5-10. Cancer Hazard Values for Occupational Cancer Risk Estimation for Leukemia

Chronic Occupational Unit Risk ^a	Reference	Overall Quality Determination
0.00489 per ppm (2.21E-03 per mg/m ³) (2.21E-06 per µg/m ³)	(Sathiakumar et al., 2021b)	Medium
^a EPA considers a range of extra cancer risk from 1E-04 to 1E-06 to be relevant benchmarks for risk assessment (U.S. EPA, 2017); however, these are not considered “bright-lines” for unreasonable risk determination.		

Table 5-11. Incorporation of Age-Dependent Adjustment Factors for General Population Leukemia Risk Estimation

Age (years)	ADAF Adjustment ^a	Adjusted Partial Life and General Population IUR
0 to <2	10×	$0.0062 \times 10 \times (2 \div 78) = 0.0016$
2 to <16	3×	$0.0062 \times 3 \times (14 \div 78) = 0.0033$
≥16 ^b	1×	$0.0062 \times 1 \times (62 \div 78) = 0.0049$
0 to 78	1.59	0.00978 per ppm (4.42E-06 per µg/m³)
^a ADAFs are applied based on the determination of a mutagenic MOA (Section 5.3) and in accordance with (U.S. EPA, 2005b).		
^b Adjusted IUR value is based on an assumption of 78 years lifetime (U.S. EPA, 2011).		

5.4.3.5 Selection for Study, Statistical Model, and Data for Bladder Cancer

To select the appropriate study to derive bladder cancer IUR, EPA considered three factors to evaluate the seven publications: (1) publications after 2009 because the study’s follow-up period ended in 2009; (2) inclusion of all male and female study participants; and (3) rating in the systematic review as high or medium. After considering all three factors, only two publications ([Sathiakumar et al., 2021a](#); [Sathiakumar et al., 2019](#)) were selected for further consideration. Sathiakumar et al. ([2021a](#)) provided the regression coefficient, which is required for lifetable analysis, but Sathiakumar et al. ([2019](#)) only included bladder cancer standardized mortality ratio (SMR) data. As a result, Sathiakumar et al. publication ([2021a](#)) is selected for bladder cancer IUR derivation.

[Sathiakumar et al. \(2021a\)](#) showed that their analyses of exposure-response relations in the SBR cohort by UAB researchers improved and extended their previous analyses, including those that informed the ORD assessment (2002). The cohort was expanded and updated to include women and 18 additional years of follow-up, which added 418,546 person-years of observation and 5,000 deaths ([Sathiakumar et al., 2021a](#)) and included the revised exposure estimates ([Macaluso et al., 2004](#)). The analytical framework in [Sathiakumar et al. \(2021a\)](#) was also updated by replacing classical grouped Poisson regression models with proportional hazards models (Cox regression model), which can allow analysts to avoid bias from grouping and assigning exposure values.

Table 5-12 shows that [Sathiakumar et al. \(2021a\)](#) used various models to estimate the association between butadiene exposure and bladder cancer. Because the purpose of IUR derivation is for 1,3-butadiene exposure and bladder cancer, the first three models that include the unexposed population are not under consideration. Between models 4 and 5, model 4 was statistically significant. Therefore, the

results from model 4 were ultimately selected for lifetable analysis and IUR derivation for 1,3-butadiene.

Table 5-12. Summary of Crucial Cox Regression Models to Analyze Exposure-Response Relations for Bladder Cancer in Sathiakumar et al. (2021a)

Statistical Model	Lag Time (years)	β (Beta-Coefficient)	Upper 95% Confidence Bound on β	Trend P-Value
1. All person-time (untrimmed, including unexposed)	0	3.84E-04	6.12E-04	0.001
2. All person-time (untrimmed, including unexposed)	10	3.87E-04	6.21E-04	0.001
3. All person-time (untrimmed, including unexposed)	20	4.22E-04	6.80E-04	0.001
4. Exposed person-time (exclude unexposed)	0	3.50E-04	5.95E-04	0.005
5. Exposure person time \leq 95th percentile: Restricted cubic spline (RCS) Cox regression model (trim to restrict data)	0	4.72E-04	13.79E-04	0.308

5.4.3.6 Bladder Cancer Lifetable Analysis

The lifetable analysis for bladder cancer uses the same method as that for leukemia that is described in Section 5.4.3.2. This method was used by EPA IRIS to derive 1,3-butadiene IUR for leukemia ([U.S. EPA, 2002a](#)). The data inputs and outputs are described below.

A. Data Input

Three kinds of inputs are essential to be used in the lifetable analysis:

1. Population statistics include U.S. age-specific all-cause mortality and cause-specific incidence/mortality. U.S. age-specific all-cause mortality rates for deaths in 2019 among all race and gender groups combined were retrieved from CDC's WONDER ([CDC, 2024](#)). For 1,3-butadiene lifetable analysis, the bladder cancer-specific incidence was obtained from the SEER 22 from NCI, National Institutes of Health ([NIH, 2024](#)). Both U.S. all-cause mortality and bladder cancer incidence are age-specific. Because rates above the age of 85 years are not available for bladder cancer-specific incidence, EPA assumed 84.99 years of exposure for the lifetable analysis.
2. Epidemiological studies with cumulative exposure: In epidemiological studies that provide exposure-response analyses, β - and the upper 95 percent confidence bound (CB) on β - were incorporated into the lifetable analysis, in accordance with direction from EPA's *Guidelines for Carcinogen Risk Assessment* recommending use of both a central tendency and 95 percent confidence interval for dose-response modeling ([U.S. EPA, 2005a](#)). Beta is the estimate of the increase in bladder cancer that results from an increase of one unit of exposure to 1,3-butadiene. If the dose-response had an exposure lag (years, e.g., 0, 10 years), that should also be included in the lifetable analysis. Bladder cancer lag of 0 years was chosen for the lifetable analysis for two reasons: (1) the model ([Sathiakumar et al., 2021a](#)) from which EPA selected the beta coefficient for lifetable analysis used the lag of 0 years; (2) the modeling of different lags time in exposure showed little effect on beta coefficients which is likely due to the extensive follow-up of the SBR

cohort (66 years) which exceeds bladder cancer latency. The lag in the lifetable should coincide with the statistical model; if the statistical model uses lag 0, the lifetable should also use lag 0. Lag time is not latency but rather, an epidemiological method used to account for biological latency in the dose-response model. The latency for bladder cancer is reported to be approximately 20 years in the literature ([Böthig et al., 2021](#); [Saginala et al., 2020](#); [Clin et al., 2014](#); [Yamaguchi et al., 1982](#); [Mazeman, 1972](#)). However, in cohort studies that have been followed for many years post-exposure, the modeling of different lag times in exposure often has little effect since the latency time is generally unexposed. Therefore, use of lag 0 in a model that best fits the data may be appropriate.

3. Selection of Benchmark Response (BMR): BMR is usually set as 1 percent for human cancer data, except for rare cancer ([U.S. EPA, 2012b](#)). Because the selected health outcome is bladder cancer, 1 percent was used for BMR.

B. Data Output

The lifetable analysis aims to find the 95 percent lower confidence limit of the exposure concentration (LEC_{BMR}) that results in bladder cancer's extra risk (ER) after exposure to 1,3-butadiene. ER is a calculation of the risk of adverse effects, which adjusts for background incidence rates of the same effect by estimating risk at dose only among the fraction of the population not expected to respond to the background causes ([U.S. EPA, 2024b](#)). The target extra risk in this lifetable analysis is set as 0.01 since 1 percent is usually used for cancer BMR ([U.S. EPA, 2012b](#)). LEC_{BMR} is the cumulative lifetime exposure levels that yield extra risk as 0.01 by interpolating the exposure level corresponding to the 95 percent upper-bound on β . Through an iterative process that evaluates the risk levels resulting from selected exposure levels, the exposure expected to result in a 1 percent excess risk can be determined.

C. Assumptions for Lifetable Analysis

The assumptions for bladder cancer lifetable analysis are the same as the assumptions for leukemia lifetable analysis. Please refer to the Paragraph "C. Assumptions for Lifetable Analysis" in Section 5.4.3.2 Leukemia Lifetable Analysis on page 86.

D. Parameter Values in the Lifetable Calculations

The values of parameters including occupational exposure duration, occupational exposure days, ventilation rate adjustment, and age-specific mortality and morbidity up to 84.99 years old in the lifetable for bladder cancer, are the same as those for leukemia. Please refer to the Paragraph "D. Parameter Values in the Lifetable Calculation" in Section 5.4.3.2.

5.4.3.7 Bladder Cancer IUR and UR Calculation

Epidemiologic data are used in the 1,3-butadiene IUR derivation because of the rich and good-quality data collected from a 66-year SBR worker cohort study. The method to calculate IUR for bladder cancer is the same as that for leukemia, which is described in Section 5.4.3.3. Please refer to Section 5.4.3.3, "Leukemia IUR and UR Calculation."

5.4.3.8 Bladder Cancer IUR and UR Results

Using the above equation for computation, the LEC_{01} calculated by lifetable analysis is 4.46 ppm ([U.S. EPA, 2025f](#)), and the adult-exposure-only UR at 95 percent upper-bound based on ages from less than 1 to 84.9 years old is 0.0022 per ppm (0.99×10^{-6} per $\mu\text{g}/\text{m}^3$) and the adult-based unit risk at 95 percent upper-bound is 0.0028 per ppm (Table 5-13). Due to the mutagenic mode of action of 1,3-butadiene, the age-dependent adjustment factor (ADAF) is applied to UR at 95 percent upper-bound to yield the IUR. After applying the ADAF to the UR at 95 percent upper-bound, the IUR is computed to be 0.0045 per ppm (2.0×10^{-6} per $\mu\text{g}/\text{m}^3$) (Table 5-15). The interpretation of the IUR (2.0×10^{-6} per $\mu\text{g}/\text{m}^3$) is that 2.0

excess bladder cancer cases (as the upper-bound estimate) are expected to develop per 1,000,000 people if exposed daily for a lifetime to 1 µg of 1,3-butadiene per m³ of air.

Table 5-13. Calculation of Bladder Cancer Unit Risk Estimate

Model of the Beta-Coefficient (β), Reference	β		Exposure Concentration Associated with BMR (1% Extra Risk) Starting Exposure at Age 16 Year		Adult-exposure-only Unit Risk (62 year) ^d		Adult-based Unit Risk (78 year) ^e	
	MLE ^a	95% UB ^b	EC ₀₁ (16+) MLE	LEC ₀₁ (16+) 5% LB ^c	MLE	95% UB ^b	MLE	95% UB ^b
Cox regression model (Sathiakumar et al., 2021a)	0.00035	0.000556	7.09 ppm	4.46 ppm	0.0014 per ppm	0.0022 per ppm	0.0018 per ppm	0.0028 per ppm
^a MLE = maximum likelihood estimate, a statistical method for estimating a population parameter most likely to have produced the sample observations. This will be used for potential benefits analysis. ^b UB = the upper-bound estimate. This is the inhalation unit risk (IUR) to be used for risk estimation. ^c LB = the lower-bound estimate. ^d Adult-exposure-only unit risk (62 year) means the unit risks for the 62-year period between age 16 and 78 years (OPPT assumption of a lifetime). ^e Adult-based unit risk (78 year) means to rescale the “adult-exposure-only” unit risk from 62-year adult period to 78-years by multiplying 78 ÷ 62.								

Table 5-14. Cancer Hazard Values for Occupational Cancer Risk Estimation for Bladder Cancer

Chronic Occupational Unit Risk ^a	Reference	Overall Quality Determination
0.00224 per ppm (1.01E-03 per mg/m ³) (1.01E-06 per µg/m ³)	(Sathiakumar et al., 2021a)	Medium
^a EPA considers a range of extra cancer risk from 1E-04 to 1E-06 to be relevant benchmarks for risk assessment (U.S. EPA, 2017); however, these are not considered bright-lines for unreasonable risk determination.		

Table 5-15. Incorporation of Age-Dependent Adjustment Factors for General Population Risk Estimation for Bladder Cancer

Age	ADAF Adjustment ^a	Adjusted Partial Life and General Population IUR
0 to <2	10×	0.0028 × 10 × (2 ÷ 78) = 0.00072
2 to <16	3×	0.0028 × 3 × (14 ÷ 78) = 0.0015
≥16 ^b	1×	0.0028 × 1 × (62 ÷ 78) = 0.0022
0 to 78	1.59	0.00445 per ppm (2.01E-06 per µg/m³)
^a ADAFs are applied based on the determination of a mutagenic MOA (Section 5.3) and in accordance with (U.S. EPA, 2005b). ^b Adjusted IUR value is based on an assumption of 78 years lifetime (U.S. EPA, 2011).		

5.4.4 Combined IUR Derivation

Once the leukemia and bladder cancer lifetime unit risks are derived, respectively, the two are then combined. It is important to note that this estimate of overall potency is not the risk of developing both cancers simultaneously. Each of the unit risks is itself an upper-bound estimate, so summing such upper-bound estimates across leukemia and bladder cancer mortality overestimates the overall risk. Thus, a statistically appropriate upper bound on the combined risk was derived to gain an understanding of the overall risk of mortality resulting from leukemia and bladder cancer, in accordance with the recommendations of the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005a). The derivation of the combined IUR of leukemia and bladder cancer and incorporation of ADAF involves several steps (U.S. EPA, 2020), detailed below:

Step 1. Combined Standard Deviation:

Combined standard deviation of leukemia and bladder cancer (SD_{L-BC}) is the square root of the sum of the squares of individual standard deviations of leukemia and bladder cancer. The assumption for this calculation is that these variables are independent and normal random variables. It is important to note that the independence of the estimated risks for leukemia and bladder cancer mortality is a theoretical assumption, under a similar context of different tumors in animals. NRC (1994) states, "...a general assumption of statistical independence of tumor-type occurrences within animals is not likely to introduce substantial error in assessing carcinogenic potency."

Equation 5-4.

$$SD_{L-BC} = \sqrt{((UR_L - CR_L)/1.645)^2 + ((UR_{BC} - CR_{BC})/1.645)^2}$$

Where:

UR_L	=	Upper-bound estimate of adult-based unit risk of leukemia
CR_L	=	Central estimate of adult-based unit risk of leukemia (using MLE)
UR_{BC}	=	Upper-bound estimate of adult-based unit risk of bladder cancer
CR_{BC}	=	Central estimate of adult-based unit risk of bladder cancer (using MLE)

The table below lists the values of the variables in Equation 5-4. Values of UR_L and CR_L are obtained from Table 5-9. Values of UR_{BC} minus CR_{BC} are obtained from Table 5-13 below.

Table 5-16. Upper and Central Estimates of Adult-Based Unit Risk of Leukemia and Bladder Cancer

Variables in Equation 5-4	UR_L	CR_L	UR_{BC}	CR_{BC}	SD_{L-BC}
Values of variables	0.0062	0.0034	0.0028	0.0018	0.0019

Step 2. Combined Central Estimate of Adult-Based Central Unit Risk of Leukemia and Bladder Cancer:

Equation 5-5.

$$CR_{L-BC} = CR_L + CR_{BC}$$

Where:

CR_{L-BC}	=	Combined central estimate of adult-based unit risk of leukemia and bladder cancer
CR_L	=	central estimate of adult-based unit risk of leukemia

CR_{BC} = Central estimate of adult-based unit risk of bladder cancer. Using the values of R_L and CR_{BC} in Table 5-16, the resulting value of CR_{L-BC} is 0.005

Step 3. Combined Adult-Based Unit Risk of Leukemia and Bladder Cancer:

Equation 5-6.

$$UR_{L-BC} = CR_{L-BC} + 1.645 \times SD_{L-BC}$$

Using the values from the results of Equation 5-4 and Equation 5-5, SD_{L-BC} and CR_{L-BC} , the resulting value of the combined adult-based unit risk of leukemia and bladder cancer is 0.008131.

Step 4. Combined IUR with ADAF Adjustment:

The last step is to apply the ADAFs, which adjust the “adult-based” lifetime age-specific unit risk for children. The weighted sum of these three partial unit risks is the ADAF-adjusted lifetime inhalation unit risk (IUR) of leukemia and bladder cancer.

Table 5-17. Incorporation of ADAF to Obtain the Combined IUR of Leukemia and Bladder Cancer

Age	ADAF Adjustment ^a	Adjusted Partial Life and General Population IUR
0 to <2	10×	$0.008131 \times 10 \times (2 \div 78) = 0.00208$
2 to <16	3×	$0.008131 \times 3 \times (14 \div 78) = 0.00438$
$\geq 16^b$	1×	$0.008131 \times 1 \times (62 \div 78) = 0.00646$
0 to 78	1.59	0.0129 per ppm (5.83E-06 per $\mu\text{g}/\text{m}^3$)
^a ADAFs are applied based on the determination of a mutagenic MOA (Section 5.3) and in accordance with (U.S. EPA, 2005b).		
^b Adjusted IUR value is based on an assumption of 78 years lifetime (U.S. EPA, 2011).		

After ADAF adjustment, the combined IUR of leukemia and bladder cancer is 0.0129 per ppm (5.83×10^{-6} per $\mu\text{g}/\text{m}^3$).

5.4.5 Derivation for Combined Unit Risk for Workers

The derivation of the combined unit risk for workers of leukemia and bladder cancer involves three steps (U.S. EPA, 2020) a similar approach as the combined IUR derivation described above.

Step 1. Combined Standard Deviation of Adult-Exposure-Only Unit Risk of Leukemia and Bladder Cancer for Ages ≥ 16 Years:

The combined standard deviation of unit risk for leukemia and bladder cancer for workers (SD_{L-BC-w}) is the square root of the sum of the squares of individual standard deviations of adult-exposure-only unit risk for workers of leukemia and bladder cancer, respectively. The derivation assumption is that the variables are independent, normally distributed random variables. The assumption of independence of the estimated risks for leukemia and bladder cancer mortality is the same as the theoretical assumption of the combined IUR described in Section 5.4.4: the development of various cancer sites within animals is independent, the common practice in animal toxicology (Farrar and Crump, 1988).

Equation 5-7.

$$SD_{L-BC-w} = \sqrt{((UR_{LW} - CR_{LW})/1.645)^2 + ((UR_{BCW} - CR_{BCW})/1.645)^2}$$

Where:

- UR_L = 95% upper-bound estimate of adult-exposure-only unit risk of leukemia for ages ≥ 16
 CR_{LW} = Central estimate of adult-exposure-only unit risk of leukemia (using MLE) for ages ≥ 16
 UR_{BCW} = 95% upper-bound estimate of adult-exposure-only unit risk of bladder cancer for ages ≥ 16
 CR_{BCW} = Central estimate of adult-exposure-only unit risk of bladder cancer (using MLE) for ages ≥ 16 .

The values of all the variables are adopted from the upper-bound estimate and central estimate of adult-exposure-only unit risk of leukemia and bladder cancer for ages greater than or equal to 16 from Table 5-9, Table 5-13, and Table 5-18 lists the values of the variables in Equation 5-7.

Table 5-18. Upper-Bound and Central Estimates of Adult-Exposure-Only Unit Risks of Leukemia and Bladder Cancer

Variables in Equation 5-7	UR_{LW}	CR_{LW}	UR_{BCW}	CR_{BCW}	SD_{L-BC-w}
Values of variables	0.0049	0.0026	0.0022	0.0014	0.0015

Step 2. Combined Central Estimate of Adult-Exposure-Only Central Unit Risk of Leukemia and Bladder Cancer for Ages ≥ 16 Years:

Equation 5-8.

$$CR_{L-BC-w} = CR_{LW} + CR_{BCW}$$

Where:

- CR_{L-BC-w} = Combined central estimate of adult-exposure-only unit risk of leukemia and bladder cancer for ages ≥ 16

CR_{LW} and CR_{BCW} are the same unit risk as the ones in Equation 5-7. Using the values of CR_{LW} and CR_{BCW} in Table 5-18, the resulting value of CR_{L-BC-w} is 0.004.

Step 3. Combined Adult-Exposure-Only Unit Risk of Leukemia and Bladder Cancer for Ages ≥ 16 :

Equation 5-9.

$$UR_{L-BC-w} = CR_{L-BC-w} + 1.645 \times SD_{L-BC-w}$$

Using the values of the results from Equation 5-8 and Equation 5-9, the resulting value of the combined adult-exposure-only unit risk of leukemia and bladder cancer for ages greater than or equal to 16 years is 0.00644 per ppm. Since the combined adult-exposure-only unit risk is for workers aged greater than or equal to 16 years, ADAF is not incorporated because there is no need to adjust for child susceptibility. In short, the combined unit risk for workers is 0.00644 per ppm (2.91×10^{-6} per $\mu\text{g}/\text{m}^3$).

5.4.6 Results for Combined IUR and UR for Workers

The combined IUR and combined unit risk for workers of leukemia and bladder cancer are summarized in Table 5-19.

Table 5-19. Combined IUR and Combined Unit Risk for Workers of Leukemia and Bladder Cancer

Unit Risk	Applied Population	Value
Combined IUR of leukemia and bladder cancer	General populations aged 0–78 years	0.0129 per ppm
Combined unit risk for workers of leukemia and bladder cancer	Workers aged 16–78 years	0.00644 per ppm

Compared with the current IRIS' IUR (3×10^{-5} per $\mu\text{g}/\text{m}^3$) published in 2002 ([U.S. EPA, 2002a](#)), this updated combined IUR (5.83×10^{-6} per $\mu\text{g}/\text{m}^3$) is approximately 5-fold lower. The updated IUR (5.83×10^{-6} per $\mu\text{g}/\text{m}^3$) derived from the 95 percent upper-bound confidence interval on β will be used for lifetime risk evaluation for the general population. The main factors contributing to the lower, updated IUR are the revised exposure assessment and the statistical model used to assess the relationship between 1,3-butadiene exposure and leukemia and bladder cancer risk (Table 5-20).

Table 5-20. Potential Effects of Certain Characteristics on the Estimated IURs Between EPA ORD (2002) and OPPT (2025)

Characteristic	EPA IRIS	EPA OPPT	Effect on Estimated IUR
Cohort			
Inclusion	15,649 men	21,087 men and women	Negligible
Follow-up	1944–1991	1944–2009	Negligible
Exposure Assessment	Original	Revised	10× lower
Exposure-response analysis			
Model type	Grouped Poisson	Proportional hazards	Unknown, probable range 0 to $\pm 10\%$
Response function form	Linear	Cox regression	Varies with exposure level
Adjustment for demographic/occupational covariates	Age, race, calendar period, time since hire, styrene	Age, age at hire, year of hire, sex, race, plant, hourly status	Minimal
Adjustment for peak exposure	No	No	Negligible
Lifetable, associated exposure, and potency estimation			
Lifetable age span (years)	0–85	0–85	Negligible
Post-estimation adjustment – total	Yes	Yes	Negligible
Incidence	Yes	Yes	Negligible
Sex and multiple tumor sites	Yes	Yes	Negligible

6 WEIGHT OF SCIENTIFIC EVIDENCE CONCLUSIONS FOR HUMAN HEALTH HAZARD

EPA considered evidence integration conclusions and dose-response considerations from Sections 4 through 7 and additional factors to choose overall hazard confidence levels based on the following characteristics:

- evidence integration/weight of scientific evidence judgments (see Appendix A);
- selection of most critical endpoint and study;
- relevance to exposure scenario;
- dose-response considerations; and
- PESS sensitivity.

The following section summarizes the strengths and limitations from summary table of confidence for each hazard endpoint and exposure duration, drawing upon information from previous sections and additional considerations as needed. Appendix D.1 presents the overall rankings for the above characteristics.

6.1 Strengths, Limitations, Assumptions, and Key Sources of Uncertainty for the Hazard Identification and Selection of PODs for Human Health Hazard Assessment

6.1.1 Acute Non-Cancer

EPA did not derive a POD for risk estimation of acute exposures (Section 4.2.2.3.1). Based on comparison of results from short-term studies with intermediate-duration studies, any potential health effects following a single exposure at relevant human exposure levels below regulatory thresholds were only rated as “slight” confidence. Additionally, the intermediate/chronic POD is protective of any plausible acute hazard. EPA therefore has robust confidence that intermediate PODs are protective of acute exposures.

6.1.2 Intermediate/Chronic Non-Cancer

Hazard ID Conclusions and Evidence Integration Judgments

All three critical health effect domains were supported by the weight of scientific evidence and considered appropriate for dose-response analysis. For all three domains there were multiple endpoints. Some differences exist in the relative evidence integration confidence across health effects. Developmental effects following gestational exposure were observed across multiple studies and in both mice and rats with additional support from a single neurodevelopmental epidemiological study. Male reproductive effects were observed in a dose-responsive manner at varying durations; however, only in mice in the absence of any relevant epidemiological studies. Hematological effects (especially anemia) were also only observed in mice with conflicting epidemiological data.

Selection of Most Critical Endpoint and Study

EPA has the strongest confidence in the selection of study and endpoints representing maternal and developmental toxicity. Although there was only a single developmental mouse study (which was selected for POD derivation), maternal weight gain, fetal body weight, and skeletal effects were all associated with each other in that study. Additionally, there were also at least indications of these effects in multiple rat studies, with fetal body weight the most unambiguously adverse endpoint that can account for the other associated effects.

Relevance to Exposure Scenarios

All endpoints were overall highly relevant to the assigned exposure duration scenario. The studies used for POD derivation were of intermediate duration, which is the most relevant category for gestation or male germ cell development. These health effects are similarly applicable to chronic exposures because gestation and male germ cell development are cyclical. Exposure to offspring is only occurring during pregnancy/lactation and mechanistic data for male reproductive toxicity demonstrates a stage-specificity, suggesting that chronic human exposure would have the same impact as intermediate exposure during critical windows. Although it is possible that chronic exposure could sensitize the reproductive system to adverse effects during critical windows, there is no evidence to support a concern for chronic reproductive effects impacting these developmental outcomes. There is some uncertainty in whether any of these intermediate effects could be applicable to acute exposures, especially at higher doses. Section 4.2.2.3.1 provides a sensitivity analysis comparing potential acute PODs to the most sensitive POD of reduced fetal body weight.

Hematological effects were observed in a chronic study and apply to chronic exposure scenarios; however, consistent statistically significant effects were only observed at the 9-month time period. There appeared to be an adaptive response at 15 months of exposure, indicating some lower confidence in the continued applicability of the endpoint and POD over decades of life.

Dose-Response Considerations

EPA has strong confidence in dose-response considerations for maternal/developmental effects from gestational exposure, especially the most sensitive and robust endpoint of reduced fetal body weight. LOAEL/NOAEL values and BMD modeling via multiple approaches resulted in PODs that were all within a few-fold of each other across both approaches and endpoints. Additionally, this health outcome was observed in both mice and rats, with only about a 5-fold difference in PODs across species, mitigating potential concern of species-specific sensitivity due to differing metabolism. This is consistent with the absence of evidence for any mechanism that would suggest significantly differential sensitivity across species. EPA therefore has very high confidence in the applicability of the selected POD for humans. There is very high confidence in the POD for reduced fetal weight that will be used for risk estimation because the same result was obtained via two different modeling parameters (see Section 4.2.2.1).

Male reproductive/developmental and hematological effects were both scored as moderate. All derived PODs can be considered co-critical as they were within only a few-fold of each other, and close to the PODs for maternal/developmental effects. Additionally, PODs were derived from studies with clear dose-response relationships and large sample sizes. Hematological data could not be BMD-modeled without dropping at least one dose, but this concern is mitigated because the resulting PODs are all within about 2-fold. Confidence is reduced for both endpoints compared to gestational effects because these effects were only observed in mice and it is unknown whether mice are uniquely sensitive compared to humans. Nonetheless, there is no indication that these endpoints result from any particular metabolite that is especially elevated in mice, and because the precise role of DEB, EB, and EBD are not well characterized.

PESS Sensitivity

Laboratory inbred animal strains were used for examination of all key endpoints and limited human evidence was available for non-cancer endpoints. Therefore, EPA was unable to quantify considerations from unique sensitivities. The Agency did identify quantifiable differences across species; however, EPA selected the most sensitive sex (male) for dose-response modeling of all endpoints. Additionally,

the maternal and male reproductive/developmental effects account for sensitive life stages. See Section 7.2 for more details on how EPA considered PESS in this human health hazard assessment.

Overall Confidence

Based on the above factors, EPA has robust overall confidence for the evidence integration, study/endpoint selection, exposure scenario applicability, dose-response, PESS sensitivity of the conclusions, PODs for maternal/developmental toxicity, and the most sensitive endpoint of reduced fetal body weight. The Agency has moderate overall confidence for the other critical hazard outcomes with PODs at very similar levels that further support the POD to be used for risk estimation.

6.1.3 Cancer: Leukemia and Bladder Cancer

EPA determined that 1,3-butadiene is carcinogenic to humans; the evidence supporting lymphohematopoietic cancer is robust based on human, animal, and mechanistic data.

Selection of Most Critical Endpoint and Study

Human epidemiological data from the UAB occupational cohort was selected for dose-response analysis. The use of human data precludes the complexities of species extrapolation from rodents, and the University of Alabama (UAB) cohort covered more than 60 years of follow-up with multiple updates over time. Leukemia was identified as the most reliable and sensitive cancer type identified in this population, supported by the robust evidence integration judgments. Seven publications used the same UAB cohort to investigate associations between bladder cancer and 1,3-butadiene exposure. Bladder cancer was recognized with moderate confidence to be positively associated with 1,3-butadiene based on these publications. Among this cohort, EPA utilized two papers by the same authors ([Sathiakumar et al., 2021b](#)) for IUR derivation. These were determined to be the best publications among all recent cohort updates that incorporated both sexes and refined exposure estimates. Based on the highly relevant occupational cohort, large sample size, decades of follow-up, and the reliability of the statistical adjustments made in the study, EPA has high confidence for this consideration.

Relevance to Exposure Scenarios

As discussed above, EPA utilized human data covering over 60 years of follow-up for derivation of lifetime inhalation unit risk. This approaches the 78-year lifespan assumed for lifetime exposure estimates. Therefore, the cancer assessment and parameters incorporated into the derived IUR are highly relevant to the lifetime exposure scenario.

Dose-Response Considerations

EPA derived novel IURs based on data from ([Sathiakumar et al., 2021b](#)), which covered up to 418,546 person-years of observation and 5,000 deaths (for leukemia). This IUR derivation involved consideration of the most appropriate exposure-response model and development of a lifetable to account for the dose-responder effects of exposure over the lifetimes of a population in the presence of competing causes of death. EPA also accounted for background population cancer risk rates and potential lag time.

PESS Sensitivity

The combined IUR for leukemia and bladder cancer incorporated data on the most highly exposed population (both men and women of the SBR cohort) and utilized the lower 95th percentile modeling estimate, assuming a linear response at low doses. Additionally, an ADAF was applied based on the mutagenic MOA to account for increased susceptibility. EPA was unable to quantitatively incorporate other considerations such as considerations lifestyle activities (*e.g.*, smoking), sociodemographic status, or nutrition.

Overall Confidence

There is robust human, animal, and mechanistic evidence associating 1,3-butadiene exposure with leukemia and other lymphohematopoietic cancers, with moderate human evidence for bladder cancer. A combined IUR for leukemia and bladder cancer was derived from a study incorporating years of updates to a large occupational cohort covering more than 60 years of follow-up, and a novel lifetable analysis was performed to account for extra risk relative to background population rates. Both men and women were included in the analysis, and an ADAF was applied to incorporate elevated childhood susceptibility. Based on the above factors, EPA has robust overall confidence in the hazard assessment and dose-response analysis for leukemia and bladder.

7 CONSIDERATION OF PESS AND AGGREGATE EXPOSURE

7.1 Hazard Considerations for Aggregate Exposure

Human exposure is only expected to occur via inhalation (see *Occupational Exposure Assessment for 1,3-Butadiene* ([U.S. EPA, 2025c](#)) and *General Population Exposure Assessment for 1,3-Butadiene* ([U.S. EPA, 2025e](#))); consumer sources of 1,3-butadiene exposure are not expected (see *Risk Evaluation for 1,3-Butadiene* ([U.S. EPA, 2025h](#))). Therefore, aggregating exposures across routes or environmental pathways is not necessary.

7.2 PESS Based on Greater Susceptibility

In this section, EPA addresses subpopulations expected to be more susceptible to 1,3-butadiene exposure than other populations. Table 7-1 presents the data sources that were used in the PESS analysis that evaluated susceptible subpopulations and identifies whether and how the subpopulation was addressed quantitatively in the risk evaluation of 1,3-butadiene.

EPA examined sources of biological susceptibility for each of the susceptibility factors in the below table. The Agency quantitatively incorporated these considerations into hazard values and subsequent risk estimates when possible; however, for many factors EPA did not identify any reasonably available information to support quantitative adjustment of hazard/risk values. For these other factors, the Agency acknowledges either direct or indirect information suggesting additional susceptibility of certain subpopulations.

EPA was able to directly incorporate life stage susceptibility into hazard values for both cancer and non-cancer endpoints. Two of the three health categories that underwent non-cancer, dose-response analysis represent developmental outcomes following exposure to either pregnant females or males of reproductive age. A $10\times$ UF_H factor was applied to account for human toxicokinetic and toxicodynamic variability, which is expected to account for considerations such as genetic polymorphisms and existing disease states. For the cancer health endpoint, EPA used an occupational epidemiological cohort, comprised of both male and female workers, with more than 50 years of follow-up and subsequent exposure estimate updates to derive inhalation hazard values for leukemia applicable to general population and occupational exposures. Due to an identified mutagenic MOA for cancer, EPA applied an ADAF for the general population to account for elevated childhood susceptibility. The combination of using the most sensitive endpoint protective of the pregnant worker (decreased fetal body weight); robust evidence from a large, highly exposed occupational human cohort tracked over many decades; along with the application of an ADAF allows the derived hazard values used for non-cancer and cancer risk characterizations to fully account for PESS.

Table 7-1. PESS Evidence Crosswalk for Biological Susceptibility Considerations

Susceptibility Factor	Examples of Specific Factors	Direct Evidence this Factor Modifies Susceptibility to 1,3-Butadiene		Indirect Evidence of Interaction with Target Organs or Biological Pathways Relevant to 1,3-Butadiene		Susceptibility Addressed in Risk Evaluation?
		Description of Interaction	Key Citation(s)	Description of Interaction	Key Citation(s)	
Life stage	Embryos/ fetuses/ infants	1,3-butadiene <i>in utero</i> exposure likely results in decreased fetal body weight with associated skeletal rib effects.	Battelle PNL (1987b) ; Hazleton Labs (1981b)			The most protective and best supported non-cancer point of departure (POD) is based on reduced fetal body weight.
	Pregnancy/ lactating status	1,3-butadiene causes decreased weight gain in pregnant rodent dams.	Battelle PNL (1987b) ; Hazleton Labs (1981b)	Pregnant women have a higher risk for anemia, which is associated with 1,3-butadiene exposure in rodents.	Le (2016)	Reduced maternal weight gain was BMD modeled and is protected for by the reduced fetal body weight POD.
	Males of reproductive age	1,3-butadiene likely causes male reproductive effects, including dominant lethality through genotoxicity to developing sperm.	Anderson et al. (1998) ; Anderson et al. (1996) ; BIBRA (1996b) ; Hackett et al. (1988a)			Dominant lethality was BMD-modeled and is protected for by the reduced fetal body weight POD.
	Children	Younger life stages are more susceptible than adults to mutagenic carcinogens. EPA identified a mutagenic MOA for 1,3-butadiene.	U.S. EPA (2005b) and Section 5.3			EPA applied age-dependent adjustment factor (ADAFs) to the IUR for in general population risk characterization (U.S. EPA, 2005b).
	Elderly			Elderly people have a higher risk for anemia; however, they should be less susceptible to reproductive issues than other life stages.	Le (2016)	This susceptibility is expected to be covered by the 10× UF _H .
Preexisting disease or disorder	Health outcome/ target organs			Any preexisting condition affecting a target organ will increase susceptibility to 1,3-butadiene-toxicity in that organ.		This susceptibility is expected to be covered by the 10× UF _H .
	Toxicokinetics			Higher metabolism of reactive metabolites would increase susceptibility.		Conservatively applied most animal PODs to humans with 10× UF _H despite indications that humans may produce less toxic metabolites.

Susceptibility Factor	Examples of Specific Factors	Direct Evidence this Factor Modifies Susceptibility to 1,3-Butadiene		Indirect Evidence of Interaction with Target Organs or Biological Pathways Relevant to 1,3-Butadiene		Susceptibility Addressed in Risk Evaluation?
		Description of Interaction	Key Citation(s)	Description of Interaction	Key Citation(s)	
Lifestyle activities	Smoking			Heavy smoking and other tobacco usage may increase susceptibility for reproductive outcomes and cancer.	CDC (2023a, 2023b)	
	Alcohol consumption			Alcohol consumption increases risk for several types of cancer, although it is not associated with leukemia or bladder cancer.	CDC (2023b)	Qualitative discussion in this section and table only. No direct evidence available.
	Physical activity			Insufficient activity may increase susceptibility to multiple health outcomes. Overly strenuous activity may also increase susceptibility.	CDC (2023a, 2023b, 2022)	Qualitative discussion in this section and table only. No direct evidence available.
Sociodemographic status	Select demographics	Workers of select demographic groups at a styrene/1,3-butadiene manufacturing facility demonstrated significantly elevated SMR for leukemia and other lymphatic neoplasms compared to average workers.	Matanoski et al. (1990)	Certain demographic groups have a higher risk for anemia, which is associated with 1,3-butadiene exposure in rodents.	Le (2016)	Qualitative discussion in this section and table only. No quantifiable data available to support dose-response analysis for this dataset.
	Socioeconomic status			Individuals with worse socioeconomic conditions may have worse health outcomes due to social needs that are not met, environmental concerns, and barriers to health care access.	ODPHP (2023b)	Qualitative discussion in this section and table only. This factor may also inform increased exposure.
	Sex/gender	Male mice demonstrated a more sensitive dose-response relationship for reduced fetal body weight and anemia. Indirect data on biomarkers suggests human males may produce higher concentrations of reactive metabolites, and a statistically significant association for leukemia was identified only for exposed male workers.	NTP (1993); Battelle PNL (1987b). Boysen et al. (2022); Boysen et al. (2012); Vacek et al. (2010); Albertini et al. (2007); Albertini et al. (2003) Sathiakumar et al. (2021b); Delzell et al. (1996)			The most sensitive sex from rodent assays were used for non-cancer dose-response modeling.

Susceptibility Factor	Examples of Specific Factors	Direct Evidence this Factor Modifies Susceptibility to 1,3-Butadiene		Indirect Evidence of Interaction with Target Organs or Biological Pathways Relevant to 1,3-Butadiene		Susceptibility Addressed in Risk Evaluation?
		Description of Interaction	Key Citation(s)	Description of Interaction	Key Citation(s)	
Nutrition	Diet			Obesity can increase susceptibility to cancer, although this is not established for leukemia or bladder cancer.	CDC (2023a)	Qualitative discussion in this section and table only. No direct evidence available.
	Malnutrition			Micronutrient malnutrition can lead to multiple developmental outcomes that include birth defects, maternal and infant deaths, low birth weight, and poor fetal growth, among others.	CDC (2023c)	Qualitative discussion in this section and table only. No direct evidence available.
Genetics/ epigenetics	Health outcome/ target organs	<p>Epigenetic variation (histone modifications and DNA methylation) across mouse strains is associated with differential levels of 1,3-butadiene-induced DNA damage.</p> <p>A study has shown that 1,3-butadiene is statistically significantly associated with over breast cancer and also in the two stratified hormonal groups: (1) positive for estrogen receptors or progesterone receptors (ER+ or PR+) group: adjusted hazard ratio = 1.17 (95% CI: 1.11–1.23); (2) negative for estrogen and progesterone receptors (ER- and PR-) group: adjusted hazard ratio = 1.24 (95% CI = 1.14–1.35).</p>	<p>Lewis et al. (2019)</p> <p>(Heck et al., 2024)</p>	<p>Breast cancer risk can be influenced by female hormones and mutations in genes (<i>e.g.</i>, BRCA1 and BRCA2). BRCA1 and BRCA2 genes are tumor suppressor genes and can interplay with these female hormones to influence breast cancer development.</p> <p>Deficient DNA repair would increase susceptibility to cancer.</p>	(Copson et al., 2018)	Application of a linear low-dose cancer dose-response model should account for varying susceptibility across populations.
	Toxicokinetics	<p>GSTM1 and GSTI1 mutations are associated with 30–60% higher sister chromatid exchange from 1,3-butadiene metabolites.</p> <p>Polymorphisms for microsomal epoxide hydrolase resulted in 3× greater mutation frequencies among exposed workers.</p> <p>CYP2E1 and microsomal epoxide hydrolase polymorphisms were associated with greater genotoxicity.</p>	<p>ATSDR (2012); U.S. EPA (2002a)</p> <p>Xiang et al. (2012); Abdel-Rahman et al. (2001);</p>	Genetic variation across populations may explain differences in relative mutation and genotoxicity rates seen across cohorts from Texas, China, and Czech Republic.	Section 5.2	EPA used the positive mutation data from Texas cohorts in supporting a mutagenic MOA and application of a linear low-dose cancer dose-response model should account for varying susceptibility across populations.

Susceptibility Factor	Examples of Specific Factors	Direct Evidence this Factor Modifies Susceptibility to 1,3-Butadiene		Indirect Evidence of Interaction with Target Organs or Biological Pathways Relevant to 1,3-Butadiene		Susceptibility Addressed in Risk Evaluation?
		Description of Interaction	Key Citation(s)	Description of Interaction	Key Citation(s)	
Other chemical and nonchemical stressors	Built environment			Poor-quality housing is associated with a variety of negative health outcomes.	ODPHP (2023a)	Qualitative discussion in this section and table only. This category is primarily relevant to increased exposure.
	Social environment			Social isolation and other social determinants (<i>e.g.</i> , decreased social capital, stress) can lead to negative health outcomes.	ODPHP (2023c)	Qualitative discussion in this section and table only. No direct or quantifiable evidence available.
	Chemical co-exposures	1,3-butadiene can degrade in the environment into other toxic chemicals, including formaldehyde. It is also often released alongside other hazardous air pollutants	U.S. EPA (2025g) EPA Final Rule Final Rule to Strengthen Standards for Synthetic Organic Chemical Plants and Polymers and Resins Plants (accessed November 20, 2025)			Qualitative discussion in this section and table only. No direct evidence available.

8 HUMAN HEALTH HAZARD ASSESSMENT CONCLUSIONS

In this human health assessment of 1,3-butadiene, EPA determined that reduced fetal body weight based on a developmental mouse study was the most sensitive and robust endpoint for risk characterization of intermediate and chronic exposures. The Agency derived point of departures (PODs) for male reproductive/developmental toxicity and hematological effects that can be considered supportive and part of the weight of evidence for selecting the fetal body weight effect. The weight of scientific evidence and dose-response considerations based on the reasonably available information did not support derivation of a POD for acute exposures. For cancer, EPA derived an inhalation unit risk (IUR) for the general population and chronic occupational unit risk (UR) for adults for leukemia and bladder based on robust data from an occupational human cohort. An age-dependent adjustment factor (ADAF) is applied to this value based on a proposed mutagenic mode of action (MOA).

Table 8-1 lists the studies and corresponding human equivalent concentrations (HECs) and uncertainty factors (Ufs) that EPA is using for risk characterization following intermediate and chronic exposure. Table 8-2 provides the IUR for evaluating lifetime exposure to workers—all of which are assumed to be either adults or adolescents of at least 16 years old and therefore ADAFs do not apply. Based on the mutagenic MOA for cancer concluded in Section 5.3, EPA also applied ADAFs to the adult-based IUR to account for childhood exposures in the general population (Table 8-3).

For consistency, all HECs and the IUR are based on daily, continuous exposure (24 hours/day) to consistent concentrations. HECs from animal studies assume an individual at resting breathing rate, while the IUR derived from an occupational cohort assumes worker breathing rate. Adjustments to exposure durations, frequencies, and breathing rates are made in the exposure estimates used to calculate risks for individual exposure scenarios.

Table 8-1. Non-Cancer Points of Departure and Critical Endpoints Used for Risk Estimates of Each 1,3-Butadiene Exposure Scenario

Target Organ System	Species	Duration	Study POD/Type	Effect	HEC (ppm) [mg/m ³]	Uncertainty Factors (UFs)	Reference	Overall Quality Determination
Intermediate/chronic exposure scenarios								
Maternal/ Developmental	Mouse (Male)	10 days throughout gestation (GD 5–16)	LOAEL = 40 ppm	Reduced fetal body weight and other indications of gestational toxicity	BMDL _{50r10} = 2.5 ppm (5.5 mg/m ³)	UF _A = 3 UF _H = 10 <i>Total UF = 30</i>	(Battelle PNL, 1987b)	Medium

Table 8-2. Cancer Hazard Values for Occupational Cancer Risk Estimation for 1,3-Butadiene

Chronic Occupational Unit Risk ^a	Reference	Overall Quality Determination
0.00644 per ppm (2.91E–03 per mg/m ³) (2.91E–06 per µg/m ³)	(Sathiakumar et al., 2021b)	Medium
^a EPA considers a range of extra cancer risk from 1E–04 to 1E–06 to be relevant benchmarks for risk assessment (U.S. EPA, 2017); however, these are not considered “bright-lines” for unreasonable risk determination.		

Table 8-3. Incorporation of Age-Dependent Adjustment Factors (ADAFs) for General Population Risk Estimation for 1,3-Butadiene

Age	ADAF Adjustment ^a	Adjusted Partial Life and General Population IUR
0 to <2	10×	$0.008131 \times 10 \times (2 \div 78) = 0.00208$
2 to <16	3×	$0.008131 \times 3 \times (14 \div 78) = 0.00438$
$\geq 16^b$	1×	$0.008131 \times 1 \times (62 \div 78) = 0.00646$
0 to 78		0.00129 per ppm (5.83E-06 per $\mu\text{g}/\text{m}^3$)
^a ADAFs applied based on the determination of a mutagenic MOA (Section 5.3) and in accordance with (U.S. EPA, 2005b).		
^b Adjusted IUR value based on an assumption of 78 years lifetime (U.S. EPA, 2011).		

REFERENCES

- Abdel-Rahman, SZ; Ammenheuser, MM; Omiecinski, CJ; Wickliffe, JK; Rosenblatt, JI; Ward, JB. (2005). Variability in human sensitivity to 1,3-butadiene: influence of polymorphisms in the 5'-flanking region of the microsomal epoxide hydrolase gene (EPHX1). *Toxicol Sci* 85: 624-631. <http://dx.doi.org/10.1093/toxsci/kfi115>
- Abdel-Rahman, SZ; Ammenheuser, MM; Ward, JB. (2001). Human sensitivity to 1,3-butadiene: role of microsomal epoxide hydrolase polymorphisms. *Carcinogenesis* 22: 415-423. <http://dx.doi.org/10.1093/carcin/22.3.415>
- Abdel-Rahman, SZ; El-Zein, RA; Ammenheuser, MM; Yang, Z; Stock, TH; Morandi, M; Ward, JB. (2003). Variability in human sensitivity to 1,3-butadiene: Influence of the allelic variants of the microsomal epoxide hydrolase gene. *Environ Mol Mutagen* 41: 140-146. <http://dx.doi.org/10.1002/em.10142>
- Adler, I; Filser, J; Gonda, H; Schriever-Schwemmer, G. (1998). Dose response study for 1,3-butadiene-induced dominant lethal mutations and heritable translocations in germs cells of male mice. *Mutat Res* 397: 85-92. [http://dx.doi.org/10.1016/s0027-5107\(97\)00198-x](http://dx.doi.org/10.1016/s0027-5107(97)00198-x)
- Adler, ID; Cao, J; Filser, JG; Gassner, P; Kessler, W; Kliesch, U; Neuhauserklaus, A; Nüsse, M. (1994). Mutagenicity of 1,3-butadiene inhalation in somatic and germinal cells of mice. *Mutat Res* 309: 307-314. [http://dx.doi.org/10.1016/0027-5107\(94\)90107-4](http://dx.doi.org/10.1016/0027-5107(94)90107-4)
- Adler, ID; Filser, JG; Gassner, P; Kessler, W; Schöneich, J; Schriever-Schwemmer, G. (1995). Heritable translocations induced by inhalation exposure of male mice to 1,3-butadiene. *Mutat Res* 347: 121-127. [Mutation research].
- Albertini, RJ; Carson, ML; Kirman, CR; Gargas, ML. (2010). 1,3-Butadiene: II. Genotoxicity profile [Review]. *Crit Rev Toxicol* 40: 12-73. <http://dx.doi.org/10.3109/10408444.2010.507182>
- Albertini, RJ; Sram, J; Vacek, PM; Lynch, J; Nicklas, JA; Van Sittert, NJ; Boogaard, PJ; Henderson, RF; Swenberg, JA; Tate, AD; Ward, JB, Jr; Wright, M. (2003). Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study. In *Res Rep Health Eff Inst* 2003, Jun(116):1-141; discussion 143-62 [Research report (Health Effects Institute)] (pp. 1-141; discussion 143-162). (ISSN 1041-5505 EISSN 2688-6855). Albertini, RJ; Sram, J; Vacek, PM; Lynch, J; Nicklas, JA; Van Sittert, NJ; Boogaard, PJ; Henderson, RF; Swenberg, JA; Tate, AD; Ward, JB, Jr; Wright, M. <https://search.proquest.com/docview/73591163?accountid=171501>
- Albertini, RJ; Sram, RJ; Vacek, PM; Lynch, J; Rossner, P; Nicklas, JA; McDonald, JD; Boysen, G; Georgieva, N; Swenberg, JA. (2007). Molecular epidemiological studies in 1,3-butadiene exposed Czech workers: female-male comparisons. *Chem Biol Interact* 166: 63-77. <http://dx.doi.org/10.1016/j.cbi.2006.07.004>
- Albertini, RJ; Sram, RJ; Vacek, PM; Lynch, J; Wright, M; Nicklas, JA; Boogaard, PJ; Henderson, RF; Swenberg, JA; Tate, AD; Ward, JB. (2001). Biomarkers for assessing occupational exposures to 1,3-butadiene. *Chem Biol Interact* 135-136: 429-453. [http://dx.doi.org/10.1016/S0009-2797\(01\)00181-8](http://dx.doi.org/10.1016/S0009-2797(01)00181-8)
- Ammenheuser, MM; Bechtold, WE; Abdel-Rahman, SZ; Rosenblatt, JI; Hastings-Smith, DA; Ward, JB. (2001). Assessment of 1,3-butadiene exposure in polymer production workers using HPRT mutations in lymphocytes as a biomarker. *Environ Health Perspect* 109: 1249-1255. <http://dx.doi.org/10.1289/ehp.011091249>
- Anderson, D; Edwards, AJ; Brinkworth, MH. (1993). Male-mediated F1 effects in mice exposed to 1,3-butadiene. In M Sorsa; K Peltonen; H Vainio; K Hemminki (Eds.), *Butadiene and styrene: Assessment of health hazards* (pp. 171-181). Lyon, France: International Agency for Research on Cancer.

- Anderson, D; Edwards, AJ; Brinkworth, MH; Hughes, JA. (1996). Male-mediated F1 effects in mice exposed to 1,3-butadiene. *Toxicology* 113: 120-127. [http://dx.doi.org/10.1016/0300-483X\(96\)03436-1](http://dx.doi.org/10.1016/0300-483X(96)03436-1)
- Anderson, D; Hughes, JA; Edwards, AJ; Brinkworth, MH. (1998). A comparison of male-mediated effects in rats and mice exposed to 1,3-butadiene. *Mutat Res* 397: 77-84. [http://dx.doi.org/10.1016/S0027-5107\(97\)00197-8](http://dx.doi.org/10.1016/S0027-5107(97)00197-8)
- Araki, A; Noguchi, T; Kato, F; Matsushima, T. (1994). Improved method for mutagenicity testing of gaseous compounds by using a gas sampling bag. *Mutat Res* 307: 335-344. [http://dx.doi.org/10.1016/0027-5107\(94\)90307-7](http://dx.doi.org/10.1016/0027-5107(94)90307-7)
- Arce, GT; Vincent, DR; Cunningham, MJ; Choy, WN; Sarraf, AM. (1990). In-vitro and in-vivo genotoxicity of 1,3-butadiene and metabolites [Review]. *Environ Health Perspect* 86: 75-78. <http://dx.doi.org/10.2307/3430935>
- ATSDR (Agency for Toxic Substances and Disease Registry). (2012). Toxicological profile for 1,3-butadiene [ATSDR Tox Profile]. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service. <http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=459&tid=81>
- Au, WW; Bechtold, WE; Whorton E B, J. R.; Legator, MS. (1995). Chromosome aberrations and response to gamma-ray challenge in lymphocytes of workers exposed to 1,3-butadiene. *Mutat Res* 334: 125-130. [http://dx.doi.org/10.1016/0165-1161\(95\)90002-0](http://dx.doi.org/10.1016/0165-1161(95)90002-0)
- Autio, K; Renzi, L; Catalan, J; Albrecht, OE; Sorsa, M. (1994). Induction of micronuclei in peripheral blood and bone marrow erythrocytes of rats and mice exposed to 1,3-butadiene by inhalation. *Mutat Res* 309: 315-320. [http://dx.doi.org/10.1016/0027-5107\(94\)90108-2](http://dx.doi.org/10.1016/0027-5107(94)90108-2)
- Barton, H; Coglian, J; Firestone, MP; Flowers, L; Setzer, RW; Valcovic, L; Woodruff, T. (2005). Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. Washington, DC: US Environmental Protection Agency.
- Battelle PNL (Battelle Pacific Northwest Laboratory). (1982). Initial submission: Tracor Jitco inhalation carcinogenesis bioassay: Chronic study report in 1,3-butadiene in mice (final report) with attachments and cover letter dated 11/21/91 [TSCA Submission]. (OTS0534965. 8EHQ-1291-1868. 88-920000513. TSCATS/420853). Shell Oil Company. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0534965.xhtml>
- Battelle PNL (Battelle Pacific Northwest Laboratory). (1987a). Inhalation developmental toxicology studies of 1,3-butadiene in the rat. (PNL-6414). Washington, DC: National Toxicology Program. <http://dx.doi.org/10.2172/5664174>
- Battelle PNL (Battelle Pacific Northwest Laboratory). (1987b). Inhalation developmental toxicology studies: Teratology study of 1,3-butadiene in mice. (PNL-6412). Washington, DC: National Toxicology Program. <http://dx.doi.org/10.2172/5555439>
- BEIR (Committee on the Biological Effects of Ionizing Radiation). (1988). Health risks of radon and other internally deposited alpha-emitters. In *Health Risks of Radon and Other Internally Deposited Alpha-Emitters*. Washington, DC: National Academy Press. <http://dx.doi.org/10.17226/1026>
- Bevan, C; Stadler, JC; Elliott, GS; Frame, SR; Baldwin, JK; Leung, HW; Moran, E; Panepinto, AS. (1996). Subchronic toxicity of 4-vinylcyclohexene in rats and mice by inhalation exposure. *Fundam Appl Toxicol* 32: 1-10. <http://dx.doi.org/10.1006/faat.1996.0101>
- Beyer, PE; Chernoff, N. (1986). The induction of supernumerary ribs in rodents: role of the maternal stress. *Birth Defects Res B Dev Reprod Toxicol* 6: 419-429.
- BIBRA (British Industrial Biological Research Association). (1996a). Detection of dominant lethal mutations and foetal malformations in the offspring of male rats treated sub-chronically w/ 1,3-butadiene by inhalation w/ cover letter dated 01/10/1997 [TSCA Submission]. (Report No. 1542/2/1/96; FYI-OTS-0197-1282). Houston, TX: Exxon Chemical Company. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0001282.xhtml>

- BIBRA (British Industrial Biological Research Association). (1996b). Initial submission: The detection of dominant lethal mutations and * in the offspring of male mice treated sub-chronically with butadiene by inhalation (Second study) w/ cover letter dated 1/10/97 [TSCA Submission]. (8EHQ-0197-13855; EPA/OTS Doc #88970000105). Houston, TX: Exxon Chemical Company. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0559090.xhtml>
- Blair, A; Stewart, P; Lubin, JH; Forastiere, F. (2007). Methodological issues regarding confounding and exposure misclassification in epidemiological studies of occupational exposures [Review]. *Am J Ind Med* 50: 199-207. <http://dx.doi.org/10.1002/ajim.20281>
- Bond, JA; Dahl, AR; Henderson, RF; Birnbaum, LS. (1987). Species differences in the distribution of inhaled butadiene in tissues. *AIHA J* 48: 867-872. [http://dx.doi.org/10.1202/0002-8894\(1987\)048<0867:SDITDO>2.0.CO;2](http://dx.doi.org/10.1202/0002-8894(1987)048<0867:SDITDO>2.0.CO;2)
- Bond, JA; Dahl, AR; Henderson, RF; Dutcher, JS; Mauderly, JL; Birnbaum, LS. (1986). Species differences in the disposition of inhaled butadiene. *Toxicol Appl Pharmacol* 84: 617-627. [http://dx.doi.org/10.1016/0041-008X\(86\)90268-1](http://dx.doi.org/10.1016/0041-008X(86)90268-1)
- Boobis, AR; Doe, JE; Heinrich-Hirsch, B; Meek, ME; Munn, S; Ruchirawat, M; Schlatter, J; Seed, J; Vickers, C. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans [Review]. *Crit Rev Toxicol* 38: 87-96. <http://dx.doi.org/10.1080/10408440701749421>
- Boogaard, PJ; Van Sittert, NJ; Watson, WP; De Kloe, KP. (2001). A novel DNA adduct, originating from 1,2-epoxy-3,4-butanediol, is the major DNA adduct after exposure to [2,3-14C]-1,3-butadiene, but not after exposure to [4-14C]-1,2-epoxy-3-butene. *Chem Biol Interact* 135-136: 687-693. [http://dx.doi.org/10.1016/S0009-2797\(01\)00202-2](http://dx.doi.org/10.1016/S0009-2797(01)00202-2)
- Böthig, R; Kowald, B; Fiebag, K; Balzer, O; Tiburtius, C; Thietje, R; Kadhum, T; Group, G-sMSSDBCEW; Golka, K. (2021). Bladder management, severity of injury and period of latency: a descriptive study on 135 patients with spinal cord injury and bladder cancer. *Spinal Cord* 59: 971-977. <http://dx.doi.org/10.1038/s41393-021-00651-3>
- Boysen, G; Georgieva, NI; Bordeerat, NK; Sram, RJ; Vacek, P; Albertini, RJ; Swenberg, JA. (2012). Formation of 1,2:3,4-diepoxybutane-specific hemoglobin adducts in 1,3-butadiene exposed workers. *Toxicol Sci* 125: 30-40. <http://dx.doi.org/10.1093/toxsci/kfr272>
- Boysen, G; Rusyn, I; Chiu, WA; Wright, FA. (2022). Characterization of population variability of 1,3-butadiene derived protein adducts in humans and mice. *Regul Toxicol Pharmacol* 132: 105171. <http://dx.doi.org/10.1016/j.yrtph.2022.105171>
- Brinkworth, MH; Anderson, D; Hughes, JA; Jackson, LI; Yu, TW; Nieschlag, E. (1998). Genetic effects of 1,3-butadiene on the mouse testis. *Mutat Res* 397: 67-75. [http://dx.doi.org/10.1016/S0027-5107\(97\)00196-6](http://dx.doi.org/10.1016/S0027-5107(97)00196-6)
- Brochot, C; Smith, TJ; Bois, FY. (2007). Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues. *Chem Biol Interact* 167: 168-183. <http://dx.doi.org/10.1016/j.cbi.2007.02.010>
- Bucher, JR; Melnick, RL; Hildebrandt, PK. (1993). Lack of carcinogenicity in mice exposed once to high concentrations of 1,3-butadiene [Letter]. *J Natl Cancer Inst* 85: 1866-1867. <http://dx.doi.org/10.1093/jnci/85.22.1866>
- Carpenter, CP; Shaffer, CB; Weil, CS; Smyth, HF, Jr. (1944). Studies on the inhalation of 1:3-butadiene; with a comparison of its narcotic effect with benzol, toluol, and styrene, and a note on the elimination of styrene by the human. *Arch Environ Occup Health* 26: 69-78.
- Cave, M; Falkner, KC; Henry, L; Costello, B; Gregory, B; McClain, CJ. (2011). Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. *J Occup Environ Med* 53: 1128-1133. <http://dx.doi.org/10.1097/JOM.0b013e31822cfd68>

- [CDC](#) (Centers for Disease Control and Prevention). (2015). 9.11 Monitoring and treatment: Minimum latency & types or categories of cancer. Atlanta, GA.
<https://www.cdc.gov/wtc/pdfs/policies/WTCHP-Minimum-Cancer-Latency-PP-01062015-508.pdf>
- [CDC](#) (Centers for Disease Control and Prevention). (2022). CDC Health Topics A-Z: Physical activity. Available online at <https://www.cdc.gov/physicalactivity/index.html>
- [CDC](#) (Centers for Disease Control and Prevention). (2023a). CDC Health Topics A-Z: Cancer. Available online at <https://www.cdc.gov/cancer/>
- [CDC](#) (Centers for Disease Control and Prevention). (2023b). CDC Health Topics A-Z: Infertility FAQs. Available online at <https://www.cdc.gov/reproductivehealth/infertility/index.htm>
- [CDC](#) (Centers for Disease Control and Prevention). (2023c). CDC Health Topics A-Z: Nutrition. Available online at <https://www.cdc.gov/nutrition/index.html>
- [CDC](#) (Centers for Disease Control and Prevention). (2024). CDC Wonder [Database]. Atlanta, GA. Retrieved from <https://wonder.cdc.gov/>
- [Checkoway, H; Williams, TM.](#) (1982). A hematology survey of workers at a styrene-butadiene synthetic rubber manufacturing plant. *Am Ind Hyg Assoc J* 43: 164-169.
<http://dx.doi.org/10.1080/15298668291409550>
- [Cheng, H; Sathiakumar, N; Graff, J; Matthews, R; Delzell, E.](#) (2007). 1,3-Butadiene and leukemia among synthetic rubber industry workers: Exposure-response relationships. *Chem Biol Interact* 166: 15-24. <http://dx.doi.org/10.1016/j.cbi.2006.10.004>
- [Cheng, X; Zhang, T; Zhao, J; Zhou, J; Shao, H; Zhou, Z; Kong, F; Feng, N; Sun, Y; Shan, B; Xia, Z.](#) (2013). The association between genetic damage in peripheral blood lymphocytes and polymorphisms of three glutathione S-transferases in Chinese workers exposed to 1,3-butadiene. *Mutat Res* 750: 139-146. <http://dx.doi.org/10.1016/j.mrgentox.2012.10.008>
- [Chi, L; Nixon, E; Spencer, F.](#) (2002). Uterine-ovarian biochemical and developmental interactions to the postimplantation treatment with a butadiene metabolite, diepoxybutane, in pregnant rats. *J Biochem Mol Toxicol* 16: 147-153. <http://dx.doi.org/10.1002/jbt.10021>
- [Clerici, LA; Cocco, B; Sacco, MG; Monteggia, E; Collotta, A.](#) (1995). The use of pre-implantation mouse embryos cultured in vitro in toxicological studies. *Toxicol In Vitro* 9: 577-581.
[http://dx.doi.org/10.1016/0887-2333\(95\)00075-j](http://dx.doi.org/10.1016/0887-2333(95)00075-j)
- [Clin, B; Group, RW; Pairon, JC.](#) (2014). Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement [Review]. *BMC Public Health* 14: 1155.
<http://dx.doi.org/10.1186/1471-2458-14-1155>
- [Cochrane, JE; Skopek, TR.](#) (1994). Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the hprt locus in splenic T cells from exposed B6C3F1 mice. *Carcinogenesis* 15: 719-723.
<http://dx.doi.org/10.1093/carcin/15.4.719>
- [Copson, ER; Maishman, TC; Tapper, WJ; Cutress, RI; Greville-Heygate, S; Altman, DG; Eccles, B; Gerty, S; Durcan, LT; Jones, L; Evans, DG; Thompson, AM; Pharoah, P; Easton, DF; Dunning, AM; Hanby, A; Lakhani, S; Eeles, R; Gilbert, FJ; Hamed, H; Hodgson, S; Simmonds, P; Stanton, L; Eccles, DM.](#) (2018). Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. *The Lancet Oncology* 19: 169-180.
[http://dx.doi.org/10.1016/S1470-2045\(17\)30891-4](http://dx.doi.org/10.1016/S1470-2045(17)30891-4)
- [Cowles, SR; Tsai, SP; Snyder, PJ; Ross, CE.](#) (1994). Mortality, morbidity, and haematological results from a cohort of long-term workers involved in 1,3-butadiene monomer production. *Occup Environ Med* 51: 323-329. <http://dx.doi.org/10.1136/oem.51.5.323>
- [Crouch, CN; Pullinger, DH; Gaunt, IF.](#) (1979). Inhalation toxicity studies with 1,3-butadiene - 2 3 month toxicity study in rats. *J Occup Environ Hyg* 40: 796-802.
<http://dx.doi.org/10.1080/15298667991430316>

- Csanady, GA; Guengerich, FP; Bond, JA. (1992). Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. *Carcinogenesis* 13: 1143-1153. <http://dx.doi.org/10.1093/carcin/13.7.1143>
- Csanády, GA; Steinhoff, R; Riester, MB; Semder, B; Pütz, C; Li, Q; Richter, N; Kessler, W; Klein, D; Filser, JG. (2011). 1,2:3,4-Diepoxybutane in blood of male B6C3F1 mice and male Sprague-Dawley rats exposed to 1,3-butadiene. *Toxicol Lett* 207: 286-290. <http://dx.doi.org/10.1016/j.toxlet.2011.09.027>
- Cunningham, MJ; Choy, WN; Arce, GT; Rickard, LB; Vlachos, DA; Kinney, LA; Sarraf, AM. (1986). In vivo sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. *Mutagenesis* 1: 449-452.
- Dahl, AR; Bechtold, WE; Bond, JA; Henderson, RF; Mauderly, JL; Muggenburg, BA; Sun, JD; Birnbaum, LS. (1990). Species differences in the metabolism and disposition of inhaled 1,3-butadiene and isoprene. *Environ Health Perspect* 86: 65-69. <http://dx.doi.org/10.1289/ehp.908665>
- Dahl, AR; Sun, JD; Birnbaum, LS; Bond, JA; Griffith, WC; Mauderly, JL; Muggenburg, BA; Sabourin, PJ; Henderson, RF. (1991). Toxicokinetics of inhaled 1,3-butadiene in monkeys: Comparison to toxicokinetics in rats and mice. *Toxicol Appl Pharmacol* 110: 9-19. [http://dx.doi.org/10.1016/0041-008X\(91\)90285-M](http://dx.doi.org/10.1016/0041-008X(91)90285-M)
- Danysh, HE; Mitchell, LE; Zhang, K; Scheurer, ME; Lupo, PJ. (2015). Traffic-related air pollution and the incidence of childhood central nervous system tumors: Texas, 2001-2009. *Pediatr Blood Cancer* 62: 1572-1578. <http://dx.doi.org/10.1002/pbc.25549>
- De Meester, C; Poncelet, F; Roberfroid, M; Mercier, M. (1980). The mutagenicity of butadiene towards salmonella typhimurium. *Toxicol Lett* 6: 125-130. [http://dx.doi.org/10.1016/0378-4274\(80\)90179-4](http://dx.doi.org/10.1016/0378-4274(80)90179-4)
- Delzell, E; Macaluso, M; Sathikumar, N; Matthews, R. (2001). Leukemia and exposure to 1,3-butadiene, styrene and dimethyldithiocarbamate among workers in the synthetic rubber industry. *Chem Biol Interact* 135-136: 515-534. [http://dx.doi.org/10.1016/S0009-2797\(01\)00223-X](http://dx.doi.org/10.1016/S0009-2797(01)00223-X)
- Delzell, E; Sathikumar, N; Graff, J; Macaluso, M; Maldonado, G; Matthew, R. (2006). An updated study of mortality among North American synthetic rubber industry workers. *Res Rep Health Eff Inst* 132: 1-63; discussion 65-74.
- Delzell, E; Sathikumar, N; Hovinga, M; Macaluso, M; Julian, J; Larson, R; Cole, P; Muir, DCF. (1996). A follow-up study of synthetic rubber workers. *Toxicology* 113: 182-189. [http://dx.doi.org/10.1016/0300-483X\(96\)03443-9](http://dx.doi.org/10.1016/0300-483X(96)03443-9)
- Desesso, JM; Scialli, AR. (2018). Bone development in laboratory mammals used in developmental toxicity studies [Review]. *Birth Defects Res* 110: 1157-1187. <http://dx.doi.org/10.1002/bdr2.1350>
- Divine, BJ; Hartman, CM. (2001). A cohort mortality study among workers at a 1,3 butadiene facility. *Chem Biol Interact* 135-136: 535-553. [http://dx.doi.org/10.1016/S0009-2797\(01\)00212-5](http://dx.doi.org/10.1016/S0009-2797(01)00212-5)
- Doerr, JK; Hollis, EA; Sipes, IG. (1996). Species difference in the ovarian toxicity of 1,3-butadiene epoxides in B6C3F1 mice and Sprague-Dawley rats. *Toxicology* 113: 128-136. [http://dx.doi.org/10.1016/0300-483x\(96\)03437-3](http://dx.doi.org/10.1016/0300-483x(96)03437-3)
- EC (Environment Canada). (2000). Priority Substances List Assessment Report: 1,3-Butadiene. Ottawa, Ontario: Government of Canada, Environment Canada, Health Canada. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/contaminants/psl2-lsp2/1_3_butadiene/1_3_butadiene-eng.pdf
- Elfarra, AA; Zhang, XY. (2012). Alcohol dehydrogenase- and rat liver cytosol-dependent bioactivation of 1-chloro-2-hydroxy-3-butene to 1-chloro-3-buten-2-one, a bifunctional alkylating agent. *Chem Res Toxicol* 25: 2600-2607. <http://dx.doi.org/10.1021/tx300369b>

- Ellis, ET; Young, SG; Carroll, R; Stahr, SD; Runnells, GA; Grasmuck, EA; Su, LJ; Park, YMM; Hsu, PC. (2025). Carcinogenic air pollutants and breast cancer risk in the Arkansas rural community health study: A nested case-control study. *Environ Pollut* 368: 125709. <http://dx.doi.org/10.1016/j.envpol.2025.125709>
- Erber, L; Goodman, S; Wright, FA; Chiu, WA; Tretyakova, NY; Rusyn, I. (2021). Intra- and Inter-Species Variability in Urinary N7-(1-Hydroxy-3-buten-2-yl)guanine Adducts Following Inhalation Exposure to 1,3-Butadiene. *Chem Res Toxicol* 34: 2375-2383. <http://dx.doi.org/10.1021/acs.chemrestox.1c00291>
- Fajen, JM; Roberts, DR; Ungers, LJ; Krishnan, ER. (1990). Occupational exposure of workers to 1,3-butadiene. *Environ Health Perspect* 86: 11-18. <http://dx.doi.org/10.2307/3430927>
- Farrar, DB; Crump, KS. (1988). Exact statistical tests for any carcinogenic effect in animal bioassays. *Fundam Appl Toxicol* 11: 652-663.
- Federico, C; Vitale, V; La Porta, N; Saccone, S. (2019). Buccal micronucleus assay in human populations from Sicily (Italy) exposed to petrochemical industry pollutants. *Environ Sci Pollut Res Int* 26: 7048-7054. <http://dx.doi.org/10.1007/s11356-019-04193-3>
- Filser, JG; Bhowmik, S; Faller, TH; Hutzler, C; Kessler, W; Midpanon, S; Pütz, C; Schuster, A; Semder, B; Veereshwarayya, V; Csanády, GA. (2010). Quantitative investigation on the metabolism of 1,3-butadiene and of its oxidized metabolites in once-through perfused livers of mice and rats. *Toxicol Sci* 114: 25-37. <http://dx.doi.org/10.1093/toxsci/kfp297>
- Filser, JG; Faller, TH; Bhowmik, S; Schuster, A; Kessler, W; Pütz, C; Csanády, GA. (2001). First-pass metabolism of 1,3-butadiene in once-through perfused livers of rats and mice. *Chem Biol Interact* 135-136: 249-265. [http://dx.doi.org/10.1016/s0009-2797\(01\)00194-6](http://dx.doi.org/10.1016/s0009-2797(01)00194-6)
- Filser, JG; Hutzler, C; Meischner, V; Veereshwarayya, V; Csanady, GA. (2007). Metabolism of 1,3-butadiene to toxicologically relevant metabolites in single-exposed mice and rats. *Chem Biol Interact* 166: 93-103. <http://dx.doi.org/10.1016/j.cbi.2006.03.002>
- Georgieva, NI; Boysen, G; Bordeerat, N; Walker, VE; Swenberg, JA. (2010). Exposure-response of 1,2:3,4-diepoxybutane-specific N-terminal valine adducts in mice and rats after inhalation exposure to 1,3-butadiene. *Toxicol Sci* 115: 322-329. <http://dx.doi.org/10.1093/toxsci/kfq060>
- Goggin, M; Sangaraju, D; Walker, VE; Wickliffe, J; Swenberg, JA; Tretyakova, N. (2011). Persistence and repair of bifunctional DNA adducts in tissues of laboratory animals exposed to 1,3-butadiene by inhalation. *Chem Res Toxicol* 24: 809-817. <http://dx.doi.org/10.1021/tx200009b>
- Goggin, M; Swenberg, JA; Walker, VE; Tretyakova, N. (2009). Molecular dosimetry of 1,2,3,4-diepoxybutane-induced DNA-DNA cross-links in B6C3F1 mice and F344 rats exposed to 1,3-butadiene by inhalation. *Cancer Res* 69: 2479-2486. <http://dx.doi.org/10.1158/0008-5472.CAN-08-4152>
- Graff, JJ; Sathiakumar, N; Macaluso, M; Maldonado, G; Matthews, R; Delzell, E. (2005). Chemical exposures in the synthetic rubber industry and lymphohematopoietic cancer mortality. *J Occup Environ Med* 47: 916-932. <http://dx.doi.org/10.1097/01.jom.0000172866.16615.db>
- Graff, JJ; Sathiakumar, N; Macaluso, M; Maldonado, G; Matthews, R; Delzell, E. (2009). The Effect of Uncertainty in Exposure Estimation on the Exposure-Response Relation between 1,3-Butadiene and Leukemia. *Int J Environ Res Public Health* 6: 2436-2455. <http://dx.doi.org/10.3390/ijerph6092436>
- Grant, RL; Haney, J; Curry, AL; Honeycutt, M. (2010). A chronic reference value for 1,3-butadiene based on an updated noncancer toxicity assessment [Review]. *J Toxicol Environ Health B Crit Rev* 13: 460-475. <http://dx.doi.org/10.1080/10937404.2010.499735>
- Green, JW. (2003). Statistical analysis of butadiene mouse data from Hackett et al. (1987). Newark, DE: E.I. Dupont de Nemours & Co. https://chemview.epa.gov/chemview/proxy?filename=09022526804d1ab7_Green-DuPont%20Statistical%20Analysis%20of%20Mouse%20Data%202003.pdf

- [Haber, F.](#) (1924). Zur Geschichte des Gaskrieges. In Fünf Vorträge aus den Jahren 1920-1923. Berlin: Springer.
- [Hackett, PL; Brown, MG; Clark, ML; Evanoff, JJ; Rowe, SE; McClanahan, BJ; Buschbom, RL; Decker, JR; Rommereim, RL; Westerberg, RB.](#) (1988a). Sperm-head morphology study in B6C3F1 mice following inhalation exposure to 1,3-butadiene. Hackett, PL; Brown, MG; Clark, ML; Evanoff, JJ; Rowe, SE; McClanahan, BJ; Buschbom, RL; Decker, JR; Rommereim, RL; Westerberg, RB.
- [Hackett, PL; Mast, TJ; Brown, MG; Clark, ML; Evanoff, JJ; Rowe, SE; McClanahan, BJ; Buschbom, RL; Decker, JR; Rommereim, RL; Westerberg, RB.](#) (1988b). Dominant lethal study in CD-1 mice following inhalation exposure to 1,3-butadiene. Hackett, PL; Mast, TJ; Brown, MG; Clark, ML; Evanoff, JJ; Rowe, SE; McClanahan, BJ; Buschbom, RL; Decker, JR; Rommereim, RL; Westerberg, RB.
- [Hall, C; Heck, JE; Ritz, B; Cockburn, M; Escobedo, LA; von Ehrenstein, OS.](#) (2019). Prenatal exposure to air toxics and malignant germ cell tumors in young children. *J Occup Environ Med* 61: 529-534. <http://dx.doi.org/10.1097/JOM.0000000000001609>
- [Hayes, RB; Xi, L; Bechtold, WE; Rothman, N; Yao, M; Henderson, R; Zhange, L; Smith, MT; Zhang, D; Wiemels, J; Dosemeci, M; Yin, S; O'Neil, JP.](#) (1996). hprt mutation frequency among workers exposed to 1,3-butadiene in China. *Toxicology* 113: 100-105. [http://dx.doi.org/10.1016/0300-483X\(96\)03433-6](http://dx.doi.org/10.1016/0300-483X(96)03433-6)
- [Hayes, RB; Zhang, L; Swenberg, JA; Yin, SN; Xi, L; Wiencke, J; Bechtold, WE; Yao, M; Rothman, N; Haas, R; O'Neill, JP; Wiemels, J; Dosemeci, M; Li, G; Smith, MT.](#) (2001). Markers for carcinogenicity among butadiene-polymer workers in China. *Chem Biol Interact* 135-136: 455-464. [http://dx.doi.org/10.1016/S0009-2797\(01\)00182-X](http://dx.doi.org/10.1016/S0009-2797(01)00182-X)
- [Hayes, RB; Zhang, L; Yin, S; Swenberg, JA; Xi, L; Wiencke, J; Bechtold, WE; Yao, M; Rothman, N; Haas, R; O'Neill, JP; Zhang, D; Wiemels, J; Dosemeci, M; Li, G; Smith, MT.](#) (2000). Genotoxic markers among butadiene polymer workers in China. *Carcinogenesis* 21: 55-62. <http://dx.doi.org/10.1093/carcin/21.1.55>
- [Hazleton Labs](#) (Hazleton Laboratories). (1981a). 1,3-Butadiene: Inhalation teratogenicity study in the rat (Final report). (2788-522/3). Houston, TX: International Institute of Synthetic Rubber Products.
- [Hazleton Labs](#) (Hazleton Laboratories). (1981b). The toxicity and carcinogenicity of butadiene gas administered to rats by inhalation for approximately 24 months (volume I - IV) (final report) w- attachments and cover letter 081182 [TSCA Submission]. (Report No. 2653-522/2. OTS0204870. 8EHQ-0882-0370. TSCATS/408839). New York, NY: International Institute of Synthetic Rubber Producers. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0204870.xhtml>
- [Heck, JE; He, D; Wing, SE; Ritz, B; Carey, CD; Yang, J; Stram, DO; Le Marchand, L; Park, SL; Cheng, I; Wu, AH.](#) (2024). Exposure to outdoor ambient air toxics and risk of breast cancer: The multiethnic cohort. *Int J Hyg Environ Health* 259: 114362. <http://dx.doi.org/10.1016/j.ijheh.2024.114362>
- [Heck, JE; Park, AS; Qiu, J; Cockburn, M; Ritz, B.](#) (2014). Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood. *Int J Hyg Environ Health* 217: 662-668. <http://dx.doi.org/10.1016/j.ijheh.2013.12.003>
- [Heck, JE; Park, AS; Qiu, J; Cockburn, M; Ritz, B.](#) (2015). Retinoblastoma and ambient exposure to air toxics in the perinatal period [Supplemental Data]. *J Expo Sci Environ Epidemiol* 25: 182-186. <http://dx.doi.org/10.1038/jes.2013.84>
- [Henderson, RF; Bechtold, WE; Thornton-Manning, JR; Dahl, AR.](#) (2001). Urinary butadiene diepoxide: a potential biomarker of blood diepoxide. *Toxicology* 160: 81-86. [http://dx.doi.org/10.1016/S0300-483X\(00\)00438-8](http://dx.doi.org/10.1016/S0300-483X(00)00438-8)

- Henderson, RF; Hahn, FF; Barr, EB; Belinsky, SA; Menache, MG; Benson, JM. (1999). Carcinogenicity of inhaled butadiene diepoxide in female B6C3F1 mice and Sprague-Dawley rats. *Toxicol Sci* 52: 33-44. <http://dx.doi.org/10.1093/toxsci/52.1.33>
- Henderson, RF; Thornton-Manning, J. R.; Bechtold, WE; Dahl, AR. (1996). Metabolism of 1,3-butadiene: Species differences [Review]. *Toxicology* 113: 17-22. [http://dx.doi.org/10.1016/0300-483X\(96\)03422-1](http://dx.doi.org/10.1016/0300-483X(96)03422-1)
- Hill, AB. (1965). The environment and disease: Association or causation? *Proc R Soc Med* 58: 295-300. <http://dx.doi.org/10.1177/003591576505800503>
- Himmelstein, MW; Acquavella, JF; Recio, L; Medinsky, MA; Bond, JA. (1997). Toxicology and epidemiology of 1,3-butadiene [Review]. *Crit Rev Toxicol* 27: 1-108. <http://dx.doi.org/10.3109/10408449709037482>
- Himmelstein, MW; Turner, MJ; Asgharian, B; Bond, JA. (1994). Comparison of blood concentrations of 1,3-butadiene and butadiene epoxides in mice and rats exposed to 1,3-butadiene by inhalation. *Carcinogenesis* 15: 1479-1486. <http://dx.doi.org/10.1093/carcin/15.8.1479>
- Himmelstein, MW; Turner, MJ; Asgharian, B; Bond, JA. (1996). Metabolism of 1,3-butadiene: Inhalation pharmacokinetics and tissue dosimetry of butadiene epoxides in rats and mice. *Toxicology* 113: 306-309. [http://dx.doi.org/10.1016/0300-483X\(96\)03462-2](http://dx.doi.org/10.1016/0300-483X(96)03462-2)
- Hoyer, PB; Sipes, IG. (2007). Development of an animal model for ovotoxicity using 4-vinylcyclohexene: A case study [Review]. *Birth Defects Res B Dev Reprod Toxicol* 80: 113-125. <http://dx.doi.org/10.1002/bdrb.20103>
- Hu, X; Christian, PJ; Thompson, KE; Sipes, IG; Hoyer, PB. (2001). Apoptosis induced in rats by 4-vinylcyclohexene diepoxide is associated with activation of the caspase cascades. *Biol Reprod* 65: 87-93. <http://dx.doi.org/10.1095/biolreprod65.1.87>
- IARC (International Agency for Research on Cancer). (2008a). 1,3-Butadiene [IARC Monograph]. In 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide) (pp. 45-184). Lyon, France. <https://monographs.iarc.fr/ENG/Monographs/vol97/mono97-6.pdf>
- IARC (International Agency for Research on Cancer). (2008b). 1,3-Butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide) [IARC Monograph]. In 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide) (pp. 3-471). Lyon, France. <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/1-3-Butadiene-Ethylene-Oxide-And-Vinyl-Halides-Vinyl-Fluoride-Vinyl-Chloride-And-Vinyl-Bromide--2008>
- IARC (International Agency for Research on Cancer). (2012). Chemical agents and related occupations: A review of human carcinogens [IARC Monograph]. Lyon, France. <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Chemical-Agents-And-Related-Occupations-2012>
- IARC. (2024). Agents classified by the IARC monographs, volumes 1-135. Lyon, France. <https://monographs.iarc.who.int/list-of-classifications>
- IISRP (International Institute of Synthetic Rubber Producers). (1986). Preliminary results of the 3-year update of a mortality study of styrene butadiene workers with cover letter dated 121286 [TSCA Submission]. (EPA/OTS Doc #FYI-OTS-1286-0525). <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS00005250.xhtml>
- IISRP (International Institute of Synthetic Rubber Producers). (1999). Lymphohematopoietic cancer among workers exposed to 1,3-butadiene, styrene and dimethyldithiocarbamate in the synthetic rubber industry. (EPA/OTS; Doc #89000000121). Washington, DC: University of Alabama, Birmingham; Environmental Protection Agency. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS05597441.xhtml>

- Irons, RD; Oshimura, M; Barrett, JC. (1987). Chromosome aberrations in mouse bone marrow cells following in vivo exposure to 1,3-butadiene. *Carcinogenesis* 8: 1711-1714. <http://dx.doi.org/10.1093/carcin/8.11.1711>
- Irons, RD; Smith, CN; Stillman, WS; Shah, RS; Steinhagen, WH; Leiderman, LJ. (1986a). Macrocytic-megaloblastic anemia in male B6C3F1 mice following chronic exposure to 1,3-butadiene. *Toxicol Appl Pharmacol* 83: 95-100. [http://dx.doi.org/10.1016/0041-008X\(86\)90326-1](http://dx.doi.org/10.1016/0041-008X(86)90326-1)
- Irons, RD; Smith, CN; Stillman, WS; Shah, RS; Steinhagen, WH; Leiderman, LJ. (1986b). Macrocytic-megaloblastic anemia in male NIH Swiss mice following repeated exposure to 1,3-butadiene. *Toxicol Appl Pharmacol* 85: 450-455. [http://dx.doi.org/10.1016/0041-008X\(86\)90352-2](http://dx.doi.org/10.1016/0041-008X(86)90352-2)
- Jauhar, PP; Henika, PR; Macgregor, JT; Wehr, CM; Shelby, MD; Murphy, SA; Margolin, BH. (1988). 1,3-butadiene induction of micronucleated erythrocytes in the peripheral blood of b6c3f-1 mice exposed by inhalation for 13 weeks. *Mutat Res* 209: 171-176. [http://dx.doi.org/10.1016/0165-7992\(88\)90037-1](http://dx.doi.org/10.1016/0165-7992(88)90037-1)
- Johanson, G; Filser, JG. (1993). A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. *Arch Toxicol* 67: 151-163. <http://dx.doi.org/10.1007/BF01973302>
- Kappeler, CJ; Hoyer, PB. (2012). 4-vinylcyclohexene diepoxide: a model chemical for ovotoxicity [Review]. *Sys Biol Reprod Med* 58: 57-62. <http://dx.doi.org/10.3109/19396368.2011.648820>
- Kirman, CR; Albertini, RA; Gargas, ML. (2010a). 1,3-Butadiene: III. Assessing carcinogenic modes of action [Review]. *Crit Rev Toxicol* 40 Suppl 1: 74-92. <http://dx.doi.org/10.3109/10408444.2010.507183>
- Kirman, CR; Albertini, RJ; Sweeney, LM; Gargas, ML. (2010b). 1,3-Butadiene: I. Review of metabolism and the implications to human health risk assessment [Review]. *Crit Rev Toxicol* 40 Suppl 1: 1-11. <http://dx.doi.org/10.3109/10408444.2010.507181>
- Kirman, CR; Grant, RL. (2012). Quantitative human health risk assessment for 1,3-butadiene based upon ovarian effects in rodents. *Regul Toxicol Pharmacol* 62: 371-384. <http://dx.doi.org/10.1016/j.yrtph.2011.11.001>
- Kirman, CR; North, CM; Tretyakova, NY; Erraguntla, N; Shen, H; Hays, SM. (2022). Use of biomarker data and metabolite relative potencies to support derivation of noncancer reference values based on the reproductive and developmental toxicity effects of 1,3-butadiene. *Regul Toxicol Pharmacol* 134: 105239. <http://dx.doi.org/10.1016/j.yrtph.2022.105239>
- Kohn, MC; Melnick, RL. (2001). Physiological modeling of butadiene disposition in mice and rats. *Chem Biol Interact* 135-136: 285-301. [http://dx.doi.org/10.1016/S0009-2797\(01\)00176-4](http://dx.doi.org/10.1016/S0009-2797(01)00176-4)
- Koturbash, I; Scherhag, A; Sorrentino, J; Sexton, K; Bodnar, W; Swenberg, JA; Beland, FA; Pardo-Manuel Devillena, F; Rusyn, I; Pogribny, IP. (2011a). Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. *Toxicol Sci* 122: 448-456. <http://dx.doi.org/10.1093/toxsci/kfr133>
- Koturbash, I; Scherhag, A; Sorrentino, J; Sexton, K; Bodnar, W; Tryndyak, V; Latendresse, JR; Swenberg, JA; Beland, FA; Pogribny, IP; Rusyn, I. (2011b). Epigenetic alterations in liver of C57BL/6J mice after short-term inhalational exposure to 1,3-butadiene. *Environ Health Perspect* 119: 635-640. <http://dx.doi.org/10.1289/ehp.1002910>
- Krause, RJ; Sharer, JE; Elfarra, AA. (1997). Epoxide hydrolase-dependent metabolism of butadiene monoxide to 3-butene-1,2-diol in mouse, rat, and human liver. *Drug Metab Dispos* 25: 1013-1015.
- Kreuzer, PE; Kessler, W; Welter, HF; Baur, C; Filser, JG. (1991). Enzyme specific kinetics of 1,2-epoxy-3-butene in microsomes and cytosol from livers of mouse, rat, and man. *Arch Toxicol* 65: 59-67. <http://dx.doi.org/10.1007/BF01973504>

- [Lähdetie, J; Peltonen, K; Sjöblom, T.](#) (1997). Germ cell mutagenicity of three metabolites of 1,3-butadiene in the rat: induction of spermatid micronuclei by butadiene mono-, di-, and diolepoxides in vivo. *Environ Mol Mutagen* 29: 230-239.
- [Le, CH.](#) (2016). The Prevalence of Anemia and Moderate-Severe Anemia in the US Population (NHANES 2003-2012). *PLoS ONE* 11: e0166635. <http://dx.doi.org/10.1371/journal.pone.0166635>
- [Leiderman, LJ; Stillman, WS; Shah, RS; Steinhagen, WH; Irons, RD.](#) (1986). Altered Hematopoietic stem cell development in male B6C3F1 mice following exposure to 1,3-butadiene. *Exp Mol Pathol* 44: 50-56. [http://dx.doi.org/10.1016/0014-4800\(86\)90032-8](http://dx.doi.org/10.1016/0014-4800(86)90032-8)
- [Lewis, L; Borowa-Mazgaj, B; De Conti, A; Chappell, GA; Luo, YS; Bodnar, W; Konganti, K; Wright, FA; Threadgill, DW; Chiu, WA; Pogribny, IP; Rusyn, I.](#) (2019). Population-Based Analysis of DNA Damage and Epigenetic Effects of 1,3-Butadiene in the Mouse. *Chem Res Toxicol* 32: 887-898. <http://dx.doi.org/10.1021/acs.chemrestox.9b00035>
- [Lin, YS; Smith, TJ; Kelsey, KT; Wypij, D.](#) (2001). Human physiologic factors in respiratory uptake of 1,3-butadiene. *Environ Health Perspect* 109: 921-926. <http://dx.doi.org/10.2307/3454993>
- [Lin, YS; Smith, TJ; Wypij, D; Kelsey, KT; Sacks, FM.](#) (2002). Association of the blood/air partition coefficient of 1,3-butadiene with blood lipids and albumin. *Environ Health Perspect* 110: 165-168. <http://dx.doi.org/10.1289/ehp.02110165>
- [Liu, S; Ao, L; Du, B; Zhou, Y; Yuan, JM; Bai, Y; Zhou, Z; Cao, J.](#) (2008). HPRT Mutations in Lymphocytes from 1,3-Butadiene-Exposed Workers in China. *Environ Health Perspect* 116: 203-208.
- [Liu, W; Wang, LY; Xing, XX; Fan, GW.](#) (2015). Conditions and possible mechanisms of VCD-induced ovarian failure. *Altern Lab Anim* 43: 385-392. <http://dx.doi.org/10.1177/026119291504300606>
- [Lovreglio, P; Bukvic, N; Fustinoni, S; Ballini, A; Drago, I; Foà, V; Guanti, G; Soleo, L.](#) (2006). Lack of genotoxic effect in workers exposed to very low doses of 1,3-butadiene. *Arch Toxicol* 80: 378-381. <http://dx.doi.org/10.1007/s00204-005-0046-0>
- [Luo, J; Hendryx, M; Ducatman, A.](#) (2011). Association between six environmental chemicals and lung cancer incidence in the United States. *J Environ Public Health* 2011: 463701. <http://dx.doi.org/10.1155/2011/463701>
- [Ma, H; Wood, TG; Ammenheuser, MM; Rosenblatt, JI; Ward, JB.](#) (2000). Molecular analysis of hprt mutant lymphocytes from 1, 3-butadiene-exposed workers. *Environ Mol Mutagen* 36: 59-71.
- [Macaluso, M; Larson, R; Delzell, E; Sathiakumar, N; Hovinga, M; Julian, J; Muir, D; P, C.](#) (1996). Leukemia and cumulative exposure to butadiene, styrene, and benzene among workers in the synthetic rubber industry. *Toxicology* 113: 190-202. [http://dx.doi.org/10.1016/0300-483X\(96\)03444-0](http://dx.doi.org/10.1016/0300-483X(96)03444-0)
- [Macaluso, M; Larson, R; Lynch, J; Lipton, S; Delzell, E.](#) (2004). Historical estimation of exposure to 1,3-butadiene, styrene, and dimethyldithiocarbamate among synthetic rubber workers. *J Occup Environ Hyg* 1: 371-390. <http://dx.doi.org/10.1080/15459620490452004>
- [Madhusree, B; Goto, S; Ohkubo, T; Tian, H; Ando, F; Fukuhara, M; Tohkin, M; Watanabe, I.](#) (2002). Mutagenicity Testing of 1,3-Butadiene, 1,4-Pentadiene-3-ol, Isoprene, 2,4-Hexadiene, cis- and trans-Piperlylene. *J Health Sci* 48: 73-78. <http://dx.doi.org/10.1248/jhs.48.73>
- [Matanoski, GM; Santos-Burgoa, C; Schwartz, L.](#) (1990). Mortality of a cohort of workers in the styrene-butadiene polymer manufacturing industry (1943-1982). *Environ Health Perspect* 86: 1990. <http://dx.doi.org/10.1289/ehp.9086107>
- [Mazeman, E.](#) (1972). [Tumors of the upper excretory urinary tract, calices, renal pelvis and ureter]. *J Urol Nephrol (Paris)* 78.
- [Meek, ME; Bucher, J. R.; Cohen, SM; Dellarco, V; Hill, RN; Lehman-Mckeeman, LD; Longfellow, DG; Pastoor, T; Seed, J; Patton, DE.](#) (2003). A framework for human relevance analysis of

information on carcinogenic modes of action [Review]. Crit Rev Toxicol 33: 591-653.

<http://dx.doi.org/10.1080/713608373>

Meng, Q; Henderson, RF; Chen, T; Heflich, RH; Walker, DM; Bauer, MJ; Reilly, AA; Walker, VE. (1999). Mutagenicity of 1,3-butadiene at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats. Mutat Res 429: 107-125. [http://dx.doi.org/10.1016/S0027-5107\(99\)00104-9](http://dx.doi.org/10.1016/S0027-5107(99)00104-9)

Meng, Q; Recio, L; Reilly, AA; Wong, BA; al., e. (1998). Comparison of the mutagenic potency of 1,3-butadiene at the hprt locus of T-lymphocytes following inhalation exposure of female B6C3F1 mice and F344 rats. Carcinogenesis 19: 1019. <http://dx.doi.org/10.1093/carcin/19.6.1019>

Meng, Q; Singh, N; Heflich, RH; Bauer, MJ; Walker, VE. (2000). Comparison of the mutations at Hprt exon 3 of T-lymphocytes from B6C3F1 mice and F344 rats exposed by inhalation to 1,3-butadiene or the racemic mixture of 1,2:3,4-diepoxybutane. Mutat Res Genet Toxicol Environ Mutagen 464: 169-184. [http://dx.doi.org/10.1016/S1383-5718\(99\)00157-6](http://dx.doi.org/10.1016/S1383-5718(99)00157-6)

Meng, Q; Walker, DM; McDonald, JD; Henderson, RF; Carter, MM; Cook, DL; Mccash, CL; Torres, SM; Bauer, MJ; Seilkop, SK; Upton, PB; Georgieva, NI; Boysen, G; Swenberg, JA; Walker, VE. (2007). Age-, gender-, and species-dependent mutagenicity in T cells of mice and rats exposed by inhalation to 1,3-butadiene. Chem Biol Interact 166: 121-131. <http://dx.doi.org/10.1016/j.cbi.2006.07.005>

Meng, Q; Walker, DM; Scott, BR; Seilkop, SK; Aden, JK; Walker, VE. (2004). Characterization of Hprt mutations in cDNA and genomic DNA of T-cell mutants from control and 1,3-butadiene-exposed male B6C3F1 mice and F344 rats. Environ Mol Mutagen 43: 75-92. <http://dx.doi.org/10.1002/em.20002>

Motwani, HV; Törnqvist, M. (2014). In vivo doses of butadiene epoxides as estimated from in vitro enzyme kinetics by using cob(I)alamin and measured hemoglobin adducts: an inter-species extrapolation approach. Toxicol Appl Pharmacol 281: 276-284. <http://dx.doi.org/10.1016/j.taap.2014.10.011>

NAC/AEGL (National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances). (2009). 1,3-butadiene (CAS reg. no. 106-99-0): Interim acute exposure guidelines levels (AEGLs). Washington, DC. http://www.epa.gov/oppt/aegl/pubs/butadiene_interim_dec_2008.pdf

Nakamura, J; Carro, S; Gold, A; Zhang, Z. (2021). An unexpected butadiene diolepoxide-mediated genotoxicity implies alternative mechanism for 1,3-butadiene carcinogenicity. Chemosphere 266: 129149. <http://dx.doi.org/10.1016/j.chemosphere.2020.129149>

Niehoff, NM; Gammon, MD; Keil, AP; Nichols, HB; Engel, LS; Sandler, DP; White, AJ. (2019). Airborne mammary carcinogens and breast cancer risk in the Sister Study. Environ Int 130: 104897. <http://dx.doi.org/10.1016/j.envint.2019.06.007>

Nieto, A; Zhang, L; Bhandari, D; Zhu, W; Blount, BC; De Jesús, VR. (2021). Exposure to 1,3-Butadiene in the U.S. Population: National Health and Nutrition Examination Survey 2011-2016. Biomarkers 26: 371-383. <http://dx.doi.org/10.1080/1354750X.2021.1904000>

NIH (National Institutes of Health). (2024). Registry groupings in SEER data and statistics. Available online at <https://seer.cancer.gov/registries/terms.html>

NRC. (1994). Science and judgement in risk assessment: Needs and opportunities [Editorial]. Environ Health Perspect 102: 908-909. <http://dx.doi.org/10.1289/ehp.94102908>

NTP (National Toxicology Program). (1984). Toxicology and carcinogenesis studies of 1,3-butadiene (CAS no. 106-99-0) in B6C3F1 mice (inhalation studies) [NTP]. (NIH publication no. 84-2544; NTP report no. NTP-83-071). Research Triangle Park, NC: National Institutes of Health. http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr288.pdf

- NTP (National Toxicology Program). (1993). NTP toxicology and carcinogenesis studies of 1,3-butadiene (CAS No. 106-99-0) in B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser 434: 1-389.
- NTP (National Toxicology Program). (2021a). 1,3-butadiene: CAS No. 106-99-0. In Report on carcinogens, fifteenth edition (15th ed.). Research Triangle Park, NC: U.S. Department of Health and Human Services. <https://ntp.niehs.nih.gov/ntp/roc/content/profiles/butadiene.pdf>
- NTP (National Toxicology Program). (2021b). Report on carcinogens, fifteenth edition. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service. <http://dx.doi.org/10.22427/NTP-OTHER-1003>
- ODPHP (Office of Disease Prevention and Health Promotion). (2023a). Healthy People 2030 - Social determinants of health literature summaries: Neighborhood and built environment. Available online at <https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries#neighborhood>
- ODPHP (Office of Disease Prevention and Health Promotion). (2023b). Healthy People 2030 - Social determinants of health literature summaries: Poverty. Available online at <https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/poverty>
- ODPHP (Office of Disease Prevention and Health Promotion). (2023c). Healthy People 2030 - Social determinants of health literature summaries: Social and community context. Available online at <https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries#social>
- OEHHA (California Office of Environmental Health Hazard Assessment). (2013). 1,3-Butadiene reference exposure levels. California Environmental Protection Agency, Office of Environmental Health Hazard Assessments. <https://oehha.ca.gov/media/downloads/cmr/072613bentcrel.pdf>
- Pacchierotti, F; Tiveron, C; Ranaldi, R; Bassani, B; Cordelli, E; Leter, G; Spano, M. (1998). Reproductive toxicity of 1,3-butadiene in the mouse: Cytogenetic analysis of chromosome aberrations in first-cleavage embryos and flow cytometric evaluation of spermatogonial cell killing. Mutat Res 397: 55-66. [http://dx.doi.org/10.1016/s0027-5107\(97\)00195-4](http://dx.doi.org/10.1016/s0027-5107(97)00195-4)
- Park, SL; Kotapati, S; Wilkens, LR; Tiirikainen, M; Murphy, SE; Tretyakova, N; Le Marchand, L. (2014). 1,3-Butadiene exposure and metabolism among Japanese American, Native Hawaiian, and White smokers [Editorial]. Cancer Epidemiol Biomarkers Prev 23: 2240-2249. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0492>
- Preston, RJ. (2007). Cancer risk assessment for 1,3-butadiene: Data integration opportunities. Chem Biol Interact 166: 150-155. <http://dx.doi.org/10.1016/j.cbi.2006.03.009>
- Pudrith, C; Dudley, WN. (2019). Sensorineural hearing loss and volatile organic compound metabolites in urine. Am J Otolaryngol 40: 409-412. <http://dx.doi.org/10.1016/j.amjoto.2019.03.001>
- Recio, L; Meyer, KG; Pluta, LJ; Moss, OR; Saranko, CJ. (1996). Assessment of 1,3-butadiene mutagenicity in the bone marrow of B6C3F1 lacI transgenic mice (Big Blue): a review of mutational spectrum and lacI mutant frequency after a 5-day 625 ppm 1,3-butadiene exposure. Environ Mol Mutagen 28: 424-429. [http://dx.doi.org/10.1002/\(SICI\)1098-2280\(1996\)28:4<424::AID-EM18>3.0.CO;2-H](http://dx.doi.org/10.1002/(SICI)1098-2280(1996)28:4<424::AID-EM18>3.0.CO;2-H)
- Recio, L; Osterman-Golkar, S; Csanady, GA; Turner, MJ; Myhr, B; Moss, O; Bond, JA. (1992). Determination of mutagenicity in tissues of transgenic mice following exposure to 1,3-butadiene and N-ethyl-N-nitrosourea. Toxicol Appl Pharmacol 117: 58-64. [http://dx.doi.org/10.1016/0041-008x\(92\)90217-g](http://dx.doi.org/10.1016/0041-008x(92)90217-g)
- Recio, L; Pluta, LJ; Meyer, KG. (1998). The in vivo mutagenicity and mutational spectrum at the lacI transgene recovered from the spleens of B6C3F1 lacI transgenic mice following a 4-week inhalation exposure to 1,3-butadiene. Mutat Res 401: 99-110. [http://dx.doi.org/10.1016/s0027-5107\(97\)00319-9](http://dx.doi.org/10.1016/s0027-5107(97)00319-9)

- [Sabourin, PJ; Burka, LT; Bechtold, WE; Dahl, AR; Hoover, MD; Chang, IY; Henderson, RF.](#) (1992). Species differences in urinary butadiene metabolites; identification of 1,2-dihydroxy-4-(N-acetylcysteinyl)butane, a novel metabolite of butadiene. *Carcinogenesis* 13: 1633-1638. [Carcinogenesis].
- [Saginala, K; Barsouk, A; Aluru, JS; Rawla, P; Padala, SA; Barsouk, A.](#) (2020). Epidemiology of Bladder Cancer [Review]. *Med Sci* 8. <http://dx.doi.org/10.3390/medsci8010015>
- [Sathiakumar, N; Bolaji, B; Brill, I; Chen, L; Tipre, M; Leader, M; Arora, T; Delzell, E.](#) (2021a). 1,3-Butadiene, styrene and selected outcomes among synthetic rubber polymer workers: Updated exposure-response analyses. *Chem Biol Interact* 347: 109600. <http://dx.doi.org/10.1016/j.cbi.2021.109600>
- [Sathiakumar, N; Bolaji, BE; Brill, I; Chen, L; Tipre, M; Leader, M; Arora, T; Delzell, E.](#) (2021b). 1,3-Butadiene, styrene and lymphohaematopoietic cancers among North American synthetic rubber polymer workers: exposure-response analyses. *Occup Environ Med* 78: 859-868. <http://dx.doi.org/10.1136/oemed-2020-107197>
- [Sathiakumar, N; Brill, I; Delzell, E.](#) (2009). 1,3-butadiene, styrene and lung cancer among synthetic rubber industry workers. *J Occup Environ Med* 51: 1326-1332. <http://dx.doi.org/10.1097/JOM.0b013e3181c3c663>
- [Sathiakumar, N; Brill, I; Leader, M; Delzell, E.](#) (2015). 1,3-Butadiene, styrene and lymphohematopoietic cancer among male synthetic rubber industry workers - Preliminary exposure-response analyses. *Chem Biol Interact* 241: 40-49. <http://dx.doi.org/10.1016/j.cbi.2015.09.003>
- [Sathiakumar, N; Delzell, E.](#) (2007). A follow-up study of women in the synthetic rubber industry: study methods. *Chem Biol Interact* 166: 25-28. <http://dx.doi.org/10.1016/j.cbi.2006.11.005>
- [Sathiakumar, N; Delzell, E.](#) (2009). A follow-up study of mortality among women in the North American synthetic rubber industry. *J Occup Environ Med* 51: 1314-1325. <http://dx.doi.org/10.1097/JOM.0b013e3181bd8972>
- [Sathiakumar, N; Delzell, E; Cheng, H; Lynch, J; Sparks, W; Macaluso, M.](#) (2007). Validation of 1,3-butadiene exposure estimates for workers at a synthetic rubber plant. *Chem Biol Interact* 166: 29-43. <http://dx.doi.org/10.1016/j.cbi.2006.08.016>
- [Sathiakumar, N; Graff, J; Macaluso, M; Maldonado, G; Matthews, R; Delzell, E.](#) (2005). An updated study of mortality among North American synthetic rubber industry workers. *Res Rep Health Eff Inst* 62: 822-829. <http://dx.doi.org/10.1136/oem.2004.018176>
- [Sathiakumar, N; Tipre, M; Leader, M; Brill, I; Delzell, E.](#) (2019). Mortality among men and women in the North American synthetic rubber industry, 1943 to 2009. *J Occup Environ Med* 61: 887-897. <http://dx.doi.org/10.1097/JOM.0000000000001688>
- [Schmidt, U; Loeser, E.](#) (1986). Epoxidation of 1,3-butadiene in liver and lung tissue of mouse, rat, monkey and man. *Adv Exp Med Biol* 197: 951-957. http://dx.doi.org/10.1007/978-1-4684-5134-4_92
- [Seed, J; Carney, EW; Corley, RA; Crofton, KM; Desesso, JM; Foster, PM; Kavlock, R; Kimmel, G; Klaunig, J; Meek, ME; Preston, RJ; Slikker, W, Jr; Tabacova, S; Williams, GM; Wiltse, J; Zoeller, RT; Fenner-Crisp, P; Patton, DE.](#) (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data [Review]. *Crit Rev Toxicol* 35: 663-672. <http://dx.doi.org/10.1080/10408440591007133>
- [Sharief, Y; Brown, AM; Backer, LC; Campbell, JA; Westbrook-Collins, B; Stead, AG; Allen, JW.](#) (1986). Sister chromatid exchange and chromosome aberration analyses in mice after in-vivo exposure to acrylonitrile styrene or butadiene monoxide. *Environ Mutagen* 8: 439-448. <http://dx.doi.org/10.1002/em.2860080312>
- [Shugaev, BB.](#) (1969). Concentrations of hydrocarbons in tissues as a measure of toxicity. *Arch Environ Occup Health* 18: 878-882. <http://dx.doi.org/10.1080/00039896.1969.10665509>

- Sielken (Sielken, Inc.). (2007). Quantitative risk assessment of exposures to butadiene in European Union occupational settings based on the University of Alabama at Birmingham epidemiology study: acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia [TSCA Submission]. (OTS0600051. 8EHQ-0108-17029. 88080000072). Shell Chemical LP. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0600051.xhtml>
- Sielken, RL; Valdez-Flores, C. (2001). Dose-response implications of the University of Alabama study of lymphohematopoietic cancer among workers exposed to 1,3-butadiene and styrene in the synthetic rubber industry. *Chem Biol Interact* 135-136: 637-651. [http://dx.doi.org/10.1016/S0009-2797\(01\)00217-4](http://dx.doi.org/10.1016/S0009-2797(01)00217-4)
- Sielken, RL; Valdez-Flores, C. (2011). Butadiene cancer exposure-response modeling: based on workers in the styrene-butadiene-rubber industry: total leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia. *Regul Toxicol Pharmacol* 60: 332-341. <http://dx.doi.org/10.1016/j.yrtph.2011.05.001>
- Sielken, RL; Valdez-Flores, C. (2013). Quantitative risk assessment of exposures to butadiene in EU occupational settings based on the University of Alabama at Birmingham epidemiological study. *Regul Toxicol Pharmacol* 65: 214-225. <http://dx.doi.org/10.1016/j.yrtph.2012.12.003>
- Sills, RC; Hong, HL; Boorman, GA; Devereux, TR; Melnick, RL. (2001). Point mutations of K-ras and H-ras genes in forestomach neoplasms from control B6C3F1 mice and following exposure to 1,3-butadiene, isoprene or chloroprene for up to 2-years. *Chem Biol Interact* 135-136: 376-386. [http://dx.doi.org/10.1016/s0009-2797\(01\)00179-x](http://dx.doi.org/10.1016/s0009-2797(01)00179-x)
- Simpson, IJ; Marrero, JE; Batterman, S; Meinardi, S; Barletta, B; Blake, DR. (2013). Air quality in the Industrial Heartland of Alberta, Canada and potential impacts on human health. *Atmos Environ* 81: 702-709. <http://dx.doi.org/10.1016/j.atmosenv.2013.09.017>
- Sisk, SC; Pluta, LJ; Bond, JA; Recio, L. (1994). Molecular analysis of lacI mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. *Carcinogenesis* OXFORD: 471-477. <http://dx.doi.org/10.1093/carcin/15.3.471>
- Sjoblom, T; Lahdetie, J. (1996). Micronuclei are induced in rat spermatids in vitro by 1,2,3,4-diepoxybutane but not by 1,2-epoxy-3-butene and 1,2-dihydroxy-3,4-epoxybutane. *Mutagenesis* 11: 525-528. <http://dx.doi.org/10.1093/mutage/11.5.525>
- Smith, TJ; Lin, YS; Mezzetti, M; Bois, FY; Kelsey, K; Ibrahim, J. (2001). Genetic and dietary factors affecting human metabolism of 1,3-butadiene. *Chem Biol Interact* 135-136: 407-428. [http://dx.doi.org/10.1016/S0009-2797\(01\)00180-6](http://dx.doi.org/10.1016/S0009-2797(01)00180-6)
- Sonich-Mullin, C; Fielder, R; Wiltse, J; Baetcke, K; Dempsey, J; Fenner-Crisp, P; Grant, D; Hartley, M; Knaap, A; Kroese, D; Mangelsdorf, I; Meek, E; Rice, JM; Younes, M. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. *Regul Toxicol Pharmacol* 34: 146-152. <http://dx.doi.org/10.1006/rtph.2001.1493>
- Šrám, RJ; Rössner, P; Peltonen, K; Podrazilová, K; Mračková, G; Demopoulos, NA; Stephanou, G; Vlachodimitropoulos, D; Darroudi, F; Tates, AD. (1998). Chromosomal aberrations, sister-chromatid exchanges, cells with high frequency of SCE, micronuclei and comet assay parameters in 1,3-butadiene-exposed workers. *Mutat Res Genet Toxicol Environ Mutagen* 419: 145-154. [http://dx.doi.org/10.1016/S1383-5718\(98\)00135-1](http://dx.doi.org/10.1016/S1383-5718(98)00135-1)
- Stayner, L; Steenland, K; Dosemeci, M; Hertz-Picciotto, I. (2003). Attenuation of exposure-response curves in occupational cohort studies at high exposure levels. *Scand J Work Environ Health* 29: 317-324. <http://dx.doi.org/10.5271/sjweh.737>
- Stephanou, G; Russo, A; Vlastos, D; Andrianopoulos, C; Demopoulos, NA. (1998). Micronucleus induction in somatic cells of mice as evaluated after 1,3-butadiene inhalation. *Mutat Res* 397: 11-20. [Mutation research]. [http://dx.doi.org/10.1016/s0027-5107\(97\)00191-7](http://dx.doi.org/10.1016/s0027-5107(97)00191-7)

- Sun, JD; Dahl, AR; Bond, JA; Birnbaum, LS; Henderson, RF. (1989). Metabolism of inhaled butadiene to monkeys: comparison to rodents. *Exp Pathol* 37: 133-135. [http://dx.doi.org/10.1016/S0232-1513\(89\)80032-5](http://dx.doi.org/10.1016/S0232-1513(89)80032-5)
- Swain, CM; Booth, ED; Watson, WP. (2003). Metabolic distribution of radioactivity in Sprague–Dawley rats and B6C3F1 mice exposed to 1,3-[2,3-14C]–butadiene by whole body exposure. *Chem Biol Interact* 145: 175-189. [http://dx.doi.org/10.1016/S0009-2797\(02\)00256-9](http://dx.doi.org/10.1016/S0009-2797(02)00256-9)
- Swenberg, JA; Bordeerat, NK; Boysen, G; Carro, S; Georgieva, NI; Nakamura, J; Troutman, JM; Upton, PB; Albertini, RJ; Vacek, PM; Walker, VE; Sram, RJ; Goggin, M; Tretyakova, N. (2011). 1,3-Butadiene: Biomarkers and application to risk assessment. *Chem Biol Interact* 192: 150-154. <http://dx.doi.org/10.1016/j.cbi.2010.10.010>
- Swenberg, JA; Boysen, G; Georgieva, N; Bird, MG; Lewis, RJ. (2007). Future directions in butadiene risk assessment and the role of cross-species internal dosimetry [Review]. *Chem Biol Interact* 166: 78-83. <http://dx.doi.org/10.1016/j.cbi.2007.01.012>
- Symanski, E; Tee Lewis, PG; Chen, TY; Chan, W; Lai, D; Ma, X. (2016). Air toxics and early childhood acute lymphocytic leukemia in Texas, a population based case control study. *Environ Health* 15: 70. <http://dx.doi.org/10.1186/s12940-016-0154-8>
- Tates, AD; Van Dam, FJ; De Zwart, FA; Darroudi, F; Natarajan, AT; Rossner, P; Peterkova, K; Peltonen, K; Demopoulos, NA; Stephanou, G; Vlachodimitropoulos, D; Sram R, JL. (1996). Biological effect monitoring in industrial workers from the Czech Republic exposed to low levels of butadiene. *Toxicology* 113: 91-99. [http://dx.doi.org/10.1016/0300-483X\(96\)03432-4](http://dx.doi.org/10.1016/0300-483X(96)03432-4)
- Tates, AD; Van Dam, FJ; De Zwart, FA; Van Teylingen, CMM; Natarajan, AT. (1994). Development of a cloning assay with high cloning efficiency to detect induction of 6-thioguanine-resistant lymphocytes in spleen of adult mice following in vivo inhalation exposure to 1,3-butadiene. *Mutat Res Rev Genet Toxicol* 309: 299-306. [http://dx.doi.org/10.1016/0027-5107\(94\)90106-6](http://dx.doi.org/10.1016/0027-5107(94)90106-6)
- Tates, AD; Van Dam, FJ; Van Teylingen, CMM; De Zwart, FA; Zwinderman, AH. (1998). Comparison of induction of hprt mutations by 1,3-butadiene and/or its metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane in lymphocytes from spleen of adult male mice and rats in vivo. *Mutat Res* 397: 21-36. [http://dx.doi.org/10.1016/S0027-5107\(97\)00192-9](http://dx.doi.org/10.1016/S0027-5107(97)00192-9)
- Thaete, LG; Levin, SI; Dudley, AT. (2013). Impact of anaesthetics and analgesics on fetal growth in the mouse. *Lab Anim* 47: 175-183. <http://dx.doi.org/10.1177/0023677213480769>
- Thornton-Manning, J. R.; Dahl, AR; Allen, ML; Bechtold, WE; Griffith, WC; Henderson, RF. (1998). Disposition of Butadiene Epoxides in Sprague-Dawley Rats Following Exposures to 8000 ppm 1,3-Butadiene: Comparisons with Tissue Epoxide Concentrations Following Low-Level Exposures. *Toxicol Sci* 41: 167-173. <http://dx.doi.org/10.1093/toxsci/41.2.167>
- Thornton-Manning, J. R.; Dahl, AR; Bechtold, WE; Griffith W C, J. R.; Pei, L; Henderson, RF. (1995). Gender differences in the metabolism of 1,3-butadiene in Sprague-Dawley rats following a low level inhalation exposure. *Carcinogenesis* 16: 2875-2878. <http://dx.doi.org/10.1093/carcin/16.11.2875>
- Thornton-Manning, JR; Dahl, AR; Bechtold, WE; Griffith, WC; Henderson, RF. (1997). Comparison of the disposition of butadiene epoxides in Sprague-Dawley rats and B6C3F1 mice following a single and repeated exposures 1,3-butadiene via inhalation. *Toxicology* 123: 125-134. [http://dx.doi.org/10.1016/S0300-483X\(97\)00112-1](http://dx.doi.org/10.1016/S0300-483X(97)00112-1)
- Thurmond, LM; Lauer, LD; House, RV; Stillman, WS; Irons, RD; Steinhagen, WH; Dean, JH. (1986). Effects of short-term inhalation exposure to 1,3-butadiene on murine immune functions. *Toxicol Appl Pharmacol* 86: 170-179. [http://dx.doi.org/10.1016/0041-008X\(86\)90047-5](http://dx.doi.org/10.1016/0041-008X(86)90047-5)
- Tice, RR. (1988). The cytogenetic evaluation of in vivo genotoxic and cytotoxic activity using rodent somatic cells. *Cell Biol Toxicol* 4: 475-486. <http://dx.doi.org/10.1007/bf00117775>

- Tice, RR; Boucher, R; Luke, CA; Shelby, MD. (1987). Comparative cytogenetic analysis of bone marrow damage induced in male B6C3F1 mice by multiple exposures to gaseous 1,3-butadiene. *Environ Mol Mutagen* 9: 235-250. <http://dx.doi.org/10.1002/em.2860090303>
- Tiveron, C; Ranaldi, R; Bassani, B; Pacchierotti, F. (1997). Induction and transmission of chromosome aberrations in mouse oocytes after treatment with butadiene diepoxide. *Environ Mol Mutagen* 30: 403-409. [http://dx.doi.org/10.1002/\(SICI\)1098-2280\(1997\)30:4<403::AID-EM5>3.0.CO;2-J](http://dx.doi.org/10.1002/(SICI)1098-2280(1997)30:4<403::AID-EM5>3.0.CO;2-J)
- Tommasi, AM; de Conti, S; Dobrzynska, MM; Russo, A. (1998). Evaluation and characterization of micronuclei in early spermatids of mice exposed to 1,3-butadiene. *Mutat Res* 397: 45-54. [http://dx.doi.org/10.1016/S0027-5107\(97\)00194-2](http://dx.doi.org/10.1016/S0027-5107(97)00194-2)
- Torrealday, S; Kodaman, P; Pal, L. (2017). Premature Ovarian Insufficiency - an update on recent advances in understanding and management [Review]. *F1000Research* 6: 2069. <http://dx.doi.org/10.12688/f1000research.11948.1>
- Tsai, SP; Ahmed, FS; Ransdell, JD; Wendt, JK; Donnelly, RP. (2005). A hematology surveillance study of petrochemical workers exposed to 1,3 butadiene. *J Occup Environ Hyg* 2: 508-515. <http://dx.doi.org/10.1080/15459620500280960>
- Tsai, SP; Wendt, JK; Ransdell, JD. (2001). A mortality, morbidity, and hematology study of petrochemical employees potentially exposed to 1,3-butadiene monomer. *Chem Biol Interact* 135-136: 555-567. [http://dx.doi.org/10.1016/S0009-2797\(01\)00186-7](http://dx.doi.org/10.1016/S0009-2797(01)00186-7)
- Tuck, AR; Robker, RL; Norman, RJ; Tilley, WD; Hickey, TE. (2015). Expression and localisation of c-kit and KITL in the adult human ovary. *Journal of Ovarian Research* 8. <http://dx.doi.org/10.1186/s13048-015-0159-x>
- U.S. EPA (U.S. Environmental Protection Agency). (1985). Mutagenicity and carcinogenicity assessment of 1,3-butadiene: Final report [EPA Report]. (EPA/600/8-85/004F). Washington, DC. <http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001EUB.txt>
- U.S. EPA. (1991). Chemical engineering branch manual for the preparation of engineering assessments. (68-D8-0112). Cincinnati, OH: US Environmental Protection Agency, Office of Toxic Substances. <https://nepis.epa.gov/Exe/ZyNET.exe/P10000VS.txt?ZyActionD=ZyDocument&Client=EPA&Index=1991%20Thru%201994&Docs=&Query=&Time=&EndTime=&SearchMethod=1&TocRestrict=n&Toc=&TocEntry=&QField=&QFieldYear=&QFieldMonth=&QFieldDay=&UseQField=&IntQFieldOp=0&ExtQFieldOp=0&XmlQuery=&File=D%3A%5CZYFILES%5CINDEX%20DATA%5C91THRU94%5CTXT%5C00000019%5CP10000VS.txt&User=ANONYMOUS&Password=anonymous&SortMethod=h%7C-&MaximumDocuments=1&FuzzyDegree=0&ImageQuality=r75g8/r75g8/x150y150g16/i425&Display=hpfr&DefSeekPage=x&SearchBack=ZyActionL&Back=ZyActionS&BackDesc=Results%20page&MaximumPages=233&ZyEntry=1>
- U.S. EPA (U.S. Environmental Protection Agency). (1994). Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry [EPA Report]. (EPA600/890066F). Research Triangle Park, NC. <https://cfpub.epa.gov/ncea/risk/recorddisplay.cfm?deid=71993&CFID=51174829&CFTOKEN=25006317>
- U.S. EPA (U.S. Environmental Protection Agency). (1999). Guidance for identifying pesticide chemicals and other substances that have a common mechanism of toxicity. Washington, DC. https://www.epa.gov/sites/default/files/2015-07/documents/guide-2-identify-pest-chem_0.pdf
- U.S. EPA (U.S. Environmental Protection Agency). (2002a). 1,3 Butadiene; CASRN 106-99-0, Integrated Risk Information Systems (IRIS) Chemical Assessment Summary. Washington, D.C.: National Center for Environmental Assessment, Integrated Risk Information System. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0139_summary.pdf

- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2002b). Health assessment of 1,3-butadiene [EPA Report]. (EPA600P98001F). Washington, DC.
<http://cfpub.epa.gov/ncea/cfm/recorddisplay.cfm?deid=54499>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2002c). A review of the reference dose and reference concentration processes [EPA Report]. (EPA630P02002F). Washington, DC.
<https://www.epa.gov/sites/production/files/2014-12/documents/rfd-final.pdf>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2005a). Guidelines for carcinogen risk assessment [EPA Report]. (EPA630P03001F). Washington, DC.
https://www.epa.gov/sites/production/files/2013-09/documents/cancer_guidelines_final_3-25-05.pdf
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2005b). Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens [EPA Report]. (EPA/630/R-03/003F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
<https://www.epa.gov/risk/supplemental-guidance-assessing-susceptibility-early-life-exposure-carcinogens>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2007). Framework for determining a mutagenic mode of action for carcinogenicity: Using EPA's 2005 cancer guidelines and supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. External Review Draft [EPA Report]. (EPA 120/R-07/002-A). Washington, DC.
<http://www.epa.gov/osa/mmoaframework/pdfs/MMOA-ERD-FINAL-83007.pdf>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011). Exposure factors handbook: 2011 edition [EPA Report]. (EPA/600/R-090/052F). Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment.
<https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100F2OS.txt>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012a). Advances in inhalation gas dosimetry for derivation of a reference concentration (RfC) and use in risk assessment (pp. 1-140). (EPA/600/R-12/044). Washington, DC.
<https://cfpub.epa.gov/ncea/risk/recorddisplay.cfm?deid=244650&CFID=50524762&CFTOKEN=17139189>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2012b). Benchmark dose technical guidance [EPA Report]. (EPA100R12001). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <https://www.epa.gov/risk/benchmark-dose-technical-guidance>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014). Guidance for applying quantitative data to develop data-derived extrapolation factors for interspecies and intraspecies extrapolation [EPA Report]. (EPA/100/R-14/002F). Washington, DC: Risk Assessment Forum, Office of the Science Advisor. <https://www.epa.gov/sites/production/files/2015-01/documents/ddef-final.pdf>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2017). Human Health Benchmarks for Pesticides: Updated 2017 Technical Document (pp. 5). (EPA 822-R -17 -001). Washington, DC: U.S. Environmental Protection Agency, Office of Water.
<https://www.epa.gov/sites/production/files/2015-10/documents/hh-benchmarks-techdoc.pdf>
- [U.S. EPA](#). (2020). Risk evaluation for asbestos, Part I: Chrysotile asbestos [EPA Report]. (EPA-740-R-8012). Washington, DC: Office of Chemical Safety and Pollution Prevention.
<https://www.regulations.gov/document/EPA-HQ-OPPT-2019-0501-0117>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2021). Draft systematic review protocol supporting TSCA risk evaluations for chemical substances, Version 1.0: A generic TSCA systematic review protocol with chemical-specific methodologies. (EPA Document #EPA-D-20-031). Washington, DC: Office of Chemical Safety and Pollution Prevention.
<https://www.regulations.gov/document/EPA-HQ-OPPT-2021-0414-0005>

- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2022). ORD staff handbook for developing IRIS assessments [EPA Report]. (EPA 600/R-22/268). Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development, Center for Public Health and Environmental Assessment.
https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=356370
- [U.S. EPA](#). (2024a). Draft Human Health Hazard Assessment for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics. <https://www.regulations.gov/document/EPA-HQ-OPPT-2024-0425-0046>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2024b). IRIS Glossary: E. Available online at <https://www.epa.gov/iris/iris-glossary#e>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2024c). IRIS Glossary: I. Washington, DC: Integrated Risk Information Systems. <https://www.epa.gov/iris/iris-glossary#i>
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025a). Benchmark Dose Modeling Results for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025b). Data Extraction Information for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025c). Environmental Release and Occupational Exposure Assessment for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025d). Further Filtering Results for Human Health Hazard Animal Toxicology and Epidemiology for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025e). General Population Exposure for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025f). Lifetable Analysis of Leukemia and Bladder Cancer for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025g). Physical Chemistry and Fate Assessment for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025h). Risk Evaluation for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [U.S. EPA](#) (U.S. Environmental Protection Agency). (2025i). Systematic Review Protocol for 1,3-Butadiene. Washington, DC: Office of Pollution Prevention and Toxics.
- [UAB](#) (University of Alabama, Birmingham). (1995a). Initial submission: Letter from intl inst syn rubber prod to USEPA RE prelim results in cohort mortality study of employees of 8 styrene butadiene rubber plants, dated 05/19/95. (EPA/OTS Doc #88-950000230). Houston, TX: International Institute of Synthetic Rubber Producers, Inc.
<https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0557873.xhtml>
- [UAB](#). (1995b). Support: a follow-up study of synthetic rubber workers (cohort mortality study of male employees of 8 styrene-butadiene rubber plants), with cover letter dated 10/24/95 [TSCA Submission] (pp. #89-960000002). (OTS0557873. 8EHQ-1095-13446. 89-960000002. TSCATS/443386). International Institute of Synthetic Rubber Producers, Inc.
- [UAB](#) (University of Alabama, Birmingham). (2007). A follow-up study of women in the synthetic rubber industry [TSCA Submission]. (OTS0600043. 8EHQ-99-14447D). International Institute of Synthetic Rubber Producers, Inc.
<https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/OTS0600043.xhtml>
- [Vacek, PM; Albertini, RJ; Sram, RJ; Upton, P; Swenberg, JA](#). (2010). Hemoglobin adducts in 1,3-butadiene exposed Czech workers: female-male comparisons. *Chem Biol Interact* 188: 668-676.
<http://dx.doi.org/10.1016/j.cbi.2010.06.017>

- Valdez-Flores, C; Erraguntla, N; Budinsky, R; Cagen, S; Kirman, CR. (2022). An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene. *Chem Biol Interact* 366: 110077. <http://dx.doi.org/10.1016/j.cbi.2022.110077>
- Victorin, K; Ståhlberg, M. (1988). A method for studying the mutagenicity of some gaseous compounds in *Salmonella typhimurium*. *Environ Mol Mutagen* 11: 65-77. <http://dx.doi.org/10.1002/em.2850110108>
- Vodicka, P; Stetina, R; Smerak, P; Vodickova, L; Naccarati, A; Barta, I; Hemminki, K. (2006). Micronuclei, DNA single-strand breaks and DNA-repair activity in mice exposed to 1,3-butadiene by inhalation. *Mutat Res Genet Toxicol Environ Mutagen* 608: 49-57. <http://dx.doi.org/10.1016/j.mrgentox.2006.05.003>
- von Ehrenstein, OS; Aralis, H; Cockburn, M; Ritz, B. (2014). In utero exposure to toxic air pollutants and risk of childhood autism. *Epidemiology* 25: 851-858. <http://dx.doi.org/10.1097/EDE.0000000000000150>
- Von Ehrenstein, OS; Heck, JE; Park, AS; Cockburn, M; Escobedo, L; Ritz, B. (2016). In utero and early-life exposure to ambient air toxics and childhood brain tumors: a population-based case-control study in California, USA. *Environ Health Perspect* 124: 1093-1099. <http://dx.doi.org/10.1289/ehp.1408582>
- Walker, VE; Degner, A; Carter, EW; Nicklas, JA; Walker, DM; Tretyakova, N; Albertini, RJ. (2019). 1,3-Butadiene metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22) translocations in human cells. *Chem Biol Interact* 312: 108797. <http://dx.doi.org/10.1016/j.cbi.2019.108797>
- Walker, VE; Meng, Q. (2000). 1,3-butadiene: cancer, mutations, and adducts. Part III: In vivo mutation of the endogenous hprt genes of mice and rats by 1,3-butadiene and its metabolites. *Res Rep Health Eff Inst* (92): 89-139; discussion 141-149.
- Wang, Q; Wang, AH; Tan, HS; Feng, NN; Ye, YJ; Feng, XQ; Liu, G; Zheng, YX; Xia, ZL. (2010). Genetic polymorphisms of DNA repair genes and chromosomal damage in workers exposed to 1,3-butadiene. *Carcinogenesis* 31: 858-863. <http://dx.doi.org/10.1093/carcin/bgq049>
- Wang, Y; Yu, YX; Luan, Y; An, J; Yin, DG; Zhang, XY. (2018). Bioactivation of 1-chloro-2-hydroxy-3-butene, an in vitro metabolite of 1,3-butadiene, by rat liver microsomes. *Chem Biol Interact* 282: 36-44. <http://dx.doi.org/10.1016/j.cbi.2018.01.006>
- Ward, EM; Fajen, JM; Ruder, AM; Rinsky, RA; Halperin, WE; Fessler-Flesch, CA. (1995). Mortality study of workers in 1,3-butadiene production units identified from a chemical workers cohort. *Environ Health Perspect* 103: 598-603. <http://dx.doi.org/10.1289/ehp.95103598>
- Ward, EM; Fajen, JM; Ruder, AM; Rinsky, RA; Halperin, WE; Fesslerflesch, CA. (1996a). Mortality study of workers employed in 1,3-butadiene production units identified from a large chemical workers cohort. *Toxicology* 113: 157-168. [http://dx.doi.org/10.1016/0300-483X\(96\)03441-5](http://dx.doi.org/10.1016/0300-483X(96)03441-5)
- Ward, JB; Abdel-Rahman, SZ; Henderson, RF; Stock, TH; Morandi, M; Rosenblatt, JI; Ammenheuser, MM. (2001). Assessment of butadiene exposure in synthetic rubber manufacturing workers in Texas using frequencies of hprt mutant lymphocytes as a biomarker. *Chem Biol Interact* 135-136: 465-483. [http://dx.doi.org/10.1016/S0009-2797\(01\)00183-1](http://dx.doi.org/10.1016/S0009-2797(01)00183-1)
- Ward, JB; Ammenheuser, MM; Whorton, EB; Bechtold, WE; Kelsey, KT; Legator, MS. (1996b). Biological monitoring for mutagenic effects of occupational exposure to butadiene. *Toxicology* 113: 84-90. [http://dx.doi.org/10.1016/0300-483X\(96\)03431-2](http://dx.doi.org/10.1016/0300-483X(96)03431-2)
- Ward, JB, Jr; Ammenheuser, MM; Bechtold, WE; Whorton, EB, Jr; Legator, MS. (1994). HPRT mutant lymphocyte frequencies in workers at a 1,3-butadiene production plant. *Environ Health Perspect* 102: 79-85. <http://dx.doi.org/10.1289/ehp.94102s979>

- Whitworth, KW; Symanski, E; Coker, AL. (2008). Childhood Lymphohematopoietic Cancer Incidence and Hazardous Air Pollutants in Southeast Texas, 1995--2004. *Environ Health Perspect* 116: 1576-1580. <http://dx.doi.org/10.1289/ehp.11593>
- Wickliffe, JK; Ammenheuser, MM; Adler, PJ; Abdel-Rahman, SZ; Ward, JB. (2009). Evaluation of frequencies of HPRT mutant lymphocytes in butadiene polymer workers in a Southeast Texas facility. *Environ Mol Mutagen* 50: 82-87. <http://dx.doi.org/10.1002/em.20437>
- WIL Research (WIL Research Laboratories). (2003). An inhalation reproduction/developmental toxicity screening study of 1,3-butadiene in rats. (WIL-186024; OLF-68.0-BD-HPV-WIL). Arlington, VA: American Chemistry Council, Olefins Panel. <https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0451-0004>
- Wu, WJ; Tang, WF; Xiang, MH; Yan, J; Cao, X; Zhou, CH; Chang, Y; Xi, J; Cao, YY; Luan, Y; Zhang, XY. (2019). Isotope dilution LC/ESI--MS-MS quantitation of urinary 1,4-bis(N-acetyl-S-cysteinyl)-2-butanone in mice and rats as the biomarker of 1-chloro-2-hydroxy-3-butene, an in vitro metabolite of 1,3-butadiene. *Chem Biol Interact* 311: 108760. <http://dx.doi.org/10.1016/j.cbi.2019.108760>
- Xiang, M; Ao, L, in; Yang, H; Liu, W; Sun, L, ei; Han, X, ue; Li, D; Cui, Z; Zhou, N; Liu, J; Cao, J, ia. (2012). Chromosomal damage and polymorphisms of metabolic genes among 1, 3-butadiene-exposed workers in a matched study in China. *Mutagenesis* 27: 415-421. <http://dx.doi.org/10.1093/mutage/ger091>
- Xiang, M; Sun, L; Dong, X; Yang, H; Liu, WB; Zhou, N; Han, X; Zhou, Z; Cui, Z; Liu, JY; Cao, J; Ao, L. (2015). Association between genetic polymorphisms of dna repair genes and chromosomal damage for 1,3-butadiene-exposed workers in a matched study in china. *BioMed Res Int* 2015: 234675. <http://dx.doi.org/10.1155/2015/234675>
- Xiao, Y; Tates, AD. (1995). Clastogenic effects of 1,3-butadiene and its metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane in splenocytes and germ cells of rats and mice in vivo. *Environ Mol Mutagen* 26: 97-108. <http://dx.doi.org/10.1002/em.2850260203>
- Yadavilli, S; Muganda, PM. (2004). Diepoxybutane induces caspase and p53-mediated apoptosis in human lymphoblasts. *Toxicol Appl Pharmacol* 195: 154-165. <http://dx.doi.org/10.1016/j.taap.2003.11.006>
- Yamaguchi, N; Tazaki, H; Okubo, T; Toyama, T. (1982). Periodic urine cytology surveillance of bladder tumor incidence in dyestuff workers. *Am J Ind Med* 3: 139-148. <http://dx.doi.org/10.1002/ajim.4700030204>
- Yuan, JM; Gao, YT; Wang, R; Chen, M; Carmella, SG; Hecht, SS. (2012). Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. *Carcinogenesis* 33: 804-809. <http://dx.doi.org/10.1093/carcin/bgs026>
- Zhao, C; Vodicka, P; Srám1, RJ; Hemminki, K. (2000). Human DNA adducts of 1,3-butadiene, an important environmental carcinogen. *Carcinogenesis* 21: 107-111. <http://dx.doi.org/10.1093/carcin/21.1.107>
- Zhao, C; Vodicka, P; Sram, RJ; Hemminki, K. (2001). DNA adducts of 1,3-butadiene in humans: relationships to exposure, GST genotypes, single-strand breaks, and cytogenetic end points. *Environ Mol Mutagen* 37: 226-230. <http://dx.doi.org/10.1002/em.1031>

APPENDICES

Appendix A EVIDENCE INTEGRATION TABLES

These evidence integration tables are presented for hazard outcomes with substantial evidence that underwent a more detailed evidence integration process in consideration of the weight of scientific evidence. The format and process for determination of the within-stream and evidence integration judgments are described in the Draft Systematic Review Protocol ([U.S. EPA, 2021](#)). This process and format was adapted from the EPA Office of Research and Development staff handbook for developing IRIS assessments ([U.S. EPA, 2022](#)), particularly the consideration of human and animal evidence streams. The TSCA Draft Systematic Review Protocol formally adds an additional evidence stream for mechanistic that incorporates both qualitative and quantitative considerations of human relevance and plausibility. The hazard identification and evidence integration for additional health outcomes with limited data are described in Appendix C.

Table_Apx A-1. Evidence Integration for Ovarian Atrophy and Associated Female Reproductive System Toxicity

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Evidence in studies of exposed humans considered for deriving toxicity values				<p><i>Overall judgment for female reproductive toxicity (ovarian atrophy) based on integration of information across evidence streams:</i></p> <p><i>Evidence suggests but is not sufficient to conclude that 1,3-butadiene exposure causes ovarian toxicity in humans under relevant exposure circumstances</i></p>
No human studies were identified that examined female reproductive toxicity.	None	None	<p><i>Key findings:</i> None</p> <p><i>Overall judgment for female reproductive toxicity based on human evidence:</i></p> <ul style="list-style-type: none"> Indeterminate 	
Evidence from <i>in vivo</i> mammalian animal studies considered for deriving toxicity values				
<p>Mouse studies <i>Subchronic studies</i></p> <ul style="list-style-type: none"> Exposed 15 days or 14 weeks to ≤8,000 ppm for 6 hours/day, 5 days/week (NTP, 1984). Evaluated histopathology and functional observations of female 	<ul style="list-style-type: none"> Ovarian atrophy observed in all acceptable studies at 13 weeks, 40 weeks, and 2 years of exposure in mice. Ovarian atrophy severity was dose-responsive and 	<ul style="list-style-type: none"> No histopathological changes observed in 15-day mouse study; however, this provides minimal weight due to the subacute exposure duration and uninformative OQD. 	<p><i>Key findings:</i> Severe ovarian toxicity is observed in mice in a dose-responsive and duration-responsive manner in both medium- and high-quality studies. However, no signs of</p>	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>reproductive organs. Overall Quality Determination (OQD) = Uninformative</p> <ul style="list-style-type: none">Exposed for 13 weeks to 980 ppm for 5 hours/day, 5 days/week (Bevan et al., 1996). Evaluated histopathology and functional observations of female reproductive organs. OQD = Medium <p><i>Chronic studies</i></p> <ul style="list-style-type: none">Exposed 40 weeks to 2 years to ≤200 ppm for 6 hours/day, 5 days/week (NTP, 1993). OQD = HighExposed 61 weeks to ≤1,250 ppm for 6 hours/day, 5 days/week (NTP, 1984). OQD = HighExposed 62 weeks to <1,250 ppm for 5 hours/day, 6 hours/day, 5 days/week (Battelle PNL, 1982). Evaluated histopathology of female reproductive organs. OQD = Uninformative <p>Rat studies</p> <p><i>Chronic studies</i></p> <ul style="list-style-type: none">Exposed for 2 years to ≤8,000 ppm for 6 hours/day, 5 days/week (Hazleton Labs, 1981b). Evaluated histopathology and functional observations of female reproductive organs. OQD = Medium	<p>observed following as low as 6.25 ppm exposure for 2 years in mice.</p> <ul style="list-style-type: none">Ovarian atrophy in mice was accompanied by an absence of oocytes, follicles, and corpora lutea along with angiectasis and uterine involution.	<ul style="list-style-type: none">No ovarian effects observed at any dose or duration in rats up to 8,000 ppm and for as long as 2 years exposure indicating a lack of consistency across species.	<p>ovarian toxicity are observed in rats exposed for 2 years to a high dose.</p> <p><i>Overall judgment for female reproductive toxicity based on animal evidence:</i></p> <ul style="list-style-type: none">Moderate	
Evidence in mechanistic studies and supplemental information				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>Metabolism differences</p> <ul style="list-style-type: none"> Multiple studies demonstrate differences in metabolism across species, although estimates vary based on sex, dose, duration, and other factors <p>Metabolite and species-specific potencies</p> <ul style="list-style-type: none"> Studies on metabolites of both DEB and analogs demonstrate differences in ovarian sensitivity between rats and mice or between mono and di-epoxides <p>Mechanism of action</p> <ul style="list-style-type: none"> The di-epoxide form of an analog appear to cause ovotoxicity through induction of apoptosis in follicles (Hoyer and Sipes, 2007; Hu et al., 2001) and DEB activates apoptotic signaling in lymphoblasts (Yadavilli and Muganda, 2004). DEB induces chromosome damage in oocytes (Tiveron et al., 1997), and a di-epoxide analog induces oocyte apoptosis through blocking the c-kit signaling pathway (Kappeler and Hoyer, 2012). 	<ul style="list-style-type: none"> Mono-epoxides are capable of inducing ovotoxicity in mice (Hoyer and Sipes, 2007; Doerr et al., 1996). DEB does form in humans, albeit orders of magnitude lower than in rodents (Motwani and Törnqvist, 2014; Swenberg et al., 2011). c-kit receptor and kit ligand have been detected in human ovaries and therefore the proposed MOA is plausible in humans (Tuck et al., 2015). 	<ul style="list-style-type: none"> Levels of the metabolite DEB are 100–300× ore more higher in mice compared to humans, 40–100× higher in mice compared to rats (Motwani and Törnqvist, 2014; Swenberg et al., 2011). Estimates of human metabolite levels are very variable however and typically use only male subjects. EB (mono-epoxide) caused ovotoxicity only in mice not rats; DEB caused effects in both, but mice were several-fold more sensitive (Doerr et al., 1996). The diepoxide form of vinylcyclohexene is 2–3× more active than the monoepoxide, and 2–3× more active in mice vs rats (Hoyer and Sipes, 2007) 	<p><i>Key findings:</i></p> <p>Studies on metabolites of both 1,3-butadiene and analog 4-vinylcyclohexene suggest that mice are both toxicokinetically and toxicodynamically more sensitive than rats, and likely humans. Humans exhibit the same metabolites and signaling pathways as mice and rats however, so ovarian toxicity in humans is qualitatively plausible, albeit likely requiring much higher exposures due to significantly reduced metabolism of DEB relative to mice. The precise quantification of metabolite levels is uncertain due to variability across experimental conditions and the use of hemoglobin adducts as a surrogate measure.</p> <p><i>Overall judgment for female reproductive toxicity based on mechanistic evidence:</i></p> <ul style="list-style-type: none"> Indeterminate 	

Table_Apx A-2. Evidence Integration for Maternal and Related Developmental Toxicity

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Evidence in studies of exposed humans considered for deriving toxicity values				Overall judgment for maternal/developmental toxicity based on integration of information across evidence streams: Evidence indicates that 1,3-butadiene exposure is likely to cause maternal and related developmental toxicity in humans under relevant exposure circumstances
<ul style="list-style-type: none">A cohort study examined risks for autism in children associated with location relative to an air monitor (von Ehrenstein et al., 2014). Overall Quality Determination (OQD) = Medium	<ul style="list-style-type: none">In utero exposure to 1,3-butadiene was positively associated with autism. Higher risks were associated with closer distance to the air monitor.	<ul style="list-style-type: none">Exposure was not directly quantified in the sole developmental toxicity study.No epidemiological studies measured similar outcomes to what was observed in animal studies.	Key findings: None Overall judgment for maternal/developmental toxicity based on human evidence: <ul style="list-style-type: none">Slight	
Evidence from in vivo mammalian animal studies considered for deriving toxicity values				
Mouse studies Female gestational exposure <ul style="list-style-type: none">Females exposed for 10 days (gestation days [GD] 6–15) to ≤1,000 ppm for 6 hours/day (Battelle PNL, 1987b). Evaluated maternal and developmental toxicity. OQD = Medium Rat studies Female gestational exposure <ul style="list-style-type: none">Females exposed for 10 days (GD 6–15) to ≤7,647 ppm for 6 hours/day (Hazleton Labs, 1981a). Evaluated maternal and developmental toxicity. OQD = MediumFemales exposed for 10 days (GD 6–15) to ≤1,005 ppm for 6 hours/day (Battelle PNL, 1987a). Evaluated maternal and developmental toxicity. OQD = High (maternal effects); Medium (developmental effects)	<ul style="list-style-type: none">In female mice exposed during gestation, maternal toxicity was observed, including three mortalities with signs of dehydration at 1,000 ppm and decreased maternal weight gain at ≥199.8 ppm (Battelle PNL, 1987b).In offspring of female mice exposed during gestation, decreased fetal body weight was observed at ≥39.9 ppm in males and at ≥200 ppm in females (Battelle PNL, 1987b).In offspring of female mice exposed during gestation increased supernumerary ribs was observed at ≥200 ppm and decreased ossification and abnormal sternebrae was observed at 1,000 ppm (Battelle PNL, 1987b).In female rats exposed during gestation, decreased maternal body weight gain during	<ul style="list-style-type: none">Inconsistent results were observed for developmental outcomes among rat studies using the same strain (Battelle PNL, 1987a; Hazleton Labs, 1981a).Maternal body weight was not decreased following a total exposure period of 60–70 days) to ≤6,006 ppm (WIL Research, 2003).	Key findings: In mice exposed during gestation, decreased maternal body weight gain, decreased fetal body weight, and increased fetal malformations were observed in a dose-responsive and dose-concordant manner in medium-quality studies. Reduced maternal weight gain was also observed in two of three rat studies (both on the same strain) and decreased female pup weight was observed following neonatal exposures, with other fetal outcomes inconsistently observed and only at high doses. Overall judgment for maternal/developmental toxicity based on animal evidence: <ul style="list-style-type: none">Robust	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p><i>Male and female exposure</i></p> <ul style="list-style-type: none"> • Males were exposed for 83–84 consecutive days and females were exposed for 60–70 days (15 exposures prior to breeding, through GD 20, and from lactation day 5 until the day prior to euthanasia, total exposure period of 60–70 days). One group of F1 pups was sacrificed at weaning; a second was exposed for 7 days (from PND 21–27) at the same concentrations as their dams; and a group of control (unexposed during gestation and lactation); a third group of F1 pups were exposed for 7 days (from PND 28–34). Exposures were $\leq 6,006$ ppm for 6 hours/day (WIL Research, 2003). Evaluated maternal and developmental toxicity. OQD = Medium 	<p>exposure was observed at ≥ 202 ppm in one study (Hazleton Labs, 1981a) and at 1,005 ppm in another study (Battelle PNL, 1987a).</p> <ul style="list-style-type: none"> • In offspring of female rats exposed during gestation, statistically significant decreased fetal body weight and crown-rump length were observed at 7647 ppm; increased (no statistics were performed) dose-responsive incidences of major skeletal defects were observed at ≥ 990 ppm with other major fetal defects observed at 7,647 ppm; litter incidences were not reported (Hazleton Labs, 1981a). • In female rats exposed before and during mating and throughout gestation and lactation, clinical signs of toxicity (chromodacryorrhea, chromorhinorrhea, and salivation) were observed in the 1 hour after exposure at $\geq 1,507$ ppm (WIL Research, 2003). • Body weight was statistically significantly reduced in female F1 pups (males had a biologically but not statistically significant reduction) exposed for 7 days to $\geq 1,507$ ppm either with or without previous gestational/lactational 			

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
	exposure(WIL Research, 2003).			
Evidence in mechanistic studies and supplemental information				
Metabolism differences <ul style="list-style-type: none">Multiple studies demonstrate differences in metabolism across species, although estimates vary based on sex, dose, duration, and other factors. Metabolite studies <ul style="list-style-type: none">Female rats were administered DEB <i>i.p.</i> for 4 days during GD 5–8 to 0.25–0.40 mmol (Chi et al., 2002). Evaluated fetal growth and viability along with placental hormones and enzymes activity.DEB was administered to early mouse embryos (1–5 μm) or pregnant dams (10 μm via injection) (Clerici et al., 1995). Evaluated embryo developmental.	<ul style="list-style-type: none">DEB negatively impacted embryonic development in mice in a dose-responsive manner.DEB negatively impacted fetal growth and viability in rats in a duration and dose-responsive manner.	<ul style="list-style-type: none">There are no available mechanistic studies investigating parental 1,3-butadiene or other metabolites for comparison with these results.	<i>Key findings:</i> The 1,3-butadiene metabolite DEB disrupts embryonic and fetal development in both mice and rats. A proposed mechanism in rats involves decreased progesterone and placental enzyme activity. <i>Overall judgment for maternal/developmental toxicity based on mechanistic evidence:</i> <ul style="list-style-type: none">Slight	

Table_Apx A-3. Evidence Integration for Male Reproductive System and Resulting Developmental Toxicity

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Evidence in studies of exposed humans considered for deriving toxicity values				
No human studies were identified that examined male reproductive toxicity	None	None	<i>Key findings:</i> None <i>Overall judgment for male reproductive toxicity based on human evidence:</i> <ul style="list-style-type: none">Indeterminate	
Evidence from <i>in vivo</i> mammalian animal studies considered for deriving toxicity values				
Sperm and testicular effects				<i>Overall judgment for male reproductive toxicity (sperm and testicular effects and dominant lethality) based on integration of information across evidence streams:</i> <i>Evidence indicates that 1,3-butadiene exposure is likely to cause male reproductive and resulting developmental toxicity in humans under relevant exposure circumstances</i>
Mouse studies <i>Subacute studies</i> <ul style="list-style-type: none">Exposed for 5 days to ≤1,300 ppm for 6 hours/day (Xiao and Tates, 1995). Evaluated testis weight. Overall Quality Determination (OQD) = LowExposed for 5 days to ≤1,300 ppm for 6 hours/day (Pacchierotti et al., 1998). Evaluated testis weight and spermatid count. OQD = LowExposed for 5 days to ≤5,000 ppm for 6 hours/day (Hackett et al., 1988a). Evaluated sperm morphology. OQD = Medium <i>Subchronic studies</i> <ul style="list-style-type: none">Exposed for 13 weeks to 980 ppm for 6 hours/day, 5 days/week (Bevan et al., 1996). Evaluated testes weight and histopathology. OQD = Medium	<ul style="list-style-type: none">Sperm-head abnormalities observed in a dose-responsive manner at ≥1,000 ppm following 5 days of exposure in mice (Hackett et al., 1988a).Reduced immature spermatid count observed in mice at ≥130 ppm for 5 days (Pacchierotti et al., 1998) in a low-quality study.Testicular atrophy observed at 980 ppm for 13 weeks (Bevan et al., 1996) and at ≥619 ppm for at least 9 months of exposure in mice (NTP, 1993, 1984). Severity at 619 ppm was greatest at 2 years of exposure and was characterized by a “uniform minimal to mild decrease in cellularity of the seminiferous tubules” (NTP, 1993).Reduced testis weight observed in mice at ≥130 ppm for 5 days	<ul style="list-style-type: none">No sperm or testicular effects observed in rats up to 6006 ppm for 12 weeks indicating a lack of consistency across species (WIL Research, 2003).	<i>Key findings:</i> Sperm and testicular effects in mice are observed in a dose- and duration-responsive manner in both medium- and high-quality studies. However, no sperm or testicular effects are observed in rats exposed for 12 weeks to a high dose, suggesting a species dependency. <i>Overall judgment for male reproductive toxicity based on animal evidence:</i> <ul style="list-style-type: none">Moderate	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment	
<p><i>Chronic studies</i></p> <ul style="list-style-type: none">Exposed for 60 weeks to ≤1236 ppm for 6 hours/day, 5 days/week (NTP, 1984). Evaluated histopathology of male reproductive organs. OQD = HighExposed for 2 years to ≤619 ppm for 6 hours/day, 5 days/week (NTP, 1993). Evaluated histopathology of male reproductive organs. OQD = High <p>Rat studies</p> <p><i>Subchronic studies</i></p> <ul style="list-style-type: none">Exposed for 12 weeks to ≤6,006 ppm for 6 hours/day, 7 days/week (WIL Research, 2003). Evaluated male reproductive performance, histopathology, and sperm parameters. OQD = Medium	<p>in two low-quality studies (Pacchierotti et al., 1998; Xiao and Tate, 1995) and at 980 ppm for 13 weeks (Bevan et al., 1996).</p>				
Dominant lethal assays					
<p>Mouse studies</p> <p><i>Acute study</i></p> <ul style="list-style-type: none">Exposed one day for 6 hours to 1,250 or 6,250 ppm (Anderson et al., 1996; Anderson et al., 1993). OQD = Uninformative for 1996 study, not determined for 1993 study <p><i>Short-term studies</i></p> <ul style="list-style-type: none">Exposed for 5 days to ≤500 ppm for 6 hours/day (Adler et al.,	<p>In dominant lethal assays, the following effects were observed in mice:</p> <ul style="list-style-type: none">Increased early fetal deaths at 500 ppm (Adler et al., 1998) and 1,300 ppm (Adler et al., 1994) at 5 days, at ≥65 ppm at 4 weeks (Anderson et al., 1998; BIBRA, 1996b), and at >125 ppm at 10 weeks (Brinkworth et al., 1998; Anderson et al., 1996);	<ul style="list-style-type: none">Reverse dose-response seen at higher doses in acute/short-term studies (Anderson et al., 1993; Hackett et al., 1988b).No effects seen in dominant lethality studies in rats.	<p><i>Key findings:</i></p> <p>Dominant lethal effects in mice are observed in a dose- and duration- responsive manner in medium-quality studies. However, no signs of dominant lethality are observed in rats exposed for 4 or 12 weeks to a high dose, suggesting a species-dependency.</p>		

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>1998).</p> <p>OQD = Medium</p> <ul style="list-style-type: none">Exposed for 5 days to 1,300 ppm for 6 hours/day (Adler et al., 1994).OQD = not determinedExposed for 5 days to ≤5,000 ppm for 6 hours/day (Hackett et al., 1988b). <p>OQD = Medium</p> <p><i>Subchronic studies</i></p> <ul style="list-style-type: none">Exposed for 4 weeks to ≤130 ppm for 6 hours/day, 5 days/week (Anderson et al., 1998; BIBRA, 1996b).OQD = MediumExposed for 10 weeks to 12.5 or 125 ppm for 6 hours/day, 5 days/week (Brinkworth et al., 1998).OQD = MediumExposed for 10 weeks to 12.5 or 1,250 ppm for 6 hours/day, 5 days/week (Anderson et al., 1996). <p>OQD = Medium</p> <p>Rat studies</p> <p><i>Subchronic studies</i></p> <ul style="list-style-type: none">Exposed for 4 weeks to ≤1,250 ppm for 6 hours/day, 5 days/week (Anderson et al., 1998).OQD = MediumExposed for 10 weeks to ≤1,250 ppm for 6 hours/day, 5 days/week (BIBRA, 1996a). <p>OQD = Medium</p>	<ul style="list-style-type: none">Decreased implantation at 1,250 ppm at 10 weeks (Anderson et al., 1996);Delayed time-to-coition at 125 ppm at 10 weeks (Brinkworth et al., 1998); andIncreased late fetal deaths including dead fetuses and abnormal fetuses at ≥12.5 ppm at 10 weeks (Anderson et al., 1996).An increased percentage of abnormal fetuses was observed at ≥12.5 ppm. External and skeletal abnormalities were reported (however, only a subset of fetuses was processed for skeletal examination) (Anderson et al., 1998; Anderson et al., 1996; BIBRA, 1996b).		<p><i>Overall judgment for dominant lethality based on animal evidence:</i></p> <ul style="list-style-type: none">Moderate	
Evidence in mechanistic studies and supplemental information				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>Mechanism of toxicity</p> <ul style="list-style-type: none"> Genotoxicity testing of 1,3-butadiene (BD) and its metabolites (diepoxybutane [DEB], epoxybutane [EB], and epoxybutanediol [EBD]) in germ cells includes evaluation of micronuclei formation, chromosome aberrations, DNA damage, and heritable translocation (U.S. EPA, 2002b) 	<ul style="list-style-type: none"> Micronuclei were increased in early-stage spermatids from mice exposed to 1,3-butadiene or its metabolites (EB, DEB, and EBD) (U.S. EPA, 2002b; Xiao and Tate, 1995). Chromosome aberrations were increased in first cleavage embryos derived from 1,3-butadiene- and EBD-exposed male mice (U.S. EPA, 2002b; Pacchierotti et al., 1998). DNA damage was reported in haploid and polyploid cells from the testis of male mice exposed to 1,3-butadiene (U.S. EPA, 2002b). Heritable translocation studies demonstrate that cytogenetic effects are transmissible across generations (U.S. EPA, 2002b; Adler et al., 1998). All three major metabolites (EB, DEB, EBD) induced clastogenicity in rat spermatids following i.p. injection (U.S. EPA, 2002b; Lähdetie et al., 1997). 	<ul style="list-style-type: none"> Dominant lethality was not observed following i.p. injection of EB or DEB in mice; however, these results may be confounded by cytotoxicity leading to decreased implantation rate (U.S. EPA, 2002b). Only DEB but not EBD or EB induced genotoxicity in cultured rat seminiferous tubule sections (U.S. EPA, 2002b; Sjoblom and Lahdetie, 1996). Mixed dominant lethality results on administered DEB and EB in mice suggest that developing sperm have stage-specific sensitivity (U.S. EPA, 2002b). 	<p><i>Key findings:</i> Dominant lethal effects appear to result from cytogenetic damage in male germ cells, especially late spermatids and spermatogonia (U.S. EPA, 2002b), and metabolites demonstrate <i>in vivo</i> germ cell genotoxicity in both mice and rats. No mechanistic data were available to evaluate testicular effects.</p> <p><i>Overall judgment for male reproductive toxicity based on mechanistic evidence:</i></p> <ul style="list-style-type: none"> Moderate 	

Table_Apx A-4. Evidence Integration for Hematological and Immune Effects

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Evidence in studies of exposed humans considered for deriving toxicity values				Overall judgment for hematologic effects based on integration of information across evidence streams: Evidence indicates that 1,3-butadiene exposure is likely to cause hematologic changes consistent with anemia in humans under relevant exposure circumstances
<ul style="list-style-type: none">Cohort study comparing butadiene polymer workers (n = 41) and internal comparison group (n = 38). Exposure evaluated by occupational history, air measurements, and hemoglobin adducts. Endpoints included erythrocyte count, leukocyte parameters, and platelet count (Hayes et al., 2000). Overall Quality Determination (OQD) = Low <p>Other human studies</p> <ul style="list-style-type: none">Cohort studies of petrochemical workers and styrene-butadiene synthetic rubber manufacturing workers (Tsai et al., 2005; Tsai et al., 2001; Cowles et al., 1994; Checkoway and Williams, 1982).	<ul style="list-style-type: none">A slight, but statistically significant, lower hemoglobin concentration was observed in exposed petrochemical workers compared to an unexposed internal referent group (Tsai et al., 2005).After adjustment for confounders, a significant association was observed between 1,3-butadiene exposure level and increased mean corpuscular hemoglobin concentration in a health survey of styrene-butadiene workers (Checkoway and Williams, 1982).	<ul style="list-style-type: none">In a low-quality cohort study with small numbers of participants, no was identified association between erythrocyte count and 1,3-butadiene exposure was observed (Hayes et al., 2000).No association between erythrocyte count and 1,3-butadiene exposure was identified in other studies of petrochemical workers (Tsai et al., 2005; Cowles et al., 1994) or styrene-butadiene workers (Checkoway and Williams, 1982). In another study, (Tsai et al., 2001), no association was identified for any hematological measure.	<p>Key findings:</p> <p>Epidemiology data on hematological effects of 1,3-butadiene are limited by small population sizes and evaluation of few hematological parameters. Two studies suggested associations between 1,3-butadiene and hemoglobin levels. None of the studies reported exposure-related alterations in erythrocyte counts.</p> <p>Overall judgment for hematologic effects based on human evidence:</p> <ul style="list-style-type: none">Indeterminate	
Evidence from in vivo mammalian animal studies considered for deriving toxicity values				
<p>Mouse studies ^a</p> <ul style="list-style-type: none">Exposed for 6, 12, or 24 weeks to 0 or 1,250 ppm (Thurmond et al., 1986). Evaluated spleen weights and histopathology of spleen and bone marrow. OQD = Low (6- and 12-week); OQD = Uninformative (24-week)Exposed 13 weeks to 0 or 980 ppm (Bevan et al., 1996). Evaluated hematology, spleen weight, and	<ul style="list-style-type: none">Hematologic changes consistent with anemia ^b observed in mice at 980 ppm for 13 weeks (Bevan et al., 1996) and ≥61.4 ppm (males) or ≥199 ppm (females) for 9 months (NTP, 1993). After 15 months, anemia was observed only at 619 ppm (NTP, 1993), possibly reflecting compensatory changes.	<ul style="list-style-type: none">In the 103-week mouse study, survival was decreased at ≥19.8 ppm, and no females at ≥199 ppm or males at 619 ppm survived to the end of exposure due to tumors (NTP, 1993), limiting interpretation of histopathology findings at 2-year sacrifice.	<p>Key findings:</p> <p>1,3-Butadiene produced dose- and duration-responsive effects on hematology parameters consistent with anemia in mice with supporting histopathological changes in the spleen and bone marrow. Exposed rats exhibited little evidence of hematological effects.</p>	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>histopathology of spleen and bone marrow. OQD = Medium</p> <ul style="list-style-type: none"> Exposed for 60–61 weeks to ≤1,236 ppm (NTP, 1984). Evaluated histopathology of spleen and bone marrow. OQD = High Exposed for up to 103 weeks to ≤619 ppm (NTP, 1993). Evaluated hematology (after 9 and 15 months), spleen weights, and histopathology of spleen and bone marrow. OQD = High Stop exposure experiments on relationship of cancer to product of concentration and duration: exposed to 199 ppm for 40 weeks, 312 ppm for 52 weeks, or 619 ppm for 13 or 26 weeks, and then monitored untreated until sacrifice at 103 weeks (NTP, 1993). Evaluated histopathology of spleen and bone marrow. OQD = Medium <p>Rat studies^a</p> <ul style="list-style-type: none"> Exposed for 13 weeks to 0 or 980 ppm (Bevan et al., 1996). Evaluated hematology, spleen weights, and histopathology of spleen and bone marrow. OQD = Medium Exposed for 13 weeks to ≤8,000 ppm (Crouch et al., 1979). Evaluated hematology, spleen 	<ul style="list-style-type: none"> Decreased spleen weights were observed in male and/or female mice at 1,250 ppm for 6 weeks or 980 ppm for 13 weeks (Bevan et al., 1996; Thurmond et al., 1986) and in females at ≥199 ppm for 9 months (NTP, 1993). After 15 months, spleen weights were increased among survivors at ≥199 ppm (females) or 619 ppm (males) (NTP, 1993). Histopathology changes in the spleen (atrophy, decreased cellularity, extramedullary hematopoiesis, erythroid hyperplasia) and/or bone marrow (atrophy, decreased cellularity) consistent with poorly regenerative macrocytic anemia were observed in mice exposed for short-term and subchronic durations (Bevan et al., 1996; NTP, 1993; Thurmond et al., 1986). In other studies of mice exposed by inhalation, macrocytic-megaloblastic anemia was observed (Irons et al., 1986a, b). Increased relative (but not absolute) spleen weight was observed among surviving male rats exposed to 8,000 ppm for 2 years (Hazleton Labs, 1981b). 	<ul style="list-style-type: none"> No treatment-related changes in hematology or spleen or bone marrow histopathology were observed in rats exposed to 980 ppm for 13 weeks (Bevan et al., 1996) or up to 8,000 ppm for up to 2 years (Hazleton Labs, 1981b). 	<p><i>Overall judgment for hematologic effects based on animal evidence:</i></p> <ul style="list-style-type: none"> Moderate 	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>weights, and histopathology of spleen. OQD = Uninformative</p> <ul style="list-style-type: none"> Exposed for 111 weeks (males) or 105 weeks (females) to 0, 1,000, or 8,000 ppm (Hazleton Labs, 1981b). Evaluated hematology (after 3, 6, 12, and 18 months), spleen weights, and histopathology of spleen and bone marrow. OQD = Medium <p>Other animal studies</p> <ul style="list-style-type: none"> Mice exposed for 6 weeks to 0 or 1,250 ppm (Irons et al., 1986a, b). 				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Evidence in mechanistic studies and supplemental information				
<p>Metabolism differences</p> <ul style="list-style-type: none"> Multiple studies demonstrate differences in metabolism across species, although estimates vary based on sex, dose, duration, and other factors. <p>Mechanism of action</p> <ul style="list-style-type: none"> Bone marrow genotoxicity and cytotoxicity were investigated in many studies of mice and two studies of rats exposed to 1,3-butadiene by inhalation (ATSDR, 2012; U.S. EPA, 2002b). Several studies evaluated genotoxicity in bone marrow or spleen of mice, rats, or hamsters exposed to metabolites of 1,3-butadiene by inhalation or i.p. injection (U.S. EPA, 2002b). Study of bone marrow stem cells exposed <i>in vitro</i> (Leiderman et al., 1986). Anemia may be associated with lymphohematopoietic cancers through bone marrow dysfunction. 	<ul style="list-style-type: none"> In mice exposed by inhalation, 1,3-butadiene exposure induced significant cytotoxicity and genotoxicity (SCEs, micronuclei, mutations) in bone marrow (ATSDR, 2012; U.S. EPA, 2002b). DEB and EB exposure induced genotoxicity in bone marrow and spleen of mice, hamsters, and rats (U.S. EPA, 2002b). EBD induced genotoxicity in bone marrow of mice (rats were not tested) (U.S. EPA, 2002b). Hemoglobin adducts have been observed in mice, rats, and humans (although it is unclear if these are merely markers of exposure) (ATSDR, 2012; U.S. EPA, 2002b). 1,3-butadiene induces lymphohematopoietic cancers in both mice and humans (ATSDR, 2012; U.S. EPA, 2002b). An <i>in vitro</i> study showed that 1,3-butadiene decreased the ratio of mature to immature bone marrow stem cells (Leiderman et al., 1986). 	<ul style="list-style-type: none"> Two studies in rats exposed to 1,3-butadiene by inhalation showed no increases in micronuclei or SCEs in bone marrow (ATSDR, 2012; U.S. EPA, 2002b). 	<p><i>Key findings:</i> Genotoxicity in bone marrow cells may contribute to 1,3-butadiene-induced hematological effects leading to anemia in mice. Other mechanistic and supporting information suggest that mechanisms underlying development of anemia should be present in humans.</p> <p><i>Overall judgment for hematologic effects based on mechanistic evidence:</i></p> <ul style="list-style-type: none"> Slight 	
<p>^a In all studies, animals were exposed for 6 hours/day, 5 days/week.</p> <p>^b Hematology changes consistent with anemia included decreased erythrocyte counts, hemoglobin concentration, and mean erythrocyte volume and increased Howell-Jolly bodies and mean cell volume</p>				

Table_Apx A-5. Evidence Integration for Carcinogenicity

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Lymphohematopoietic cancers				<p><i>Overall judgment for carcinogenicity based on integration of information across evidence streams:</i></p> <p>Based on EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), EPA concludes that 1,3-butadiene is carcinogenic to humans</p>
Evidence for lymphohematopoietic cancers in studies of exposed humans ^a				
<ul style="list-style-type: none">Retrospective cohort studies of SBR workers (n > 22,000 men and women) (Sathiakumar et al., 2021b; Sathiakumar et al., 2019; Sathiakumar et al., 2015; Sielken and Valdez-Flores, 2011; Graff et al., 2009; Sathiakumar and Delzell, 2009; Cheng et al., 2007; Delzell et al., 2006; Graff et al., 2005; Sathiakumar et al., 2005; Delzell et al., 2001; IISRP, 1999; Delzell et al., 1996; UAB, 1995a) Overall Quality Determination (OQD) = Medium; (Valdez-Flores et al., 2022; Sielken and Valdez-Flores, 2013; Sielken, 2007; Sielken and Valdez-Flores, 2001; IISRP, 1986) OQD = LowRetrospective cohort study of butadiene monomer workers (n = 2,800 men) (Divine and Hartman, 2001). OQD = MediumCase-control study of ALL and AML in children <6 years old, exposure based on ambient air monitoring data at station nearest maternal address during pregnancy (Heck et al., 2014). OQD = MediumCase-control study of ALL in children <5 years old, exposure based on modeled air concentration	<ul style="list-style-type: none">In a large cohort of SBR workers, exposure to 1,3-butadiene was associated with increased risk of mortality from leukemia in men and women. The risk increased with magnitude and duration of exposure and remained elevated after control for covariates including styrene exposure, consideration of alternative exposure assessments, and longer follow-up times (Valdez-Flores et al., 2022; Sathiakumar et al., 2021b; Sathiakumar et al., 2019; Sathiakumar et al., 2015; Sielken and Valdez-Flores, 2013, 2011; Graff et al., 2009; Cheng et al., 2007; Graff et al., 2005; Sathiakumar et al., 2005; Delzell et al., 2001; Sielken and Valdez-Flores, 2001; IISRP, 1999; Delzell et al., 1996; UAB, 1995a; IISRP, 1986).The most recent analyses with longest follow-up of this cohort reported an exposure-response trend for lymphoid leukemia but not myeloid leukemia, and trends for B-cell malignancies and NHL in some, but not all, analyses (Sathiakumar et al.,	<ul style="list-style-type: none">In butadiene monomer workers, the increased mortality from lymphohematopoietic cancer was not correlated with employment duration (Divine and Hartman, 2001).Classification of lymphohematopoietic cancers is complex and has changed over time.	<p><i>Key findings:</i> Extensive analyses of a large cohort of SBR workers document a clear association between occupational 1,3-butadiene exposure and exposure-related increases in mortality from leukemia. This finding is supported by studies of smaller cohorts and case-control studies of exposure to ambient air. Subtype analyses suggest the strongest association with lymphoid leukemias.</p> <p><i>Overall judgment for lymphohematopoietic system tumors based on human evidence:</i></p> <ul style="list-style-type: none">Robust	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment	
<p>at maternal address at birth (Symanski et al., 2016). OQD = Medium</p> <ul style="list-style-type: none">Case-control study of leukemia, Hodgkin's disease, and NHL in people <20 years old, exposure based on modeled air concentration at residence at time of diagnosis (Whitworth et al., 2008). OQD = Medium <p>Other human studies</p> <ul style="list-style-type: none">Authoritative reviews of older epidemiology data (ATSDR, 2012; IARC, 2008b; U.S. EPA, 2002b) have concluded that occupational exposure to 1,3-butadiene was associated with increased mortality from leukemia and NHL.One semiquantitative study assessed relative levels of male hematopoietic cancer nearby hydrocarbon processing centers in Canada (Simpson et al., 2013).	<p>2021b)</p> <ul style="list-style-type: none">In butadiene monomer workers, exposure to 1,3-butadiene was associated with increased mortality from lymphohematopoietic cancer (Divine and Hartman, 2001).In case-control studies of non-occupational populations, higher measured or modeled air concentration of 1,3-butadiene was associated with increased odds of leukemia, ALL, and/or AML (Symanski et al., 2016; Heck et al., 2014; Whitworth et al., 2008).Male hematopoietic cancers were elevated (no statistics provided) near a hydrocarbon processing center with high 1,3-butadiene levels (Simpson et al., 2013)				
Evidence for lymphohematopoietic cancers from <i>in vivo</i> mammalian animal studies ^b					
<p>Mouse studies</p> <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = HighStop-exposure studies (males only) (NTP, 1993). OQD = Medium≤10,000 ppm for single 2-hour exposure and followed for 2 years	<ul style="list-style-type: none">Significant dose-related trends and pairwise comparisons with concurrent controls for histiocytic sarcoma in male and female mice in one study (NTP, 1993). Significant increases remained after adjustment for survival. Significantly increased incidences were seen in male mice in all stop-exposure groups.	<ul style="list-style-type: none">No increase in hematopoietic system tumor incidence in rats indicating a lack of consistency across species (Hazleton Labs, 1981b).	<p><i>Key findings:</i> Exposure to 1,3-butadiene induced dose-related increased incidences of hematopoietic system cancers in male and female mice and these cancers were the primary cause of early deaths in exposed mice in both available studies. No increase in hematopoietic system cancer incidence was observed in exposed rats.</p>		

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>(Bucher et al., 1993).</p> <p>OQD = Low</p> <p>Rat studies</p> <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). <p>OQD = High</p>	<ul style="list-style-type: none">• Significant dose-related trends and pairwise comparisons with concurrent controls for malignant lymphoma/lymphocytic lymphoma in male and female mice in both studies and in all groups of the stop-exposure experiment (NTP, 1993, 1984). In the 103-week study, significant increases remained after adjustment for survival.• In both mouse studies, malignant lymphomas occurred as early as week 20-23 and were the primary cause of early death (NTP, 1993, 1984).		<p><i>Overall judgment for hematopoietic system tumors based on animal evidence:</i></p> <ul style="list-style-type: none">• Robust	
Bladder cancer				
Evidence for bladder cancer in studies of exposed humans ^a				
<ul style="list-style-type: none">• Retrospective cohort studies of SBR workers (n > 22,000 men and women) (Valdez-Flores et al., 2022; Sathiakumar et al., 2021a; Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; Sathiakumar et al., 2005; UAB, 1995a). <p>OQD = Medium (IISRP, 1986);</p> <p>OQD = Low</p> <ul style="list-style-type: none">• Retrospective cohort study of butadiene monomer workers (n = 2,800 men) (Divine and Hartman, 2001). <p>OQD = Medium</p>	<ul style="list-style-type: none">• In the most recent analyses with longest follow-up of SBR workers, exposure to 1,3-butadiene was associated with increased risk of mortality from bladder cancer. The increase exhibited an exposure-response trend (Valdez-Flores et al., 2022; Sathiakumar et al., 2021a; Sathiakumar et al., 2019).	<ul style="list-style-type: none">• The association with bladder cancer in SBR workers may be confounded by smoking, as data on smoking were not available for the cohort (Valdez-Flores et al., 2022; Sathiakumar et al., 2021a; Sathiakumar et al., 2019).• No association between 1,3-butadiene exposure and bladder cancer was observed in a smaller cohort of butadiene monomer workers (Divine and Hartman, 2001).	<p><i>Key findings:</i></p> <p>An association between 1,3-butadiene exposure and exposure-related increase in bladder cancer mortality was observed in SBR workers, but lack of data on smoking precluded consideration of this potential confounder.</p> <p><i>Overall judgment for bladder tumors based on human evidence:</i></p> <ul style="list-style-type: none">• Moderate	
Evidence for bladder cancer from <i>in vivo</i> mammalian animal studies ^b				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Mouse studies <ul style="list-style-type: none">• ≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High• ≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium Rat studies <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">• None	<ul style="list-style-type: none">• No increased incidences of tumors originating in bladder tissues were observed in mice or rats (NTP, 1993, 1984; Hazleton Labs, 1981b). Bladder tumors of lymphohematopoietic origin are considered under lymphohematopoietic cancers.• The 103-week study in mice examined bladders only if there were gross abnormalities (NTP, 1993).	<i>Key findings:</i> No association between 1,3-butadiene exposure and bladder tumors in high- and medium-quality studies of mice and rats. <i>Overall judgment for bladder tumors based on animal evidence:</i> <ul style="list-style-type: none">• Indeterminate	
Central nervous system cancer				
Evidence for central nervous system cancer in studies of exposed humans ^a				
<ul style="list-style-type: none">• Retrospective cohort studies of SBR workers (n>22,000 men and women) (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; Sathiakumar et al., 2005). OQD = Medium (IISRP, 1986); OQD = Low• Retrospective cohort study of butadiene monomer workers (n = 2,800 men) (Divine and Hartman, 2001). OQD = Medium• Ecological study of central nervous system tumors in children and modeled air concentration at residence at time of diagnosis (Danysh et al., 2015). OQD = Medium	<ul style="list-style-type: none">• Increased incidence rate ratio for astrocytomas other than juvenile pilocytic astrocytoma (JPA) associated with modeled 1,3-butadiene concentrations in quartile 2 (Q2) and Q3, but not Q4 (Danysh et al., 2015).• In another human study, increased odds of primitive neuroectodermal tumors were associated with 1,3-butadiene in ambient air during pregnancy and first year of life (Von Ehrenstein et al., 2016).	<ul style="list-style-type: none">• In the study by (Danysh et al., 2015), exposure misclassification is likely given the use of census tract-level estimates to represent individual exposure. In addition, exposure estimates were assigned based on address at time of diagnosis.• In the study by (Danysh et al., 2015), confounding is likely because exposure estimates were higher near major metropolitan areas but, urban/rural status was not evaluated as a potential confounder; and the modeled 1,3-butadiene concentration was highly	<i>Key findings:</i> An association between modeled 1,3-butadiene concentration and non-JPA astrocytomas in children was reported in an ecological study but not in the highest quartile of exposure. The study was limited by its design as well as lack of adjustment for important confounders and co-exposures. <i>Overall judgment for brain tumors based on human evidence:</i> <ul style="list-style-type: none">• Indeterminate	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Other human studies <ul style="list-style-type: none">Case-control study of central nervous system tumors in children, exposure based on ambient air monitoring data at station nearest to residence during pregnancy and first year of life (Von Ehrenstein et al., 2016).		<p>correlated with modeled concentrations of other chemicals but confounding by co-exposures was not evaluated (Danysh et al., 2015).</p> <ul style="list-style-type: none">No association was observed between 1,3-butadiene exposure and astrocytomas in the study by (Von Ehrenstein et al., 2016)No association was observed between 1,3-butadiene exposure and central nervous system cancer and/or central nervous system cancer mortality in occupational populations (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; Sathiakumar et al., 2005; Divine and Hartman, 2001; IISRP, 1986).Increased odds of astrocytoma or medullablastoma were not associated with 1,3-butadiene in ambient air during pregnancy and first year of life (Von Ehrenstein et al., 2016).		
Evidence for central nervous system cancer from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High	<ul style="list-style-type: none">Significant dose-related trend for increased incidence of brain glial cell tumors in male rats (Hazleton Labs, 1981b).	<ul style="list-style-type: none">No statistically significant pairwise comparisons with concurrent control group for male rats. No historical	<i>Key findings:</i> Brain glial cell tumors were observed in exposed male rats with dose-related trend and low	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<ul style="list-style-type: none">• ≤619 ppm for 103 weeks (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium <p>Rat studies</p> <ul style="list-style-type: none">• ≤8,000 ppm for 105-111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">• In the 60-week study, brain gliomas were identified in two male mice at 619 ppm and one male mouse at 1260 ppm, and an ependymoma of the brain was observed in 1 male mouse at 619 ppm (NTP, 1984).• In the 103-week study, malignant glioma was observed in 1 male mouse at 199 ppm (NTP, 1993).• In the stop-exposure studies at 619 ppm, malignant gliomas were found in two male mice after 13 weeks exposure and in one male mouse after 26 weeks, and malignant neuroblastomas were identified in two male mice after 13 weeks (NTP, 1993).• Gliomas and neuroblastomas are rare in B6C3F1 mice and were not seen in historical controls according to (NTP, 1993).	<p>control data were reported (Hazleton Labs, 1981b).</p> <ul style="list-style-type: none">• No brain glial cell tumors were observed in female rats (Hazleton Labs, 1981b). No gliomas, ependymomas, or neuroblastomas were observed in female mice (NTP, 1993), indicating a lack of consistency across sexes.	<p>incidences of gliomas, neuroblastomas, and ependymoma in exposed male B6C3F1 mice. These tumors are rare in B6C3F1 mice.</p> <p><i>Overall judgment for brain tumors based on animal evidence:</i></p> <ul style="list-style-type: none">• Slight	
Gastrointestinal tumors				
Evidence for gastrointestinal tumors in studies of exposed humans ^a				
<ul style="list-style-type: none">• Retrospective cohort studies of SBR workers (n > 22,000 men and women) (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; Sathiakumar et al., 2005; UAB, 1995a). OQD = Medium (IISRP, 1986); OQD = Low• Retrospective cohort study of butadiene monomer workers (n =	<ul style="list-style-type: none">• In a retrospective cohort study of a small group of butadiene monomer workers, employment in the rubber reserve unit for at least 2 years was associated with increased mortality from stomach cancer. Exposure levels were not quantified. (Ward et al., 1996a; Ward et al., 1995).	<ul style="list-style-type: none">• In larger retrospective cohort studies of SBR workers (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; Sathiakumar et al., 2005; UAB, 1995a; IISRP, 1986) and butadiene monomer workers (Divine and Hartman, 2001), exposure to 1,3-butadiene	<p><i>Key findings:</i> The weight of evidence from available studies does not support an association with stomach cancer.</p> <p><i>Overall judgment for stomach cancer based on human evidence:</i></p> <ul style="list-style-type: none">• Indeterminate	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment	
2,800 men) (Divine and Hartman, 2001). OQD = Medium <ul style="list-style-type: none">Retrospective cohort study of butadiene monomer workers (n = 364 men) (Ward et al., 1996a; Ward et al., 1995).		was not associated with mortality from cancers of the gastrointestinal tract.			
Evidence for gastrointestinal tumors from <i>in vivo</i> mammalian animal studies ^b					
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks (NTP, 1993). OQD = HighStop-exposure studies (males only) (NTP, 1993). OQD = Medium≤10,000 ppm for single 2-hour exposure and followed for 2 years (Bucher et al., 1993). OQD = Low Rat studies <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">Significant dose-related trends and/or pairwise comparisons with concurrent controls for forestomach papilloma or carcinoma incidences in male and female mice in two studies (NTP, 1993, 1984). In the 103-week study, significant increases remained after adjustment for survival.Significantly increased incidences of forestomach papilloma or carcinoma were also seen in male mice in stop-exposure studies (NTP, 1993).	<ul style="list-style-type: none">No increase in forestomach tumor incidence in rats, indicating a lack of consistency across species (Hazleton Labs, 1981b).	<i>Key findings:</i> Exposure to 1,3-butadiene induced increased incidences of forestomach papilloma or carcinoma in male and female mice. No increase in forestomach tumor incidence was observed in exposed rats. <i>Overall judgment for forestomach tumors based on animal evidence:</i> <ul style="list-style-type: none">Moderate		
Germ cell cancers					
Evidence for germ cell cancers in studies of exposed humans ^a					
<ul style="list-style-type: none">Case-control study of germ cell cancers in children; exposure based on ambient air monitoring data at station nearest to residence during pregnancy (Hall et al., 2019). OQD = Medium	<ul style="list-style-type: none">Increased odds of all germ cell tumors and yolk sac tumors associated with 1,3-butadiene concentration in ambient air during second trimester (Hall et al., 2019).	<ul style="list-style-type: none">No associations identified for germ cell tumors or yolk sac tumors with 1,3-butadiene concentration in ambient air during first or third trimester (Hall et al., 2019).	<i>Key findings:</i> In a single study, an association was observed between 1,3-butadiene concentration in ambient air during pregnancy and all germ cell tumors and yolk sac tumors in children. No		

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
		<ul style="list-style-type: none">One known risk factor for germ cell tumors, cryptorchidism, was not accounted for in the study because data were not available for the study population.	<p>other studies of this endpoint were located.</p> <p><i>Overall judgment for germ cell tumors based on human evidence:</i></p> <ul style="list-style-type: none">Indeterminate	
Evidence for germ cell cancers from <i>in vivo</i> mammalian animal studies ^b				
No data. <i>Overall judgment for germ cell tumors based on animal evidence:</i> Indeterminate				
Lung cancer				
Evidence for lung cancer in studies of exposed humans ^a				
<ul style="list-style-type: none">Retrospective cohort studies of SBR workers (n > 22,000 men and women) (Sathiakumar et al., 2019; Sathiakumar et al., 2009; Sathiakumar and Delzell, 2009; Sathiakumar et al., 2005; UAB, 1995a). OQD = Medium (IISRP, 1986); OQD = LowRetrospective cohort study of butadiene monomer workers (n = 2,800 men) (Divine and Hartman, 2001). OQD = MediumEcological study of lung cancer incidence using TRI data for exposure and SEER data for outcome (Luo et al., 2011). OQD = LowNested case-control study of smokers in cohort of men in Shanghai, exposure based on urinary monohydroxybutyl mercapturic acid (MHBMA) (Yuan et al., 2012). OQD = Medium	<ul style="list-style-type: none">In a large cohort of SBR workers, exposure to 1,3-butadiene was associated with mortality from lung cancer among female workers (Sathiakumar et al., 2019; Sathiakumar et al., 2009; Sathiakumar and Delzell, 2009).	<ul style="list-style-type: none">In female SBR workers, there was no exposure-response trend for lung cancer, and the analyses were not adjusted for smoking. The study authors indicated that indirect adjustment for smoking partially explained the increase in mortality among female workers (Sathiakumar et al., 2019).No association was observed between 1,3-butadiene exposure and lung cancer in male SBR workers (Sathiakumar et al., 2019; Sathiakumar et al., 2009; Sathiakumar et al., 2005; Divine and Hartman, 2001; UAB, 1995a; IISRP, 1986).General population studies provided limited information on lung cancer due to ecological study	<p><i>Key findings:</i> An association between 1,3-butadiene exposure and lung cancer mortality was observed in female SBR workers, but not male SBR workers. The observed association lacked a dose-response relationship and may have been confounded by smoking.</p> <p><i>Overall judgment for lung tumors based on human evidence:</i></p> <ul style="list-style-type: none">Indeterminate	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
		design (Luo et al., 2011) or analysis limited to male smokers (Yuan et al., 2012).		
Evidence for lung cancer from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">• ≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High• ≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High Stop-exposure studies (males only) (NTP, 1993). OQD = Medium• ≤10,000 ppm for single 2-hour exposure and followed for 2 years (Bucher et al., 1993). OQD = Low Rat studies <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">• Significant dose-related trends and pairwise comparisons with concurrent controls for alveolar/bronchiolar adenoma, adenocarcinoma, and/or carcinoma in male and female mice in two studies (NTP, 1993, 1984). In the 103-week study, incidences exceeded the upper limit for historical control ranges, and significant increases remained after adjustment for survival. Significantly increased incidences were also seen in male mice in all stop-exposure groups (NTP, 1993).	<ul style="list-style-type: none">• In the 103-week study, the incidence of alveolar/bronchiolar adenoma, adenocarcinoma, or carcinoma incidence in concurrent control males exceeded the upper limit for historical controls (NTP, 1993).• No increase in lung tumor incidence in rats, indicating a lack of consistency across species (Hazleton Labs, 1981b).	<i>Key findings:</i> Exposure to 1,3-butadiene induced increased incidences of lung tumors in male and female mice. No increase in lung tumor incidence was observed in exposed rats. <i>Overall judgment for lung tumors based on animal evidence:</i> <ul style="list-style-type: none">• Moderate	
Ocular tumors				
Evidence for ocular tumors in studies of exposed humans ^a				
<ul style="list-style-type: none">• Retrospective cohort study of male SBR workers (IISRP, 1986). OQD = Low• Case-control study of retinoblastoma in children, exposure based on ambient air monitoring data at station nearest to residence (Heck et al., 2015). OQD = Medium	<ul style="list-style-type: none">• Increased odds of retinoblastoma associated with 1,3-butadiene concentration in ambient air during pregnancy (Heck et al., 2015).	<ul style="list-style-type: none">• No association between 1,3-butadiene exposure and mortality from ocular tumors in large cohort of male SBR workers (IISRP, 1986).	<i>Key findings:</i> In a single study, an association was observed between 1,3-butadiene concentration in ambient air during pregnancy and retinoblastoma in children. No other studies of this endpoint were located. <i>Overall judgment for ocular tumors based on human evidence:</i>	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
			<ul style="list-style-type: none">Indeterminate	
Evidence for ocular tumors from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks (NTP, 1993). OQD = HighStop-exposure studies (males only) (NTP, 1993). OQD = Medium Rat studies <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). QD = High	<ul style="list-style-type: none">None	<ul style="list-style-type: none">No increased incidences of ocular tumors were observed in mice or rats (NTP, 1993, 1984; Hazleton Labs, 1981b). Harderian gland tumors are considered separately.Available studies in mice examined the eyes for histopathology only if there were gross abnormalities.	<i>Key findings:</i> No association between 1,3-butadiene exposure and ocular tumors in high- and medium-quality studies of mice and rats. <i>Overall judgment for bladder tumors based on animal evidence:</i> <ul style="list-style-type: none">Indeterminate	
Liver tumors				
Evidence for liver tumors in studies of exposed humans ^a				
<ul style="list-style-type: none">Retrospective cohort studies, occupational populations (men and women) (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007; Sathiakumar et al., 2005; UAB, 1995a). OQD = Medium (IISRP, 1986). OQD = Low	<ul style="list-style-type: none">None	<ul style="list-style-type: none">No association between 1,3-butadiene exposure and liver cancer in occupational studies of men and women (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007; Sathiakumar et al., 2005; UAB, 1995a; IISRP, 1986).	<i>Key findings:</i> No association between 1,3-butadiene exposure and liver tumors in several medium-quality and one low-quality studies. <i>Overall judgment for liver tumors based on human evidence:</i> <ul style="list-style-type: none">Indeterminate	
Evidence for liver tumors from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High	<ul style="list-style-type: none">Significant dose-related trend (NTP, 1984) and pairwise comparisons with concurrent controls for hepatocellular	<ul style="list-style-type: none">No increase in liver tumor incidence in rats indicating a lack of consistency across	<i>Key findings:</i> Exposure to 1,3-butadiene induced increased incidences of hepatocellular adenomas or	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<ul style="list-style-type: none">• ≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium• ≤10,000 ppm for single 2-hour exposure and followed for 2 years (Bucher et al., 1993). OQD = Low <p>Rat studies</p> <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">• adenoma and/or carcinoma in female mice in two studies (NTP, 1993, 1984).• Survival-adjusted incidences were significantly increased in both male and female mice in the 103-week study (NTP, 1993).	<ul style="list-style-type: none">• species (Hazleton Labs, 1981b).	<ul style="list-style-type: none">• carcinomas in male and female mice. No increase in liver tumor incidence was observed in exposed rats. <p><i>Overall judgment for liver tumors based on animal evidence:</i></p> <ul style="list-style-type: none">• Moderate	
Mammary gland/Breast tumors/Breast cancer				
Evidence for mammary gland tumors in studies of exposed humans ^a				
<ul style="list-style-type: none">• Retrospective cohort follow-up studies, occupational populations (n = 4,863 women in each study), quantitative exposure assessment (Sathiakumar and Delzell, 2009; UAB, 2007). OQD=Medium.• Retrospective cohort study, occupational population (n = 17,924 men, 4,861 women), qualitative and quantitative exposure assessment (Sathiakumar et al., 2019). OQD = Medium• General population, cohort study (n = 49,718 women), quantitative exposure assessment (Niehoff et al., 2019). OQD = Medium• One cohort epidemiological studies investigated the association between 1,3-Butadiene exposure	<ul style="list-style-type: none">• Heck et al. (2024) studied 48,665 California women and found a statistical significant adjusted Hazard Ratio (HR) for breast cancer risk of 1.18, 95% CI= 1.13-1.23.	<ul style="list-style-type: none">• No association between 1,3-butadiene exposure and breast cancer mortality in occupational studies (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007).• No elevated risk for overall breast cancer or estrogen receptor positive (ER+) invasive breast cancer (Niehoff et al., 2019).• In the SBR cohort, two publications (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2007) investigated the standardized mortality ratio (SMR) of breast cancer, but they did not find	<p><i>Key findings:</i> No association between 1,3-butadiene exposure and breast cancer in several medium-quality studies.</p> <p><i>Overall judgment for mammary gland tumors based on human evidence:</i></p> <ul style="list-style-type: none">• Indeterminate	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment	
and breast cancer (n = 48,665 women), quantitative exposure assessment (Heck et al., 2024). OQD = Medium <ul style="list-style-type: none">One nested case-control of a population-based cohort epidemiological studies investigated the association between 1,3-Butadiene exposure and breast cancer, (n = 574 cases and 2295 controls) quantitative exposure assessment (Ellis et al., 2025). OQD = Medium		significantly higher breast mortality (SMR <100). A nested case-control study (Ellis et al., 2025) found no statistically significant odds ratio (OR) of overall breast cancer risk for Arkansas women.			
Evidence for mammary gland tumors from <i>in vivo</i> mammalian animal studies ^b					
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks (NTP, 1993). OQD = High≤10,000 ppm for single 2-hour exposure and followed for 2 years (Bucher et al., 1993). OQD = Low Rat studies <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">Significant dose-related trends and/or pairwise comparisons with concurrent control for mammary gland acinar cell carcinoma in female mice (NTP, 1984) and for mammary gland adenoacanthoma, carcinoma, or malignant mixed tumor in female mice (NTP, 1993). In the 103-week study, significant increases in adenoacanthoma or carcinoma incidence remained after adjustment for survival.Significant dose-related trends and pairwise comparisons with concurrent control for increased incidences of benign and total (benign + malignant) mammary gland tumors in female rats (Hazleton Labs, 1981b).	<ul style="list-style-type: none">Historical control incidences were not reported for mice or rats.	<i>Key findings:</i> Exposure to 1,3-butadiene induced increased incidences of mammary gland tumors in female mice and female rats. <i>Overall judgment for mammary gland tumors based on animal evidence:</i> <ul style="list-style-type: none">Moderate		
Ovarian tumors					

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Evidence for ovarian tumors in studies of exposed humans ^a				
<ul style="list-style-type: none">Retrospective cohort studies, (n = 4,863 women/study), quantitative exposure assessment (Sathiakumar and Delzell, 2009; UAB, 2007). OQD = MediumRetrospective cohort study, occupational population (n = 4,861 women), qualitative and quantitative exposure assessment (Sathiakumar et al., 2019). OQD = Medium	<ul style="list-style-type: none">None	<ul style="list-style-type: none">No association between 1,3-butadiene exposure and ovarian tumors in workers (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007).	<p><i>Key findings:</i> No association between 1,3-butadiene exposure and ovarian tumors in three medium-quality occupational studies.</p> <p><i>Overall judgment for ovarian tumors based on human evidence:</i></p> <ul style="list-style-type: none">Indeterminate	
Evidence for ovarian tumors from <i>in vivo</i> mammalian animal studies ^b				
<p>Mouse studies</p> <ul style="list-style-type: none">≤1,250 ppm for 61 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High≤10,000 ppm for single 2-hour exposure and followed for 2 years (Bucher et al., 1993). OQD = Low <p>Rat studies</p> <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">Significant dose-related trends and pairwise comparisons with concurrent control for ovarian granulosa cell tumors in female mice in two studies (NTP, 1993, 1984). In the 103-week study, significant increases remained after adjustment for survival, and survival-adjusted rates exhibited monotonicity with exposure (NTP, 1993).	<ul style="list-style-type: none">No increase in ovarian tumor incidence in female rats, indicating a lack of consistency across species (Hazleton Labs, 1981b).	<p><i>Key findings:</i> Exposure to 1,3-butadiene induced increased incidences of ovarian granulosa cell tumors in mice. No increase in ovarian tumor incidence was observed in exposed rats.</p> <p><i>Overall judgment for ovarian tumors based on animal evidence:</i></p> <ul style="list-style-type: none">Slight	
Pancreatic tumors				
Evidence for pancreatic tumors in studies of exposed humans ^a				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<ul style="list-style-type: none">Retrospective cohort studies, occupational populations (men and women) (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007; Sathiakumar et al., 2005; Divine and Hartman, 2001; UAB, 1995a).OQD = Medium (IISRP, 1986).OQD = Low	<ul style="list-style-type: none"><u>None</u>	<ul style="list-style-type: none">No association between 1,3-butadiene exposure and pancreatic cancer in male or female workers (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007; Sathiakumar et al., 2005; Divine and Hartman, 2001; UAB, 1995a; IISRP, 1986).	<p><i>Key findings:</i> No association between 1,3-butadiene exposure and pancreatic cancer in several medium- and low-quality studies.</p> <p><i>Overall judgment for pancreatic tumors based on human evidence:</i></p> <ul style="list-style-type: none">Indeterminate	
Evidence for pancreatic tumors from <i>in vivo</i> mammalian animal studies ^b				
<p>Mouse studies</p> <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984).OQD = High≤619 ppm for 103 weeks (NTP, 1993).OQD = HighStop-exposure studies (males only) (NTP, 1993).OQD = Medium <p>Rat studies</p> <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b).OQD = High	<ul style="list-style-type: none">Significant dose-related trend and pairwise comparison with concurrent control for increased incidence of pancreatic exocrine adenomas in male rats (Hazleton Labs, 1981b).	<ul style="list-style-type: none">No increase in pancreatic tumor incidence in mice (NTP, 1993, 1984), indicating a lack of consistency across species.No increase in pancreatic tumor incidence in female rats indicating a lack of consistency across sexes of rat (Hazleton Labs, 1981b).Historical control incidences were not reported (Hazleton Labs, 1981b).	<p><i>Key findings:</i> Exposure to 1,3-butadiene induced increased incidences of pancreatic exocrine adenomas in male rats; no increase in pancreatic tumor incidence was observed in exposed female rats or in exposed male or female mice.</p> <p><i>Overall judgment for pancreatic tumors based on animal evidence:</i></p> <ul style="list-style-type: none">Slight	
Subcutaneous skin tumors				
Evidence for subcutaneous skin tumors in studies of exposed humans ^a				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<ul style="list-style-type: none">Retrospective cohort studies, occupational populations (men) (Divine and Hartman, 2001; UAB, 1995a).OQD = Medium (IISRP, 1986);OQD = Low	<ul style="list-style-type: none"><u>None</u>	<ul style="list-style-type: none">No association between 1,3-butadiene exposure and skin cancer in male workers (Divine and Hartman, 2001; UAB, 1995a; IISRP, 1986).	<p><i>Key findings:</i> No association between 1,3-butadiene exposure and skin tumors in two medium-quality and one low-quality studies.</p> <p><i>Overall judgment for skin tumors based on human evidence:</i></p> <ul style="list-style-type: none">Indeterminate	
Evidence for subcutaneous skin tumors from <i>in vivo</i> mammalian animal studies ^b				
<p>Mouse studies</p> <ul style="list-style-type: none">≤619 ppm for 103 weeks (NTP, 1993).OQD = HighStop-exposure studies (males only) (NTP, 1993).OQD = Medium <p>Rat studies</p> <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b).OQD = High	<ul style="list-style-type: none">Significant dose-related trend and pairwise comparison with concurrent control for increased incidences of subcutaneous skin hemangiosarcoma and neurofibrosarcoma or sarcoma in female mice. Incidences in several groups exceeded the upper limits of the respective historical control ranges (NTP, 1993).	<ul style="list-style-type: none">No increase in subcutaneous skin tumor incidence in male mice in two studies (NTP, 1993, 1984).No increase in subcutaneous skin tumor incidence in rats indicating a lack of consistency across species (Hazleton Labs, 1981b).	<p><i>Key findings:</i> Increased incidences of subcutaneous skin tumors were observed in female mice exposed to 1,3-butadiene. No increase in subcutaneous skin tumor incidence was observed in exposed male mice or in male or female rats.</p> <p><i>Overall judgment for subcutaneous skin tumors based on animal evidence:</i></p> <ul style="list-style-type: none">Slight	
Thyroid tumors				
Evidence for thyroid tumors in studies of exposed humans ^a				
<ul style="list-style-type: none">Retrospective cohort study, occupational population (n > 12,000 men), qualitative exposure assessment (IISRP, 1986).OQD = Low	<ul style="list-style-type: none"><u>None</u>	<ul style="list-style-type: none">No association between 1,3-butadiene exposure and thyroid tumors in male workers (IISRP, 1986).	<p><i>Key findings:</i> None</p> <p><i>Overall judgment for thyroid tumors based on human evidence:</i></p> <ul style="list-style-type: none">Indeterminate	
Evidence for thyroid tumors from <i>in vivo</i> mammalian animal studies ^b				

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Mouse studies <ul style="list-style-type: none">• ≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High• ≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium Rat studies <p>≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High</p>	<ul style="list-style-type: none">• Significant dose-related trend and pairwise comparison with concurrent control for increased incidence of thyroid follicular cell adenomas in female rats (Hazleton Labs, 1981b).	<ul style="list-style-type: none">• No increase in thyroid tumor incidence in male rats (Hazleton Labs, 1981b), indicating a lack of consistency across sexes.• No increase in thyroid tumor incidence in mice (NTP, 1993, 1984), indicating a lack of consistency across species.	<p><i>Key findings:</i> Increased incidences of thyroid tumors were observed in female rats. No increase in thyroid tumor incidence was observed in exposed male rats or mice of either sex.</p> <p><i>Overall judgment for thyroid tumors based on animal evidence:</i></p> <ul style="list-style-type: none">• Slight	
Uterine tumors				
Evidence for uterine tumors in studies of exposed humans ^a				
Retrospective cohort studies, occupational populations (women), qualitative and quantitative exposure assessment (Sathiakumar et al., 2019 ; Sathiakumar and Delzell, 2009 ; UAB, 2007). OQD = Medium	<ul style="list-style-type: none">• <u>None</u>	<ul style="list-style-type: none">• No association between 1,3-butadiene exposure and uterine tumors in occupational studies in women (Sathiakumar et al., 2019; Sathiakumar and Delzell, 2009; UAB, 2007).	<p><i>Key findings:</i> No association between 1,3-butadiene exposure and uterine tumors in three medium-quality studies.</p> <p><i>Overall judgment for uterine tumors based on human evidence:</i></p> <ul style="list-style-type: none">• Indeterminate	
Evidence for uterine tumors from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">• ≤1,250 ppm for 61 weeks (NTP, 1984). OQD = High• ≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High	<ul style="list-style-type: none">• Significant dose-related trend for increased incidence of uterine sarcomas in female rats (Hazleton Labs, 1981b).	<ul style="list-style-type: none">• No significant pairwise comparisons with concurrent control for uterine sarcomas in female rats. No historical control data reported for uterine tumors in female rats (Hazleton Labs, 1981b).	<p><i>Key findings:</i> A dose-related trend for increased uterine tumors without significant pairwise comparisons was seen in rats. No increase in uterine tumor incidence was observed in exposed mice.</p>	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Rat studies <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High		<ul style="list-style-type: none">• No increase in uterine tumor incidence in female mice (NTP, 1993, 1984), indicating a lack of consistency across species.	<i>Overall judgment for uterine tumors based on animal evidence:</i> <ul style="list-style-type: none">• Indeterminate	
Heart hemangiosarcomas				
Evidence for heart hemangiosarcomas in studies of exposed humans ^a				
No data. <i>Overall judgment for heart hemangiosarcomas based on human evidence:</i> Indeterminate				
Evidence for heart hemangiosarcomas from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">• ≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High• ≤619 ppm for 103 weeks ^c (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium• ≤10,000 ppm for single 2-hour exposure and followed for 2 years (Bucher et al., 1993). OQD = Low	<ul style="list-style-type: none">• Significant dose-related trends and pairwise comparisons with concurrent controls for heart hemangiosarcoma in male and female mice in two studies (NTP, 1993, 1984). Significant increases remained after adjustment for survival. Significantly increased incidences were seen in male mice in all stop-exposure groups (NTP, 1993).• Heart hemangiosarcomas are rare in B6C3F1 and were not seen in historical controls according to (NTP, 1993).• In the 103-week study, heart hemangiosarcomas were the second-most common cause of early death (NTP, 1993).	<ul style="list-style-type: none">• No increase in heart tumor incidence in rats, indicating a lack of consistency across species (Hazleton Labs, 1981b).	<i>Key findings:</i> Exposure to 1,3-butadiene induced dose-related increased incidences of heart hemangiosarcomas in male and female mice and these cancers were the second-most common cause of early deaths in exposed mice in both studies. No increase in heart tumor incidence was observed in exposed rats. <i>Overall judgment for heart tumors based on animal evidence:</i> <ul style="list-style-type: none">• Robust	
Harderian gland tumors				
Evidence for harderian gland tumors in studies of exposed humans ^a				
<i>Harderian gland tumors are not relevant to humans.</i>				
Evidence for harderian gland tumors from <i>in vivo</i> mammalian animal studies ^b				
Mouse studies	<ul style="list-style-type: none">• Significant dose-related trend and pairwise comparisons with	<ul style="list-style-type: none">• No increase in Harderian gland tumor incidence in	<i>Key findings:</i>	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<ul style="list-style-type: none">• ≤619 ppm for 103 weeks (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium <p>Rat studies</p> <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). QD = High	<p>concurrent controls for Harderian gland adenoma or carcinoma in male mice. Significant increases remained after adjustment for survival. Significantly increased incidences were seen in male mice in all stop-exposure groups (NTP, 1993).</p> <ul style="list-style-type: none">• Survival-adjusted incidences of Harderian gland adenoma or carcinoma were significantly increased (pairwise relative to concurrent control) in female mice (NTP, 1993).	<p>rats, indicating a lack of consistency across species (Hazleton Labs, 1981b).</p> <ul style="list-style-type: none">• The concurrent female mouse control incidence exceeded the upper limit of historical control incidence (NTP, 1993).	<p>Exposure to 1,3-butadiene induced increased incidences of Harderian gland adenoma or carcinoma in male and female mice. No increase in Harderian gland tumor incidence was observed in exposed rats.</p> <p><i>Overall judgment for Harderian Gland tumors based on animal evidence:</i></p> <ul style="list-style-type: none">• Moderate	
Preputial gland tumors				
Evidence for preputial gland tumors in studies of exposed humans ^a				
No data and questionable relevance to humans. <i>Overall judgment for testicular tumors based on human evidence:</i> Indeterminate				
Evidence for preputial gland tumors from <i>in vivo</i> mammalian animal studies ^b				
<p>Mouse studies</p> <ul style="list-style-type: none">• ≤619 ppm for 103 weeks (NTP, 1993). OQD = High• Stop-exposure studies (males only) (NTP, 1993). OQD = Medium	<ul style="list-style-type: none">• Significant pairwise comparisons with concurrent controls for preputial gland adenoma or carcinoma in mice in the stop-exposure experiments with highest cumulative exposures (NTP, 1993).• In the 103-week experiment, the survival-adjusted incidence for preputial gland carcinoma was significantly increased compared to concurrent controls.• Preputial gland carcinomas are rare in B6C3F1 mice and were not observed in historical	<ul style="list-style-type: none">• Data on preputial gland tumors are from a single study in one species (NTP, 1993).	<p><i>Key findings:</i></p> <p>Increased incidences of preputial gland adenomas and/or carcinomas were observed in mice exposed to higher cumulative levels of 1,3-butadiene in a single study. There are no data on this endpoint for rats.</p> <p><i>Overall judgment for preputial gland tumors based on animal evidence:</i></p> <ul style="list-style-type: none">• Slight	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
	controls according to (NTP, 1993).			
Testicular tumors				
Evidence for testicular tumors in studies of exposed humans ^a				
• No data. Overall judgment for testicular tumors based on human evidence: Indeterminate				
Evidence for testicular tumors from in vivo mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks (NTP, 1993). OQD = High Stop-exposure studies (males only) (NTP, 1993). OQD = Medium Rat studies <ul style="list-style-type: none">≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">Significant dose-related trend and pairwise comparison with concurrent control for testicular Leydig cell tumors in male rats (Hazleton Labs, 1981b).	<ul style="list-style-type: none">No increase in testicular tumor incidence in male mice (NTP, 1993, 1984), indicating a lack of consistency across species.	<i>Key findings:</i> Increased incidences of testicular Leydig cell tumors were observed in rats. No increase in testicular tumor incidence was observed in exposed mice. <i>Overall judgment for testicular tumors based on animal evidence:</i> <ul style="list-style-type: none">Slight	
Zymbal gland tumors				
Evidence for Zymbal gland tumors in studies of exposed humans ^a				
Zymbal gland tumors are not relevant to humans.				
Evidence for Zymbal gland tumors from in vivo mammalian animal studies ^b				
Mouse studies <ul style="list-style-type: none">≤1,250 ppm for 60–61 weeks (NTP, 1984). OQD = High≤619 ppm for 103 weeks (NTP, 1993). OQD = High Stop-exposure studies (males only) (NTP, 1993). OQD = Medium	<ul style="list-style-type: none">Significant dose-related trend for increased incidence of Zymbal gland carcinomas in female rats (Hazleton Labs, 1981b).Low incidences (1–2 mice) of Zymbal gland adenomas and carcinomas were seen in male and/or female mice in all mouse studies including the	<ul style="list-style-type: none">No significant pairwise comparisons for Zymbal gland carcinomas in female rats. No increase in tumor incidence in male rats. Historical control incidences were not reported (Hazleton Labs, 1981b).	<i>Key findings:</i> Zymbal gland tumors were observed in female rats with dose-related trend and at low incidences in male and female B6C3F1 mice. These tumors are rare in B6C3F1 mice.	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
Rat studies <ul style="list-style-type: none">• ≤8,000 ppm for 105–111 weeks (Hazleton Labs, 1981b). OQD = High	<ul style="list-style-type: none">• stop-exposure studies (NTP, 1993, 1984).• Zymbal gland tumors are rare in B6C3F1 mice and were not seen in historical controls according to (NTP, 1993)	<ul style="list-style-type: none">• Tumor incidences in mice were not significantly increased over concurrent controls at any exposure level and there were no significant dose-related trends (NTP, 1993, 1984).	<i>Overall judgment for Zymbal gland tumors based on animal evidence:</i> <ul style="list-style-type: none">• Slight	
Evidence in mechanistic studies and supplemental information				
<i>Mechanistic evidence in lymphohematopoietic cells and tissues</i>				
Mutagenic Mode-of-Action (MOA) Key Events (KEs) KE1 Bioactivation to DNA reactive metabolites <ul style="list-style-type: none">• Studies of 1,3-butadiene metabolism in multiple species (ATSDR, 2012; Albertini et al., 2010; Kirman et al., 2010a; U.S. EPA, 2002a; Himmelstein et al., 1997).• Genotoxicity studies in lymphohematopoietic tissues using metabolites (ATSDR, 2012; Swenberg et al., 2011; U.S. EPA, 2002a; Cochrane and Skopek, 1994). KE2 Formation of DNA adducts <ul style="list-style-type: none">• Studies demonstrating DNA adduct formation <i>in vitro</i> and in lymphohematopoietic tissues following <i>in vivo</i> exposure (ATSDR, 2012; U.S. EPA, 2002a).• Studies of DNA adducts in lymphohematopoietic cells from occupationally exposed workers (ATSDR, 2012; U.S. EPA, 2002a).	<ul style="list-style-type: none">• Interspecies variation in cancer susceptibility is consistent with documented differences in 1,3-butadiene metabolism and resulting genotoxicity (Albertini et al., 2010; Kirman et al., 2010a; Himmelstein et al., 1997).• Electrophilic metabolites form DNA adducts, induce DNA strand breaks, stimulate unscheduled DNA synthesis and DNA excision repair, and trigger sister-chromatid exchange (Albertini et al., 2010)• Several studies show a positive correlation between occupational exposure to 1,3-butadiene and levels of DNA adducts in peripheral blood lymphocytes (ATSDR, 2012; U.S. EPA, 2002a).• Mutagenic activity arises from epoxide metabolites (ATSDR, 2012; U.S. EPA, 2002a) and potentially from novel bifunctional metabolites such	<ul style="list-style-type: none">• While the weight of evidence sufficiently supports a mutagenic MOA for 1,3-butadiene carcinogenicity, the possibility of alternative or additional MOAs cannot be excluded, although these have not been definitively identified or supported by the existing evidence.• An <i>in vitro</i> study showed that 1,3-butadiene decreased the ratio of mature to immature bone marrow stem cells (Leiderman et al., 1986)	<i>Key findings:</i> The weight of evidence strongly supports a mutagenic MOA for 1,3-butadiene in the development of lymphohematopoietic malignancies in both rodents and humans. The primary driver of 1,3-butadiene’s mutagenic MOA is the formation of electrophilic metabolites which readily react with DNA, causing adduct formation and other types of DNA damage. If not repaired, this persistent damage can lead to mutations, particularly in oncogenes and tumor suppressor genes. The accumulation of mutations in critical genes results in uncontrolled cell proliferation and cancer development. The variability in 1,3-butadiene’s mutagenic and carcinogenic potential across species and cancer types is attributed to differences in 1,3-butadiene metabolism, resulting in varying levels and types of	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>KE3 Chromosomal aberrations and/or mutations</p> <ul style="list-style-type: none">• <i>In vitro</i> mutation assays conducted on human and rodent lymphohematopoietic cells (ATSDR, 2012; U.S. EPA, 2002a).• Studies of mutagenicity in lymphohematopoietic cells from rodents exposed <i>in vivo</i> and in tissues from exposed workers (ATSDR, 2012; Meng et al., 2007; Meng et al., 2004; U.S. EPA, 2002a; Ammenheuser et al., 2001; Ward et al., 2001; Ma et al., 2000; Meng et al., 2000; Meng et al., 1999; Ward et al., 1996b; Cochrane and Skopek, 1994). <p>Alternative mode-of-action studies</p> <ul style="list-style-type: none">• Study of bone marrow stem cells exposed <i>in vitro</i> (Leiderman et al., 1986)	<p>as chlorinated and ketone/aldehyde derivates (Nakamura et al., 2021; Wu et al., 2019; Wang et al., 2018; Elfarra and Zhang, 2012).</p> <ul style="list-style-type: none">• 1,3-Butadiene induces specific mutations in key genes involved in cancer development, including oncogenes (<i>e.g.</i>, K-ras) and tumor suppressor genes (<i>e.g.</i>, Trp53), as well as those in the Wnt signaling pathway (ATSDR, 2012; U.S. EPA, 2002a).• Mice and rats had increased HPRT locus mutations in splenic T cells (Meng et al., 2007; Meng et al., 2004; Meng et al., 2000; Meng et al., 1999; Cochrane and Skopek, 1994).• In a transgenic mouse, increased <i>lacI</i> mutant frequency was observed in both spleen and bone marrow (U.S. EPA, 2002b).• In workers, a potential association was observed between 1,3-butadiene exposure and increased frequencies of <i>hprt</i> variants in lymphocytes (Ammenheuser et al., 2001; Ward et al., 2001; Ma et al., 2000; Ward et al., 1996b).		<p>DNA damaging electrophilic metabolites.</p> <p><i>Overall judgment for lymphohematopoietic carcinogenicity based on mechanistic evidence:</i></p> <ul style="list-style-type: none">• Robust	
Mechanistic evidence in other cells and tissues				
<ul style="list-style-type: none">• Mutation assays in bacteria and fruit flies (ATSDR, 2012; IARC,	<ul style="list-style-type: none">• 1,3-butadiene induced reverse mutations in bacteria in the	<ul style="list-style-type: none">• No increase in <i>lacZ</i> mutation frequency was	<p><i>Key findings:</i> There is generalized evidence</p>	

Database Summary	Factors That Increase Strength	Factors That Decrease Strength	Summary of Key Findings and Within-Stream Strength of the Evidence Judgment	Inferences Across Evidence Streams and Overall Evidence Integration Judgment
<p>2008b; U.S. EPA, 2002a)</p> <ul style="list-style-type: none"> • Genotoxicity studies in rat skin and embryonic fibroblasts, mouse skin fibroblasts, mouse lung, and rat and mouse germ cells using metabolites (IARC, 2008b; U.S. EPA, 2002a) • Studies of DNA adduct formation, DNA damage, and/or micronuclei in rat and mouse liver and lung following <i>in vivo</i> exposure (ATSDR, 2012; IARC, 2008b; U.S. EPA, 2002a) • <i>In vivo</i> mutation assays in liver and lung of transgenic mice (ATSDR, 2012; U.S. EPA, 2002a). 	<p>presence of S9 (ATSDR, 2012; IARC, 2008b; U.S. EPA, 2002a)</p> <ul style="list-style-type: none"> • Electrophilic metabolites induced gene mutations, micronuclei, and SCEs in rat and mouse skin fibroblasts, rat embryo fibroblasts, mouse lung, and rat and mouse germ cells (IARC, 2008b; U.S. EPA, 2002a) • <i>In vivo</i> studies of rats and mice exposed to 1,3-butadiene demonstrated DNA adduct formation, DNA damage, and/or micronuclei in rat and mouse liver, lung, and germ cells (ATSDR, 2012; IARC, 2008b; U.S. EPA, 2002a) • Frequencies of <i>lacZ</i>⁺ and <i>lacI</i> mutations were increased in the lungs of transgenic mice exposed to 1,3-butadiene (ATSDR, 2012; IARC, 2008b; U.S. EPA, 2002b). 	<p>observed in the livers of transgenic mice exposed to 1,3-butadiene (ATSDR, 2012).</p>	<p>of genotoxicity and mutagenicity in bacteria and various rodent tissues, however the data for each particular tissue type is limited.</p> <p><i>Overall judgment for carcinogenicity in other tissues based on mechanistic evidence:</i></p> <ul style="list-style-type: none"> • Slight 	
<p>ALL: acute lymphoblastic/lymphocytic leukemia; AML: acute myeloid leukemia; DNA: deoxyribonucleic acid; NHL: non-Hodgkin's lymphoma; SCE: sister chromatid exchange; SEER: Surveillance, Epidemiology, and End Results database of the National Cancer Institute; TRI: Toxics Release Inventory</p> <p>^a Except where noted, associations reported in the table are statistically significant and denote increased risk with increased exposure (<i>i.e.</i>, associations are not inverse).</p> <p>^b Except where noted, all studies exposed both male and female animals for 6 hours/day, 5 days/week.</p> <p>^c In the 103-week mouse study, survival was decreased at ≥ 20 ppm and no females at ≥ 199 ppm or males at 619 ppm survived to the end of exposure.</p>				

Appendix B BENCHMARK DOSE MODELING RESULTS FOR CRITICAL ENDPOINTS

BMD modeling was conducted with the EPA's BMD software (BMDS 3.3.2). For continuous data, the Exponential, Hill, Linear, Polynomial, and Power Continuous models available within the software were fit employing a BMR of 1 SD for maternal body weight gain as well as 1 SD, 5 percent relative deviation (RD) and 10 percent RD for fetal body weight and mean percent of supernumerary ribs per litter. An adequate fit was judged based on the χ^2 goodness-of-fit p value ($p > 0.1$), magnitude of the scaled residuals in the vicinity of the BMR, and visual inspection of the model fit. In addition to these three criteria for judging adequacy of model fit, a determination was made as to whether the variance across dose groups was constant. If a constant variance model was deemed appropriate based on the statistical test provided in BMDS (*i.e.*, Test 2; p-value > 0.05 [note: this is a change from previous versions of BMDS, which required variance p-value > 0.10 for adequate fit]), the final BMD results were estimated from a constant variance model. If the test for homogeneity of variance was rejected (p-value < 0.05), the model was run again while modeling the variance as a power function of the mean to account for this nonconstant variance. If this nonconstant variance model did not adequately fit the data (*i.e.*, Test 3; p-value < 0.05), the dataset was considered unsuitable for BMD modeling. Among all models providing adequate fit, the lowest BMDL has been selected if the BMDLs estimated from different models varied greater than 3-fold; otherwise, the BMDL from the model with the lowest Akaike Information Criterion (AIC) has been selected.

For dichotomous data, the Gamma, Logistic, Log Logistic, Log-Probit, Multistage, Probit, Weibull, and Quantal Linear Dichotomous models available within the software were fit using a benchmark response (BMR) of 5 percent and 10 percent extra risk. Adequacy of model fit has been judged based on the χ^2 goodness-of-fit p-value ($p > 0.1$), magnitude of scaled residuals in the vicinity of the BMR, and visual inspection of the model fit. Among all models providing adequate fit, the lowest BMDL has been selected if the BMDLs estimated from different models varied greater than 3-fold; otherwise, the BMDL from the model with the lowest AIC has been selected.

Dichotomous nested modeling of data was conducted for the number of fetuses with supernumerary ribs and male fetuses with body weight below the 5th or 10th percentiles of control male fetal body weight. The Nested Logistic model available within the software was fit using a benchmark response (BMR) of 5 percent and 10 percent extra risk. Litter size was used for the litter-specific covariate (lsc). The models were applied with and without the litter-specific covariate to determine whether or not the litter-specific covariate contributes to a better explanation of the observation. Models are also run with and without the intralitter correlation (ilc) to estimate the degree to which observations within the same litter are correlated. The forms of the models include lsc+ilc+, lsc+ilc-, lsc-ilc+, and lsc-ilc-. The "overall mean" (default) was selected for the litter-specific covariate option. Adequacy of model fit has been judged based on the χ^2 goodness-of-fit p-value ($p > 0.1$). The overall model should be considered questionable if the scaled residuals are greater than 2 or less than -2 for several individual dose and litter-specific covariate combinations, particularly near the control or dose group nearest the BMD. Among the forms of the models providing adequate fit, the model form with the lowest AIC has been selected.

Results for maternal and related developmental toxicity endpoints are presented in Table_Apx B-1. Results for male reproductive system and resulting developmental toxicity endpoints are presented in Table_Apx B-2. Results for hematological endpoints are presented in Table_Apx B-3. Full BMD modeling results including all approaches, endpoints, BMRs, model fits, and statistics are included in *Benchmark Dose Modeling Results for 1,3-Butadiene* ([U.S. EPA, 2025a](#)).

Table_Apx B-1. BMD Modeling Results for Maternal and Related Developmental Toxicity Endpoints

Table Apx B-1. BMD Modeling Results for Maternal and Related Developmental Toxicity Endpoints												
Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Mouse data (Battelle PNL, 1987b)												
Maternal absolute body weight gain (GD 11–16) (g)	Exponential 5 (constant variance)	58.2	10.4	NA	NA	NA		NA				The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, only the Exponential 5 model provided an adequate fit to the means (test 4 p-value > 0.1); therefore, this model was selected.
Maternal extragestational weight gain (g) (gravid uterus adjusted) GD 0–18	Exponential 3 (constant variance)	337	193	NA	NA	NA		NA				The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, only the Exponential 3 model provided adequate fit to the means (test 4 p-value > 0.1); therefore, this model was selected.
Mean fetal body weight in male fetuses/litter (g)	ND	ND	ND	ND	ND	ND	ND	NA		NA		Both the constant and nonconstant variance models provide adequate fit to the variance data; however with either variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). This dataset is not suitable for BMD modeling; no model selected.
Mean fetal body weight in male fetuses/litter (g) – highest concentration dropped	Exponential 3 (constant variance)	19.6	15.3	13.1	10.7	26.8	22.1	NA		NA		The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, the Exponential 3, Polynomial 2-degree, Power, and Linear models provided adequate fit to the means (test 4 p-value > 0.1). The goodness of fit test for the means (test 4) could not be calculated for the Exponential 5 and Hill models because the models

Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
												were saturated (degree of freedom = 0). BMDLs of the fit models were sufficiently close (differed by < 3-fold); therefore, the model with the lowest AIC was selected.
Mean fetal body weight – male fetuses (g)	ND	ND	ND	ND	ND	ND	ND	NA		NA		Neither the constant nor nonconstant variance provided an adequate fit to the variance data. This dataset is not suitable for BMD modeling; no model selected.
Mean fetal body weight – male fetuses (g) – highest concentration dropped	ND	ND	ND	ND	ND	ND	ND	NA		NA		Neither the constant nor nonconstant variance provided an adequate fit to the variance data. This dataset is not suitable for BMD modeling; no model selected.
Male fetuses with body weight below 5th percentile of control male fetal body weight – Nested model	Nested Logistic (lsc-ilc+); overall mean	NA		NA		NA		5.49	2.52	10.4	5.32	The model forms applying the intralitter correlation (ilc +) provided adequate fit to the data (chi-square p-value > 0.1) both with and without the litter-specific covariate (lsc) applied. Model forms without the intralitter correlation (ilc-) did not provide adequate fits. Between the Nested Logistic (lsc+ilc+) and Nested Logistic (lsc-ilc+), the Nested Logistic (lsc-ilc+) had the lower AIC; therefore this model form is selected.

Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Male fetuses with body weight below 10th percentile of control male fetal body weight – Nested model	Nested Logistic (lsc-ilc+); overall mean	NA		NA		NA		3.41	1.20	6.09	2.53	The model forms applying the intralitter correlation (ilc +) provided adequate fit to the data (chi-square p-value > 0.1) both with and without the litter-specific covariate (lsc) applied. Model forms without the intralitter correlation (ilc-) did not provide adequate fits. Between the Nested Logistic (lsc+ilc+) and Nested Logistic (lsc-ilc+), the Nested Logistic (lsc-ilc+) had the lower AIC; therefore this model form is selected.
Mean fetal body weight – males and females combined (g)	ND	ND	ND	ND	ND	ND	ND	NA		NA		Neither the constant nor nonconstant variance provided an adequate fit to the variance data. This dataset is not suitable for BMD modeling; no model selected.
Mean fetal body weight – males and females combined (g) – highest concentration dropped	ND	ND	ND	ND	ND	ND	ND	NA		NA		Neither the constant nor nonconstant variance provided an adequate fit to the variance data. This dataset is not suitable for BMD modeling; no model selected.
Number of litters with supernumerary ribs	Multistage 3-degree	NA		NA		NA		14.2	1.38	18.0	2.84	All models provided adequate fit to the data (chi-square p-value > 0.1). The Weibull model was considered unusable because the BMDL computation failed. BMDLs of the fit models were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected.
Number of fetuses with supernumerary ribs	ND	NA		NA		NA		ND	ND	ND	ND	None of the models provided an adequate fit to the data (chi-square p-value > 0.1). This dataset is not

Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
												suitable for BMD modeling; no model selected.
Number of fetuses with supernumerary ribs – highest concentration dropped	Gamma	NA		NA		NA		34.7	10.7	38.2	16.7	The Gamma and Multistage 2-degree models provided adequate fit to the data (chi-square p-value > 0.1). The goodness of fit test (x ² p-value) could not be calculated for the Dichotomous Hill, Log-logistic, Weibull, and Log-probit models because the models were saturated (degree of freedom = 0). BMDLs of the fit models were sufficiently close (differed by < 3-fold); therefore, the model with the lowest AIC was selected.
Number of fetuses with supernumerary ribs – nested model	Nested Logistic (lsc-ilc+); overall mean	NA		NA		NA		6.31	2.9	11.9	6.13	The model forms applying the intralitter correlation (ilc +) provided adequate fit to the data (chi-square p-value > 0.1) both with and without the litter-specific covariate (lsc) applied. Model forms without the intralitter correlation (ilc-) did not provide adequate fits. Between the Nested Logistic (lsc+ilc+) and Nested Logistic (lsc-ilc+), the Nested Logistic (lsc-ilc+) had the lower AIC; therefore, this model form is selected.
Mean % of supernumerary ribs per litter	ND	ND	ND	ND	ND	ND	ND	NA		NA		Both the constant and nonconstant variance models provide adequate fit to the variance data; however with either variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). This dataset is not suitable for BMD modeling; no model selected.

Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Mean % of supernumerary ribs per litter – highest concentration dropped	Polynomial 2-degree (nonconstant variance)	34.5	22.2	ND	ND	9.43	1.37	NA		NA		The constant variance model did not provide adequate fit to the variance data, but the nonconstant variance model did. With the nonconstant variance model applied, only the Polynomial 2-degree model provided adequate fit to the means (test 4 p-value > 0.1). The goodness of fit test for the means (test 4) could not be calculated for the Exponential 3 and 5, Hill, and Power models because the models were saturated (degree of freedom = 0). The polynomial 2-degree model was selected for BMRs of 1 SD and 10% RD. When applying a BMR of 5% RD, the Polynomial 2-degree model was considered questionable because the BMDL value was 10 times lower than the lowest non-zero dose; no model was selected for this BMR.
Rat data (Hazleton Labs, 1981a)												
Absolute body weight gain in maternal SD rats for GD 6–15	Hill (constant variance)	101.3	48.9	NA		NA		NA		NA		The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, only the Exponential 5 and Hill models provided adequate fit to the means (test 4 p-value > 0.1). The BMDLs for the fit models were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected.

Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Mean uterine-adjusted body weight in maternal SD rats for GD 20	Exponential 3 (constant variance)	2321	1528	NA		4701	1995	NA		NA		The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, the Exponential 3, Polynomial 3-degree, Power, and Linear models provided adequate fit to the means (test 4 p-value > 0.1); the BMD computation failed for the Exponential 5 and Hill models. BMDLs for the fit models were sufficiently close (differed by < 3-fold); therefore, the model with the lowest AIC was selected.
Uterine-adjusted body weight gain in maternal SD rats for GD 0–20	ND	ND	ND	NA		NA		NA		NA		Both the constant and nonconstant variance models provide adequate fit to the variance data; however with either variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). The goodness of fit test for the means (Test 4) could not be calculated for the Exponential 5 and Hill models because the models were saturated (degree of freedom = 0). This dataset is not suitable for BMD modeling; no model selected.
Uterine-adjusted body weight gain in maternal SD rats for GD 0–20 – Highest concentration dropped	Linear (constant variance)	295	193	NA		NA		NA		NA		The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, only the Linear model provided adequate fit to the means (test 4 p-value > 0.1); therefore this model was selected. The goodness of fit test for the means (test 4) could not be calculated for all other models because the models were saturated (degree of freedom = 0).

Endpoint	Recommended Model	1 SD		5% RD		10% RD		5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
BMD = benchmark dose; BMDL = benchmark dose (lower 95 percentile); ER = extra risk; ND = not determined, no model selected; NA = BMR not applied; RD = relative deviation												
^a Modeled concentrations were duration adjusted for 6 hours/day												

Table_Apx B-2. BMD Modeling Results for Male Reproductive System and Resulting Developmental Toxicity Endpoints

Endpoint (Studies)	Recommended Model	5% ER		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Incidence of all deaths – (Anderson et al., 1996)	Log-Logistic	54.2	41.9	114	88.5	All models provided adequate fit to the data (chi-square p-value > 0.1) except for the Dichotomous Hill and Log-Probit models; these models were saturated (degree of freedom = 0) and considered questionable. BMDLs of the fit models were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected.
Incidence of all deaths – combined (Brinkworth et al., 1998 ; Anderson et al., 1996)	Log-Probit	13	4.83	55.0	30.1	Only the Log-Probit and Dichotomous Hill models provided adequate fit to the data (chi-square p-value > 0.1). Between these two models, the BMDLs were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected.
AIC = Akaike Information Criterion; BMD = benchmark dose; BMDL = benchmark dose (lower 95 percentile); ER = extra risk						
^a Modeled concentrations were duration adjusted for 6 hours/day, 5 days/week						

Table_Apx B-3. BMD Modeling Results for Hematological Endpoints

Endpoint	Recommended Model	1 SD		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Erythrocyte counts in male mice (10 ⁶ /μL)	ND	ND	ND	ND	ND	The constant variance model did not provide adequate fit to the variance data, but the nonconstant variance model did. With the nonconstant variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). This dataset is not suitable for BMD modeling; no model selected.
Erythrocyte counts in male mice (10 ⁶ /μL) – highest concentration dropped	BMR: 1 SD: Exponential 5 (constant variance); BMR: 10% RD: Exponential 3 (constant variance)	10.7	8.07	46.7	35.7	The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, all models provided adequate fit to the means (test 4 p-value > 0.1) when using the BMR of 1SD. The BMDLs for the fit models were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected (Exponential 5). When applying a BMR of 10% RD, the BMD computation failed for the Exponential 5 and Hill models, and they were unusable. Among the remaining models, the BMDLs were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected (Exponential 3); using a BMR of 10% RD resulted in BMD and BMDL values being higher than the maximum modeled concentration.
Hemoglobin concentration in male mice (g/dL)	ND	ND	ND	ND	ND	The constant variance model did not provide adequate fit to the variance data, but the nonconstant variance model did. With the nonconstant variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). This dataset is not suitable for BMD modeling; no model selected.
Hemoglobin concentration in male mice (g/dL) – highest concentration dropped	ND	ND	ND	ND	ND	The constant variance model did not provide adequate fit to the variance data, but the nonconstant variance model did. With the nonconstant variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). This dataset is not suitable for BMD modeling; no model selected.
Hemoglobin concentration in male mice (g/dL) – two highest concentrations dropped	Power (constant variance)	10.9	7.95	11.6	11.3	The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, all models, except for the Exponential 5 and Hill models, provided adequate fit to the means (test 4 p-value > 0.1); the goodness of fit test for the means (test 4) could not be calculated for the Exponential 5 and Hill models because the models were saturated (degree of freedom = 0). The BMDLs for the fit models were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected. Using a BMR of 10% RD resulted in BMD and BMDL values being (slightly) higher than the maximum modeled concentration.
Packed red cell volume in male mice (mL/dL)	ND	ND	ND	ND	ND	The constant variance model did not provide adequate fit to the variance data, but the nonconstant variance model did. With the nonconstant variance model applied, none of the models provided adequate fit to the means (test 4 p-value < 0.1). This dataset is not suitable for BMD modeling; no model selected.

Endpoint	Recommended Model	1 SD		10% ER		Notes ^a
		BMD (ppm)	BMDL (ppm)	BMD (ppm)	BMDL (ppm)	
Packed red cell volume in male mice (mL/dL) – highest concentration dropped	BMR: 1 SD: Hill (constant variance); BMR 10% RD: Exponential 3 (constant variance)	10.8	3.91	62.5	41.9	The constant variance model provided an adequate fit to the variance data. With the constant variance model applied, all models provided adequate fit to the means (test 4 p-value > 0.1) when using the BMR of 1SD. The BMDLs for the fit models were not sufficiently close (differed by >3-fold); therefore, the model with the lowest BMDL was selected (Hill, which also had the lowest AIC). When applying a BMR of 10% RD, the BMD computation failed for the Hill model, and it was unusable. Among the remaining models, the BMDLs were sufficiently close (differed by <3-fold); therefore, the model with the lowest AIC was selected (Exponential 3); using a BMR of 10% RD resulted in BMD and BMDL values being higher than the maximum modeled concentration.
AIC = Akaike Information Criterion; BMD = benchmark dose; BMDL = benchmark dose (lower 95 percentile); ER = extra risk; ND = not determined; no model selected; SD = standard deviation						
^a Modeled concentrations were duration adjusted for 6 hours/day, 5 days/week						

Appendix C OTHER HAZARD OUTCOMES

This appendix discusses organ systems that have weaker evidence integration conclusions and insufficient information to develop a detailed evidence integration table. *None of these outcomes were considered for dose-response.* See full data extraction for all relevant studies in *Data Extraction Information for Human Health Hazard Animal Toxicology and Epidemiology* ([U.S. EPA, 2025b](#)) and *Further Filtering Results for Human Health Hazard Animal Toxicology and Epidemiology* ([U.S. EPA, 2025d](#))).

C.1 Neurotoxicity, Sensory Effects, and Non-Cancer Mortality

Human Evidence

1,3-butadiene has demonstrated only very mild acute toxicity in human subjects. Eye irritation and impaired visual focus were observed in two single subjects following 7 hours of exposure to 2,000 or 4,000 ppm 1,3-butadiene, without any more severe symptoms observed at 8,000 ppm. No effects on psychomotor responses were observed ([Carpenter et al., 1944](#)). In a cross-sectional study of adults, increased urinary 1,3-butadiene metabolite levels was statistically significantly associated with hearing loss, based on data collected during the 2011 to 2012 cycle of CDC's U.S. National Health and Nutritional Examination Survey (NHANES) ([Pudrith and Dudley, 2019](#)). As previously described in Section 4.1.2.1.1, environmental *in utero* exposure to 1,3-butadiene has also been associated with increased risk for autism ([von Ehrenstein et al., 2014](#)).

Laboratory Animal Evidence

A majority of rabbits died following only 23 minutes of exposure and demonstrated central nervous system (CNS) depression following less than 2 minutes of exposure to the very high dose of 250,000 ppm 1,3-butadiene ([Carpenter et al., 1944](#)), while the lethal concentration resulting in death to 50 percent of test subject (LC50) values are 122,000 ppm for mice exposed for 2 hours and 129,000 for rats exposed for 4 hours. According to the interim Acute Exposure Guideline Levels (AEGL) document for 1,3-butadiene ([NAC/AEGL, 2009](#)), guinea pigs demonstrated 100 percent mortality following 10 hours of exposure to 89,000 ppm 1,3-butadiene but no mortality following 30-minute exposure to 200,000 ppm. Rabbits also survived a 25-minute exposure to 200,000 ppm while two of five rats died following a 30-minute exposure to the same concentration.

As summarized by ATSDR ([2012](#)), no mortality was observed in rats following 13 weeks of 8,000 ppm or 8 months of 6,700 ppm exposure. Guinea pigs, rabbits, and dogs also did not die following 8 months of 6,700 ppm exposure. The LOAEC for increased mortality in mice was 5,000 ppm (NOAEC = 2,500 ppm) exposure for 6 hours/day, 5 days/week for 14 weeks ([NTP, 1984](#)). Chronic exposure resulted in increased mortality to both mice and rats; however, this is associated with cancer and is discussed in Section 5.1.

No effects on neuromuscular function or observed histopathology were observed in rats exposed for 13 weeks to as high as 8,000 ppm ([Crouch et al., 1979](#)). Reduced balance/locomotor function and decreased brain weight in females were observed following 1,000 or 8,000 ppm exposure for 2 years ([Hazleton Labs, 1981b](#)); however, tumors were also present at these doses and may have impeded mobility. No functional, measured, or histopathological effects were observed for any other parameter following 2 years of exposure to 619 ppm ([NTP, 1993](#)).

Mechanistic and Supporting Evidence

EPA did not identify any reasonably available information to provide any mechanistic support for potential neurotoxicity.

Evidence Integration Summary and Conclusions

Evidence *suggests but is not sufficient to conclude* that 1,3-butadiene causes neurotoxicity and/or sensory effects in humans under relevant exposure circumstances. This conclusion is based on slight evidence of functional and developmental neurotoxicity outcomes in limited human studies, slight evidence in animals based on inconsistent effects observed greater or equal to 1,000 ppm and indeterminate mechanistic data.

For acute/intermediate non-cancer mortality, *strong evidence supports no effect* in humans under relevant exposure circumstances. Only mild irritation effects were observed in humans at exposures several orders of magnitude higher than any realistic occupational or general population exposure. In animals, rodent acute LC50s (the amount of a substance that is lethal to half of a test population) were similarly above 100,000 ppm and intermediate exposures resulted in death only in mice but not other model species at or above 5,000 ppm.

Based on the evidence integration conclusions and absence of strong dose-response data for these endpoints, dose-response analysis is not considered for neurotoxicity or non-cancer mortality.

C.2 Respiratory Toxicity

Human Evidence

Individual case reports of qualitative occupational exposure to 1,3-butadiene mention irritation of respiratory tissues including nose, throat, and lungs (as well as eyes). Some workers also experienced coughing, fatigue, and drowsiness ([ATSDR, 2012](#)). Details on exposure levels were not provided.

Laboratory Animal Evidence

As summarized by ATSDR ([2012](#)), chronic exposure to 1,250 ppm 1,3-butadiene in mice caused inflammation of the nasal cavity along with fibrosis, metaplasia, and atrophy of olfactory epithelium and hyperplasia of the respiratory epithelium ([NTP, 1993, 1984](#)). In contrast, respiratory effects were not observed in rats, guinea pigs, rabbits, or dogs exposed to as much as 6,700 ppm 1,3-butadiene for 8 months ([Carpenter et al., 1944](#)) or rats exposed to 8,000 ppm for approximately 3 months ([Crouch et al., 1979](#)). However, 2 years of 8,000 ppm exposure did cause lung metaplasia in rats ([Hazleton Labs, 1981b](#)). Hyperplasia of the epithelium was increased following as little as 20 ppm exposure for 15 months to 2 years of exposure in females (at higher doses in males); however, the outcome was not dose- or duration-responsive ([NTP, 1993](#)).

Mechanistic and Supporting Evidence

EPA did not identify any reasonably available information to provide any mechanistic support for potential respiratory toxicity. However, indications of human respiratory irritation suggest that either parent 1,3-butadiene or metabolites may be cytotoxic to respiratory tissue—leading to subsequent proliferation, repair, and other responses as observed in animals.

Evidence Integration Summary and Conclusions

Evidence *suggests but is not sufficient to conclude* that 1,3-butadiene causes respiratory toxicity in humans under relevant exposure circumstances. This conclusion is based on (1) slight qualitative evidence of irritation in human case studies, (2) moderate evidence in animals due to multiple adverse effects observed in mice and metaplasia observed at a high dose following a 2-year exposure period in rats, and (3) indeterminate mechanistic data.

Based on the evidence integration conclusions and absence of strong dose-response data for these endpoints, dose-response analysis is not considered for respiratory toxicity.

C.3 Liver Toxicity

Human Evidence

In 1 study on 82 male elastomer/polymer workers with mean duration of employment over 21 years, 39 percent of acrylonitrile, 1,3-butadiene, and styrene-exposed workers had elevated serum cytokeratin 18 levels indicative of liver disease, but cumulative 1,3-butadiene exposure was higher for healthy workers ([Cave et al., 2011](#)).

Laboratory Animal Evidence

Effects on liver were not observed after 3 months of exposure to 1,3-butadiene in rats or mice ([NTP, 1984](#); [Crouch et al., 1979](#)). The only observed liver effects in rats was increased liver weight following 2 years of exposure to at least 1,000 ppm ([Hazleton Labs, 1981b](#)) but without any indication of adversity from histopathology.

1,3-Butadiene did cause increased liver necrosis in mice following 14 to 15 months of exposure to at least 625 ppm ([NTP, 1993, 1984](#)) and following 2 years of exposure to 20 to 62.5 ppm (statistical significance unclear) ([NTP, 1993](#)). Absolute weights were correspondingly increased only in females dosed to at least 62.5 ppm ([NTP, 1993](#)) and neither sex showed consistent other evidence of histopathology.

Mechanistic and Supporting Evidence

EPA did not identify any reasonably available information to provide any mechanistic support for potential liver toxicity.

Evidence Integration Summary and Conclusions

Evidence *suggests but is not sufficient to conclude* whether 1,3-butadiene exposure may cause liver toxicity in humans under relevant exposure circumstances. This conclusion is based on indeterminate evidence in humans, slight evidence in animals (with supporting evidence primarily from mice), and indeterminate mechanistic evidence.

Based on the evidence integration conclusions and absence of strong dose-response data for these endpoints, dose-response analysis is not considered for liver toxicity.

C.4 Kidney Toxicity

Human Evidence

EPA did not identify any reasonably available information assessing effects of 1,3-butadiene exposure on kidney in humans.

Laboratory Animal Evidence

Blood chemistry assessment and urinalysis of rats, guinea pigs, rabbits, and dogs did not demonstrate any atypical measurements for nitrogen, bilirubin, glucose, albumin, sugar, or casts following 8 months of exposure to as high as 6,700 ppm 1,3-butadiene in a poorly described, early study ([Carpenter et al., 1944](#)). Both rats and mice did not demonstrate any signs of kidney toxicity after approximately 3 months of exposure to as high as 8,000 ppm ([NTP, 1984](#); [Crouch et al., 1979](#)). In chronic studies, nephrosis and increased kidney weight was seen in male rats after 2 years of exposure to the highest dose of 8,000 ppm ([Hazleton Labs, 1981b](#)) and increased absolute kidney weight was observed in females after 2 years of exposure to 625 ppm in mice ([NTP, 1993](#)). The adversity of the increased kidney weight in mice is uncertain because histopathology was not observed at any dose after either 14 weeks or 2 years of exposure ([NTP, 1993, 1984](#)).

Mechanistic and Supporting Evidence

EPA did not identify any reasonably available information to provide any mechanistic support for potential kidney toxicity. The observations in male rats was not associated with an increase in alpha 2 (α 2u)-globulin (measured at 3, 6, and 12 months)—although globulins were not measured at the 2-year termination of the experiment when the kidney effects were observed ([Hazleton Labs, 1981b](#)).

Therefore, the significance of the male kidney effects has some uncertainty because α 2u-globulin-mediated kidney toxicity in male rats is not relevant to humans.

Evidence Integration Summary and Conclusions

Evidence is inadequate to assess whether 1,3-butadiene exposure may cause kidney toxicity in humans under relevant exposure circumstances. This conclusion is based on indeterminate human, animal, and mechanistic evidence. The only indication of adverse effects on kidney is from male rats, for which the relevance to humans cannot be confirmed due to the absence of measurements at relevant timepoints for α 2u-globulin.

Based on the evidence integration conclusions and absence of strong dose-response data for these endpoints, dose-response analysis is not considered for kidney toxicity.

Appendix D HUMAN HEALTH HAZARD CONFIDENCE SUMMARY

D.1 Human Health Hazard Confidence Summary

Table_Apx D-1 summarizes the confidence ratings for each factor for the critical human health hazard endpoints and associated hazard values considered for acute, intermediate, and chronic non-cancer scenarios as well as cancer lifetime exposure scenarios. The bolded rows in the table are the most robust and sensitive health effect for each exposure scenario and will be used to calculate risks for 1,3-butadiene.

Table_Apx D-1. Confidence Summary for Human Health Hazard Assessment

Table Apx B-1. Confidence Summary for Human Health Hazard Assessment						
Hazard Domain	Evidence Integration Conclusion	Selection of Most Critical Endpoint and Study	Relevance to Exposure Scenarios	Dose-Response Considerations	PESS Sensitivity	Overall Hazard Confidence
Acute non-cancer						
None	Not applicable					Indeterminate to Slight
Intermediate/chronic non-cancer						
Maternal/ Developmental	++	+++	++	+++	++	Robust
Male Reproductive/ Developmental	++	+++	++	++	++	Moderate
Hematological	++	+++	++	++	+	Moderate
Lifetime cancer						
Leukemia and Bladder Cancer	+++	+++	+++	+++	++	Robust
<p>+++ Robust confidence suggests thorough understanding of the scientific evidence and uncertainties. The supporting weight of scientific evidence outweighs the uncertainties to the point where it is unlikely that the uncertainties could have a significant effect on the hazard estimate.</p> <p>++ Moderate confidence suggests some understanding of the scientific evidence and uncertainties. The supporting scientific evidence weighed against the uncertainties is reasonably adequate to characterize hazard estimates.</p> <p>+ Slight confidence is assigned when the weight of scientific evidence may not be adequate to characterize the scenario, and when the assessor is making the best scientific assessment possible in the absence of complete information. There are additional uncertainties that may need to be considered.</p>						

D.2 Other Uncertainty Factors Not Applied in this Assessment

LOAEL-to-NOAEL Uncertainty Factor (UF_L)

A UF_L is applied when adverse effects are identified at the lowest dose/concentration tested and the POD cannot be refined through BMD modeling. A value of 3 or 10 can be applied based on the magnitude of the observed effect and the dose-response curve. The POD chosen to calculate intermediate, and chronic risks is a BMDL and therefore, EPA did not apply this UF.

Subchronic-to-Chronic Uncertainty Factor (UF_s)

A UF_s may be justified when a POD from a shorter study is used to characterize a longer duration. For 1,3-butadiene, the intermediate PODs were all based on intermediate developmental and/or pre-mating exposures and therefore no extrapolation across durations was required. For chronic exposures, these intermediate PODs are directly applicable because additional exposure is not expected to be relevant outside the developmental/pre-mating windows. The hematological effects are from a chronic study and are also directly applicable to chronic durations.

Database Uncertainty Factor (UF_D)

EPA may consider application of a UF_D on a case-by-case basis when the available quantitative data may insufficiently account for expected adverse effects from chemical exposure. For 1,3-butadiene EPA is utilizing the most sensitive and well-supported POD from the more sensitive species for risk estimates. There is insufficient evidence of neurological effects in animals (Appendix C.1) to indicate that a neurodevelopmental study would result in a lower POD and there was no increased sensitivity or severity of outcomes in an OECD 421 reproductive study ([WIL Research, 2003](#)) in rats compared to a 10-day developmental toxicity study ([Hazleton Labs, 1981a](#)). Therefore, a UF_D is not applied for this assessment.